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Abstract
The clinical effectiveness and cost-effectiveness of 
bariatric (weight loss) surgery for obesity: a systematic 
review and economic evaluation
J Picot,* J Jones, JL Colquitt, E Gospodarevskaya, E Loveman, L Baxter 
and AJ Clegg
Southampton Health Technology Assessments Centre, University of Southampton, UK
*Corresponding author
Objectives: To assess the clinical effectiveness and cost-
effectiveness of bariatric surgery for obesity.
Data sources: Seventeen electronic databases were 
searched [MEDLINE; EMBASE; PreMedline In-Process 
& Other Non-Indexed Citations; The Cochrane Library 
including the Cochrane Systematic Reviews Database, 
Cochrane Controlled Trials Register, DARE, NHS EED 
and HTA databases; Web of Knowledge Science Citation 
Index (SCI); Web of Knowledge ISI Proceedings; 
PsycInfo; CRD databases; BIOSIS; and databases listing 
ongoing clinical trials] from inception to August 2008. 
Bibliographies of related papers were assessed and 
experts were contacted to identify additional published 
and unpublished references
Review methods: Two reviewers independently 
screened titles and abstracts for eligibility. Inclusion 
criteria were applied to the full text using a standard 
form. Interventions investigated were open and 
laparoscopic bariatric surgical procedures in widespread 
current use compared with one another and with 
non-surgical interventions. Population comprised adult 
patients with body mass index (BMI) ≥ 30 and young 
obese people. Main outcomes were at least one of the 
following after at least 12 months follow-up: measures 
of weight change; quality of life (QoL); perioperative 
and postoperative mortality and morbidity; change 
in obesity-related comorbidities; cost-effectiveness. 
Studies eligible for inclusion in the systematic review for 
comparisons of Surgery versus Surgery were RCTs. For 
comparisons of Surgery versus Non-surgical procedures 
eligible studies were RCTs, controlled clinical trials and 
prospective cohort studies (with a control cohort). 
Studies eligible for inclusion in the systematic review 
of cost-effectiveness were full cost-effectiveness 
analyses, cost-utility analyses, cost-benefit analyses and 
cost-consequence analyses. One reviewer performed 
data extraction, which was checked by two reviewers 
independently. Two reviewers independently applied 
quality assessment criteria and differences in opinion 
were resolved at each stage. Studies were synthesised 
through a narrative review with full tabulation of 
the results of all included studies. In the economic 
model the analysis was developed for three patient 
populations, those with BMI ≥ 40; BMI ≥ 30 and < 40 
with Type 2 diabetes at baseline; and BMI ≥ 30 and <35. 
Models were applied with assumptions on costs and 
comorbidity.
Results: A total of 5386 references were identified 
of which 26 were included in the clinical effectiveness 
review: three randomised controlled trials (RCTs) 
and three cohort studies compared surgery with non-
surgical interventions and 20 RCTs compared different 
surgical procedures. Bariatric surgery was a more 
effective intervention for weight loss than non-surgical 
options. In one large cohort study weight loss was 
still apparent 10 years after surgery, whereas patients 
receiving conventional treatment had gained weight. 
Some measures of QoL improved after surgery, but 
not others. After surgery statistically fewer people had 
metabolic syndrome and there was higher remission 
of Type 2 diabetes than in non-surgical groups. In one 
large cohort study the incidence of three out of six 
comorbidities assessed 10 years after surgery was 
significantly reduced compared with conventional 
therapy. Gastric bypass (GBP) was more effective for 
weight loss than vertical banded gastroplasty (VBG) and 
adjustable gastric banding (AGB). Laparoscopic isolated 
sleeve gastrectomy (LISG) was more effective than AGB 
in one study. GBP and banded GBP led to similar weight 
loss and results for GBP versus LISG and VBG versus 
AGB were equivocal. All comparisons of open versus 
laparoscopic surgeries found similar weight losses in 
each group. Comorbidities after surgery improved in 
all groups, but with no significant differences between 
different surgical interventions. Adverse event reporting 
varied; mortality ranged from none to 10%. Adverse Abstract
iv
events from conventional therapy included intolerance 
to medication, acute cholecystitis and gastrointestinal 
problems. Major adverse events following surgery, some 
necessitating reoperation, included anastomosis leakage, 
pneumonia, pulmonary embolism, band slippage and 
band erosion. Bariatric surgery was cost-effective in 
comparison to non-surgical treatment in the reviewed 
published estimates of cost-effectiveness. However, 
these estimates are likely to be unreliable and not 
generalisable because of methodological shortcomings 
and the modelling assumptions made. Therefore a new 
economic model was developed. Surgical management 
was more costly than non-surgical management in each 
of the three patient populations analysed, but gave 
improved outcomes. For morbid obesity, incremental 
cost-effectiveness ratios (ICERs) (base case) ranged 
between £2000 and £4000 per QALY gained. They 
remained within the range regarded as cost-effective 
from an NHS decision-making perspective when 
assumptions for deterministic sensitivity analysis were 
changed. For BMI ≥ 30 and < 40, ICERs were £18,930 
at two years and £1397 at 20 years, and for BMI ≥ 30 
and <35, ICERs were £60,754 at two years and £12,763 
at 20 years. Deterministic and probabilistic sensitivity 
analyses produced ICERs which were generally within 
the range considered cost-effective, particularly at the 
long twenty year time horizons, although for the BMI 
30-35 group some ICERs were above the acceptable 
range.
Conclusions: Bariatric surgery appears to be a 
clinically effective and cost-effective intervention for 
moderately to severely obese people compared with 
non-surgical interventions. Uncertainties remain and 
further research is required to provide detailed data on 
patient QoL; impact of surgeon experience on outcome; 
late complications leading to reoperation; duration of 
comorbidity remission; resource use. Good-quality RCTs 
will provide evidence on bariatric surgery for young 
people and for adults with class I or class II obesity. 
New research must report on the resolution and/or 
development of comorbidities such as Type 2 diabetes 
and hypertension so that the potential benefits of early 
intervention can be assessed.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Background 
The prevalence of overweight and obesity among 
people in England and Wales is increasing. 
Associated serious health consequences in adults 
include Type 2 diabetes, cardiovascular disease, 
musculoskeletal disorders, certain cancers and 
increased mortality. Childhood obesity is associated 
with a higher chance of premature death and 
disability in adulthood. Obesity imposes a 
considerable economic burden on society. Weight 
loss improves obesity-related comorbidities and 
may have a mortality benefit. The intensity of 
intervention depends on the degree of obesity and 
presence of comorbidities. Management begins in 
primary care, but moves to the specialist setting 
when initial measures have failed and surgery is 
being considered. Bariatric (weight loss) surgery 
is increasing, but is not uniformly available across 
the country and a significant proportion is funded 
privately.
Objectives 
To assess the clinical effectiveness and cost-
effectiveness of bariatric surgery for obesity.
Methods 
Data sources
Seventeen electronic resources, including 
MEDLINE, EMBASE and Cochrane, were searched 
from inception to August 2008. Bibliographies 
of related papers were assessed and experts were 
contacted to identify additional published and 
unpublished references.
Study selection
Titles and abstracts were screened for eligibility 
by two independent reviewers. Inclusion criteria 
were defined a priori and applied to the full text 
of retrieved papers by two independent reviewers 
using a standard form. The inclusion criteria were 
as follows:
•	 Intervention  Open and laparoscopic bariatric 
surgical procedures in widespread current use.
•	 Comparators  Surgical procedures in current use 
in comparison with one another; open surgery 
compared with laparoscopic surgery for the 
same procedure; surgical procedures in current 
use compared with non-surgical interventions 
(medical management, usual care or no 
treatment).
•	 Population  Adult patients fulfilling the standard 
definition of obese [body mass index (BMI) 
of 30 or over] and young people who fulfil 
the definition of obesity for their age, sex and 
height.
•	 Main outcomes  At least one of the following 
reported following a minimum of 12 months 
follow-up: measures of weight change; quality 
of life (QoL); perioperative and postoperative 
mortality and morbidity; change in obesity-
related comorbidities; cost-effectiveness 
[reporting outcomes as either life-years or 
quality-adjusted life-years (QALYs)].
The study types that were eligible for inclusion 
were:
•	 Systematic review of clinical effectiveness  Surgery 
versus surgery – randomised controlled 
trials (RCTs); surgery versus non-surgical 
procedure – RCTs, controlled clinical trials 
and prospective cohort studies (with a control 
cohort).
•	 Systematic review of cost-effectiveness  Full cost-
effectiveness analyses, cost–utility analyses, 
cost–benefit analyses and cost–consequence 
analyses.
Data extraction and 
quality assessment
Data extraction was undertaken by one reviewer 
and checked by two reviewers. Two reviewers 
independently applied quality assessment criteria. 
Differences in opinion were resolved through 
discussion at each stage.
Executive summary Executive summary
x
Data synthesis
Studies were synthesised through a narrative review 
with full tabulation of the results of all included 
studies. 
Economic model
The analysis was developed for three patient 
populations covered by studies included in the 
clinical effectiveness review:
•	 patients with morbid obesity BMI ≥ 40 
undergoing adjustable gastric banding (AGB) 
or gastric bypass (GBP)
•	 patients with moderate-to-severe obesity (BMI 
≥ 30 and < 40) with significant comorbidity at 
baseline (Type 2 diabetes) undergoing AGB
•	 patients with moderate obesity (BMI ≥ 30 and 
< 35) undergoing AGB.
A model developed previously was used for 
patients with morbid obesity (BMI ≥ 40), with 
updated assumptions on costs, diabetes incidence, 
permanency of diabetes remission following 
surgery, and on the impact of BMI on health-state 
utility.
A new model, including cardiac heart disease 
and stroke was applied in the analysis of AGB for 
moderate-to-severely obese (BMI ≥ 30 and < 40) 
patients with Type 2 diabetes and for moderately 
obese (BMI ≥ 30 and < 35) patients. The analysis 
was initially undertaken for the period of the trial 
follow-up only, but also included extrapolations up 
to 20 years following surgery.
Results 
Quantity and quality of studies 
A total of 5386 references were identified. Twenty-
six studies (reported in 52 publications) were 
included in the review of clinical effectiveness. 
Three RCTs and three cohort studies compared 
surgery with non-surgical interventions; 20 RCTs 
compared different surgical procedures. Two 
studies focused on patients with a lower BMI (< 35 
or < 40). The risk of bias of most of the trials was 
uncertain, only nine of the RCTs reported adequate 
sequence generation and only five reported 
adequate allocation concealment.
Summary of clinical effectiveness
Surgery versus non-surgical interventions
The evidence indicates that bariatric surgery is a 
more effective intervention for weight loss than 
non-surgical options. Surgery led to a greater 
reduction in weight in all six studies and the 
difference was statistically significant in five studies 
reporting a statistical comparison. In the two RCTs 
that reported outcomes at two years, mean per cent 
initial weight loss in the surgical groups was 20% 
and 21.6%, whereas the non-surgical groups had 
lost only 1.4% and 5.5% of their initial weight. 
In the two cohort studies reporting outcomes at 
two years, per cent weight change ranged from 
a weight loss of 16% to 28.6% in the surgical 
groups, but the non-surgical groups had gained 
weight with per cent weight change ranging from 
0.1 to 0.5%. A large prospective cohort study 
[Swedish Obese Subjects (SOS) study] found that 
weight loss was still apparent 10 years following 
surgery, whereas patients receiving conventional 
treatment had gained weight. One RCT and one 
of two cohort studies assessing QoL found greater, 
and statistically significant, improvements after 
surgery on some measures, but not others. Two 
RCTs found that significantly fewer people had 
metabolic syndrome in the surgical group, and 
one found significantly higher remission of Type 2 
diabetes following surgery. The SOS study found a 
statistically significant reduction in the incidence of 
three out of six comorbidities assessed at 10 years 
follow-up after surgery compared with conventional 
therapy. 
Comparison of surgical procedures
Of the available surgical options assessed by RCTs 
there is evidence that GBP is more effective for 
weight loss than vertical banded gastroplasty (VBG) 
and AGB. Five of the seven included RCTs reported 
greater weight loss following GBP than VBG with 
per cent excess weight loss at one year ranging 
between 62.9% and 78.3% for GBP, and ranging 
between 43% and 62.9% for VBG. In two studies 
there was no statistically significant difference in 
‘success rate’ or ‘per cent ideal body weight’. One 
RCT found per cent excess weight loss of 66.6% 
was significantly greater up to five years following 
laparoscopic GBP than following laparoscopic 
AGB, which led to per cent excess weight loss of 
47.5% (p < 0.001). Evidence from one RCT shows 
laparoscopic isolated sleeve gastrectomy to be more 
effective than AGB with greater excess weight loss 
up to three years (median per cent excess weight 
loss 66% versus 48%, p = 0.0025). GBP and banded 
GBP led to similar weight loss up to 24 months 
follow-up among patients with BMI > 50 (57.2% 
and 64.2%, p = ns) in the single RCT making this 
comparison. Comparisons of GBP and laparoscopic 
sleeve gastrectomy (LSG), and of VBG and AGB 
produced equivocal results. One RCT found 
slightly greater per cent excess weight loss with LSG DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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(69.7%) than GBP (60.5%, p = 0.05) at 12 months, 
but no statistically significant difference in mean 
BMI or mean weight loss. Three RCTs found that 
measures of weight loss at one year follow-up 
favoured VBG over AGB, but longer-term results 
were conflicting. All the comparisons of open 
versus laparoscopic surgeries (GBP four RCTs; VBG 
one RCT; AGB one1 RCT) found that both groups 
lost similar amounts of weight. 
QoL was assessed by only two RCTs. One RCT 
found that QoL was significantly better following 
GBP than VBG on some items. The other found 
that there was no significant difference in QoL 
following either open or laparoscopic GBP.
Changes in comorbidities after surgery were 
assessed by five of the 20 RCTs. In general, 
comorbidities improved in all groups with no 
significant differences in improvements observed 
between different surgical interventions.
Adverse events
The extent of reporting of adverse events varied 
between studies; few were compared statistically 
and none were powered to do so. Fourteen RCTs 
reported no deaths. Where deaths were reported 
separately for each RCT trial arm, mortality 
ranged from 2% (1/51 patients receiving Open 
GBP within the first 30 postoperative days) to 10% 
(2/20 patients receiving Open GBP, one on the 
fourth postoperative day, one after 13 months). 
The large SOS study reported mortality of 0.25% in 
the surgical cohort (5/2010 patients within 90 days 
of surgery). Adverse events from conventional 
therapy included intolerance to medication, 
acute cholecystitis and gastrointestinal problems. 
Major adverse events following surgery, some 
necessitating reoperation, included anastomosis 
leakage, pneumonia, pulmonary embolism, band 
slippage and band erosion. 
Summary of cost-effectiveness 
All modelled economic evaluations assessed 
in this report found that bariatric surgery was 
cost-effective in comparison to non-surgical 
treatment although the variability in estimates 
of costs and outcomes is large. The results of the 
economic evaluation alongside a clinical trial were 
inconclusive. However, because of the numerous 
methodological shortcomings and some poorly 
justified modelling assumptions the reported 
results are unlikely to be reliable and generalisable 
estimates of the incremental cost-effectiveness of 
bariatric surgery in comparison to non-surgical 
treatment.
Summary of economic model 
Surgical management with GBP or AGB of morbid 
obesity (BMI > 40) was more costly than non-
surgical management, but results in improved 
outcomes (in terms of QALYs) over the modelled 
20-year time horizon. The incremental cost-
effectiveness ratios (ICERs) ranged between 
£2000 and £4000 per QALY gained. The results 
were generally robust to changes in assumptions 
in the deterministic sensitivity analysis, and in 
all cases the ICERs remained within the range 
conventionally regarded as cost-effective from an 
NHS decision-making perspective.
Surgical management (with AGB) of moderate 
to severe obesity (BMI ≥ 30 and < 40) in patients 
with Type 2 diabetes was more costly than non-
surgical management, but resulted in improved 
outcomes. The ICER reduced with a longer time 
horizon from £18,930 at two years to £1367 at 
20 years. The results were generally robust to 
changes in assumptions in the deterministic 
sensitivity analysis. In the probabilistic sensitivity 
analysis the probability of surgical management 
being cost-effective (compared with non-surgical 
management) was 2.5% at a willingness-to-pay 
threshold of £20,000 per QALY and 50.6% at a 
willingness-to-pay threshold of £30,000 per QALY, 
for a two-year time horizon, and was 100% at both 
thresholds, for a 20-year time horizon.
Surgical management (with AGB) of moderate 
obesity (BMI ≥ 30 and < 35) was estimated to 
be more costly than non-surgical management, 
but resulted in improved outcomes, though 
the QALY gain at two years is small (0.08). The 
ICER reduced with a longer time horizon from 
£60,754 at two years to £12,763 at 20 years. There 
was considerable variability in results, in the 
deterministic sensitivity analysis, with ICERs above 
the range conventionally deemed acceptable in 
some scenarios even for longer time horizons. In 
the probabilistic sensitivity analysis the probability 
of surgical management being cost-effective 
(compared with an intensive medical programme) 
was 64% at a willingness-to-pay threshold of 
£20,000 per QALY and 98% at a willingness-to-pay 
threshold of £30,000 per QALY with a 20-year time 
horizon. In contrast, for a two-year time horizon, 
the probability of surgical management being cost-
effective was zero at both thresholds.Executive summary
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Conclusions 
Bariatric surgery appears to be a clinically effective 
and cost-effective intervention for moderately to 
severely obese people compared with non-surgical 
interventions. Uncertainties remain and further 
research is required, including:
•	 good-quality, long-term RCTs and cohort 
studies to provide detailed data on:
  – patient QoL to inform on the gains in 
utility associated with reduction in BMI
  – impact of surgeon experience on outcome 
of surgery
  – late complications leading to reoperation
  – more than one weight outcome measure 
with standard deviation about the mean 
reported to enable future meta-analysis
  – duration of remission of comorbidities and 
factors affecting this
  – resource use across the entire patient 
pathway to develop robust costings 
•	 good-quality RCTs to provide evidence on 
bariatric surgery for young people and for 
adults with class I or class II obesity. New 
research must report on the resolution and/or 
development of comorbidities such as Type 2 
diabetes and hypertension so that the potential 
benefits of early intervention can be assessed.
•	 A core set of important adverse bariatric 
surgery outcomes should be identified so that 
a standardised approach to describing adverse 
outcomes can be developed and their impacts 
on patients’ QoL determined.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
1
Description of 
health problem 
Aetiology (cause of disease)
The development of obesity, at a simple level, 
occurs when energy taken into the body as food 
exceeds the amount of energy expended by the 
body. However, in reality, obesity is the outcome 
of a heterogeneous collection of disorders arising 
from a number of different causes. There is a 
complex interplay between genetic,1 biochemical, 
neural and psychological factors, and external 
aspects such as environmental, social and economic 
factors.2 
Natural history
Overweight and obesity are defined as abnormal 
or excessive fat accumulation that may impair 
health. However, the natural history of weight gain 
over time and progression to the development of 
overweight, obesity or morbid obesity have not 
been well documented. Some people are able to 
maintain a healthy weight throughout their life, 
but others will be at risk for weight gain. The age 
of onset and rate of progression of weight gain 
varies between individuals. Longitudinal studies 
have shown that age, sex and ethnicity are key risk 
factors for weight gain.3–5 Such studies also suggest 
that, without intervention, reversal of overweight 
and obesity is uncommon.4,6
Classification (measurement 
of disease)
The most commonly used measure for classifying 
overweight and obesity is the Body Mass Index 
(BMI). This is a simple index of weight-for-height 
that is defined as the weight in kilograms divided 
by the square of the height in metres (kg/m2). In 
adults overweight is most commonly defined as a 
BMI of 25 or over, obesity as a BMI of 30 or over, 
and severe or morbid obesity as a BMI of 40 or 
over (Table 1).7,8 BMI (adjusted for age and gender) 
is also recommended by the National Institute for 
Health and Clinical Excellence (NICE) guideline 
on obesity9 as a practical estimate of overweight 
in children and young people, but the guideline 
points out that this needs to be interpreted with 
caution because it is not a direct measure of 
adiposity (the amount of body fat). For children 
and young people, overweight and obesity are 
not defined according to a particular BMI. The 
NICE obesity guideline recommends instead that 
tailored clinical intervention should be considered 
for children with a BMI at or above the 91st 
centile and assessment of comorbidity should be 
considered for children with a BMI at or above the 
98th centile.
Epidemiology 
Incidence
There is a large body of work reporting on the 
prevalence of obesity (see below), but much less 
information regarding the incidence of obesity. 
The published information regarding the incidence 
of obesity relates to the USA and Sweden, but no 
information has been found that is specific for the 
UK.
Adults
A recent study10 evaluated trends in the incidence 
of overweight and obesity in the USA from 1950 
to 2000 using data from the Framingham study 
participants. The results indicated that the overall 
incidence rates of overweight increased twofold, 
and that of obesity more than threefold over five 
decades. Per decade, there was an increase in the 
incidence of overweight of 25% in women and 20% 
in men. The corresponding per decade increases 
in women and men were 34% and 29% for the 
incidence of obesity, and 31% and 97% for the 
incidence of class II obesity.
A second study has compared trends in the 
incidence of overweight and obesity in a rural 
population from Sweden, and one from the USA 
between 1989 and 1999.11 The 10-year incidence 
of overweight was similar in the two countries 
(337/1000 in Sweden, 336/1000 in the USA). 
However, the 10-year incidence of obesity was 
greater in the USA (173/1000) where 21.3% were 
obese in 1989 rising to 32.3% in 1999, than in 
Sweden (120/1000) where the prevalence of obesity 
was lower at both time points (9.6% in 1989 and 
18.4% in 1999).
Chapter 1 
Background Background
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TABLE 1  The international classification of adult underweight, overweight and obesity according to BMI7,8
Classification BMI Risk of comorbidities
Underweight < 18.5 Low (but risk of other clinical problems increased)
Normal range 18.50–24.99 Average
Overweight ≥ 25.00
Preobese 25.00–29.99 Increased
Obese ≥ 30.00
Obese class I 30.00–34.99 Moderate
Obese class II 35.00–39.99 Severe
Obese class III 
(morbid obesity)a
≥ 40.00 Very severe
BMI, body mass index.
a  When BMI is over 50 this is sometimes referred to as ‘super-obesity’.
Adolescents and children
Calculating the incidence of overweight or 
obesity in adolescents and children is particularly 
problematic. For adolescents who are approaching 
adulthood the difficulty lies in ensuring that 
the data sets employed in the study have used 
a definition of obesity that is comparable for 
the age groups of interest. Gordon-Larsen and 
colleagues6 have used data from a longitudinal, 
nationally representative, school-based study of US 
adolescents and estimated that obesity incidence 
over the five-year study period was 12.7%. In 
contrast, fewer than 2% of the total sample of 
young adults who were obese as adolescents 
became non-obese.
The generalisability of the findings reported above 
to adults and children in the UK is unknown.
Prevalence
Adults
The World Health Organization (WHO)'s 
projections indicated that globally in 2005 
approximately 1.6 billion adults (age 15 +) were 
overweight and at least 400 million adults were 
obese.12 In England in 2006 the prevalence of 
overweight in people aged 16 and over was 38% 
(approximately 15.4 million people), with 24% 
obese (approximately 9.8 million people).13 In 
Wales in 2007, 57% of adults were classified as 
overweight or obese, including 21% obese.14 
The prevalence of obesity (BMI > 30) among 
adults in England and Wales is increasing. In 
2006 reported obesity prevalence in England was 
23.7% for men and 24.2% for women. The increase 
was clear when the 2006 figures are compared 
with those for 1998 which were 17.3% for men 
and 21.2% for women.15 The 2006 prevalence of 
morbid obesity (BMI > 40)16 was 2.1% (just under 
863,000 people) with women being more likely 
to be morbidly obese than men (2.7% of women 
versus 1.5% of men). In comparison, the 1998 
figures for morbid obesity were 0.6% for men and 
1.9% for women. For a standard primary-care trust 
(PCT) population of 250,000, there would be 5250 
cases of morbid obesity (based on the overall 2006 
population value for England of 2.1% morbid 
obesity).
Prevalence of obesity increases with age, until 
age 55–64 years in men and until age 65–74 years 
in women, when it begins to decline16 (Table 2). 
The number of men and women with obesity in 
England is shown in Table 3.17,18 Obesity in women 
is more common in households where the current 
or former occupation of the household reference 
person is classified as routine and manual than 
in those households classified as intermediate, or 
managerial and professional (Table 4).16 For morbid 
obesity in women the prevalence was 1.6% in 
managerial and professional households, but 4.0% 
in routine and manual households. Differences 
for men by category based on occupation was less 
marked.16 Data from the Welsh Health Survey 
also indicate a rise in obesity among people aged 
16 years and over from 18% in 2003–4 to 19% in 
2005–6.19
The prevalence of obesity is predicted to rise in 
the future. WHO has projected that by 2015 more 
than 700 million adults will be obese. In the UK, 
the Foresight programme provides visions of the 
future using science-based methods. The Foresight 
project ‘Tackling Obesities: Future Choices’ 
produced a report made up of a number of DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 2  BMI among adults by age and gender 200616
Age (years)
Total 16–24 25–34 35–44 45–54 55–64 65–74 75 +
% % % % % % % %
Men
Underweight 5.5 0.2 0.4 0.1 0.5 0.4 0.6 1.2
Normal 60.8 37.7 26.5 23.7 19.9 19.2 30.5 31.7
Overweight 24.7 41.3 48.1 48.1 46.6 49.4 51.0 43.4
Obese 9.0 20.7 25.0 28.1 33.0 31.1 17.8 23.7
Overweight including obese 33.7 62.0 73.1 76.2 79.6 80.4 68.8 67.1
Morbidly obese 0.9 1.1 1.6 1.7 2.7 1.2 0.2 1.5
Mean BMI 24.1 26.7 27.8 28.0 28.6 28.3 27.0 27.2
Women
Underweight 6.5 2.2 1.0 0.7 1.2 1.3 2.3 2.1
Normal 61.8 50.3 45.2 36.9 33.0 26.5 28.7 41.8
Overweight 19.7 29.2 30.1 35.2 35.7 37.5 41.6 31.9
Obese 12.0 18.2 23.7 27.2 30.2 34.7 27.4 24.2
Overweight including obese 31.7 47.5 53.8 62.4 65.9 72.2 69.0 56.1
Morbidly obese 1.4 2.0 3.1 3.1 3.4 3.6 1.6 2.7
Mean BMI 24.0 25.9 26.8 27.6 28.0 28.6 27.5 26.8
BMI, body mass index.
TABLE 3  Numbers with obesity by age and sex in England 200317,18
Age (years)
16–34 35–54 55–74 75 + Total
Men
Overweight 2,066,211 3,281,310 2,349,520 706,323 8,403,365
Obese 851,769 1,848,110 1,305,710 296,998 4,302,588
Overweight including obese 2,917,981 5,129,420 3,655,231 1,003,321 12,705,953
Women
Overweight 1,470,007 2,329,645 2,021,398 951,706 6,772,757
Obese 980,440 1,695,650 1,455,904 622,087 4,754,080
Overweight including obese 2,450,447 4,025,295 3,477,302 1,573,793 11,526,837
Numbers represent the estimated number of people within each age group who are either overweight, obese or 
overweight including obese.
documents which forms a long-term vision of how 
a sustainable response to obesity can be delivered 
in the UK over the next 40 years. The modelling 
section of the Foresight Report predicts that in 
England, if current trends persist, 36% of men 
and 28% of women aged 21 to 60 will be obese in 
2015.20 Predicting trends in morbid obesity is more 
problematic. The Foresight modelling projection 
to 2050 suggests figures of 1% for males and 4% 
for females.20 In contrast a different Foresight 
project output has estimated that the proportion 
of morbidly obese English males and females will 
reach nearly 3% and 6%, respectively, in 2030.21 Background
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TABLE 4  BMI by age and gender classified by occupation of the head of the household England 200316
Men Women
BMI
Occupation of head of householda Occupation of head of household
All 
adults 
(%)
Managerial 
and 
professional 
(%)
Intermediate 
(%)
Routine 
and 
manual 
(%)
All 
adults 
(%)
Managerial 
and 
professional 
(%)
Intermediate 
(%)
Routine 
and 
manual 
(%)
Underweight 1.4 1.3 0.6 1.9 2.1 2.1 1.3 2.3
Normal 33.2 32.1 33.0 34.6 42.3 48.1 43.0 36.2
Overweight 43.2 45.8 42.3 40.8 32.6 31.1 36.1 32.5
Obese 21.2 20.2 22.9 21.6 20.1 17.0 17.0 25.0
Morbidly 
obese
1.0 0.7 1.2 1.1 2.9 1.6 2.6 4.0
Overweight 
including 
obese
65.4 66.6 66.4 63.5 56.0 49.8 55.7 61.5
BMI, body mass index.
a  Categories based on the current or last job of the household reference person. Where that person was a full-time 
student, had an inadequately described occupation, had never worked or was long-term unemployed they are included in 
the All adults column.
Children
As noted, overweight and obesity in children 
and young people are not defined according 
to a particular BMI. This means that varying 
prevalences of overweight and obesity in children 
and young people will be obtained depending on 
the particular definitions used.22 This not only 
makes it difficult to obtain an accurate prevalence 
estimate, but also creates problems when trying 
to compare prevalences reported by studies 
employing different definitions. The NICE obesity 
guideline states that BMI measurement in children 
and young people should be related to the UK 
1990 BMI charts to give age- and gender-specific 
information.9
Despite the difficulties in assessing the prevalence 
of overweight and obesity in children and young 
people there is general agreement that these are 
increasing. The National Statistics for England16 
report that between 1995 and 2005 the proportion 
of boys aged 2 to 15 years who were obese increased 
from 10.9% to 18.3%. For girls a similar pattern 
was seen with the proportion of obese 2–15-year-
olds increasing from 12.0% in 1995 to 18.3% in 
2005 (Table 5). In the 11–15 years age group the 
prevalence of obesity in 2005 was very similar in 
boys and girls at 20.4% and 20.8% respectively. In 
general the proportion of children who are obese 
increases with age until age 13–15 (Table 6).16 These 
prevalence figures were derived using the UK 
National BMI percentile classification to describe 
childhood overweight and obesity. This uses a 
BMI threshold for each age above which a child is 
considered overweight or obese. The classification 
estimates were produced by calculating the 
percentage of boys and girls who were over the 
85th (overweight) or 95th (obese) BMI percentiles 
based on the 1990 UK reference population.
Impact of health problem
Obesity can have a variety of adverse health 
consequences including a risk of death. An 
increased risk of health problems starts when 
someone is only very slightly overweight, and the 
likelihood of adverse health consequences increases 
as someone becomes progressively more overweight 
and obese.12 The risks of obesity also apply to 
children as childhood obesity is associated with a 
higher chance of premature death and disability in 
adulthood.12 The health consequences associated 
with obesity, such as those listed in Table 7, impose 
a considerable economic burden on society.
Health risks of overweight and obesity
The current NICE guideline on obesity9 
recommends that the assessment of the health risks 
associated with overweight and obesity in adults 
should be based on BMI and waist circumference 
(Table 8). The proportion of English men and 
women who fall into different health risk categories DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 5  Overweight and obesity prevalence among children in England by age and gender for 1995 and 200516
Overweight Obese Overweight including obese
1995 2005a 1995 2005a 1995 2005a
Boys
Aged 2–10 12.9 16.1 9.6 16.9 22.5 33.0
Aged 11–15 13.4 15.0 13.5 20.4 26.9 35.3
Aged 2–15 13.1 15.7 10.9 18.3 24.0 33.9
Girls
Aged 2–10 12.6 12.2 10.3 16.8 22.9 29.0
Aged 11–15 13.9 14.1 15.4 20.8 29.3 34.9
Aged 2–15 13.1 12.9 12.0 18.3 25.0 31.2
a  From 2003 data were weighted for non-response.
TABLE 6  Obesity prevalence by age16
2002–2004a
Age (years)
Obese 
%
Overweight including obese 
%
2–3 11.6 25.2
4–5 12.8 27.2
6–7 13.5 26.7
8–10 18.7 31.8
11–12 22.0 37.6
13–15 19.5 34.1
a  Data aggregated over three years to achieve a sufficiently large sample for analysis at this level.
as defined in the NICE guidelines have been 
estimated by the National Statistics Information 
Centre (Table 9).16
Health consequences of 
overweight and obesity
The counterweight program, which has been 
developed and evaluated to be an effective model 
for obesity management with general practice in 
the UK, undertook a cross-sectional survey of the 
records of 6150 obese adults. It found that obese 
patients made significantly more visits to their 
general practitioner (GP), practice nurse and 
hospital outpatient departments than patients 
classified as normal weight, even after adjustments 
had been made for confounding factors.23 Over 
the last 10 years there were 17,458 Finished 
Consultant Episodes with a primary diagnosis of 
obesity. Almost a quarter of these (4068) occurred 
in 2006–7.16 
Health consequences in adults
The predominant serious health consequences 
associated with overweight and obesity in 
adults include Type 2 diabetes, cardiovascular 
disease (CVD) (mainly heart disease and stroke), 
musculoskeletal disorders such as osteoarthritis, 
and certain cancers (Table 7) and are discussed 
in more detail below. As indicated in Table 8 and 
Table 9 the risk of serious health consequences 
increases with increasing obesity (greater detail is 
provided in Chapter 5, Data sources, Effectiveness 
data). Some of these health consequences may 
constitute the principal cause of death, e.g. heart 
disease, stroke, some cancers; whereas, others 
such as Type 2 diabetes lead to a reduced life 
expectancy. Other important health consequences 
that have a negative impact on quality of life (QoL) 
are obstructive sleep apnoea, infertility, obstetric 
complications and psychiatric comorbidity.Background
6
TABLE 7  Estimated increased risk for the obese of developing obesity-associated diseases
Disease
Relative riska – women 
(England)24
Relative riska – men 
(England)24
WHO estimate of increased 
risk (men and women 
worldwide)8
Type 2 diabetes 12.7 5.2 Greatly increased
Dyslipidaemia – – Greatly increased
Insulin resistance – – Greatly increased
Breathlessness – – Greatly increased
Sleep apnoea – – Greatly increased
Cardiovascular disease – – Moderately increased
Myocardial infarction 3.2 1.5
Angina 1.8 1.8
Stroke 1.3 1.3
Hypertension 4.2 2.6 Moderately increased
Cancer of the colon 2.7 3.0 Slightly increased
Gall bladder diseases 1.8 1.8 Greatly increased
Osteoarthritis 1.4 1.9 Moderately increased (knees)
Hyperuricaemia and gout – – Moderately increased
Ovarian cancer 1.7 –
Breast cancer in postmenopausal 
women
– – Slightly increased
Endometrial cancer – – Slightly increased
Reproductive hormone 
abnormalities
– – Slightly increased
Polycystic ovary syndrome – – Slightly increased
Impaired fertility – – Slightly increased
Fetal defects associated with 
maternal obesity
– – Slightly increased
Low back pain due to obesity – – Slightly increased
Risk of anaesthesia complications – – Slightly increased
WHO, World Health Organization.
a  All relative-risk values are approximate.
The WHO finds that the relative risks of particular 
disease in obese people, compared with lean 
people, are fairly similar throughout the world and 
have classified these into three broad categories: 
greatly increased risk (relative risk much greater 
than 3); moderately increased risk (relative risk 
2–3); and slightly increased risk (relative risk 1–2) 
(Table 7).8 The best estimates of the increased 
disease risk due to obesity for the English 
population were calculated from international 
studies by the National Audit Office24 for a number 
of these conditions and these risk estimates are 
also shown alongside the WHO estimates in Table 
7. Although the results should be interpreted with 
some caution (some studies that contributed data 
used an alternative cut-off point for obesity instead 
of the widely used definition of a BMI of 30 or 
above) they do provide a broad indication of the 
strength of the association between obesity and 
disease.
Increased mortality
Obesity significantly increases the risk of mortality 
at any given age (including after adjustment for 
other risk factors such as smoking) and those who 
have been overweight for the longest are at the 
highest risk. The National Audit Office (NAO) has 
reported that evidence from studies suggests that 
young adults with a BMI of 30 have a mortality 
risk that is about 50% higher than that of a young 
adult with a healthy BMI (18.5–25).24 For a young 
adult with a BMI of 35 the mortality risk is more 
than doubled. One study reported that 40-year-old 
obese (BMI greater than or equal to 30) women DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 8  NICE guideline recommendation for the assessment of health risks associated with overweight and obesity9
Waist circumference
BMI classification 
Overweight Obesity Ia
Low
Men < 94 cm; Women < 80 cm
No increased risk  Increased risk
High
Men 94–102 cm; Women 80–88 cm
Increased risk  High risk
Very high
Men > 102 cm; Women > 88 cm
High risk Very high risk
BMI, body mass index
a  As defined in Table 1.
TABLE 9  Percentage of adults within each health-risk category associated with overweight and obesity in adults by gender 200616
Men Women
Over-
weight
Obesity 
I
Obesity 
II
Obesity 
III All 
Over-
weight
Obesity 
I
Obesity 
II
Obesity 
III All 
No increased 
risk
13 45 4 45
Increased 
risk
19 0 20 12 0 14
High risk 11 3 13 15 1 16
Very high risk 15 4 1 21 14 6 3 23
Grey shading indicates that health-risk category does not apply at this level of overweight or obesity, e.g. people who are 
overweight and have a very high waist circumference measurement do not fall into the very high health-risk category (as 
shown in Table 8), and those with the lowest waist circumference measurement and class I obesity have an increased health 
risk (therefore the ‘No increased health risk’ category is not applicable).
and men lost 7.1 and 5.8 years of life, respectively, 
compared with 40-year-old non-smoking women 
and men of normal weight.25 In 2004, a House of 
Commons Select Committee report estimated that 
6.8% of all deaths in England were attributable to 
obesity.26
Type 2 diabetes
Type 2 diabetes is the most common form 
of diabetes, accounting for over 90% of all 
diabetes in the UK.13 It is characterised by 
insulin resistance and is a serious life-shortening 
condition. The ‘first-line’ treatment is diet, weight 
control and physical activity but drug therapy, 
e.g. with metformin, sulphonylurea drugs, 
thiazolidinediones (commonly called glitazones), 
or insulin therapy may become necessary. The risk 
of developing diabetes rises with increasing BMI 
even below the threshold of clinical obesity. The 
Health Survey for England (HSE) data have been 
used to examine the association between a number 
of risk factors and Type 2 diabetes in adults aged 
35 years and over. Men and women who were obese 
had approximately double the odds of having Type 
2 diabetes compared with those who had a BMI 
of less than 25 (after adjusting for other factors). 
A raised waist circumference was also linked to 
increased odds of having Type 2 diabetes, in men 
the odds were doubled, whereas women with a 
raised waist circumference were four times more 
likely to have Type 2 diabetes than those without a 
raised waist circumference measurement.13
Cardiovascular disease 
and CVD risk factors
The term CVD encompasses ischaemic heart 
disease (IHD) [also known as coronary heart 
disease (CHD)], stroke and peripheral vascular 
disease. Obesity is an independent risk factor for 
CVD. Data from the HSE 200317 demonstrate 
that a relationship between IHD and BMI is 
present in men and women. The prevalence of Background
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IHD or stroke was lowest among people with 
a normal BMI, but increased for people in the 
overweight category and was highest among obese 
women and men. However, in women, the higher 
prevalence in the obese was no longer significant 
following age standardisation (Table 10). A raised 
waist circumference is also linked to an increased 
prevalence of CVD in men and women.
Hypertension is a key risk factor for CVD and 
the positive association between blood pressure 
and BMI is well documented. Data from the HSE 
200317 shows that overweight men and women 
(BMI between 25 to less than 30) and obese men 
and women (BMI 30 or more) both have a higher 
blood pressure than those with a normal BMI 
(Table 11). The link between high blood pressure 
and obesity was also observed during the HSE 
2005 which focused on people aged 65 years and 
over.27 In this age group hypertension was twice 
as common in obese men and women, and more 
prevalent in overweight women, compared with 
those with a weight in the normal range.
Abnormalities in serum lipid levels [raised 
total cholesterol, triglycerides and low-density 
lipoprotein (LDL), with reduced high-density 
lipoprotein (HDL)] are a further risk factor 
for CVD. The National Health and Nutrition 
Examination Survey (NHANES) III28 found that 
the prevalence of raised cholesterol (≥ 240 mg/
dl) in obese men and women was 22% and 27%, 
respectively, compared with 13% of adults with 
BMI < 25. HDL-cholesterol decreased with 
increasing BMI. The prevalence of low HDL-
cholesterol (< 35 mg/dl men, < 45 mg/dl women) in 
obese adults was 31% of men and 41% of women 
compared with 9% and 17%, respectively, in adults 
with desirable weight. A more recent publication 
employing data from the survey of health, ageing 
and retirement in Europe (SHARE) also found 
that the odds ratios for high cholesterol were 
significantly increased for overweight and obese 
adults.29
Cancer
A systematic review and meta-analysis of 
prospective observational studies reported that 
in men, a 5 kg/m² increase in BMI was strongly 
associated with oesophageal adenocarcinoma 
[relative risk (RR) 1·52, p < 0·0001] as well as 
thyroid (1·33, p = 0·02), colon (1·24, p < 0·0001) 
and renal (1·24, p < 0·0001) cancers. For 
women, the strong associations were between 
a 5 kg/m² increase in BMI and endometrial 
(1·59, p < 0·0001), gall bladder (1·59, p = 0.04), 
oesophageal adenocarcinoma (1·51, p < 0·0001) 
and renal (1·34, p < 0·0001) cancers. There were 
also weaker positive associations between increased 
BMI and some other cancers in both men and 
women.30 As health risks increase with increasing 
obesity, increases in BMI greater than 5 kg/m² may 
be associated with greater cancer risks.
A study assessing the cost of obesity to the UK 
estimated that the cancers with some relationship 
with overweight and obesity (breast cancer, colon/
rectum cancer and corpus uteri cancer) were 
responsible for 6.2% of all mortality.31
TABLE 10  Relationship between BMI and ischaemic disease17
Observed prevalence 2003 Age-standardised prevalence 2003
Any CVD (%) IHD or stroke Any CVD (%) IHD or stroke
Men
Normal range 10 4 10 5
Overweight 14 8 11 6
Obese 17 10 13 8
Women
Normal range 10 3 11 4
Overweight 13 6 12 5
Obese 16 7 14 6
BMI, body mass index; CVD, cardiovascular disease; IHD, ischaemic heart disease.
Normal range = BMI over 18.5–25, overweight = BMI over 25–30, obese = BMI over 30DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 11  Relationship between overweight or obesity and blood pressure in men and women17
Difference from the reference category 
mmHg (95% CI)
Men
Reference category: normal range 0
Overweight 2.86 (1.15 to 4.21)
Obese 6.22 (4.71 to 7.73)
Women
Reference category: normal range 0
Overweight 3.32 (2.29 to 4.34)
Obese 6.02 (4.76 to 7.29)
BMI, body mass index; CI, confidence interval.
Normal range = BMI over 18.5 to 25, overweight = BMI over 25 to 30, obese = BMI over 30.
Osteoarthritis
Osteoarthritis, or degenerative disease of the 
knee and other weight-bearing joints, and lower 
back pain are common in obesity. Some effects are 
thought to be the result of excess weight; BMI has 
been associated with the incidence and progression 
of knee osteoarthritis, but not associated with the 
incidence and progression of hip osteoarthritis. 
However, it has also been postulated that some 
obesity-related osteoarthritis may be the result 
of a metabolic effect.32,33 Whatever the cause, an 
estimated 27% of hip replacements and 69% of 
knee replacements in middle-aged women in the 
UK are attributable to obesity.34 
Respiratory disorders
Respiratory disorders such as obstructive sleep 
apnoea are associated with obesity. It has been 
estimated that approximately 17% of adults aged 
30–69 years in the USA have sleep-disordered 
breathing graded as ‘mild or worse’ and it is 
further estimated that in 41% of these adults 
their sleep-disordered breathing can be attributed 
to having a BMI ≥ 25. The study has similarly 
estimated that 5.7% of adults have sleep-disordered 
breathing graded ‘moderate or worse’ which in 
58% of cases may be attributed to excess weight.35
Reproductive disorders
Reproductive disorders are common in obesity, 
occurring in both women and men. Cohort studies 
have identified obese women as having a higher 
risk of complications during pregnancy, such as 
pregnancy-induced hypertension, antepartum 
venous thromboembolism, induction of labour, 
caesarean delivery and wound infection, pre-
eclampsia, premature labour, gestational diabetes 
and macrosomia (large-for-date fetuses).36–40 Some 
studies have found evidence for an increased risk 
of adverse pregnancy outcomes such as perinatal 
death,41 but others have not found evidence for an 
increased risk.38
Health consequences in 
children and young people
Overweight and obese children and young people 
are at high risk of developing comorbidities, 
either while still young, or as they progress into 
adulthood. The current NICE Obesity guideline 
recommends that assessment of comorbidity should 
be considered for children with a BMI at or above 
the 98th centile. 
It is not surprising that studies reporting on the 
health consequences of overweight and obesity in 
children and young people have found many of the 
comorbid conditions described above for adults.42–45 
However, caution should be exercised in applying 
findings from one population to another. One 
recent study aimed to investigate the prevalence 
of comorbidity in a population representative of 
the general obese childhood population in the UK 
and found that the prevalence of abnormal blood 
test results (e.g. for insulin, glucose, triglycerides 
and cholesterol) may be lower than those published 
in the USA and from a UK tertiary referral centre 
(Great Ormond Street, London, UK).46
Other health consequences
There are likely to be a number of other potential 
health consequences that have not been mentioned 
above which are associated with overweight and 
obesity but for which, at the moment, there are 
insufficient data to enable the health risks to be Background
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robustly estimated. For example, there is emerging 
evidence that suggests obese people are more 
likely than people of normal weight to develop 
various types of infection, including postoperative 
infections.47
Benefits of weight loss
Although the success of weight loss interventions 
are often expressed in terms of the amount 
of weight lost, improvements in QoL and 
comorbidities are generally a more meaningful 
indication of success for individuals.48–50 A 
systematic review of the long-term effects of obesity 
treatments on body weight, risk factors for disease 
and disease51 found that weight loss from surgical 
and non-surgical interventions for people suffering 
from obesity was associated with decreased risk of 
development of diabetes, and a reduction in LDL-
cholesterol, total cholesterol and blood pressure, 
in the long term. The effects of bariatric (weight 
loss) surgery on weight and Type 2 diabetes have 
also been reviewed.52 The authors reported that 
bariatric surgery not only led to weight reduction, 
but also that preoperative diabetes resolved 
postsurgery in more than 75% of cases. A further 
systematic review of the long-term weight loss 
effects on all-cause mortality in overweight/
obese populations53 concludes that there is some 
evidence that intentional weight loss has long-
term benefits on all-cause mortality for women 
and more so for people with diabetes. However, 
the long-term effects for men are not clear. Weight 
loss in obese patients with knee osteoarthritis has 
also been systematically reviewed and the results 
of meta-analysis indicated that disability could be 
significantly improved when weight was reduced 
over 5.1%, or at the rate of > 0.24% reduction per 
week.54 Weight loss has not been found to have a 
beneficial effect on risk of stroke.55
Adverse effects of weight loss
It is important that obese patients are made 
aware of the potential adverse effects of weight 
loss so that they can come to a judgement about 
the balance between the risks and benefits of 
the approaches to weight loss that they are 
considering.49,50,56 Not only are adverse effects 
associated with the various pharmaceutical and 
surgical interventions for achieving weight loss, 
but adverse effects are also associated with dietary 
regimens. In particular rapid weight loss is an 
important risk factor for gallstone development, 
there is evidence that obese women who lose 
4–10 kg in weight have a 44% increase in risk of 
gallstones caused by the increase in circulating 
cholesterol.8 However, it has been estimated that 
the incidence of gallstone formation is unchanged 
below rates of weight loss of 1.5 kg per week.57 
Weight loss may also decrease bone density.8 
Contradictory evidence has been published with 
regard to the effect of weight loss and mortality. A 
recent review of the evidence has suggested that 
the impact of weight loss may be gender specific, 
there was some evidence for long-term benefits on 
mortality in women, but the long-term effects for 
men were not clear.53
Current service provision 
Management of disease 
Non-surgical interventions are the cornerstone of 
overweight and obesity treatment. The intensity 
of management for overweight and obesity will 
depend on the level of risk of health problems and 
the potential to gain benefit from weight loss.
Adults 
Management initially takes place within the 
general practice setting provided by the GP 
or practice nurse. As the degree of overweight 
increases, and depending on the presence or 
absence of comorbidities, intensity of management 
should increase to include dietary, physical 
exercise and lifestyle advice. The current NICE 
obesity guideline9 states that multicomponent 
interventions are the treatment of choice. Weight 
management programmes should include 
behaviour change strategies to increase people’s 
physical activity levels or decrease inactivity, 
improve eating behaviour and the quality of the 
person’s diet and reduce energy intake.9 The NICE 
guideline suggests that in adults a prescription for 
drugs for weight control should be considered for 
people who are overweight with obesity-related 
comorbidities (BMI 25.00–29.99) or who meet the 
criteria for class I obesity (BMI 30.00–34.99) with 
obesity-related comorbidities, or who meet the 
criteria for class II obesity (BMI 35.00–39.99). The 
currently approved drugs are orlistat, sibutramine 
and, for obese people who have tried orlistat 
and sibutramine or who are unable to tolerate 
these two drugs, rimonabant. The NICE obesity 
guideline lists the situations when onward referral 
to specialist care should be considered:
•	 the underlying causes of overweight and 
obesity need to be assessed
•	 the person has complex disease states and/or 
needs that cannot be managed adequately in 
either primary or secondary careDOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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•	 conventional treatment has failed in primary or 
secondary care
•	 drug therapy is being considered for a person 
with a BMI more than 50
•	 specialist interventions [such as a very-low-
calorie diet (VLCD) for extended periods] may 
be needed
•	 surgery is being considered.
Surgery is usually considered a last resort 
intervention. NICE obesity guidelines recommend 
bariatric surgery as a treatment option only when 
all of the listed criteria are fulfilled:
•	 the person has a BMI of 40 or more, or a 
BMI between 35 and 40 and other significant 
disease (for example, Type 2 diabetes or high 
blood pressure) that could be improved with 
weight loss
•	 all appropriate non-surgical measures have 
been tried but have failed to achieve or 
maintain adequate, clinically beneficial weight 
loss for at least six months 
•	 the person has been receiving or will receive 
intensive management in a specialist obesity 
service 
•	 the person is generally fit for anaesthesia and 
surgery 
•	 the person commits to the need for long-term 
follow-up. 
The guidelines also recommend bariatric surgery as 
a first-line option (instead of lifestyle interventions 
or drug treatment) for adults with a BMI of 
more than 50 in whom surgical intervention is 
considered appropriate.
Children and young people 
As with adults, management initially takes place 
within the general practice setting provided by 
the GP or practice nurse. The NICE Obesity 
guideline9 indicates that BMI measurement in 
children and young people should be related to 
the UK 1990 BMI charts to give age- and gender-
specific information. A tailored clinical intervention 
should be considered for children with a BMI 
at or above the 91st centile, depending on the 
needs of the individual child and family. NICE 
guidelines do not recommend a dietary approach 
alone for children and young people. Instead 
any dietary recommendations must be part of a 
multicomponent intervention. For children with a 
BMI at or above the 98th centile an assessment of 
comorbidity should be considered.
Referral to an appropriate specialist should be 
considered for children who are overweight or 
obese and have significant comorbidity or complex 
needs (for example, learning or educational 
difficulties). In secondary care, the assessment 
of overweight or obese children and young 
people should include assessment of associated 
comorbidities and possible aetiology. This can 
include investigations of blood pressure, fasting 
lipid profile, fasting insulin and glucose levels and 
liver and endocrine functions.
Orlistat and sibutramine do not have UK 
marketing authorisation for use in children; 
however, the NICE obesity guideline does not 
preclude their use in children. In children younger 
than 12 years, drug treatment may be used only 
in exceptional circumstances, e.g. if severe life-
threatening comorbidities are present, and only 
in specialist paediatric settings. In children 
aged 12 years and older, treatment with orlistat 
or sibutramine may be started in a specialist 
paediatric setting by multidisciplinary teams 
experienced in prescribing for this age group. 
However, treatment is only recommended if 
physical comorbidities or severe psychological 
comorbidities are present. Rimonabant has recently 
been approved by NICE for use in adults when 
certain conditions are met, but it is not approved 
for use in children. 
NICE obesity guidelines do not recommend 
bariatric surgery as a general treatment option 
for obese children and young people. However, 
the guideline acknowledges that there may be 
exceptional circumstances in which bariatric 
surgery can be considered providing the 
young person has achieved, or nearly achieved 
physiological maturity.
Current service cost
A recent study has estimated the direct cost of 
overweight and obesity to the NHS at £3.2 billion.31 
The majority of the costs attributable to overweight 
and obesity were the result of stroke, CHD, 
hypertensive disease and diabetes mellitus. This 
study was based on including people with a BMI of 
22 and above, and because cost estimates are very 
sensitive to the BMI cut-off point chosen, the cost 
estimate from this study is higher than those of 
other studies.
A House of Commons Health Committee report26 
estimated the direct treatment costs of obesity for 
2002 were between £46 million and £49 million. 
The costs included in calculating this estimate 
were those for GP consultations, ordinary 
admissions, day cases, outpatient attendances and Background
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prescriptions. The cost estimate for treating the 
consequences of obesity (comorbidities) in 2002 
was between £945 million and £1075 million. When 
the direct treatment costs and consequences of 
obesity costs were combined the total range for the 
direct costs of treating obesity and its consequences 
for 2002 was £990 to 1225 million (2.3–2.6% of 
net NHS expenditure in 2001–2). These figures 
were based on including people with a BMI of 25 
and over, this is one reason why the estimate may 
be lower than for the more recent study above. 
However, it must be acknowledged that the Health 
Committee report stresses that these figures are 
still likely to underestimate the true cost of treating 
obesity and its consequences.
Relevant national guidelines
Three pieces of guidance with relevance to the UK 
are:
•	 Obesity: the prevention, identification, 
assessment and management of overweight and 
obesity in adults and children. NICE clinical 
guideline 43. Issue date: December 2006.9 
This guideline replaces three earlier pieces 
of NICE guidance [TA22 Obesity – orlistat, 
TA31 Obesity – sibutramine and TA46 Obesity 
(morbid) – surgery] and largely supersedes 
the 2003 Royal College of Physicians report 
‘Anti-obesity drugs. Guidance on appropriate 
prescribing and management’.58
•	 Rimonabant for the treatment of overweight 
and obese patients. NICE Technology 
appraisal. Issue date June 2008.59 NICE has 
temporarily withdrawn its guidance on the use 
of rimonabant for the treatment of overweight 
and obese patients. The withdrawal of this 
guidance follows the decision of the European 
Medicines Agency (EMEA) in October 2008 
to recommend suspension of the marketing 
authorisation for rimonabant. The EMEA 
concluded that the benefits of rimonabant no 
longer outweigh its risks. NICE will continue 
to review the status of its guidance in light of 
any further changes to rimonabant’s marketing 
authorisation.
•	 The Scottish Intercollegiate Guidelines 
Network (SIGN) is in the process of updating it 
guidance on obesity.
Description of technologies 
under assessment 
Surgical procedures for those with obesity aim 
to reduce weight and maintain any loss through 
restriction of intake and/or malabsorption of food. 
It is hoped that as a consequence eating behaviour 
is modified, with patients consuming smaller 
quantities of food more slowly. In addition to 
modifying eating habits, patients are encouraged 
to commit to daily exercise as part of a wider 
change in lifestyle. Surgery for obesity is a major 
surgical intervention with a risk of significant 
early and late morbidity and of perioperative 
mortality. Contraindications for bariatric surgery 
include poor myocardial reserve, significant 
chronic obstructive airways disease or respiratory 
dysfunction, non-compliance of medical treatment 
and psychological disorders of a significant degree.
Before surgery, patients should be made aware of 
the nature of the procedure and how it fits into 
the overall management programme for morbid 
obesity. Particularly important before surgery are 
the preoperative breathing exercises to reduce the 
incidence and severity of postoperative pulmonary 
insufficiency and assessment through spirometry. 
Patients may require antibiotic prophylaxis at 
anaesthesia and prophylactic measures to guard 
against perioperative thromboembolic disease. 
It is rare that patients will require ventilatory 
support and many, particularly if the surgery has 
been conducted laparoscopically, will not require 
intensive care nursing in a high dependency unit.
Several different surgical procedures have been 
used for people with morbid obesity. This review 
will focus on the principal types of surgical 
procedure that are in current use, including 
gastric bypass, gastric banding, biliopancreatic 
diversion and vertical banded gastroplasty. Of the 
procedures in current use gastric bypass and gastric 
banding are much more commonly performed 
than the others. Procedures that are no longer 
practised, such as jejunoileal bypass and horizontal 
gastroplasty, are not considered by this report. The 
following section briefly discusses these procedures 
and their complications. The section does not 
provide a comprehensive discussion of the many 
variants of these procedures that have developed. 
Intragastric balloons are not discussed because 
these are considered a short-term or temporary 
measure and not a comparator for the other 
surgical procedures.
Gastric bypass
The Roux-en-Y and resectional gastric bypass 
procedures combine restriction and malabsorption 
techniques, creating both a small gastric pouch and 
a bypass that prevents the patient from absorbing 
all they have eaten.15 The Roux-en-Y procedure DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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entails partition of the upper part of the stomach 
using surgical staples to create a small pouch (50 ml 
or less) with a small outlet (gastroenterostomy 
stoma) to the intestine that is attached to the 
pouch. The Roux-en-Y technique is used to avoid 
loop gastroenterostomy and the bile reflux that 
may ensue. Adaptations of the procedure include 
lengthening of the Roux-en-Y limb to 100–150 cm 
and use of retrocolic and retrogastric routing of 
the gastrojejunostomy. Often a prosthetic band, 
such as a Silastic ring or Gortex band, is positioned 
above the junction of the gastric pouch and 
small intestine to stabilise the gastroenterostomy, 
preventing late stretching of the opening and 
improving long-term weight control. Banded 
gastric bypass is not undertaken in the UK and 
because there is some disagreement as to whether 
it constitutes a separate procedure it is considered 
separately in this review. It is technically possible to 
reverse a gastric bypass. All patients who undergo 
gastric bypass procedures need long-term vitamin 
B12 replacement and oral iron therapy. Patients 
may be at risk from postgastrectomy bone disease. 
Advice on diet suggests a liquid diet for several 
weeks after the operation and improved eating 
habits involving small meals and multivitamin 
supplementation. Typically gastric bypasses which 
are performed laparoscopically require up to three 
to five days of inpatient stay (the open procedure, 
which is rarely undertaken now, requires a longer 
inpatient stay), with most patients unable to go 
back to work until after one month following 
surgery. 
Complications associated with gastric bypass 
include failure of the staple partition, leaks at the 
junction of the stomach and small intestine, acute 
gastric dilatation, delayed gastric emptying either 
spontaneously or secondary to a blockage of the 
efferent limb. Failures of the staple line have been 
overcome by either transection of the stomach 
(staple line is divided and the cut ends over sewn) 
or superimposed staple rows causing firm scarring 
along the staple line. Other complications may 
occur following surgery including: vomiting caused 
by narrowing of the stoma as the result of scar 
tissue development, correctable through stretching 
by use of an endoscopic balloon dilatation as a day 
case; wound hernias and intestinal obstruction; 
anaemia as a result of lack absorption of iron 
and vitamin B12 and calcium deficiency (all are 
overcome by supplements). Dumping syndrome 
can also occur (an adverse event caused by 
eating refined sugar, symptoms of which include 
rapid heart rate, nausea, tremor, faint feeling 
and diarrhoea). It is thought that the dumping 
syndrome aids weight loss by conditioning the 
patient against eating sweets.
Adjustable gastric banding
Gastric banding is the least invasive of the 
purely restrictive bariatric surgery procedures. 
It limits food intake by placing a constricting 
ring completely around the top end (fundus) of 
the stomach, below the junction of the stomach 
and oesophagus. While early bands were non-
adjustable, those used currently incorporate an 
inflatable balloon within their lining to allow 
adjustment of the size of the stoma to regulate 
food intake. Adjustment is undertaken without 
the need for surgery by adding or removing saline 
through a subcutaneous access port. As a restrictive 
procedure, gastric banding avoids the problems 
associated with malabsorptive techniques. Gastric 
banding is technically a reversible procedure. 
Surgery to fit an adjustable gastric band is typically 
undertaken laparoscopically and involves a short 
hospital stay, usually a maximum of two or three 
days. Following surgery, patients are usually seen 
regularly until they achieve their target weight 
and then on an infrequent basis thereafter. 
Often patients will be advised on nutrition 
postoperatively. 
Complications include those associated with the 
operative procedure, splenic injury, oesophageal 
injury, wound infection, band slippage, band 
erosion (or migration), reservoir deflation/leak, 
persistent vomiting, failure to lose weight and 
acid reflux. Some studies have documented a high 
need for revisional or band-removal surgery as a 
result of complications,60 with major reoperations 
required by over 20% of patients after mean follow-
up periods of about five years.61,62 Expert opinion 
suggests that band failure rate may be greater than 
this, possibly approaching 30%.
Biliopancreatic diversion
Biliopancreatic diversion was first reported in 1978 
by Scopinaro.63 It has become popular in Europe 
and is primarily a malabsorptive procedure. The 
standard procedure involves the removal of part of 
the stomach (a limited horizontal gastrectomy) to 
limit oral intake and induce weight loss. The gastric 
pouch which is created is larger than that of gastric 
bypass or the restrictive procedures therefore 
allowing larger meals, and patients remain on a 
less restricted diet than would be the case following 
gastric bypass. Part of the small intestine is also 
bypassed (the malabsorptive component) by the Background
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construction of a long limb Roux-en-Y anastomosis 
with a short common ‘alimentary’ channel of 50 cm 
length. As the procedure does not defunctionalise 
any part of the small intestine fewer liver problems 
are caused than occurred with jejunoileal bypass 
procedures.64 Biliopancreatic diversion is only a 
partially reversible procedure. The combination 
of biliopancreatic diversion with duodenal switch 
is an additional adaptation of the standard 
procedure. It has a sleeve gastrectomy rather than a 
horizontal gastrectomy. Length of hospital stay for 
biliopancreatic diversion ranges between two and 
seven days.
Biliopancreatic diversion is considered to be 
a technically demanding procedure with an 
operative mortality of 2% and major perioperative 
morbidity of 10%.65 Side effects of the procedure 
include loose stools, stomal ulcers, offensive 
body odour and foul smelling stools and flatus. 
Serious complications include anastomotic leak 
and anastomotic ulceration (3%–10%), protein 
malnutrition (3%–4%), hypoalbuminaemia, 
anaemia (< 5%), oedema, asthenia (lack of energy) 
and alopecia (hair loss).65,66 In some instances 
patients require further hospitalisation and 
hyperalimentation. As a result of malabsorption, 
patients usually need calcium and vitamin 
supplements and lifelong follow-up. In an attempt 
to overcome these complications, particularly 
stomal ulceration and diarrhoea, several variants 
of the procedure have been developed. Sleeve 
resection of the stomach maintains continuity of 
the gastric lesser curve while the duodenal switch 
maintains continuity of the gastroduodeno–jejunal 
axis.
Sleeve gastrectomy
For some patients who are at high risk from 
bariatric surgery a sleeve gastrectomy is considered. 
This is generally seen as the first part of a two-
part surgical procedure, being followed at a later 
date by a conversion to either a gastric bypass or 
a duodenal switch. However, for some, enough 
weight is lost with the sleeve gastrectomy alone. 
The sleeve gastrectomy divides the stomach 
vertically to reduce its size to about 25%. It leaves 
the pyloric valve at the bottom of the stomach 
intact, which means that the stomach function 
remains unaltered and digestion is therefore 
unaltered. After 6–12 months the stomach may 
have expanded and does not restrict intake as 
much, this is when the gastric bypass can then be 
added if necessary. The sleeve gastrectomy is not 
reversible.
Complications are reduced because digestion 
is unaffected; however, patients are at risk 
from leaking from the newly formed stomach 
or vomiting as a result of over-eating. As with 
all surgery, there is a risk from postoperative 
complications such as postoperative bleeding and 
small bowel obstruction. 
This operation is relatively quick to perform, which 
reduces the risk from complications. Hospital stay 
is normally one or two days.
Vertical banded gastroplasty
Vertical banded gastroplasty is now used 
infrequently; however, it has been used in a number 
of studies as the comparator intervention and 
hence is included here. Vertical banded gastroplasty 
partitions the stomach, using surgical staples, to 
create a small segment at the top of the stomach 
which is partially separated from the remainder 
of the stomach, with only a small gap (stoma) 
remaining. In addition, a polypropylene band 
may be used around the lower end of the vertical 
pouch to prevent stretching. The intention is to 
cause the person to have the sensation of fullness 
from a limited intake of food. This procedure has 
the advantage of being a restrictive procedure with 
no malabsorption component or dumping, but 
weight regain is common. The only restrictions 
are that people should chew food thoroughly to 
avoid vomiting and high-calorie liquids should 
be avoided. Vertical banded gastroplasty usually 
requires similar inpatient stay and time to return to 
work as gastric bypass, up to 10 days hospitalisation 
and return to work after at least a month. 
Complications are relatively rare, with a low 
postoperative mortality rate (1%). Revision rates 
requiring further surgical intervention are often 
high at approximately 30%. Specific complications 
include bolus obstruction and there are few 
instances of anaemia or calcium or vitamin 
deficiencies. Other complications associated with 
the operative procedure include leakage, stenosis, 
ulcer, incisional hernia, wound infection, staple-line 
disruption, pouch dilatation and band erosion. 
Laparoscopic versus 
open procedures
Laparoscopic surgery has become a major 
advance for bariatric surgery. The learning curve 
is long, the technique is challenging, and there 
may be differences in open and laparoscopic 
versions of particular procedures. Nevertheless, DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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gastric banding, gastric bypass, vertical banded 
gastroplasty and sleeve gastrectomy procedures 
are increasingly undertaken laparoscopically. 
This decreases the time spent in hospital and the 
recovery time for the patient. In the current review 
comparisons of laparoscopic and open procedures 
have been included. 
Place in the treatment pathway
As noted in the Current service provision section, 
bariatric surgery for morbid obesity is usually only 
considered after patients have attempted other 
forms of weight loss such as behaviour change, 
increased physical activity and drug therapy, but 
without achieving permanent weight loss. The 
exception to this is adults with a BMI of more 
than 50 where NICE guidelines recommend 
bariatric surgery as a first-line option (instead of 
lifestyle interventions or drug treatment) if surgical 
intervention is considered appropriate. The NICE 
guideline indicates that patients being considered 
for surgery should receive intensive management 
in a specialist obesity clinic. These clinics offer 
a combination of interventions, including drug 
therapy, VLCDs and sometimes psychologist 
input as well as surgery. An NAO report24 cites 
an unpublished survey carried out by the NHS 
Clinical Obesity Group in 1998. This identified 12 
obesity clinics in England, eight of which were run 
by physicians and four by surgeons. In addition, 
four physicians and 28 surgeons in England were 
seeing patients for their obesity outside obesity 
clinics. These data are now 10 years out of date 
and expert opinion suggests that there are many 
more specialist obesity clinics now. The British 
Obesity Surgery Patients Association (BOSPA) 
website provides a UK surgery directory which in 
June 2008 listed NHS hospitals in about 50 English 
and Welsh towns and cities where a surgeon can 
be contacted regarding referral for NHS bariatric 
surgery. In addition, contact details are provided 
for surgeons who only undertake private practice 
work.
Following surgery, patients require ongoing dietary 
advice and support. Those who have had an 
adjustable gastric band fitted will need access to a 
band adjustment service.
Current usage in the NHS 
A recent assessment of obesity surgery in England 
between 1996 and 2005 found that the rate of 
obesity surgery had risen from 72 procedures in 
1996 to 347 procedures in 2004 (equivalent to a 
rate of seven per million population).67 Additional 
information68 published alongside the NICE 
obesity guideline included results of a survey of 
surgeons performing bariatric surgery in England 
in 2006 (survey by BariatricEdge, a division of 
Ethicon Endo Surgery: a Johnson & Johnson 
company, unpublished data). This survey estimated 
that the total average rate of bariatric surgery was 
6.5 per 100,000 population, of which around three 
per 100,000 population were funded by the NHS. 
Both the published study67 and the unpublished 
survey reported variable levels of bariatric surgery 
occurring in different parts of the country, but 
these variations did not mirror regional differences 
in estimated levels of morbid obesity. This suggests 
that the intervention is not uniformly available 
across the country and there may be inequalities in 
service delivery.
BOSPA69 have undertaken an audit of the criteria 
that PCTs use to approve funding for surgery. In 
June 2008 more than half of the 151 PCTs listed 
were basing their funding decisions on NICE 
criteria, but more than a fifth of the PCTs were 
using criteria that were more stringent than the 
NICE criteria and information was not available 
for a further fifth of the PCTs listed. A minority of 
PCTs use criteria that are not based on a particular 
BMI.
Expert opinion indicates that in addition to 
inequalities in availability of bariatric surgery, band 
adjustment services are also not uniformly available 
across the country.
Anticipated costs associated 
with intervention
Bariatric surgery is a highly specialised and low 
volume activity and is not included in the NHS 
Reference Costs returns. Costings developed 
for this review estimate the cost of the surgical 
procedures alone at £6985 for laparoscopic gastric 
bypass and £4304 for laparoscopic adjustable 
gastric banding. Approximately £1200 to £2000 
of these costs are associated with high-cost 
consumables (including staples used in gastric 
bypass procedures and the gastric bands, and 
a range of single-use equipment). In addition 
to the procedure costs the estimate for costs 
of preoperative assessments is £1114, while 
postdischarge care of surgical patients will cost up 
to £1800 in the two years following gastric bypass 
surgery and up to £1900 following gastric banding 
(if costs of band fill and adjustments are included). 
Overall the anticipated costs for laparoscopic Background
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gastric bypass are £11,462 and for laparoscopic 
adjustable gastric banding are £8762. These overall 
costs include estimates of additional resource use 
arising from adverse events during the initial 
hospitalisation, reoperations within two years for 
patients whose initial surgery was unsuccessful, 
abdominal hernia procedures and additional 
cholecystectomies in patients within two years of a 
bariatric procedure.
The cost estimates developed for this review may 
not reflect the scarcity of surgeons with appropriate 
training and experience to perform bariatric 
procedures. The previous review15 developed a 
scenario to assess the impact of involving surgeons 
at an early stage of the learning curve – the likely 
impacts that directly affect treatment costs were 
identified as being reflected in longer operating 
times (50% higher), a doubling in revision rates. 
Including these effects raises the estimated cost 
of gastric bypass surgery to £14,787 (of which the 
procedure cost is £8795), while the estimated cost 
of adjustable gastric banding increases to £11,310 
(of which £5510 is the procedure cost). Additional 
impacts of involving less experienced surgeons, 
that are not directly reflected in cost estimates, were 
identified in an increased risk of surgical mortality 
and a likelihood of poorer outcomes (in terms of 
percentage weight loss following surgery).
Rationale for this study
The prevalence of obesity (BMI > 30) and morbid 
obesity (BMI ≥ 40) among adults is increasing. A 
similar pattern of increasing prevalence of obesity 
is seen in children and young people. A systematic 
review and economic evaluation of surgery for 
morbid obesity was conducted in 200215 and it 
found that although surgery appeared effective in 
terms of weight change, there was limited evidence 
addressing the long-term consequences and its 
influence on the QoL of patients. The economic 
evaluation was based on several assumptions 
because of the limitations of the data available, and 
it found that surgery offered additional quality-
adjusted life-years (QALYs) at an additional cost 
when compared with non-surgical management 
over a 20-year period, but comparison of the 
different procedures suggested that the difference 
in cost per QALY was less clear. The review 
found that there were few economic evaluations 
comparing the different surgical interventions, 
and the availability of costing and resource-use 
data was limited. The systematic review of clinical 
effectiveness was also published as a Cochrane 
review70 which was updated in 2005,71 when further 
trials were identified, but an economic evaluation 
was not undertaken. 
The earlier reviews15,70,71 identified needs for 
further research. There was a need for good-quality 
randomised controlled trials (RCTs) comparing 
either surgery with non-surgical interventions, 
or comparing one type of surgical procedure 
with another surgical procedure. Further key 
implications for research were the need for an 
assessment of outcomes over longer time periods 
(at least five years) and the need to include 
QoL outcomes. Further good quality economic 
evaluations were also needed.
An update of the systematic review and economic 
evaluation is therefore required which will 
include data from more recent trials, including 
any that may have assessed new bariatric surgical 
techniques. Any good-quality research that 
has assessed bariatric surgery for young obese 
people will be considered for inclusion in the 
review because some current guidelines9,64 do 
not rule out surgical intervention for young 
people. Furthermore the updated review will 
include people with lower BMIs than the previous 
reviews15,72 (BMI > 30), to take account of the 
emerging literature that possible benefits of early 
intervention (particularly in reducing obesity-
related comorbidity) outweigh the potential harms. 
This is reflected in one guideline64 that allows for 
surgery in people with a BMI greater than 30 and 
serious comorbid disease.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Decision problem 
Obesity is associated with increased morbidity 
and mortality. Bariatric (weight loss) surgery 
for obesity is considered when other treatments 
have failed. The aim of this health technology 
assessment is to assess the clinical effectiveness and 
cost-effectiveness of bariatric surgery in the obese. 
This report is an update of a previously published 
systematic review and economic evaluation.15,70,71 To 
ensure that the systematic review remains relevant 
to current practice, some small changes have been 
made to the eligibility criteria at each update. The 
changes made to the eligibility criteria for this 
update are discussed below.
Population including subgroups 
The original review was restricted to adults aged 
18 years or over with BMI greater than 40 or BMI 
greater than 35 with serious comorbid disease.15,70,71 
The present review has been broadened to include 
people of all ages undergoing surgery for obesity, 
in order to reflect some current guidelines which 
do not rule out surgical intervention in young 
people9,64 and indications from the literature that 
weight loss surgery is undertaken in young people 
under 18 years of age. The present review also 
includes people with a BMI greater than 30 with 
serious comorbid disease, again to reflect changing 
guidelines from the American Society for Bariatric 
Surgery64 and emerging literature suggesting that 
benefits may outweigh the harms in this group. 
People with a BMI 30 to 35 do not meet the current 
NICE guideline for bariatric surgery,9 therefore 
this subgroup will be considered separately where 
appropriate and if data allow. A further subgroup 
of people with BMI greater than 50 (super-
obese) will also be considered separately where 
appropriate. 
Interventions
Surgical procedures in current use are included, 
such as gastric bypass, biliopancreatic diversion 
sleeve gastrectomy, vertical banded gastroplasty 
and adjustable gastric banding. Four procedures 
that are not in current use have been excluded:
•	 Jejunoileal bypass was included in the original 
review,15 but was excluded from the Cochrane 
reviews70,71 and the present update because this 
procedure is not in current practice as a result 
of unacceptably high morbidity and mortality. 
Three studies (seven publications) of jejunoileal 
bypass that were included in the original 
review15 were excluded from later updates70,71 
and the present review.
•	 Horizontal gastroplasty was included in the 
previous versions of this review.15,70,71 However, 
this surgical intervention is not currently 
practiced and the most recent trial was 
published over 20 years ago. Seven studies (13 
publications) of horizontal gastroplasty were 
therefore excluded from this update. 
•	 One study included in previous versions of 
this review assessed vertical gastroplasty that 
was not banded.15,70,71 This intervention has 
also been excluded because it is no longer 
practiced.
•	 Non-adjustable gastric banding. One study 
published as an abstract only73 and included 
in the Cochrane reviews70,71 included a 
non-adjustable gastric band as one of three 
interventions assessed. All bands in current use 
are adjustable so this arm of the trial has been 
excluded from the current review. The surgical 
cohort of the Swedish Obese Subjects (SOS) 
study includes a minority of participants who 
received either adjustable or non-adjustable 
gastric bands. However, this study is included 
in the current review because those who 
received gastric banding of any type make 
up less than a fifth of the surgical cohort and 
much of the data are reported for the surgical 
cohort as a whole.
Relevant comparators 
As bariatric surgery is usually an intervention of last 
resort when all other methods have failed, much 
of the published evidence reports comparisons 
between one type of bariatric surgery and another. 
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It is anticipated that there will be few RCTs 
comparing surgery with no surgery (no treatment, 
medical management, e.g. VLCD or drugs such 
as orlistat or sibutramine or usual care), therefore 
prospective cohort studies are also included for 
these comparisons. Open surgery compared with 
laparoscopic surgery for the same procedure is 
also assessed. Comparisons of variations of surgical 
techniques rather than different procedures are 
excluded.
Outcomes 
The primary outcomes of interest are measures 
of weight change, QoL, perioperative and 
postoperative mortality and morbidity, change 
in obesity-related comorbidities, and cost-
effectiveness. It will be necessary to identify 
the resource implications of interventions and 
comparators, for example time in surgery, because 
these factors will help to inform the economic 
model. It is anticipated that the principal outcome 
of the economic model will be expressed in terms 
of incremental cost per QALY gained.
Overall aims and 
objectives of assessment 
The aim of this report was to assess the clinical 
effectiveness and cost-effectiveness of bariatric 
surgery for obesity by updating and expanding the 
previous systematic review and economic evaluation 
of surgery for morbid obesity.15,70,71
The objectives were to:
•	 summarise the evidence of clinical 
effectiveness and cost-effectiveness of surgery 
when compared with no surgery (medical 
management, usual care or no treatment)
•	 summarise the evidence of clinical effectiveness 
and cost-effectiveness comparing different 
surgical procedures in current use
•	 develop, where appropriate, an economic 
model adapting an existing cost-effectiveness 
model or constructing a new model using 
best available evidence to determine cost-
effectiveness in the UK
•	 identify priorities for future research.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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This report is an update of a previously published 
systematic review and economic evaluation.15,70,71 
The a priori methods for systematically reviewing 
the evidence of clinical and cost-effectiveness are 
described in the research protocol (Appendix 1). 
The protocol was sent to experts for comment; 
although helpful comments were received relating 
to the general content of the research protocol, 
there were none that identified specific problems 
with the methods of the review. The methods 
outlined in the protocol are briefly summarised 
below.
Search strategy
The search strategy for the update review was 
refined by an experienced information scientist. 
Separate searches were conducted to identify 
studies of clinical effectiveness, cost-effectiveness, 
QoL, resource use/costs and epidemiology/natural 
history. Sources of information and search terms 
are provided in Appendix 2, and a flow chart of 
identification of studies can be seen in Appendix 3. 
The most recent search was carried out in August 
2008.
Searches for clinical effectiveness and cost-
effectiveness literature were undertaken from 
the date of the last search of the previous 
review.71 Electronic databases searched included: 
MEDLINE; EMBASE; PreMedline In-Process & 
Other Non-Indexed Citations; The Cochrane 
Library including the Cochrane Systematic Reviews 
Database, Cochrane Controlled Trials Register, 
DARE, NHS EED and HTA databases; Web of 
Knowledge Science Citation Index (SCI); Web 
of Knowledge ISI Proceedings; PsycInfo; CRD 
databases; BIOSIS; and databases listing ongoing 
clinical trials. A total of 17 electronic resources 
were searched: 12 resources (encompassing 15 
databases) listing published papers and abstracts 
and five databases listing ongoing clinical studies. 
Searches were not restricted by language and 
conference abstracts were not excluded from the 
search strategy (see Inclusion criteria section, this 
chapter, for inclusion criteria on language and 
conference abstracts as these differed between 
the reviews of clinical effectiveness and cost-
effectiveness studies). Bibliographies of related 
papers were screened for relevant studies, and 
the expert advisory group was also contacted for 
advice and peer review, and to identify additional 
published and unpublished references.
Inclusion and data 
extraction process
Titles and abstracts identified by the search 
strategy for the clinical effectiveness section of the 
review were assessed for possible eligibility by two 
reviewers independently. The full texts of relevant 
papers were then obtained and inclusion criteria 
were again applied by two reviewers independently 
using a standardised form. Any disagreements 
over eligibility were resolved by consensus or by 
recourse to a third reviewer. Data were extracted by 
one reviewer using a standardised data extraction 
form and independently checked by two further 
reviewers.
Titles and abstracts identified by the search strategy 
for the cost-effectiveness section of the review 
were assessed for potential eligibility by two health 
economists. Economic evaluations were considered 
for inclusion if they reported both health-service 
costs and effectiveness, or presented a systematic 
review of such evaluations. Full papers were 
formally assessed by one health economist with 
respect to their potential relevance to the research 
question.
Quality assessment
Within the clinical effectiveness section of the 
review the quality of included cohort studies 
was assessed using criteria recommended by 
NHS Centre for Reviews and Dissemination 
(CRD)74 (Appendix 4). RCTs were assessed 
using the Cochrane criteria for judging risk 
of bias (Appendix 4).75 These criteria include 
consideration of the following factors:
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1.  sequence generation
2.  allocation concealment
3.  blinding of participants, personnel and 
outcome assessors
4.  incomplete outcome data
5.  selective outcome reporting
6.  topic-specific, design-specific or other potential 
threats to validity.
Quality criteria were applied independently by two 
reviewers. At each stage, any differences in opinion 
were resolved through discussion or consultation 
with a third reviewer. 
For the cost-effectiveness section of the review the 
included studies were summarised and critically 
appraised by two health economists to identify:
•	 the number and characteristics of alternative 
surgical interventions included in economic 
evaluations 
•	 the choice of a comparator treatment
•	 population to whom the results of the 
economic evaluations apply
•	 approach and assumptions used in decision 
analytic models
•	 methods used in transforming clinical and 
economic data to the needs of economic 
modelling
•	 methods of dealing with uncertainties and 
potential bias in estimated results
•	 other issues as recommended by the checklist 
for economic evaluation publications 
(Drummond and Jefferson76) and the 
guidelines for good practice in decision-
analytic modelling in health technology 
(Phillips and colleagues77).
Inclusion criteria
The eligibility criteria for the systematic review 
of clinical effectiveness differ slightly from those 
of the previously published versions of the 
review;15,70,71 these differences are described in 
Chapter 2, Decision problem section. The inclusion 
criteria for the present review are described below.
Patients
•	 Adult patients fulfilling the standard definition 
of obese, i.e. people with a BMI of 30 or over.
•	 Young people who fulfil the definition of 
obesity for their age, sex and height.
•	 Where data were available, clinical effectiveness 
and cost-effectiveness will be reported 
separately for patients who meet current NICE 
guidelines for bariatric surgery, those with a 
lower BMI who would not currently meet the 
NICE criteria for bariatric surgery, and young 
people.
Interventions
•	 Open and laparoscopic bariatric surgical 
procedures in widespread current use. 
Clinical experts were consulted to ensure 
that the included procedures are those 
which are most relevant to current clinical 
practice. The procedures included are gastric 
bypass, biliopancreatic diversion (including 
biliopancreatic diversion with duodenal switch), 
sleeve gastrectomy, adjustable gastric banding 
and vertical banded gastroplasty.
Comparators
•	 Surgical procedures in current use in 
comparison with one another.
•	 Open surgery compared with laparoscopic 
surgery for the same procedure.
•	 Surgical procedures in current use compared to 
non-surgical interventions. These non-surgical 
interventions may have included drugs such as 
orlistat and sibutramine, dietary interventions, 
exercise and combinations of non-surgical 
interventions such as diet and exercise, or no 
surgery.
Outcomes
•	 To be included, studies must have reported 
outcomes following a minimum of 12 months 
of follow-up.
•	 Included studies had to have reported on at 
least one of the following outcomes: measures 
of weight change, QoL, perioperative and 
postoperative mortality and morbidity, 
change in obesity-related comorbidities, cost-
effectiveness (i.e. both costs and outcomes 
should be reported). For cost-effectiveness, 
intermediate outcomes (in BMI) had to have 
been converted to final outcomes [i.e. either 
life-years (LYs) or QALYs], cost-effectiveness 
studies where results were reported only with 
respect to intermediate outcomes other than 
BMI (e.g. cost per kg of excess weight loss; cost 
per adverse event avoided) were not eligible for 
inclusion.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
21
Types of studies
•	 Systematic review of clinical effectiveness: 
RCTs were eligible for inclusion. For the 
comparisons of surgical procedures with non-
surgical procedures controlled clinical trials 
and prospective cohort studies (with a control 
cohort) were also eligible for inclusion (because 
it was anticipated that few or no RCTs would be 
found).
•	 Systematic review of cost-effectiveness: full 
cost-effectiveness analyses, cost–utility analyses, 
cost–benefit analyses and cost–consequence 
analyses. Only publications in English were 
eligible for inclusion in the systematic review of 
cost-effectiveness.
•	 Studies published as abstracts or conference 
presentations were eligible for inclusion in the 
clinical effectiveness section if sufficient details 
were presented to allow an appraisal of the 
methodology and the assessment of results to 
be undertaken. Conference abstracts were not 
eligible for inclusion in the cost-effectiveness 
section.
Data synthesis
Data were synthesised through a narrative 
review with tabulation of results of all included 
studies. Full data extraction forms are presented 
in Appendix 5 to Appendix 15. Within the 
clinical effectiveness section studies using similar 
surgical procedures were grouped together to aid 
interpretation. However, within these groupings 
there may be differences in procedures, such as 
modifications of procedures (for example variations 
of gastric bypass), or open or laparoscopic 
procedures. These are noted where appropriate. 
It was not considered appropriate to combine the 
included RCTs in a meta-analysis because of the 
heterogeneity in the patient groups, comparator 
treatments and outcomes (see Chapter 4, 
Assessment of clinical effectiveness and Chapter 7 
Strengths and limitations of the assessment).DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Quantity and quality of 
research available 
Studies identified
As this report is an update of a systematic review 
and economic evaluation originally published in 
2002,15 with the review of clinical effectiveness 
updated for the Cochrane Library in 200370 
and 2005,71 searching and screening have been 
conducted on a number of occasions. Moreover, 
each version update differs slightly in the studies 
included as the review has evolved. Appendix 3 
explains how the review has evolved and notes the 
main differences between the reviews with respect 
to the eligibility criteria and studies included in 
each publication. A flow chart of the identification 
of studies at each stage can also be seen in 
Appendix 3.
In summary, a total of 5386 references were 
identified through the previous and current 
searches. Twenty-six studies reported in 52 
publications met the current inclusion criteria.
Assessment of inter-
rater agreement
Inter-rater agreement for study selection 
was excellent (Cohen’s kappa = 0.84). Initial 
disagreements were resolved though discussion in 
all cases.
Excluded studies
The reasons for excluding 32 studies after 
examination of the full papers from the 2005 and 
2008 updated searches can be seen in Appendix 
16. Studies excluded from the original searches 
have been described previously.15,70 Studies were 
often excluded for more than one reason, but the 
most common reason for exclusion was a study 
design other than an RCT for comparisons of 
surgical procedures, or a controlled prospective 
cohort study for comparisons of surgery versus 
non-surgical management. Four studies published 
as abstracts only were excluded because of 
inadequate length of follow-up.78–81 The authors 
of these trials were contacted to determine if 
further follow-up was available, but no replies were 
received.
Characteristics of included studies
Twenty-three of the 26 included studies were RCTs. 
One study (SOS) was a prospective multicentre 
cohort study with matched concurrent controls. 
This study has multiple publications, 20 of 
which have been included in this review.82–101 
Throughout the review, this study will be referred 
to as the SOS study, with specific references cited 
where appropriate. Two studies had prospective 
cohort designs (Stoeckli and colleagues102–104 and 
Buddeberg-Fischer and colleagues105). Two of 
the included studies were reported as abstracts 
only.73,106 Table 12 summarises the comparisons 
identified by the searches.
Participants
Most studies included participants with morbid 
obesity, and where this was described further, a 
definition of BMI greater than 40 was commonly 
used, often with the additional criteria of BMI 
greater than 35 or 37 with comorbid disease (Table 
13). However, Angrisani and colleagues107 included 
participants with BMI greater than 35, and the 
SOS study included men and women with a BMI 
greater than or equal to 34 and 38 respectively. 
A maximum of BMI of 50, 107,108,109,110,111 55,112 or 
60113,114 was also specified by some studies. 
Three studies included participants notably 
different from the rest of the studies in this review; 
with two studies focusing on the lower side of 
the obesity continuum, and one focusing on the 
upper side. O’Brien and colleagues115,116 included 
participants with a BMI of 30 to 35 (Class I 
obesity) and identifiable comorbidities. Dixon and 
colleagues117 limited inclusion to people diagnosed 
with Type 2 diabetes and a BMI of 30 to 40. At the 
other extreme, Bessler and colleagues118 required 
participants to have a BMI greater than 50.
The individual study sample size ranged from 
20102–104 to 4047 (SOS study); however, the number 
of participants included in the analysis of the SOS 
study depended on the length of follow-up which 
varied for the different outcomes reported in 
different publications. 
The majority of participants in the studies were 
female, the proportion of female participants in 
studies ranged from 53% to 94% where reported. 
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TABLE 12  List of identified comparisons
Comparisona Study
Surgery vs non-surgical interventions (RCTs and prospective cohort studies)
Laparoscopic adjustable gastric banding vs conventional 
therapy117 OR 
Intensive medical programme115,116 OR 
No surgery102–104 (vs open gastric bypass102–104)
1. Dixon et al., 2008,117 RCT; 
2. O’Brien et al., 2006,115,116 RCT; 
3. Stoeckli et al., 2004,102–104 Cohort study
Biliopancreatic diversion vs diet  1. Mingrone et al., 2002,119 RCT
Surgery (various) vs conventional treatment83–90 1. SOS 1997 to 2007,82–101 Cohort study; 
2. Buddeberg-Fischer et al., 2006,105 Cohort study
Comparisons of different surgical procedures (RCTs)
Gastric bypass vs vertical banded gastroplasty 1. Howard et al., 1995120; 
2. VanWoert et al., 1992106; 
3. MacLean et al., 1995121,122; 
4. Sugerman et al., 1987123; 
5. Lee et al., 2004124; 
6. Olbers et al., 2005108,109; 
7. Agren and Naslund, 198973,b
Gastric bypass (non-banded) vs banded gastric bypass 1. Bessler et al., 2007118 
Laparoscopic gastric bypass vs laparoscopic adjustable gastric 
banding 
1. Angrisani et al., 2007107 
Laparoscopic Roux-en-Y gastric bypass vs laparoscopic sleeve 
gastrectomy
1. Karamanakos et al., 2008125
Vertical banded gastroplasty vs adjustable gastric banding 1. Nilsell et al., 2001126; 
2. Morino et al., 2003110; 
3. van Dielen et al., 2005127,128
Laparoscopic adjustable gastric banding vs laparoscopic 
isolated sleeve gastrectomy
1. Himpens et al., 2006129 
Open gastric bypass vs laparoscopic gastric bypass 1. Puzziferri et al., 2006113,114; 
2. Lujan et al., 2004130; 
3.Westling and Gustavsson, 2001131; 
4. Sundbom and Gustavsson, 2004112 
Open vertical banded gastroplasty vs laparoscopic vertical 
banded gastroplasty
1. Davila-Cervantes et al., 2002111 
Open adjustable silicone gastric banding vs laparoscopic 
adjustable silicone gastric banding
1. de Wit et al., 1999132
RCT(s), randomised controlled trial(s); SOS, Swedish Obese Subjects.
a  Note: studies may vary in technique or procedure within these groupings.
b  The study by Agren and Naslund, 1989,73 includes a third arm, gastric banding (not adjustable), which has been reported 
in previous versions of this review.70,71 However, because non-adjustable gastric bands are no longer used this comparison 
is not included in the current review.
Mean age ranged from 31 years in one arm of the 
RCT by Karamanakos and colleagues125 to 49 years 
in the SOS study (Table 13). Excluding the three 
studies with notably different inclusion criteria, 
mean baseline BMI ranged from 37 in the RCT 
by Himpens and colleagues129 (inclusion criteria 
were not reported by this study) to 52 in the study 
by vanWoert and colleagues.106 Baseline BMI in 
the study focusing on Class I obesity was 34 in 
each group,115,116 and was 37 in each group in the 
study focusing on Type 2 diabetes.117 The study 
by Bessler and colleagues,118 which focused on 
participants with BMI greater than 50, had a mean 
baseline BMI of 59.4 in the banded gastric bypass 
group and 59.7 in the non-banded group.
Baseline characteristics were similar between 
groups in most of the studies. However, the 
SOS study involved an interval of about nine 
months between matching of controls and the 
start of treatment (surgery) that led to significant 
differences in weight and other possible risk 
factors. The surgical group were younger than 
controls, had a higher prevalence of hypertension, DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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and had increased BMI, blood pressure and energy 
intake at the time of surgery. The authors state that 
dissimilarities between groups at inclusion were 
adjusted for in the calculations. Sundbom and 
Gustavsson112 stated that groups were well matched 
for age, sex, BMI, previous abdominal surgery 
and comorbid conditions; however, comorbidity 
appears to be higher in the open surgery group. 
Patients in the study by Karamanakos and 
colleagues125 had a statistically significant difference 
in mean age between groups {37 years [standard 
deviation (SD 8.25)] versus 30.6 years (SD 7.8), 
p = 0.023}.
Interventions
The included studies compared a variety of 
interventions, which are summarised in Table 12 
and displayed visually in Figure 1. Although these 
studies have been grouped according to the type of 
surgery for the purposes of this systematic review, 
there may be variations in surgical technique or 
procedure within the groupings. Three RCTs 
and three cohort studies (one cohort study had 
three arms) compared surgery with non-surgical 
interventions. The remaining 20 RCTs compared 
different surgical procedures, including various 
types of gastric bypass, vertical banded gastroplasty, 
adjustable gastric banding and isolated sleeve 
gastrectomy, performed with open or laparoscopic 
surgery. Gastric bypass (usually Roux-en-Y gastric 
bypass) and vertical banded gastroplasty were 
the most commonly investigated procedures 
and formed the majority of the evidence base. 
Comparisons of open versus laparoscopic surgery 
for gastric bypass (four RCTs), vertical banded 
gastroplasty (one RCT) and adjustable gastric 
banding (one RCT) were also assessed.
Outcomes
Several different measures of weight change were 
reported by the studies, namely BMI, change in 
BMI, weight, weight loss, per cent weight loss, 
per cent excess weight loss, fat mass, fat free mass, 
per cent ideal body weight and proportion of 
‘successes’. Some of the studies did not report 
measures of variability such as confidence intervals 
or standard deviations.
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FIGURE 1  Network of comparisons of surgical interventions for obesity. Note: The lines between interventions represent comparisons 
(either trials or pairs of trial arms where a study has compared more than two procedures). The numbers along the lines indicate the 
number of trials (or pairs of trial arms) for that comparison. Trials are RCTs unless otherwise stated. AGB, adjustable gastric banding; 
BPD, biliopancreatic diversion; GBP , gastric bypass; lap, laparoscopic surgery; LSG, laparoscopic sleeve gastrectomy; open, open surgery; 
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TABLE 13  Characteristics of included studies
Study details Intervention
Target population and selected baseline characteristics 
(mean and SD unless stated otherwise)
Surgery versus non-surgical interventions (RCTs and prospective cohort studies)
Dixon, 2008117
Australia
RCT, follow-up: 24 months 
1. LAGB (n = 30)
2. Con therapy (n = 30)
Target pop: Type 2 diabetes, BMI 30–40, age 20–60 years
AGE, years: LAGB 46.6 (7.4); con therapy 47.1 (8.7) 
SEX (M : F): LAGB 15 : 15, con therapy 13 : 17
BMI: LAGB 37.0 (2.7); con therapy 37.2 (2.5) 
O’Brien, 2006115,116 
Australia
RCT, follow-up: 24 months
1. LAGB (n = 40)
2. Intensive non-surgical 
programme (n = 40)
Target pop: BMI 30 to 35 with comorbidities, age 20–50 years
AGE, years: LAGB 41.8 (6.4); non-surgical 40.7 (7.0)
SEX (M : F): LAGB 10 : 30; non-surgical 9 : 31
BMI: LAGB 33.7 (1.8); non-surgical 33.5 (1.4)
Mingrone, 2002119
Italy
RCT, follow-up: 1 year
1. BPD (n = 46)
2. Diet (n = 33)
Target pop: morbidly obese
AGE, years: 30–45 
SEX (M : F): BPD 15 : 31, diet 12 : 21 
BMI: women, diet 48.4 (8.9), BPD 48.3 (6.3). men, diet 47.8 
(8.8), BPD 48.0 (5.4)
SOS, 1997 to 200782–101
Sweden
Multicentre, cohort study,
follow-up: up to 10 years
1. Surgery (VBG, Gband 
or GBP) (n = 2010)
2. Controls: conventional 
treatment, not 
standardised, best 
non-surgical options 
available at the time 
(n = 2037)
Target pop: BMI ≥ 34 (men) and ≥ 38 (women), 37–60 years
AGE, years: surgery 47.2 (5.9), control 48.7 (6.3) 
SEX: (M : F) surgery 590 : 1420, control 590 : 447 
BMI: surgery 42.4 (4.5), control 40.1 (4.7)
(all data here taken from most recently published study)
Stoeckli, 2004102–104 
Switzerland
Cohort study, follow-up: 24 
months
1. LAGB (n = 8) 
2. Open RYGBP (n = 5)
3. Control (n = 7)
Target pop: morbid obesity (BMI > 37)
AGE, years (SE): LAGB 41.1 (2.6), RYGBP 43.8 (4.4), controls 
49.9 (2.6)
SEX (M : F): LAGB 2 : 6, RYGBP 0 : 5, controls 2 : 5
BMI: LAGB 41.7 (1.0), RYGBP 43.6 (2.0), controls 41.1 (1.0)
Buddeberg-Fischer, 2006105 
Switzerland
Cohort study
Mean follow-up 3.2 years  
(SD 1.3, range 0.28–5.8)
1. Surgery (LAGB, 
LRYGBP) (n = 63) 
2. No surgery (n = 30)
Target pop: BMI > 40, or > 35 with substantial comorbidity
AGE, years 43.5 (9.8, range 21.65)
SEX (M : F) 23 : 70
BMI: surgery, 44.7 (6.1) [LRYGBP (n = 23), 47.3 (7.8); LAGB 
(n = 40), 43.4 (4.5)]; no surgery 42.9 (5.5)
Comparisons of different surgical procedures (all RCTs)
Howard, 1995120 
USA
Follow-up: 12 to 78 months
1. GBP (n = 20)
2. VBG (n = 22)
Target pop: Class IV obesity (BMI > 40); < 50 years old
AGE, years: GBP 38.1 (SE 1.9), VBG 36.5 (SE 2.3)
SEX (M : F): GBP 5 : 15, VBG 4 : 18 
BMI: not reported
VanWoert, 1992106 
USA (abstract)
Follow-up: 36 months
1. GBP (n = 15)
2. VBG (n = 17)
Target pop: BMI > 40
AGE, years: GBP 38 (8), VBG 38 (10)
SEX (M : F): GBP 4 : 11, VBG 3 : 14
BMI: GBP 52 (SD 10), VBG 51 (SD 6)
MacLean, 1995121,122 
Canada
Follow-up: up to 6.5 years
1. VBG (n = 54)
2. RYGBP (n = 52)
Target pop: target population not stated
AGE, years: VBG 38.8 (9.5), RYGBP 40.1 (7.7)
SEX: not reported
BMI: VBG 48.2 (6.5), RYGBP 49.9 (7.4)DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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Study details Intervention
Target population and selected baseline characteristics 
(mean and SD unless stated otherwise)
Sugerman, 1987123 
USA
Follow-up: 3 years
1. RYGBP (n = 20)
2. VBG (n = 20)
Target pop: more than 100 lb (45.5 kg) above ideal weight
AGE, years: RYGBP 38 (11), VBG 38 (9) 
SEX (M : F): RYGBP 2 : 18, VBG 2 : 18
BMI: not reported
Lee, 2004124 
Taiwan
Follow-up: Mean 20 months 
(range 18 to 30)
1. LVBG (n = 40)
2. LRYGBP (n = 40)
Target pop: significant obesity > 5 years, BMI > 40 or BMI > 35 
with comorbidities, age 18–59
AGE, years: LVBG 32.5 (7.8), LRYGBP 31.6 (8.6)
SEX (M : F): LVBG 11 : 29, LRYGBP 13 : 27
BMI: LVBG 43.14 (6.1), LRYGBP 43.18 (7.5)
Olbers, 2006108,109
Sweden
Follow-up: 24 months
1. LRYGBP (n = 37)
2. LVBG (n = 46)
Target pop: BMI > 40 or > 35 with obesity-associated morbidity, 
BMI < 50
AGE (median, range), years: LRYGBP 37 (34–61); LVBG 34 
(26–60) 
SEX (M : F): LRYGBP 12 : 25; LVBG 10 : 36
BMI: LRYGBP 42.7 (4.0); LVBG 42.1 (4.2)
Agren and Naslund, 198973 
Sweden
Follow-up: 18 months
1. VBG (n = 27)
2. Loop GBP (n = 25)
Target pop: morbidly obese
AGE: not reported
SEX: not reported
BMI 42.8
Bessler, 2007118
USA
Follow-up: up to 36 months
1.Banded long-limb GBP 
(n = 46)
2. Non-banded long-limb 
GBP (n = 44)
Target pop: BMI > 50 
AGE, years: banded GBP 40.6 (7.4); non-banded GBP 42.6 (7.2)
SEX (M : F): banded GBP 20 : 26; non-banded GBP 12 : 32
BMI: banded GBP 59.4 ± 7.3; non-banded GBP 59.7 ± 7.1
Angrisani, 2007107
Italy
Follow-up: 60 months
1. LRYGBP (n = 24)
2. LAGB (n = 27)
Target pop: BMI > 35 to < 50, age > 16 years but < 50 years
AGE, years: LRYGBP 34.1 (8.9); LAGB 33.8 (9.1) 
SEX (M : F): LRYGBP 4 : 20; LAGB 5 : 22
BMI (range): LRYGBP 43.8 ± 4.1 (38.9–48.9); LAGB 43.4 ± 4.2 
(38.1–49.2)
Nilsell, 2001126
Sweden
Follow-up: 4–5 years
1. AGB (n = 29)
2. VBG (n = 30)
Target pop: BMI > 40 or BMI >37 with obesity associated 
comorbidity
AGE, years: AGB 38 (20–58), VBG 39 (19–59)
SEX (M : F): AGB 8 : 21, VBG 6 : 24
BMI: AGB 42.8 (5.4), VBG 43.9 (3.8)
Morino, 2003110
Italy
Follow-up: mean 33.1 months 
(range 24–46)
1. LAGB (n = 49)
2. LVBG (n = 51)
Target pop: BMI 40–50, aged 18–60 years
AGE, years: LAGB 37.2 (20–55), LVBG 38.2 (21–58)
SEX (M : F): LAGB 11 : 38, LVBG 8 : 43
BMI: LAGB 44.7 (40.1–50.0), LVBG 44.2 (40.0–50.0)
van Dielen, 2005127,128
The Netherlands
Follow-up: 24 months and 84 
months
1. Open VBG (n = 50)
2. LAGB (n = 50)
Target pop: BMI > 40 or > 35 with comorbidities; age 18–
60 years
AGE: VBG 39 (8.5) years; LAGB 37.2 (9.7) years
SEX (M : F): Open VBG 10 : 40; LAGB 10 : 40
BMI: VBG 46.6 (6.4); LAGB 46.7 (6.1)
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Study details Intervention
Target population and selected baseline characteristics 
(mean and SD unless stated otherwise)
Karamanakos, 2008125
Greece
Follow-up: 1 year
1. LRYGBP (n = 16)
2. LSG (n = 16)
Target pop: not reported
AGE, years: LRYGBP 37 (8.25), LSG 30.6 (7.8), p = 0.023
SEX (M : F): LRYGBP 4 : 12, LSG 1 : 15
BMI: LRYGBP 46.6 (3.7), LSG 45.1 (3.6)
Himpens, 2006129 
Belgium
Follow-up: 36 months
1. LAGB (n = 40)
2. LISG (n = 40)
Target pop: not stated
AGE (median, range), years: LAGB 36 (20–61); LISG 40 (22–65)
SEX (M : F): LAGB 7 : 33; LISG 9 : 31
BMI (median, range): LAGB 37 (30–47); LISG 39 (30–53)
Puzziferri, 2006113,114 
USA
Follow-up: 36 months
1. LRYGBP (n = 79)
2. Open RYGBP (n = 76)
Target pop: BMI 40–60; age 21–60 years
AGE: LRYGBP 40 years (± 8), RYGBP 42 years (± 9)
SEX (M : F): LRYGBP 7 : 72, RYGBP 9 : 67
BMI: LRYGBP 47.6 (± 4.7), RYGBP 48.4 (± 5.4)
Lujan, 2004130 
Spain
Follow-up: mean 23 months
1. LGBP (n = 53)
2. Open GBP (n = 51)
Target pop: BMI > 40 or BMI > 35 with coexisting pathologic 
disorders
AGE, years: LGBP 37 (18–64), GBP 38 (20–63)
SEX (M : F): LGBP 10 : 43, GBP 13 : 38
BMI: LGBP 48.53 (36–78), GBP 52.20 (37–80)
Westling and Gustavsson, 
2001131
Sweden (abstract)
Follow-up: 1 year
1. LRYGBP (n = 30)
2. Open RYGBP (n = 21)
Target pop: BMI > 40 or BMI > 35 with significant comorbidity
AGE overall group: 36 years (SD 9)
SEX overall group: 94% female
BMI LRYGBP 41 (SD 4), RYGBP 44 (SD 4)
Sundbom and Gustavsson, 
2004112
Sweden
Follow-up: 1 year
1. Hand-LRYGBP (n = 25)
2. Open RYGBP (n = 25)
Target pop: BMI < 50. minimum BMI not reported
AGE (range), years: hand-LRYGBP 37 (19–54), RYGBP 38 
(24–54)
SEX (M : F): hand-LRYGBP 2 : 23, RYGBP 3 : 22
BMI: hand-LRYGBP 44 (range 36–54), RYGBP 45 (range 34–54)
Davila-Cervantes, 2002111
Mexico
Follow-up: 1 year
1. Open VBG (n = 14)
2. LVBG (n = 16)
Target pop: BMI 40–50
AGE median (range), years: VBG 36.5 (22–56), LVBG 34.5 
(24–46) 
SEX (M : F) VBG 1 : 13, LVBG 2 : 14
BMI median (range): VBG 43 (37–50), LVBG 45 (38–50)
de Wit, 1999132
The Netherlands
Follow-up: 1 year
1. Open AGB (n = 25)
2. LAGB (n = 25)
Target pop: BMI > 40, aged 18–55 years
AGE: not reported
SEX (M : F): LAGB 8 : 17, AGB 8 : 17
BMI: LAGB 51.3 (10.4), AGB 49.7 (5.6)
AGB, adjustable gastric banding; BMI, body mass index; BPD, biliopancreatic diversion; Con therapy, conventional therapy; 
GBP , gastric bypass; Hand-LRYGBP , hand-assisted laparoscopic Roux-en-Y gastric bypass; LAGB, laparoscopic adjustable 
gastric banding; LGBP , laparoscopic gastric bypass; LRYGBP , laparoscopic Roux-en-Y gastric bypass; LVBG, laparoscopic 
vertical banded gastroplasty; LSG, laparoscopic sleeve gastrectomy; LISG, laparoscopic isolated sleeve gastrectomy; open, 
open surgery; RYGBP , Roux-en-Y gastric bypass; RCT, randomised controlled trial; VBG, vertical banded gastroplasty.
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QoL was reported by just five 
studies,86,100,105,113–116,124 (three RCTs and two cohort 
studies) and comorbidities were reported by eight 
studies88,89,97,107,113–118,127,129 (seven RCTs and one 
cohort study).
Mortality, adverse events and/or additional 
procedures were reported by most studies.
Follow-up
The minimum duration of follow-up for inclusion 
in this review was 12 months, and most studies 
followed participants for 12, 24 or 36 months. 
Studies with longer follow-up periods included 
Nilsell and colleagues126 (four to five years), 
Angrisani and colleagues107 (60 months), Howard 
and colleagues120 (12 to 78 months), MacLean 
and colleagues121,122 (6.5 years), van Dielen and 
colleagues127,128 (24 months and 84 months). The 
longest follow-up was for 10 years by the SOS study 
(Table 13). It should be noted that some studies did 
not follow all participants for the given length of 
time.
Country
Six studies, including the SOS study, were 
conducted in Sweden73,108,109,112,126,131 and five 
studies were conducted in the USA.106,113,114,118,120,123 
Three studies were conducted in Italy.107,110,119 Two 
studies were conducted in each of Switzerland,102–105 
the Netherlands127,128,132 and Australia.115–117 One 
study was conducted in Belgium,134 Canada,121,122 
Mexico,111 Spain,130 Taiwan124 and Greece.125
Risk of bias in included studies
Randomised controlled trials
The summary of risk of bias assessment of RCTs 
can be seen in Table 14. 
Allocation
Nine of 23 RCTs described adequate allocation 
sequence generation,108–110,115–117,123,125,127,128,130,132 
and just five had adequate concealment of 
allocation.110,115,116,118,130,132 The method of allocation 
sequence generation and concealment was not 
reported by the remaining studies, therefore they 
were judged to be of uncertain risk of bias.
Blinding
Only one RCT reported that outcome assessors 
were blinded to the intervention assignment.125 
Outcome assessors were not blinded to the 
intervention assignments in three RCTs,115–117,126 
therefore they were judged to be at high risk of 
bias. This information was not reported by the 
remaining RCTs.
Six RCTs assessed outcomes self-reported 
by participants. In four of these studies 
participants were not blinded to the intervention 
received,113–116,126,131 and in two studies blinding of 
participants was not reported or was unclear.118,124
Incomplete outcome data
Incomplete outcome data for weight loss were 
adequately addressed by 14 RCTs (Table 14.3).107–
110,112,117,119,120,123,125–129,131,132 The remaining nine 
RCTs were judged to be at uncertain risk of bias. 
The withdrawals in the study by O’Brien and 
colleagues115,116 were uneven between groups, but 
as reasons were not provided for all withdrawals it 
was not clear whether withdrawals were related to 
outcome. In the studies by Lujan and colleagues130 
and Bessler and colleagues,118 the number of 
participants included at each follow-up was not 
reported. The study by Puzziferri and colleagues 
was reported in two publications,113,114 the most 
recent of which contained a smaller number 
of participants, but no explanation for this was 
given. Information in the study by MacLean and 
colleagues121,122 was contradictory between tables 
and text. Presence or absence of missing outcome 
data was not reported by four studies.73,106,124,129
Three RCTs assessed QoL.113–116,124 Incomplete 
outcome data for QoL were not reported by Lee 
and colleagues.124 O’Brien and colleagues115,116 
analysed QoL data only for those who completed 
the study, which suffered from uneven withdrawals 
between the groups as previously stated. QoL in 
the study by Puzziferri and colleagues113,114 was 
reported only for 44 of 155 patients originally 
randomised, with no explanation given.
Comorbidity was assessed by seven RCTs. 
Incomplete outcome data for comorbidity were 
adequately addressed by three studies,107,117,127,128,132 
but the remaining four studies were judged to be of 
uncertain risk of bias.113–116,118,129
Selective reporting
The study by Bessler and colleagues118 was judged 
not to be free of selective outcome reporting, as 
per cent excess weight loss was reported at 6, 12, 
24 and 36 months follow-up (with a statistically 
significant difference at 36 months), while BMI 
was reported at 12 and 24 months only, with no 
measure of variance or statistical analysis. The 
remaining studies were judged to be of uncertain 
risk of bias. For example, the studies by Agren 
and Naslund73 and VanWoert and colleagues106 are 
reported as abstracts only, therefore limited data 
were provided. Lujan and colleagues130 reported 
BMI in a figure only, with no exact data reported Clinical effectiveness
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and no measure of variance. Mingrone and 
colleagues119 did not report adverse effects. 
Other potential sources of bias
Four RCTs were judged to be at high risk of bias 
because they used block randomisation in an 
unblinded trial which can mean it is possible 
to predict future assignments.113,114,117,123,131 In 
addition, recruitment to the RCT by Sugerman 
and colleagues123 was stopped early (after nine 
months) following an a priori stopping rule which 
stated that when a significant difference (p < 0.05) 
in weight loss was noted for either treatment, 
patient recruitment would cease until patients 
had achieved the same follow-up after surgery. 
The study would have reopened if statistical 
significance p < 0.01 was not present when all 
patients had reached an equivalent time frame 
after surgery. Studies that are stopped early are 
more likely to show extreme treatment effects than 
those that continue to the end.135 Sundbom and 
Gustavsson112 was also judged to be at high risk of 
bias, as there appeared to be higher comorbidity 
on one of the treatment arms. The remaining 
RCTs were judged to be of uncertain risk of bias, 
because there was either insufficient information to 
assess whether an important risk of bias exists, or 
insufficient rationale or evidence that an identified 
problem will introduce bias. For example, Olbers 
and colleagues108,109 excluded 17 patients after 
randomisation either because they expressed a 
preference about the surgery they received, or 
were found to have a BMI > 50; the effect of 
the exclusion of these patients was unclear. Also, 
Angrisani and colleagues107 reported that they were 
in the early phase of the learning curve for one 
intervention, whereas the senior author had more 
experience with the comparator.
Prospective cohort studies
The summary of quality assessment of three 
included cohort studies can be seen in Table 
15. The SOS study and the study by Stoeckli 
and colleagues102–104 adequately described the 
groups and the distribution of prognostic factors. 
Buddeberg-Fischer and colleagues105 did not report 
baseline characteristics separately for each group, 
therefore it was uncertain whether the groups were 
comparable on all important confounding factors. 
Although the groups in the SOS study were not 
comparable on all important factors, these were 
adjusted for in the analysis. The groups in the 
study by Stoeckli and colleagues102–104 were judged 
to be comparable. It was not clear in any of the 
studies whether the groups were assembled at a 
similar point in their disease progression. Outcome 
assessors were not blind to the intervention in the 
SOS study or in the study by Buddeberg-Fischer 
and colleagues,105 in which all measures, including 
BMI, were self-reported by participants. Blinding 
was not reported by Stoeckli and colleagues.102–104 
Dropout rates for each group and reasons for 
dropout were not reported by any of the studies.
Allocation of participants 
in the cohort studies
In the SOS study, participants could volunteer 
for conventional or surgical treatment. For each 
surgical case a control was matched by computer 
taking into account 18 variables. The study by 
Stoeckli and colleagues102–104 included participants 
opting for surgical treatment, choosing either 
adjustable silicone gastric banding or gastric 
bypass. The control group were patients attending 
diet consultation, although the reasons for the 
patients not undergoing surgery are not given. 
Buddeberg-Fischer and colleagues105 included 
patients applying for bariatric surgery. However, 
the comparability of the surgery and no-surgery 
groups is unclear because although one paper 
states that all but three participants met the criteria 
for surgery (one had BMI 31.6, two were aged 
> 60 years),105 about nine participants in an earlier 
publication said that the reason for not undergoing 
surgical treatment was that their BMI was under 
the limit for morbid obesity.133
Missing outcome data due 
to participant withdrawals 
and losses to follow-up
Reporting of missing outcome data formed part 
of the quality assessment of the included studies 
(see Risk of bias in included studies, this chapter). 
Here, two factors contributing to missing outcome 
data within RCTs: participant withdrawals from 
studies, and losses to follow-up are addressed. 
Reporting of these factors within the RCTs 
included in this review was variable. Only two RCTs 
specifically reported on study withdrawals. In the 
study by Dixon and colleagues117 one participant 
(3.3%) withdrew in the LAGB group and four 
participants (13.3%) withdrew in the conservative 
therapy group, leading to an overall follow-up of 
55 of 60 participants (92%) at two years. O’Brien 
and colleagues115,116 reported the withdrawal of 
one participant (2.5%) in the surgical group and 
five withdrawals (12.5%) from the non-surgical 
group, leading to an overall follow-up of 74 of 
80 participants (93%) at two years. O’Brien and 
colleagues also reported that two (5%) participants 
were lost to follow-up from the non-surgical group DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 14  Summary of quality assessment of 23 RCTs
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Agren and Naslund, 198973 ? ? ? n/a ? n/a n/a ? ?
Angrisani, 2007107 ? ? ? n/a + n/a + ? ?
Bessler, 2007118 ? + ? ? ? n/a ? – ?
Davilla-Cervantes, 2002111 ? ? ? n/a + n/a n/a ? ?
de Wit, 1999132 + + ? n/a + n/a n/a ? ?
Dixon, 2008117 + ? – n/a + n/a + ? –
Himpens, 2006129 ? ? ? n/a ? n/a ? ? ?
Howard, 1995120 ? ? ? n/a + n/a n/a ? ?
Karamanakos, 2008125 + ? + n/a + n/a n/a ? ?
Lee, 2004124 ? ? ? ? ? ? n/a ? ?
Lujan, 2004130 + + ? n/a ? n/a n/a ? ?
MacLean, 1995121,122 ? ? ? n/a ? n/a n/a ? ?
Mingrone, 2002119 ? ? ? n/a + n/a n/a ? ?
Morino, 2003110 + + ? n/a + n/a n/a ? ?
Nilsell, 2001126 ? ? – – + n/a n/a ? ?
O’Brien, 2006115,116 + + – – ? ? ? ? ?
Olbers, 2005108,109 + ? ? n/a + n/a n/a ? ?
Puzziferri, 2001113,114 ? ? ? – ? ? ? ? –
Sugerman, 1987123 + ? ? n/a + n/a n/a ? –
Sundbom and Gustavsson, 2004112 ? ? ? n/a + n/a n/a ? –
Van Dielen, 2005127,128 + ? ? n/a + n/a + ? ?
VanWoert, 1992106 ? ? ? n/a ? n/a n/a ? ?
Westling and Gustavsson, 2001131 ? ? ? – + n/a n/a ? –
‘+’, yes (low risk of bias); ‘–’, no (high risk of bias); ‘?’, unclear (uncertain risk of bias); ‘n/a’, not applicable; QoL, quality of 
life.
because they moved overseas. There was therefore 
an overall loss to follow-up in this study of 2.5% 
at two years. Seven further RCTs also reported 
on participants lost to follow-up (Table 16) with 
these losses ranging from 1% to 9% for the overall 
study population. Five RCTs reported that no 
patients were lost to follow-up (Karamanakos and 
colleagues,125 Lujan and colleagues,130 Westling and 
Gustavsson,131 Sundbom and Gustavsson112 and 
Davila-Cervantes and colleagues111). One RCT (Lee 
and colleagues124) states that an intention-to-treat 
(ITT) analysis was conducted, but it is unclear if 
this applied to the weight loss at two years outcome 
where a figure suggests less than two-thirds of the 
participants contribute data and no information 
is provided regarding patients lost to follow-up. Clinical effectiveness
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TABLE 15  Summary of quality assessment of three included non-randomised studies 
Quality item
Buddeberg- Fischer, 
2006105 SOS study Stoeckli, 2004102–104
Is there sufficient description of 
the groups and the distribution of 
prognostic factors?
No Yes – differences between 
groups
Yes
Are the groups assembled at a similar 
point in their disease progression?
Uncertain Unclear Uncertain
Is the intervention/treatment reliably 
ascertained?
Yes Yes Yes
Were the groups comparable on all 
important confounding factors?
Uncertain No – significant differences 
between groups
Yes
Was there adequate adjustment for the 
effects of these confounding variables?
No Yes – states adjustments 
made where appropriate
Not applicable
Was outcome assessment blind to 
exposure status?
No. All measures, including 
BMI, were self-reported
No Uncertain
Was follow-up long enough for the 
outcomes to occur?
Yes Yes Yes
What proportion of the cohort was 
followed up?
119/131 at first follow-up, 
93/131 at second follow-
up.  
At 2 years: 84% surgical, 
93% control  
At 8 years: 73% of surgical, 
67% control
Uncertain
Were dropout rates and reasons for 
dropout similar across intervention and 
unexposed groups?
No Unclear – numbers and 
reasons not given
Uncertain
SOS, Swedish Obese Subjects.
The number of participants contributing data is 
observed to decrease over time in four RCTs but 
no reasons are provided for this.110,113,114,118,120 In 
the remaining four RCTs losses, to follow-up are 
not reported and it is not possible to ascertain how 
many patients contribute data at each follow-up 
time point.73,106,119,134
Assessment of clinical 
effectiveness evidence
Meta-analysis was considered inappropriate. In 
some cases, a comparison of surgical procedures 
(such as gastric bypass versus adjustable gastric 
banding, or adjustable gastric banding versus 
isolated sleeve gastrectomy) was assessed by just 
one study. Where the same procedures were 
compared by more than one RCT, there were often 
differences in the outcomes reported or the patient 
groups. The studies comparing surgery with non-
surgical interventions also differed in the surgical 
procedures and the non-surgical comparators. 
Standard deviations (or any data by which to 
calculate them) were not reported by the majority 
of studies. This is discussed further in Chapter 7, 
Strengths and limitations of the assessment.
Surgery versus non-
surgical interventions
Three RCTs and three cohort studies compared 
surgery with non-surgical interventions; however, 
the types of surgery or the comparators differed 
between the studies. The results below are 
discussed according to study design.
Weight change
Randomised controlled trials
The two RCTs that compared laparoscopic 
adjustable gastric banding with non-surgical 
interventions in obese people (BMI 40 or 
less) with identifiable comorbidities, reported 
statistically significant benefit on measures of 
weight change for those receiving laparoscopic 
adjustable gastric banding115–117 (Table 17). In a 
comparison of laparoscopic adjustable gastric 
banding with non-surgical interventions in people 
with a BMI ranging from 30 to 35 and identifiable 
comorbidities, O’Brien and colleagues115,116 
reported a statistically significant (p < 0.001) 
difference in the weight of participants at 12, 18 
and 24 months. While people in the laparoscopic 
adjustable gastric banding group consistently lost 
weight during the two-year follow-up, those in the 
non-surgical group increased in weight, despite an DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 16  Withdrawals and losses to follow-up
Study arm A Study arm B Overall Other comments
Withdrawals
Dixon, 2008117 LAGB: 1/30 
(3.3%) 
Conservative therapy: 
4/30 (13.3%)
5/60 (8%) at 2 
years
ITT analysis
O’Brien, 
2006115,116
Surgical: 1/40 
(2.5%)
Non-surgical: 5/40 
(12.5%)
6/80 (7%) at 2 
years
Lost to follow-up also reported, but 
no other missing data
Lost to follow-up
O’Brien, 
2006115,116
Surgical: 0 Non-surgical: 2/40 
(5%)
2/80 (2.5%) at 2 
years
Withdrawals also reported, but no 
other missing data
Maclean, 
1995121,122
GBP/VBG: 1 participant (study arm not 
stated)
1/106 (1%) at 3 
years
Other outcome data missing. Reasons 
not stated
Sugerman, 1987123 GBP: 0 VBG: 1/20 (5%) 1/40 (2.5%) at 3 
years
Reasons for other missing data 
provided
Olbers, 2005108,109 LGBP: 1/37 
(2.7%)
LVBG: 2/46 (4.3%) 3/83 (3.6%) at 2 
years
Reasons for other missing data 
provided
Angrisani, 2007107 LAGB: 1/27 
(3.7%)
LGBP: 0/24 1/51 (2%) at 5 
years
States not ITT. Unclear how many 
participants contribute data at each 
time point.
Nilsell, 2001126 VBG: 2/30 
(6.7%)
AGB: 3/29 (10.3%) 5/59 (8.5%) at 5 
years
Not all participants followed up at 
every time point.
Van Dielen, 
2005127,128
Open VBG LAGB 9% at 7 yearsa
de Wit, 1999132 Open AGB: 1/25 
(4%)
Lap AGB: 0/25 1/50 (2%) at 1 
year
AGB, adjustable gastric banding; GBP , gastric bypass; ITT, intention to treat; LAGB, laparoscopic adjustable gastric banding; 
LGBP , laparoscopic gastric bypass; LVBG, laparoscopic vertical banded gastroplasty; lap, laparoscopic surgery; VBG, vertical 
banded gastroplasty.
a  This follow-up period reported by a recent abstract128 was for a mean of 84 months.
initial loss of weight at six months. The differences 
in weight change were reflected in their respective 
BMIs, with statistically significant (p < 0.001) 
differences at beyond the six-month follow-up. 
Participants in the laparoscopic adjustable gastric 
banding group experienced a decrease in their 
BMI from 33.7 at baseline to 26.4 at two years 
compared with a decrease from a BMI of 33.5 
at baseline to 31.5 at two years for those in the 
non-surgical group. By two years people receiving 
laparoscopic adjustable gastric banding had lost 
87.2% of excess weight, statistically significantly 
(p < 0.001) more than the 21.8% lost by people in 
the non-surgical group. Some 98% of those people 
with a laparoscopic adjustable gastric banding had 
achieved a satisfactory weight loss (greater than 
25% of excess weight loss) at two years, compared 
with 35% of people in the non-surgical group.
Dixon and colleagues,117 who assessed the 
effectiveness of laparoscopic adjustable gastric 
banding and conventional therapy on obese 
people (BMI 30 to 40) diagnosed with Type 2 
diabetes at two years follow-up, found a statistically 
significantly (p< 0.001) greater mean percentage 
weight loss following laparoscopic adjustable gastric 
banding (20.0%) compared with conventional 
therapy (1.4%). This equated to a statistically 
significant (p < 0.001) difference in mean weight 
loss with those receiving laparoscopic adjustable 
gastric banding losing an additional 19.6 kg. 
The change in weight resulted in a reduction in 
the mean BMI for people in the laparoscopic 
adjustable gastric banding group from 36.9 to 
29.5, while those in the conventional therapy 
group declined from a BMI 37.1 to 36.6. Dixon 
and colleagues reported that the loss of weight 
represented a loss of 62.5% of excess weight 
(using BMI 25 as ideal weight) for people with 
the laparoscopic adjustable gastric banding and 
4.3% for people receiving conventional therapy. 
Similar benefits were noted on measures of waist 
circumference and waist : hip ratio for those in 
the laparoscopic adjustable gastric banding group 
compared with the conventional therapy group 
(Appendix 5).Clinical effectiveness
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Mingrone and colleagues119 randomised patients 
to either biliopancreatic diversion or a diet of 
20 kcal/kg fat-free mass, 55% carbohydrates and 
15% proteins that was modified every six months 
according to analysis of fat-free mass. Weight, 
BMI, fat-free mass and fat mass were significantly 
reduced in both men and women 12 months 
following biliopancreatic diversion compared 
with baseline (p < 0.0001). Weight loss in women 
and men following surgery was 35 kg and 52 kg, 
respectively, and 7 kg and 9 kg, respectively, 
following the diet. The study did not present 
a statistical comparison of surgery versus diet, 
and because the results reflect a before and after 
comparison only they should be treated with 
caution. 
Cohort studies
In 3505 participants who completed two years 
follow-up, the SOS study reported a significantly 
greater weight loss among gastric surgery patients 
(23.4%) than for those receiving conventional 
treatment (0.1% gain) [difference 22.2, 95% 
confidence interval (CI) 21.6 to 22.8, p < 0.001]97 
(Table 17). Among 1276 patients followed for 
10 years, patients in the surgical group had a 
16% (SD 12.1) weight loss compared with a 1.5% 
(SD 9.9) gain in weight for patients receiving 
conventional treatment. This equates to a mean 
reduction in weight and BMI of – 19.7 kg (SD 
15.8) and – 6.7 (SD 5.4), respectively, for the 
surgical group versus a gain in weight and BMI 
of 1.3 kg (SD 13.8) and 0.7 (SD 4.9), respectively 
for the conventional treatment group, a 
statistically significant difference between groups 
(p < 0.0001).100 Weight loss after 10 years was 
greater following gastric bypass (25%, SD 11) than 
following vertical banded gastroplasty (16%, SD 11) 
or gastric banding (adjustable or non-adjustable) 
(14%, SD 14), although it should be noted that this 
was not tested statistically and may be subject to 
selection bias (systematic differences between the 
groups) as the groups were not randomised. After 
15 years, the weight loss was 27% (SD 12), 18% (SD 
11) and 13% (SD 14), for the three surgical groups 
respectively; although it should be noted that the 
numbers followed for this duration were much 
smaller (Appendix 5).99
One small cohort study, reported by Buddeberg-
Fischer and colleagues,105 compared participants 
undergoing laparoscopic gastric banding or 
laparoscopic gastric bypass (surgery group) with 
a no-surgery control group. While mean BMI was 
not shown to be statistically significantly different 
between the two groups at end point (mean 
3.2 years follow-up), the mean change in BMI was 
(p < 0.001), indicating greater BMI reduction in 
the surgery group (Table 4.6). The percentage of 
excess weight loss was also seen to be statistically 
significantly better in the surgery group compared 
with the no-surgery group (p < 0.001). It should 
be noted, however, that there is some potential for 
bias as these measures were self-reported and the 
rates of dropout were different between the two 
groups over time. The study also assessed BMI 
and percentage excess weight loss between the two 
types of surgical procedures used within the surgery 
arm. The study showed that the mean change in 
BMI was greater in those undergoing laparoscopic 
gastric bypass than those undergoing laparoscopic 
gastric banding [– 27.7 (SD 12.6) versus –17.2 (SD 
12.5) for the two groups respectively, p = 0.002], 
and that the percentage excess weight loss was 
greater in the laparoscopic gastric bypass subgroup 
than the laparoscopic gastric banding group [52.8% 
(SD 17.0) versus 36.0% (SD 24.5) respectively, 
p = 0.005] (Appendix 5). Care should be used when 
interpreting these results, however, because the 
sample sizes were small, there was some degree of 
crossover between surgical options, this was not 
a planned comparison, and the surgical groups 
were not randomised and therefore were subject to 
selection bias.
The small cohort study with just 20 participants, 
reported by Stoeckli and colleagues,102–104 also 
found a statistically significant lower mean BMI 
two years following surgery [gastric bypass 32.9 
(SD 6.7); laparoscopic adjustable silicone gastric 
banding 33.2 (SD 4.7); compared with a control 
group who did not undergo surgery 41.0 (SD 3.4)].
Quality of life
Randomised controlled trials
O’Brien and colleagues compared changes in the 
short-form health survey (SF-36) domain scores 
from baseline to two years follow-up for people 
undergoing laparoscopic adjustable gastric banding 
and non-surgical therapy.115,116 Although no point 
estimates were reported, O’Brien and colleagues 
noted improvements in scores on all eight domains 
for the laparoscopic adjustable gastric banding 
group and on three domains (physical function, 
vitality and mental health) for the non-surgical 
therapy group. Statistically significantly greater 
improvements were reported for five of the eight 
domains for laparoscopic adjustable gastric 
banding compared with the non-surgical group 
(Table 18).DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 17  Summary of results: surgery versus non-surgical management – weight change 
Dixon, 2008117  LAGB (n = 30) Con therapy (n = 30) Effect size/p-value 
(95% CI)
% initial weight loss at 2 years 20.0 (± 9.4) 1.4 (± 4.9) p < 0.001
% excess weight loss at 2 years 62.5 4.3
Weight loss (kg) at 2 years – 21.1 (± 10.5) – 1.5 (± 5.4) Difference –19.6 
(–23.8 to – 15.2) 
p < 0.001
Reduction in BMI at 2 years from 36.9 to 29.5 from 37.1 to 36.6
O’Brien, 2006115,116 LAGB (n = 40) Non surgical (n = 40)
Weight at 12 months  
[mean (95% CI) kg]
76.3 (74.1–78.5) 85.3 (83.0–87.5) p < 0.00 1
Weight at 18 months  
[mean (95% CI) kg]
75.2 (73.1–77.4) 87.7 (79.9–83.0) p < 0.001
Weight at 24 months  
[mean (95% CI) kg]
74.5 (72.4–76.7) 89.5 (80.5–83.6) p < 0.001
BMI at 12 months [mean (95% CI)] 27.0 (26.2–27.8) 29.9 (29.1–30.8) p < 0.001
BMI at 18 months [mean (95% CI)] 26.7 (25.9–27.5) 30.9 (30.0–31.8) p < 0.001
BMI at 24 months [mean (95% CI)] 26.4 (25.6–27.2) 31.5 (30.6–32.4) p < 0.001
% of initial weight lost at 2 years 
[mean (95% CI)]
21.6 (19.3–23.9) 5.5 (3.2–7.9)
% excess weight lost at 12 months 
[mean (95% CI)]
78.6 (69.2–88.1) 41.1 (31.2–50.9) p < 0.001
% excess weight lost at 2 years 
[mean (95% CI)]
87.2 (77.7–96.6) 21.8 (11.9–31.6) p < 0.001
Proportion achieving excess weight 
loss > 50% at 2 years
33/39 (85%) 8/31 (26%) p < 0.001
Proportion achieving satisfactory 
weight loss
(> 25% excess weight lost)
39/40 (98%) 14/40 (35%) p < 0.001
Mingrone, 2002119 BPD (n = 46) Diet (n = 33)
Weight (kg) women
Baseline 125.3 (± 12.8) 121.6 (± 24.1)
1 year, p-value vs baseline 90.2 (± 15.0), p < 0.0001 114.5 (± 24.5)
Weight (kg) men
Baseline 151.8 (± 17.1) 147.3 (± 26.8)
1 year, p-value vs baseline 99.7 (± 7.0), p < 0.0001 138.2 (± 27.1)
BMI women
Baseline 48.3 (± 6.3) 48.4 (± 8.9)
1 year, p-value vs baseline 35.2 (± 7.6), p < 0.0001 43.8 (± 7.7)
BMI men
Baseline 48.0 (± 5.4) 47.8 (± 8.8)
1 year, p-value vs baseline 30.4 (± 3.5), p < 0.0001 44.8 (± 8.4)
Fat-free mass (kg) women
Baseline 59.3 (± 5.6) 58.3 (± 8.8)
1 year, p-value vs baseline 50.5 (± 4.7), p < 0.0001 56.7 (± 8.8)
continuedClinical effectiveness
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Fat-free mass (kg) men
Baseline 88.7 (± 8.1) 87.3 (± 11.4)
1 year, p-value vs baseline 74.2 (± 5.4), p < 0.0001 83.7 (± 11.8)
Fat mass (kg) women
Baseline 65.9 (± 10.2) 63.3 (± 16.2)
1 year, p-value vs baseline 39.8 (± 12.7), p < 0.0001 57.8 (± 16.5)
Fat mass (kg) men
Baseline 63.1 (± 10.2) 60.0 (± 15.6)
1 year, p-value vs baseline 25.5 (± 2.7), p < 0.0001 54.6 (± 15.6)
SOS study, 1997–200797,99,100 Surgery Control
% weight change at 2 years97 – 23.4 (n = 1845) 0.1 (n = 1660) Difference 22.2 (21.6 
to 22.8), p < 0.001
% BMI change at 2 years97 – 23.3 (n = 1845) 0.1 (n = 1845) 22.1 (21.5 to 22.7), 
p < 0.001
Weight at 10 years, kg100 100.5 (± 17.7) (n = 655) 115.2 (± 19.9) (n = 621) p < 0.0001
Weight change at 10 years (kg)100 – 19.7 (± 15.8) (n = 655) 1.3 (± 13.8) (n = 621) p < 0.0001
Weight % change at 10 years100 – 16 (± 12.1) (n = 655) 1.5 (± 9.9) (n = 621)
BMI at 10 years100 35.3 (± 5.4) (n = 655) 40.6 (± 5.9) (n = 621)
Change in BMI at 10 years100 – 6.7 (± 5.4) (n = 655) 0.7 (± 4.9) (n = 621) p < 0.0001
Buddeberg-Fischer, 2006105 Surgery (n = 63) No surgery (n = 30)
BMI at mean 3.2 years 34.9 (± 5.5)  40.6 (± 7.4)  p < 0.09
BMI change at mean 3.2 years – 21.0 (± 13.4)  – 5.5 (± 11.1)  p < 0.001
% EWL at mean 3.2 years 42.2 (± 23.4)  11.5 (± 25.8)  p < 0.001
Stoeckli, 2004102–104 LAGB (n = 8) Open RYGBP 
(n = 5)
Controls (n = 7)
BMI
Baseline 41.7 (± 2.8) 43.6 (± 4.4) 41.1 (± 2.6)
24 months 33.2 (± 4.7)* 32.9 (± 6.7)* 41.0 (± 3.4) * vs control p < 0.001
Weight, mean (SEM) kg
Baseline 117.2 (2.5) 113.3 (4.9) 113.5 (4.9)
% change –16.0 (3.2) 
p < 0.01
– 28.6 (3.6) + 0.5 (1.2)
Total fat mass, mean (SEM) kg
Baseline 63.7 (2.2) 63.6 (2.2) 64.8 (4.7)
% change – 33.9 (5.3) 
p < 0.001
– 51.0 (5.2) + 2.5 (3.3)
BMI, body mass index; BPD, biliopancreatic diversion; CI, confidence interval; Con therapy, conventional therapy; EWL, 
exccess weight loss; LAGB, laparoscopic adjustable gastric banding; LRYGBP , laparoscopic Roux-en-Y gastric bypass; open, 
open surgery; RYGBP , Roux-en-Y gastric bypass; SD, standard deviation; SEM, standard error of the mean; SOS, Swedish 
Obese Subjects.
All mean (± SD) unless stated.
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Quality of life was not reported by either Dixon 
and colleagues117 or Mingrone and colleagues.119
Cohort studies
The SOS study assessed Health Related Quality of 
Life (HRQoL) using several measures, including 
general health perceptions from the General 
Health Rating Index, social interaction from 
the Sickness Impact Profile, overall mood from 
the Mood Adjective Check List (MACL), the 
obesity-related problems scale and the Hospital 
Anxiety and Depression scale. At baseline the 
patients in the surgery group had generally worse 
HRQoL than those in the conventional treatment 
group.86,100 These differences may reflect the 
significant differences in BMI and prevalence of 
hypertension that developed between matching of 
controls and start of treatment, or may indicate bias 
in the selection of patients for surgery.
The two-year results of 974 participants have 
been tabulated and discussed in the previous 
report15 and can be seen in Appendix 5. In brief, 
at two years follow-up gastric surgery patients had 
significant improvements in all HRQoL measures 
compared with patients receiving conventional 
treatment. These changes were significantly related 
to the magnitude of the weight loss and may 
have been expected given that the patients in the 
surgical group had significantly higher BMI at the 
time of treatment compared with the controls.86
A more recent report of 1276 participants found 
that improvements in HRQoL, which peaked one 
year after surgery, were followed by a gradual 
decline between one and six years, and then 
observations were relatively stable between six and 
ten years follow-up.100 All HRQoL measures were 
improved at 10 years compared with baseline for 
the surgery group, but for the conventional group 
some had improved while others had worsened. 
After 10 years follow-up, the mean level of current 
health perception, social interaction, obesity-
related problems, overall mood and depression 
did not differ significantly between the surgery 
and conventional treatment groups, although 
the surgery group had more anxiety (p < 0.01). 
However, statistically significantly greater 10-
year change was observed in the surgery group 
for current health perceptions, social interaction, 
obesity-related problems and depression. There 
was no statistically significant difference in 10-year 
change for overall mood and anxiety (Table 18).
Buddeberg-Fischer and colleagues105 applied a 
range of validated questionnaires related to quality 
of life to participants via telephone interview. The 
study reported that the Psychosocial Stress and 
Symptom Questionnaire (PSSQ) was used which 
incorporated the Hospital Anxiety and Depression 
Scale (HADS), the Bing Scale Questionnaire (BSQ) 
and the Psychosocial Assessment Questionnaire 
(PAssQ), although no results were reported for the 
overall PSSQ questionnaire. After a mean follow-
up of 3.2 years there were no statistically significant 
differences between groups on mean scores from 
any of the three questionnaires (Table 18).
Buddeberg-Fischer and colleagues105 also presented 
self-reported assessment of overall physical and 
mental health. This was also undertaken via 
telephone interview and while the results give an 
indication of the individuals’ perception of their 
health this was not a validated measure and is likely 
to be measuring the state of the individual at that 
particular point in time only. Higher proportions 
of participants in the surgical group (79.3%) 
rated their physical health as good compared 
with the no-surgery group (64.5%), but this was 
not statistically significantly different (p = 0.10). 
A similar pattern emerged for ratings of mental 
health (77.6% versus 67.7% for the two groups 
respectively, p = 0.22). No analysis was presented 
of the proportions rating their health as poor 
(Appendix 5).
Quality of life was not reported by Stoeckli and 
colleagues.102–104
Comorbidities
Randomised controlled trials
Dixon and colleagues assessed the effects of 
laparoscopic adjustable gastric banding compared 
with conventional therapy on measures of 
glycaemic control and use of diabetes medication 
among 60 obese people with Type 2 diabetes.117 
Remission of Type 2 diabetes at two years follow-
up was statistically significantly (p < 0.001) higher 
following laparoscopic adjustable gastric banding 
(73%) than conventional therapy (13%) (RR 5.5; 
95% CI 2.2, 14.00) (Table 19). Similarly, people 
undergoing laparoscopic adjustable gastric 
banding were statistically significantly less likely 
to suffer from metabolic syndrome (70% versus 
13%, p < 0.001). Measures of glycaemic control 
improved more following laparoscopic adjustable 
gastric banding than conventional therapy with 
statistically significantly greater decreases in 
mean levels of HbA1c (glycosylated haemoglobin; 
difference – 1.43, 95% CI – 2.1 to 0.80, p < 0.001), 
plasma glucose (difference – 31.8, 95% CI – 53.1 
to – 12.3, p = 0.002), plasma insulin (difference Clinical effectiveness
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TABLE 18  Summary of results: surgery versus non-surgical management – quality of life
O’Brien, 2006115,116  LAGB (n = 39) Non-surgical (n = 33) Effect size/p-value
Mean SF-36 domain scores,a at 2 years
Physical function 90 87 p < 0.05
Physical role 92 70 p < 0.05
Pain 83 78 p = ns
General health 73 68 p < 0.05
Vitality 66 57 p < 0.05
Social functioning 85 81 p = ns
Emotional role 92 72 p < 0.05
Mental health 76 72 p = ns
SOS study, 1997–2007100 b Surgery (n = 655) Control (n = 621)
Current health perceptionc
1-year follow-up,% improvement 48%  7%
10-year follow-up 57.5 (± 26.8) 55.4 (± 25.1) p = ns 
10-year change 5.8 (± 27.6) (11% 
improvement)
– 3.4 (± 25.2) p < 0.0001 
Effect size of change 0.21 – 0.13
Obesity-related problemsd 
1-year follow-up,% improvement ~ 63%  7%
10-year follow-up 29.7 (± 27.3) 31.3 (± 25.5) p = ns 
10-year change 28.3 (± 28.3) 9.6 (± 22.6) p < 0.0001 
Effect size of change 1.00 0.42
Social interactione
1-year follow-up,% improvement ~60%  7%
10-year follow-up 8.4 (± 12.4) 7.7 (± 11.1) p = ns 
10-year change – 3.2 (± 13.0) 0.5 (± 10.0) p < 0.01 
Effect size of change 0.25 – 0.05
MACL Overall moodf
10-year follow-up 3.06 (± 0.59) 3.11 (± 0.56) p = ns 
10-year change 0.14 (± 0.56) 0.05 (± 0.51) p = ns
Effect size of change 0.25 0.10
HADS Depressiong
10-year follow-up 3.7 (± 3.7) 3.7 (± 3.5) p = ns 
10-year change – 1.4 (± 3.9) – 0.5 (± 3.4) p < 0.05 
Effect size of change 0.35 0.14
HADS Anxietyg
10-year follow-up 4.6 (± 4.4)  4.0 (± 4.2) p < 0.01 
10-year change – 1.4 (± 4.3) – 1.4 (± 3.9) p = ns 
Effect size of change  0.33 0.35DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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Buddeberg-Fischer, 2006105 Surgery (n = 63) No surgery (n = 30)
HADS – Anxiety Scoreg: mean 3.2 years 
follow-up
5.76 (± 4.27)  6.53 (± 4.29)  p = 0.21
HADS – Depression Scoreg: mean 3.2 years 
follow-up
4.67 (± 4.58)  4.33 (± 3.01)  p = 0.65
BSQ Scoreh: mean 3.2 years follow-up 7.16 (± 9.68) 8.87 (± 9.52)  p = 0.55
PassQ Scorei: mean 3.2 years follow-up 2.11 (± 2.04)  1.87 (± 2.08)  p = 0.99
BSQ, Bing Scale Questionnaire; HADS, Hospital Anxiety and Depression Scale; HRQol, health-related quality of life; 
LAGB, laparoscopic adjustable gastric banding; MACL, Mood Adjective Check List; ns, not statistically significant; PassQ, 
Psychosocial Assessment Questionnaire; SD, standard deviation; SF-36, short form health survey; SOS, Swedish Obese 
Subjects.
All mean (± SD) unless stated.
a  Mean Short Form-36 QoL domain scores estimated from figure (95% CIs presented in figure but not possible to extract 
data reliably). Higher scores indicate better health status. 
b  SOS study: HRQoL at 10 years in surgically treated patients by weight change, and 10-year trends in weight loss and 
HRQoL in surgically treated patients with weight loss ≥ 10% vs < 10% after 10 years reported but not extracted. Effect 
size (ES) of change calculated to provide standardized effect levels regardless of sample size and scaling properties of 
HRQoL instruments (where 0 to < 0.20 trivial, 0.20 to < 0.50 small, 0.50 to < 0.80 moderate, ≥ 0.80 large). 
c  Health perceptions from the General Health Rating Index (score range 0–100, higher score indicates more positive 
perceived health status).
d  Obesity-related problems scale (score range 0–100, higher score indicates greater impairment of psychosocial 
functioning).
e  Social interaction from the Sickness Impact Profile (score range 0–100, higher score indicates more dysfunction in social 
interaction). 
f  Overall mood from the Mood Adjective Check List (a higher overall mood score indicates more positive mood states). 
g  Hospital Anxiety and Depression scale (a score of less than eight is considered in the normal range, a score of 8–10 
indicates a possible case and a score > 10 indicates a probable case of mood disorder).
h  Binge scale questionnaire (higher score indicates greater severity of binge eating).
i  Psychosocial assessment questionnaire (score range 0–11, higher score indicates greater psychosocial stress).
– 13.4, 95% CI – 19.6 to – 7.3, p < 0.001), and 
HDL-cholesterol (difference 10.0, 95% CI 5.8 to 
14.2, p < 0.001). There were greater improvements 
in other indices of glycaemic control (e.g. blood 
pressure, total cholesterol) for the laparoscopic 
adjustable gastric banding group compared with 
the conventional therapy group, although these 
were not statistically significant (Appendix 5). The 
benefits of laparoscopic adjustable gastric banding 
compared with conventional therapy were evident 
in the reduction in the use of diabetes medication. 
At two years follow-up a greater proportion of 
those receiving laparoscopic adjustable gastric 
banding no longer required diabetes medication 
compared with conventional therapy (change from 
baseline 83% versus 15% respectively, not tested 
for statistical significance). There were similar 
improvements from baseline to two years follow-
up for those in the laparoscopic adjustable gastric 
banding group compared to the conventional 
therapy group in their use of metformin (86.3% 
versus 30.8%), other hypoglycaemics (27.6% 
versus 3.2%), insulin (3.4% versus 11.5%), anti-
hypertensives (48% versus 0%) and lipid-lowering 
agents (27.6% versus 3.9%) although these 
differences between the groups were also not tested 
for statistical significance. 
O’Brien and colleagues noted that the group 
receiving laparoscopic adjustable gastric banding 
experienced a statistically significant reduction in 
the proportion of people with metabolic syndrome 
at two years follow-up (baseline 37.5%, two years 
2.7%, p < 0.001).115,116 For those in the non-surgical 
group the proportion with metabolic syndrome 
decreased, but not significantly (baseline 37.5%, 
two years 24%, p = 0.22). There was a statistically 
significant difference in the number of participants 
with metabolic syndrome between the two 
interventions, at two years p = 0.006 (Table 19). 
Comorbidities were not reported by Mingrone and 
colleagues.119
Cohort studies
Earlier publications from the SOS study of two-
year and eight-year data on the incidence of 
diabetes and hypertension in 483 participants89 
and two-year data on lipid disturbances in 1449 
participants88 have been summarised previously15 
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and can be seen in Appendix 5. More recently 
reported data including 3505 participants at two-
year follow-up and 1268 participants at 10-year 
follow-up97 are discussed here.
The incidence of diabetes (2 years: 1% versus 8%, 
p < 0.001; 10 years: 7% versus 24%, p < 0.001), 
hypertriglyceridaemia (2 years: 8% versus 22%, 
p < 0.001; 10 years: 17% versus 27%, p = 0.03) 
and hyperuricaemia (2 years: 4% versus 16%, 
p < 0.001; 10 years: 17% versus 28%, p < 0.001) was 
significantly lower in the surgery group at both 2 
and 10 years follow-up (Table 19). The incidence 
of low HDL-cholesterol was significantly lower in 
the surgery group at two years (2% versus 10%, 
p < 0.001), but not 10 years (3% versus 6%, p = 0.12) 
follow-up, and there was no statistically significant 
difference in the incidence of hypertension 
(2 years: 24% versus 29%, p = 0.06; 10 years: 41% 
versus 49%, p = 0.13) and hypercholesterolaemia 
(2 years: 27% versus 24%, p = 0.11; 10 years: 30% 
versus 27%, p = 0.57) at 2 or 10 years follow-up. 
Participants who underwent surgery were more 
likely to recover from diabetes (2 years: 72% 
recovered versus 21%, p < 0.001; 10 years: 36% 
versus 13%, p < 0.001), hypertension (2 years: 
34% recovered versus 21%, p < 0.001; 10 years: 
19% versus 11%, p = 0.02), hypertriglyceridaemia 
(2 years: 62% recovered versus 22%, p < 0.001; 
10 years: 46% versus 24%, p < 0.001), low HDL-
cholesterol (2 years: 76% recovered versus 39%, 
p < 0.001; 10 years: 73% versus 53%, p < 0.001) 
and hyperuricaemia (2 years: 71% recovered 
versus 31%, p < 0.001; 10 years: 48% versus 27%, 
p < 0.001) than those with conventional treatment, 
at 2 and 10 years follow-up, but there was no 
statistically significant difference in recovery from 
hypercholesterolaemia between groups (2 years: 
22% recovered versus 17%, p = 0.07; 10 years: 21% 
versus 17%, p = 0.14) (Table 19). 
Of patients who were on diabetes medication at 
baseline, significantly fewer surgery patients were 
on diabetes medication at six years follow-up 
compared with controls [68.8% versus 100%, RR 
0.71 (95% CI 0.56 to 0.89), p < 0.05]. This was 
also the case for patients who were not on diabetes 
medication at baseline [2.1% versus 11.3%, RR 0.20 
(95% CI 0.10 to 0.38), p < 0.05].136
Of patients who were on CVD medication at 
baseline, significantly fewer surgery patients 
were on CVD medication at six years follow-up 
compared with controls [64.7% versus 86.4%, 
RR 0.77 (95% CI 0.67 to 0.88), p < 0.05]. Of 
patients who were not on medication at baseline, 
the difference in the proportion on medication 
was statistically significant at two years follow-up 
[surgery 3.1%, control 10.1%, RR 0.28 (95% CI 
0.14 to 0.56), p < 0.05], but not at six years follow-
up [surgery 13.3%, control 16.7%, RR 0.80 (95% CI 
0.56 to 1.16)].136
At two years follow-up, men with surgery had more 
cholelithiasis [4.0% versus 1.2%, p = 0.011, OR 4.2 
(95% CI 1.5 to 12.0)], cholecystectomy [3.4% versus 
0.7%, p = 0.008, OR 5.4 (95% CI 1.5 to 19.6], 
cholecystitis [2.5% versus 0.7%, p = 0.058, OR 4.5 
(95% CI 1.2 to 17.1)] and total biliary disease [4.1% 
versus 1.5%, p = 0.024, OR 3.5 (95% CI 1.3 to 
9.2)] than male controls. There was no difference 
in pancreatitis among men, and there were no 
statistically significant differences in these diseases 
among women.96
Incidence of cancer during an average of 11 years 
follow-up in the SOS study has been reported in a 
recent abstract.101 In the surgery group (n = 2010) 
there were 126 cases of first-time cancers and in 
the control group (n = 2037) there were 173 cases. 
The unadjusted hazard ratio for overall cancer 
incidence was 0.71 (p = 0.003) and the hazard ratio 
adjusted for risk factors was 0.74 (p = 0.011). The 
unadjusted hazard ratio for men (n = 1178) was 
0.98 (95% CI 0.63–1.51, p = 0.91) and for women 
(n = 2867) was 0.63 (95% CI 0.48–0.82, p = 0.001) 
(Appendix 5).
Only data on medication use were reported by 
Buddeberg-Fischer and colleagues.105 In the last 
three months of the study those in the surgery 
group were found to use statistically significantly 
fewer numbers of different obesity-related drugs 
than those in the no-surgery group (p < 0.001). 
There were no statistically significant differences in 
the number of different medications being taken 
for somatic comorbidity or psychiatric comorbidity 
(Table 19). Caution is required in interpreting these 
outcomes as these were medications used only in 
the last three months of a study with a mean of 
3.2 years follow-up, no measures of variance around 
the mean values were reported, results were based 
on self-reports and no further definition of the 
drugs was given.
Comorbidities were not reported by Stoeckli and 
colleagues.102–104
Complications and additional 
operative procedures
Randomised controlled trials
O’Brien and colleagues found a higher proportion 
of adverse events among those people in the 
non-surgical therapy group (58%, n = 31) than DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 19  Summary of results: surgery versus non-surgical management – comorbidities
Dixon, 2008117 LAGB  
(n = 30)
Con therapy 
(n = 30)
Effect size/p-value  
(95% CI)
Remission of Type 2 diabetes at 2 years 22/30 (73%) 4/30 (13%) RR 5.5 (95% CI 2.2 to 14.0) p < 0.001
Metabolic syndromea 
At baseline 1 (3%) 1 (3%)
At 2 years 21 (70%); p < 0.001 4 (13%); p = 0.22 p < 0.001
No diabetes medication 
At baseline 2/29 (6.9%) 4/26 (15.4%)
At 2 years 26/29 (89.7%) 8/26 (30.8%)
Metformin use
At baseline 28/29 (96.6%) 26/26 (100%)
At 2 years 3/29 (10.3%) 18/26 (69.2%)
Other hypoglycaemic use
At baseline 9/29 (31%) 8/26 (30.8%)
At 2 years 1/29 (3.4%) 7/26 (26.9%)
Insulin use
At baseline 1/29 (3.4%) 0
At 2 years 0 3/26 (11.5%)
Antihypertensive agents
At baseline 20/29 (70%) 15/26 (57.7%)
At 2 years 6/29 (20.7%) 15/26 (57.7%)
Lipid-lowering agents
At baseline 12/29 (41.4%) 8/26 (30.8%)
At 2 years 4/29 (13.8%) 7/26 (26.9%)
O’Brien, 2006115,116 LAGB (n = 39) Non-surgical 
(n = 33)
Metabolic syndrome
Before treatment 15/40 (37.5%) 15/40 (37.5%)
2 years after treatment 1/39 (2.7%) 8/33 (24%) p = 0.006
SOS study, 1997–200796,97,136,b Surgery Controls
Incidence of diabetes at 2 years 15/1489 (1%) 112/1402 (8%) OR 0.14 (0.08 to 0.24), p < 0.001
Incidence of diabetes at 10 years 36/517 (7%) 129/539 (24%) OR 0.25 (0.17 to 0.38), p < 0.001
Recovery of diabetes at 2 years 246/342 (72%) 52/248 (21%) OR 8.42 (5.68 to 12.5), p < 0.001
Recovery of diabetes at 10 years 42/118 (36%) 11/84 (13%) 3.45 (1.64 to 7.28), p < 0.001
No. on diabetes medication136 at 
baseline
(n=32) (n=21)
% at 2 years 56.2 100.0 RR 0.56 (0.41 to 0.76), p < 0.05
% at 6 years 68.8 100.0 RR 0.71 (0.56 to 0.89), p < 0.05
No. not on diabetes medication136 at 
baseline
(n=478) (n=434)
% at 2 years 0.2 3.7 RR 0.08 (0.01 to 0.58), p < 0.05
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% at 6 years  2.1 11.3 RR 0.20 (0.10 to 0.38), p < 0.05
Incidence of hypertension at 2 years 149/623 (24%) 223/770 (29%) OR 0.78 (0.60 to 1.01), p = 0.06
Incidence of hypertension at 10 years 88/215 (41%) 137/279 (49%) OR 0.75 (0.52 to 1.08), p = 0.13
Recovery from hypertension at 2 years 409/1204 (34%) 185/880 (21%) 1.72 (1.40 to 2.12), p < 0.001
Recovery from hypertension at 10 
years
81/424 (19%) 38/342 (11%) OR 1.68 (1.09 to 2.58), p = 0.02
Incidence of hypertriglyceridaemia at 
2 years
58/731 (8%) 176/801 (22%) OR 0.29 (0.21 to 0.41), p < 0.001
Incidence of hypertriglyceridaemia at 
10 years 
38/225 (17%) 75/281 (27%) OR 0.61 (0.39 to 0.95), p = 0.03
Recovery from hypertriglyceridaemia 
at 2 years
683/1102 (62%) 187/850 (22%) OR 5.28 (4.29 to 6.49), p < 0.001
Recovery from hypertriglyceridaemia 
at 10 years
185/402 (46%) 79/331 (24%) OR 2.57 (1.85 to 3.57), p < 0.001
Incidence of low HDL-cholesterol at 
2 years 
25/1293 (2%) 117/1174 (10%) OR 0.21 (0.14 to 0.32), p < 0.001
Incidence of low HDL-cholesterol at 
10 years
13/431 (3%) 26/440 (6%) OR 0.57 (0.29 to 1.15), p = 0.12
Recovery from low HDL-cholesterol 
at 2 years
338/445 (76%) 154/396 (39%) 5.28 (3.85 to 7.23), p < 0.001
Recovery from low HDL-cholesterol 
at 10 years
123/169 (73%) 88/166 (53%) 2.35 (1.44 to 3.84), p < 0.001
Incidence of hypercholesterolaemia at 
2 years
136/504 (27%) 143/596 (24%) OR 1.27 (0.95 to 1.69), p = 0.11
Incidence of hypercholesterolaemia at 
10 years 
40/135 (30%) 51/188 (27%) OR 1.16 (0.69 to 1.95), p = 0.57
Recovery from hypercholesterolaemia 
at 2 years
292/1327 (22%) 178/1048 (17%) 1.22 (0.98 to 1.51), p = 0.07
Recovery from hypercholesterolaemia 
at 10 years 
105/498 (21%) 74/435 (17%) OR 1.30 (0.92 to 1.83), p = 0.14
Incidence of hyperuricaemia at 2 years 42/1044 (4%) 163/1017 (16%) OR 0.22 (0.15 to 0.31), p < 0.001
Incidence of hyperuricaemia at 10 
years 
58/342 (17%) 107/382 (28%) OR 0.49 (0.34 to 0.71), p < 0.001
Recovery from hyperuricaemia at 2 
years
562/792 (71%) 197/637 (31%) OR 5.36 (4.23 to 6.78), p < 0.001
Recovery from hyperuricaemia at 10 
years 
140/292 (48%) 66/243 (27%) OR 2.37 (1.61 to 3.47), p < 0.001
Biliary disease and pancreatitis frequencies over 2 years (%)96
(n = 1422) (n = 1260)
Cholelithiasis 
Men 4.0 1.2 OR 4.2 (1.5 to 12.0), p = 0.011
Women 5.5 4.5 OR 1.1 (0.7 to 1.8), p = 0.328
Cholecystitis 
Men 2.5 0.7 OR 4.5 (1.2 to 17.1), p = 0.058
Women 3.3 2.5 OR 1.4 (0.7 to 2.5), p = 0.379
Cholecystectomy
Men 3.4 0.7 OR 5.4 (1.5 to 19.6), p = 0.008
Women 3.5 2.3 OR 1.6 (0.9 to 3.0), p = 0.191
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Total biliary disease
Men 4.1 1.5 OR 3.5 (1.3 to 9.2), p = 0.024
Women 6.8 5.3 OR 1.2 (0.8 to 1.9), p = 0.223
Pancreatitis 
Men 1.1 0.2 OR 3.6 (0.4 to 31.2), p = 0.219
Women 0.7 0.4 OR 1.8 (0.4 to 7.6) p = 0.514
Cardiovascular disease medication136
On medication at baseline  n = 150 n = 125
% on medication at 2 years 61.7 91.2 RR 0.69 (0.60 to 0.80), p < 0.05
% on medication at 6 years 64.7 86.4 RR 0.77 (0.67 to 0.88), p < 0.0 5
Not on medication at baseline n = 360 n = 330
% on medication at 2 years 3.1 10.1 RR 0.28 (0.14 to 0.56), p < 0.05
% on medication at 6 years 13.3 16.7 RR 0.80 (0.56 to 1.16)
Buddeberg-Fischer, 2006105 Surgery 
(n = 59/63)
No surgery 
(n = 30/30)
Number of different drugs at mean 3.2 
years for [mean, median (range)]:
Obesity 0.03, 0 (0–1) 0.32, 0 (0–2)  p < 0.001
Somatic comorbidity 2.29, 2 (0–15) 2.10, 1 (0–9) p = 0.98
Psychiatric comorbidity 0.17, 0 (0–3) 0.6, 0 (0–2) p = 0.25
CI, confidence interval; Con therapy, conventional therapy; LAGB, laparoscopic adjustable gastric banding; OR, odds ratio; 
RR, relative risk; SOS, Swedish Obese Subjects.
All mean (± SD) unless stated.
a  Reports the number of patients not meeting the criteria for metabolic syndrome.
b  For incidence of and recovery from comorbidities at 2 and 10 years the n values used for numerators were calculated by 
reviewer and rounded.
in the laparoscopic adjustable gastric banding 
group (18%, n = 39)115,116 (Table 20). For those 
receiving non-surgical therapy the most common 
adverse events were intolerance to orlistat (26%), 
acute cholecystitis (13%), the need for operative 
interventions (13%) and intolerance to a VLCD 
(3%). Adverse events reported by people in 
the laparoscopic adjustable gastric banding 
group included operative interventions (13%), 
laparoscopic revision (prolapse or posterior) 
(10%), 5-mm port site infection (2.6%) and acute 
cholecystitis (2.6%). Loss to follow-up was higher 
in the non-surgical group (16%) compared with 
the laparoscopic adjustable gastric banding group 
(2.6%) (but reasons were not given).
Dixon and colleagues reported several adverse 
events among people in the laparoscopic adjustable 
gastric banding group (n = 30), including a 
superficial wound infection (one patient), gastric 
pouch enlargement requiring revisional surgery 
(two patients), eating difficulties and persistent 
regurgitation requiring band removal (one 
patient), postoperative febrile episode (one 
patient), hypoglycaemic episode (one patient) and 
gastrointestinal tract intolerance to metformin (one 
patient)117 (Table 20). People in the conventional 
therapy group (n = 30) suffered minor adverse 
events associated with their medication which 
resolved following discontinuation of treatment, 
including gastrointestinal problems (two patients), 
persistent diarrhoea with metformin (one patient), 
and vasculitic rash (one patient). Other adverse 
events included multiple hypoglycaemic episodes 
(one patient), angina and transient cerebral 
ischaemic episode requiring admission to hospital 
(one patient) and intolerance to very-low-calorie 
meal replacement (two patients). Dixon and 
colleagues noted that the mean procedure time for 
placement of the laparoscopic adjustable gastric 
banding was 54 minutes and that 80% of patients 
were kept in hospital for only one day.
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Complications and additional operative procedures 
were not reported by Mingrone and colleagues.119
Cohort studies
Within 90 days of surgery in the SOS study there 
were five deaths (0.25%) in the surgery group 
(four from peritonitis with organ failure, one from 
sudden death) and two deaths in the control group 
(one from pancreatic cancer, one from alcohol-
related causes).99
Perioperative complications were experienced 
by 13% of 1164 patients in the SOS study, these 
included bleeding (0.9%), thromboembolic events 
(0.8%), wound complications (1.8%), abdominal 
infection (2.1%), pulmonary symptoms (6.2%) 
and miscellaneous (4.8%) (Table 20). Postoperative 
complications requiring reoperation were 
experienced by 2.2% of patients in the surgery 
group. The patients in the SOS study underwent 
vertical banded gastroplasty, gastric banding or 
gastric bypass, but the complications are only 
reported for the surgery group as a whole. Surgical 
reoperations or conversions (excluding operations 
caused by postoperative complications) were 
reported for 1338 patients followed for at least 
10 years, and occurred in 31% of gastric banding 
patients, 21% of vertical banded gastroplasty 
patients and 17% of gastric bypass patients.
The Buddeberg-Fischer and colleagues105cohort 
study reported reoperations only. Seven of 69 
participants in the surgery group were reported 
to have a reoperation; five participants with 
laparoscopic gastric banding were converted to 
Roux-en-Y gastric bypass and two had their bands 
removed. Nine patients in the no-surgery group 
underwent gastric bypass. No further details are 
reported. 
Complications and additional operative procedures 
were not reported by Stoeckli and colleagues.102–104
Cumulative overall mortality
The SOS study reported cumulative overall 
mortality during a period of up to 16 years (mean 
10.9 years follow-up).99 The hazard ratio of the 
surgery group compared with the control group 
was 0.76 [(95% CI 0.59 to 0.99) p = 0.04]. There 
were 101 (5%) deaths in the surgery group and 
129 deaths (6.3%) in the control group. Table 21 
displays the causes of death; the most common 
causes of death were cancer (surgery 29 cases, 
control 47 cases), sudden death (surgery 20 cases, 
control 14 cases) and myocardial infarction (surgery 
13 cases, control 25 cases).
Summary
Three RCTs (one with a low risk of selection bias, 
one with a high risk of selection bias and one of 
uncertain risk of bias) and three cohort studies 
(of variable size and quality) were included. 
Regardless of the surgical intervention used or the 
type of patients included, all studies reporting a 
statistical comparison found statistically significant 
benefits on measures of weight change compared 
with no surgery at two to three years follow-up. 
A large cohort study found weight loss was still 
significantly greater at 10 years follow-up compared 
with conventional treatment. One RCT found 
statistically significantly greater improvements 
in five of eight domains of the SF-36 following 
laparoscopic adjustable gastric banding compared 
with no surgery, but one cohort study found no 
statistically significant difference in mean scores of 
the PSSQ between surgery and no-surgery groups. 
The SOS study found mixed results in HRQoL at 
10 years follow-up, with significantly greater 10-
year change following surgery observed in some 
measures, but not others. The RCT of people 
with Type 2 diabetes found significantly higher 
remission of the disease following laparoscopic 
adjustable gastric banding than conventional 
therapy, and two RCTs reporting metabolic 
syndrome found significantly fewer people with 
the syndrome two years after surgery. The SOS 
study found a statistically significant reduction in 
the incidence in three of six comorbidities assessed 
at 10-year follow-up after surgery compared with 
conventional therapy. Significantly fewer surgery 
patients than conventional therapy patients 
were on diabetes medication at two and six years 
follow-up, and on CVD medication at two, but not 
six years follow-up. Two RCTs reported adverse 
events from following surgery (e.g. operative 
interventions, revisional surgery, port-site infection) 
and from conventional therapy (e.g. intolerance to 
medication, acute cholecystitis, need for operative 
intervention, gastrointestinal problems). Within 
90 days of surgery in the SOS study there were five 
deaths (0.25%) in the surgery group and two deaths 
in the control group. Perioperative complications 
occurred in 13% of patients. DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 20  Summary of results: surgery versus non-surgical management – complications and additional procedures
Dixon, 2008117 LAGB (n = 30) Conventional therapy 
(n = 30)
Mean procedure time (SD, range) 54 minutes (10.8, 40 to 74)
Length of hospital stay
1 day 23 (80%) 
2 day 5 (17%)
4 days  1 (3%)
Adverse events (n)
Superficial wound infection 1
Gastric pouch enlargement at 10 months 2
Band removal 1
Febrile episodes 1
Minor hypoglycaemic episode 1
Intolerance to metformin  1
Minor gastrointestinal tract adverse events  2
Persistent diarrhoea with metformin 1
Vasculitic rash  1
Multiple hypoglycaemic episodes 1
Angina and transient cerebral ischaemic episode 1
Intolerant to very low-calorie meal replacement 2
O’Brien, 2006115,116 LAGB (n = 39) Non-surgical (n = 31)
Total of adverse events (%) 7/39 (18) 18/31 (58)
5-mm port site infection (%) 1/39 (2.6) n/a
Acute cholecystitis (%) 1/39 (2.6) 4/31 (13)
Prolapse, posterior (laparoscopic revision) (%) 4/39 (10) n/a
Intolerance to very-low-calorie diet (%) n/a 1/31 (3)
Intolerance to orlistat (%) n/a 8/31 (26)
Operative interventions (%) 5/39 (13)a 4/31 (13)b
SOS study, 1997–200799 Surgery (n = 2010) Control (n = 2037)
Deaths within 90 days of surgery 5 (0.25%) (four peritonitis with 
organ failure, one sudden death)
2 (0.10%) (one pancreatic 
cancer, one alcohol-related 
causes)
Peri/postoperative complications97,137 (n = 1164)
No. of patients with complications (%) 151 (13%)
Total no. of complications 193
Bleeding 0.9%
Thromboembolic events 0.8%
Wound complications 1.8%
Abdominal infection 2.1%
Pulmonary symptoms 6.2%
Miscellaneous 4.8%
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Postoperative complications requiring reoperation 26 patients (2.2%)
Surgical reoperations or conversions (excluding 
operations caused by postoperative complications) in 
those followed up for at least 10 years
(n = 1338); banding 31%, VBG 21%, 
GBP 17%
Buddeberg-Fischer, 2006105 Surgery (n = 56) No surgery (n = 37)
Reoperation 7/56; LAGB (n = 47) conversion to 
RYGBP 5, reversed (debanding) 2;  
RYGBP (n = 9) 0
Underwent RYGBP 9/37
GBP , gastric bypass; LAGB, laparoscopic adjustable gastric banding; RYGBP , Roux-en-Y gastric bypass; SOS, Swedish Obese 
Subjects; VBG, vertical banded gastroplasty.
a  The operative interventions were undertaken for the following adverse events: the four cases of prolapse of the 
posterior gastric wall through the band, and the single case of acute cholecystitis.
b  The operative interventions were all undertaken for the adverse event of acute cholecystitis that occurred in four 
patients.
TABLE 21  Overall mortality from the SOS study
SOS study99 Surgery (n = 2010) Control (n = 2037)
Number of deaths (%) 101/2010 (5.0%) 129/2037 (6.3%)
Cause of death: cardiovascular condition
Any event (number of subjects) 43 53
Cardiaca 35 44
Stroke 6 6
Other 2 3
Cause of death: non-cardiovascular 
Any event (number of subjects) 58 76
Tumour 29 (all cancer) 48 (47 cancer, 1 non-malignant)
Infection 12 3
Thromboembolic disease 5 7
Other 12 18
SOS, Swedish Obese Subjects.
a  Cardiac events included myocardial infarction, heart failure and sudden death.
TABLE 20  Summary of results: surgery versus non-surgical management – complications and additional procedures (continued)
Comparisons of different 
surgical procedures
Gastric bypass versus vertical 
banded gastroplasty
Weight change
Three of the seven RCTs that compared vertical 
banded gastroplasty with gastric bypass (open or 
laparoscopic surgery) demonstrated statistically 
significantly greater percentage of excess weight 
loss with gastric bypass108,109,120,123 (Table 22). 
Howard and colleagues120 found that patients 
with open gastric bypass (n = 20) had 78% excess 
weight loss compared with 52% excess weight loss 
for patients undergoing open vertical banded 
gastroplasty (n = 22) (p < 0.05) at 12 months 
follow-up. At five years excess weight loss was 70% 
and 37% for gastric bypass and vertical banded 
gastroplasty, respectively (p < 0.05), although only 
six patients in each group were followed for this 
length of time. All gastric bypass patients had lost 
at least 50% of excess weight at 12 months and 
60 months follow-up, whereas only 55% of vertical 
banded gastroplasty patients had achieved this at 
12 months, and none by 60 months (p-value not 
stated, Appendix 6). Sugerman and colleagues123 
found that excess weight loss for open gastric 
bypass was significantly greater than for open 
vertical banded gastroplasty at 12 months [68% DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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(SD 17) versus 43% (SD 18), p < 0.001], 24 months 
[66% (SD 29) versus 39% (SD 24), p < 0.001] and 
36 months [62% (SD 18) versus 37% (SD 19), 
p < 0.001]. As previously stated, this study has a 
high risk of bias because recruitment was stopped 
early when a significant difference (p < 0.05) in 
weight loss was noted in favour of gastric bypass. 
At this point 20 patients had been recruited to 
each arm of the study, and were followed up 
for three years. Before surgery, Sugerman and 
colleagues classified patients as ‘sweets eaters’ 
or ‘non-sweets eaters’. They noted that gastric 
bypass surgery led to a significantly greater excess 
weight loss for sweets eaters than did vertical 
banded gastroplasty (p < 0.0001). For non-sweets 
eaters gastric bypass caused greater decreases 
in excess weight compared with vertical banded 
gastroplasty, but differences were not significant 
[p = ns (not statistically significant)] (Appendix 
6). The authors attribute this difference to the 
development of dumping syndrome symptoms in 
sweets eaters with gastric bypass. However, caution 
is required when interpreting these results because 
sample sizes were small and the comparisons 
were not randomised. A third study, Olbers and 
colleagues,108,109 which compared laparoscopic 
gastric bypass with laparoscopic vertical banded 
gastroplasty also reported that excess weight loss 
for gastric bypass was significantly greater than for 
vertical banded gastroplasty at 12 months [78.3% 
(SD 20) versus 62.9% (SD 28.4), p = 0.009], and 
at 24 months [84.4% (SD 22.1) versus 59.8% (SD 
29.6), p < 0.001]. A greater proportion of patients 
(34 of 36) who received laparoscopic gastric bypass 
achieved an excess weight loss of at least 50% 
without remedial surgery, in comparison to those 
receiving laparoscopic vertical banded gastroplasty 
(21 of 35) (Appendix 6). Weight loss was also 
reflected in mean BMI values which had fallen to 
29 in the laparoscopic Roux-en-Y gastric bypass 
group and 32 in the laparoscopic vertical banded 
gastroplasty group (p-value not reported), but there 
was little further change at two years when BMI 
values were 28 and 32, respectively (p-value not 
reported).
Two of the seven trials reported greater weight loss 
in the gastric bypass group, but did not indicate 
whether or not this difference was statistically 
significant (Table 22). The trial by Agren and 
Naslund,73 which was reported only as an abstract, 
found greater mean excess weight loss with loop 
gastric bypass (76.6%) than with vertical banded 
gastroplasty (59.8%) at 18 months follow-up. 
Lee and colleagues124 compared laparoscopic 
gastric bypass and laparoscopic vertical banded 
gastroplasty and reported that at two years follow-
up the gastric bypass group had lower BMI (28.5 
versus 31.9) and greater excess weight loss (71.4% 
versus 53.1%).
The remaining two trials that compared gastric 
bypass with vertical banded gastroplasty found 
that there was no significant difference in weight 
loss between the groups (Table 22). VanWoert 
and colleagues106 reported, in an abstract only, 
per cent of ideal body weight at 36 months to be 
121% in the gastric bypass group, and 123% in the 
vertical banded gastroplasty group. Success rates, 
defined as a BMI < 35 or < 50% excess weight and 
reoperation not required, were compared for Roux-
en-Y gastric bypass and vertical banded gastroplasty 
with surgical isolation of the gastric pouch by 
MacLean and colleagues.121,122 When compared at 
three years and five to six years follow-up, there was 
no significant difference in success rates between 
gastric bypass and vertical banded gastroplasty 
[about three years: 58% versus 39% (p = 0.08); 
five to six years: 34% versus 16%, (p = 0.112)]. 
Failures were converted to isolated gastric bypass, 
which had a success rate of 63% at five to six years. 
Although comparisons of the three procedures 
were reported to show a significantly greater 
success rate for isolated gastric bypass compared 
with gastric bypass (p < 0.0009) and vertical banded 
gastroplasty (p = 0.0001), these were not valid 
because the periods of follow-up differed.
Quality of life and comorbidities
Only one RCT comparing gastric bypass 
with vertical banded gastroplasty reported 
on QoL measures, and this study performed 
both procedures laparoscopically.124 Using the 
gastrointestinal quality of life index (GIQLI), 
patients in both groups had significant 
improvements in physical function, emotional 
function and social function domains, but patients 
with vertical banded gastroplasty had a significant 
decrease in the domain of symptoms (p-values not 
reported) (Table 23). Patients with gastric bypass 
scored significantly better on seven of 19 symptom 
items, four of five emotional items, one of seven 
physical items and two of five social items (p-values 
ranged from p = 0.04 to p < 0.001, see Appendix 
6). Patients with vertical banded gastroplasty scored 
better on the symptom of abdominal flatulence 
(p = 0.02). 
Data on comorbidities were not assessed.
Complications and additional 
operative procedures
Of the seven RCTs comparing vertical banded 
gastroplasty with gastric bypass surgery, five Clinical effectiveness
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TABLE 22  Summary of results: gastric bypass versus vertical banded gastroplasty – weight change
Howard, 1995120  GBP (n = 20) VBG (n = 22) p-value
% excess weight loss 1 yeara 78 (n = 20) 52 (n = 20) p < 0.05
% excess weight loss 5 yearsa 70 (n = 6) 37 (n = 6) p < 0.05
Patients with at least 50% of excess 
weight loss
12 months 100% 55% p not stated
60 months 100% (n = 6) 0% (n = 6) p not stated
Patients with more than 75% of excess 
weight loss
12 months 60% 18% p not stated
60 months 50% (n = 6) 0% (n = 6) p not stated
Sugerman, 1987123 RYGBP (n = 20) VBG (n = 20)
% excess weight loss 1 year 68 (± 17) n = 19 43 (± 18) n = 18 p < 0.001
% excess weight loss 2 yearsa 66 (± 29) n = 18 39 (± 24) n = 17 p < 0.001
% excess weight loss 3 yearsa 62 (± 18) n = 18 37 (± 19) n = 16 p < 0.001
% ideal body weight 12 months 138 (± 32) n = 19 176 (± 41) n = 18 p < 0.01
% ideal body weight 24 months 139 (± 32) n = 18 178 (± 41) n = 17 p < 0.01
% ideal body weight 36 months 142 (± 37) n = 18 180 (± 44) n = 16 p < 0.01
Weight loss (kg) 12 months 43.5 (± 11.3) n = 19 32.2 (± 10.9) n = 18 p < 0.001
Weight loss (kg) 24 months 43.5 (± 15.4) n = 18 30.4 (± 12.2) n = 17 p < 0.001
Weight loss (kg) 36 months 41.3 (± 12.7) n = 18 27.2 (± 14.5) p < 0.01
% weight lost 12 months 33 (± 7) n = 19 22 (± 8) n = 18 p < 0.001
% weight lost 24 months 33 (± 9) n = 18 22 (± 9) n = 17 p < 0.001
% weight lost 36 months 32 (± 9) n = 18 20 (± 10) n = 16 p < 0.01
Olbers, 2005108,109 LRYGBP (n = 37) LVBG (n = 46)
% excess weight loss 1 year 78.3 (± 20.0) n = 36 62.9 (± 28.4) n = 39 p = 0.009
% excess weight loss 2 years 84.4 (± 22.1) n = 36 59.8 (± 29.6) n = 35 p < 0.001
BMI at 1 yeara 29 (n = 36) 32 (n = 39)
BMI at 2 yearsa 28 (n = 36) 32 (n = 35)
Proportion achieving excess weight loss 
of at least 50% without remedial surgery 
after 2 years
34/36 (94.4%) 21/35 (60%)
Agren and Naslund, 198973 Loop GBP (n = 25) VBG (n = 27)
% excess weight loss 1 year 76.6  58.3 
% excess weight loss 18 months 76.6  59.8 
Lee, 2004124 LRYGBP (n = 40) LVBG (n = 40)
% excess weight loss 1 year 62.9 (n = 40) 55.4 (n = 40)
% excess weight lost 2 years 71.4 (n = 26) 53.1 (n = 27)
BMI 1 year 29.6 31.1
BMI 2 years 28.5 31.9DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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VanWoert, 1992106 GBP (n = 15) VBG (n = 17)
% ideal body weight at 3 years 121% 123% p = ns
MacLean, 1995, 1993121,122 RYGBP (n = 52) VBG (n = 54)
Success rateb ~ 3 years  30 (58%) 21 (39%) p = 0.08
Success rate up to 6.5 years 16 (34%) 9 (16%)  p = 0.112
BMI, body mass index; GBP , gastric bypass; LRYGBP , laparoscopic Roux-en-Y gastric bypass; LVBG, laparoscopic vertical 
banded gastroplasty; RYGBP , Roux-en-Y gastric bypass; VBG, vertical banded gastroplasty.
All mean (± SD) unless stated.
a  Data estimated from figure.
b  Success defined as BMI < 35 or < 50% excess weight and no reoperation.
TABLE 22  Summary of results: gastric bypass versus vertical banded gastroplasty – weight change (continued)
TABLE 23  Summary of results: gastric bypass versus vertical banded gastroplasty – QoL
Lee, 2004124 LRYGBP (n = 40) LVBG (n = 40) p-value
Mean GIQLI domain score at 12 months:
Symptoms (baseline 63.7)  60.9 54.3
Physical function (baseline 16.1)  24 20.9
Emotional function (baseline 12.8)  17.7 14.7
Social function (baseline 14.3)  18.4 16.5
Overall score (baseline 106.9) 121 106.4
GIQLI; gastrointestinal quality of life index; LRYGBP , laparoscopic Roux-en-Y gastric bypass; LVBG, laparoscopic vertical 
banded gastroplasty. 
Baseline data reported for both groups combined only. GIQLI scored 0–4 (worst–best), maximum score 144.
reported no deaths.106,108,109,120–122,124 Three of these 
trials were comparisons of open procedures,106,120–122 
the other two were comparisons of laparoscopic 
procedures.108,109,124 One trial reported no deaths 
in the vertical banded gastroplasty group but two 
deaths (10%) in the gastric bypass group, occurring 
after three days and 13 months as the result of 
assumed arrhythmia.123 Agren and Naslund73 
reported one death, but did not state when this 
occurred or whether following gastric bypass, 
vertical banded gastroplasty or gastric banding 
(unbanded, intervention not included in systematic 
review) (Table 24).
Complications were not reported by all studies, but 
when they were reported they differed between the 
various surgical procedures (Table 24).
Of the two studies that compared laparoscopic 
procedures, Olbers and colleagues108,109 reported 
no conversions to open surgery, but Lee and 
colleagues124 reported that conversion to open 
surgery occurred in one (2.5%) patient with 
laparoscopic gastric bypass and none of the 
patients with laparoscopic vertical banded 
gastroplasty (p = ns). Operative time was 
significantly less with laparoscopic vertical banded 
gastroplasty in both studies [126 minutes (SD 
38) versus 209 minutes (SD 50), p < 0.001124, and 
105 minutes (SD 35) versus 138 minutes (SD 41), 
p < 0.001108,109]. In one study mean postoperative 
stay was also significantly shorter for the 
laparoscopic vertical-banded gastroplasty group 
[3.5 days (0.9) versus 5.7 days (2.2), p < 0.001124], 
whereas in the other study there appeared to be 
little difference in the length of hospital stay (LOS) 
[median three days (range 1–16 days) versus three 
days (range 2–15 days)108,109].
In one study124 early postoperative complications 
were significantly more common following 
laparoscopic gastric bypass (17.5%, seven patients) Clinical effectiveness
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than laparoscopic vertical banded gastroplasty 
(2.5%, one patient). Three of the seven early 
postoperative complications experienced by 
laparoscopic gastric bypass patients were major 
complications. These required interventional 
management and hospitalisation for over 
14 days. Two with anastomotic leakage required 
reoperation, the third had an abdominal 
abscess. The remaining four early postoperative 
complications in this group were classed as minor 
and included upper gastrointestinal bleeding, a 
sutured nasogastric tube, and minor leakage from 
a drainage tube. Only one early postoperative 
complication occurred in the laparoscopic vertical 
banded gastroplasty group and this was a wound 
infection that was classed as a minor complication. 
Analgesic use was also higher [2.4 units (3.0) 
versus 1.4 units (1.5), respectively (p < 0.05)] in 
this study.124 The second study that compared 
laparoscopic procedures108,109 reported five early 
reoperations in the gastric bypass group (three 
for haemorrhage, one for stenosis and one 
for suspected leak) and one early reoperation 
in the vertical banded gastroplasty group (for 
suspected leak), but this difference was not 
significant (p = 0.080). A statistical comparison 
of the perioperative complications reported by 
Olbers and colleagues108,109 (in addition to the 
reoperations) is not provided, but these appear 
similar (gastric bypass group: two minor bleeding, 
one deep infection; vertical banded gastroplasty 
group: four minor bleeding, one deep infection) 
(Table 24). Neither group experienced a thrombotic 
complication, and there was no difference in the 
incidence of pulmonary complications between the 
groups (p = 0.888). One patient in the laparoscopic 
Roux-en-Y gastric bypass group experienced an 
intra-abdominal abscess after discharge.
Readmission for late complications reported by 
Lee and colleagues124 was similar between the 
laparoscopic procedures (10% versus 5%, p = ns). 
Late complications associated with laparoscopic 
gastric bypass included marginal ulcer requiring 
blood transfusion (two patients), anastomotic 
stricture (one patient), and pyothorax (pus in 
the chest cavity) (one patient). Two patients (5%) 
with laparoscopic vertical banded gastroplasty 
experienced the late complication of reflux 
oesophagitis, one of which required laparoscopic 
revision surgery. Olbers and colleagues,108,109 
however, reported that remedial surgical 
intervention was required for eight participants 
in the vertical banded gastroplasty group (four 
in the first year and four in the second year, all 
conversion to Roux-en-Y gastric bypass, due to: one 
migration of outlet restricting band, five vomiting 
and insufficient weight loss, two vomiting and 
excessive weight loss), but for none in the gastric 
bypass group.
In the comparisons of open procedures73,106,120–123 
gastric bypass patients suffered from symptomatic 
ulcer disease (25% of patients),120 staple-line fistula 
(23%),121,122 stomal ulcers (13% of patients),121,122 
intractable vomiting and stomal stenosis (25%),123 
marginal ulcer of jejunal side of gastrojejunostomy 
(5%),123 cholelithiasis (gallstone formation) 
(13%),106 and peptic gastro-oesophagitis (33%).106 
Vertical banded gastroplasty patients suffered 
stenosis (20%),121,122 enlarged orifice (13%),121,122 
staple-line fistula (4%),121,122 clinical failure 
(4%),121,122 abscess (2%),121,122 superficial stomal 
erosions (5%),123 cholelithiasis (24%)106 and peptic 
gastro-oesophagitis (18%).106 Intraoperative 
cholecystectomy and postoperative cholecystectomy 
were reported for gastric bypass (20% and 29% 
respectively) and vertical banded gastroplasty (14% 
and 29% respectively) (Table 24).120
In the trial by MacLean and colleagues,121,122 
failures of vertical banded gastroplasty (due to 
stenosis and enlargement of the gastroplasty 
orifice), and failures of gastric bypass (due to 
perforation of the vertical staple line), were 
converted to normal (9% versus 2%) or isolated 
gastric bypass (44% versus 37%). In another trial 
by Sugerman and colleagues,123 a total of four 
(20%) vertical banded gastroplasty patients were 
converted to Roux-en-Y gastric bypass. One patient 
was converted at one month due to staple-line 
disruption, and a further three patients were 
converted due to a failure to lose weight, one 
at 18 months, and two at 38 months following 
surgery. After 2 years there were no significant 
deficiencies in most vitamins, electrolytes, renal 
or liver function tests. However, vitamin B12 levels 
were lower in patients with Roux-en-Y gastric 
bypass than those with vertical banded gastroplasty 
(286 pg/ml versus 461 pg/ml, p<0.05) (Appendix 
6). Agren and Naslund73 found just one patient 
(4%) with vertical banded gastroplasty required 
reoperation for staple-line disruption. Agren and 
Naslund73 reported that morbidity was low and not 
significantly different between the groups, but no 
data were presented.
Summary
Seven RCTs were included. Six trials were of 
uncertain risk of bias as many factors were not 
reported. One study by Sugerman and colleagues 
had a high risk of bias because of an a priori DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 24  Summary of results: gastric bypass versus vertical banded gastroplasty – complications and additional procedures
Howard, 1995120 GBP (n = 20) VBG (n = 22) p-value
Deaths 0 0
Early complication: wound infection 1 (2%) super-obese patient
Late complication: symptomatic ulcer 
disease
25% (half required surgical 
intervention)
0%
Intraoperative cholecystectomya 20% 14%
Late complication: postoperative 
cholecystectomy
29% 29%
Sugerman, 1987123 RYGBP (n = 20) VBG (n = 20)
Deaths 2/20 (10%) 0
Conversions VBG to RYGBP 1/20 (5%) at 1 month; 1/20 
(5%) at 18 months; 2/20 
(10%) at 38 months
Intractable vomiting and stomal stenosis 5/20 (25%)
Marginal ulcer of jejunal side of 
gastrojejunostomy
1/20 (5%)
Superficial stomal erosion 1/20 (5%)
Vitamin B12 at 24 months, pg/ml [mean 
(SD)]
286 (± 149) 461 (± 226) p < 0.05
Olbers, 2005108,109 LRYGBP (n = 37) LVBG (n = 46)
Deaths 0 0
Conversions to open surgery 0 0
Operating time [mean (SD)] 138 (± 41) minutes 105 (± 35) minutes p < 0.001
Early reoperation (n) 5 1 p = 0.080
Haemorrhage 3 0
Stenosis 1 0
Suspected leak 1 1
Perioperative complications (n)b
Minor bleeding 2 4
Deep infection 1 1
Thrombotic complications 0 0
Pulmonary complications States no difference between groups p = 0.888
Median hospital stay, days 3 (range 2–15) 3 (range 1–16)
Remedial surgical intervention (n, 
conversion to RYGBP)
0 8
Due to migration of outlet restricting 
band
1
Vomiting and insufficient weight loss 5
Vomiting and excessive weight loss 2
Intra-abdominal abscess after discharge (n) 1 0
continuedClinical effectiveness
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Agren and Naslund, 198973 Loop GBP (n = 25) VBG (n = 27)
Deaths 1 (group not statedc)
Reoperation  1/27 (4%) 
Lee, 2004124 LRYGBP (n = 40) LVBG (n = 40)
Deaths 0 0 p = ns
Conversions to open surgery 1/40 (2.5%) 0 p = ns
Mean operative time (minutes) 209 (± 50) 126 (± 38) p < 0.001
Intraoperative blood loss (ml) 35 (± 26) 31 (± 77) p = ns
Postoperative flatus passage (days) 2.5 (± 1.2) 1.9 (± 0.6) p < 0.01
Early postoperative complication 7/40 (17.5%) 1/40 (2.5%) p < 0.05
Major early complication (n)d 3 0
Anastomotic leakage 2 (reoperation)
Abdominal abscess 1
Minor early complication (n) 4 1
Included upper gastrointestinal 
bleeding, a sutured nasogastric 
tube, and minor leakage from a 
drainage tube
4
Wound infection 1
Analgesic use (units) 2.4 (± 3.0) 1.4 (± 1.5) p < 0.05
Postoperative stay (days) 5.7 (± 2.2) 3.5 (± 0.9) p < 0.001
Late complications (readmission) 4/40 (10%) 2/40 (5%) p = ns
Anastomotic stricture  1
Marginal ulcer 2
Pyothorax 1
Reflux oesophagitis  2 (1 laparoscopic revision 
surgery)
VanWoert, 1992106 GBP (n = 15) VBG (n = 17)
Deaths 0 0
Major late complication: cholelithiasis 13% 24%
Major late complication: peptic gastro-
oesophagitis
33% 18%
MacLean, 1995, 1993121,122 RYGBP (n = 52) VBG (n = 54)
Deaths 0 0
Conversions at approx. 3 years 0 to normal; 12/52 (23%) to 
IGBP
5/54 (9%) to normal; 18/54 
(33%) to IGBP
Conversions up to 6.5 years 1/52 (2%) to normal; 19/52 
(37%) to IGBP .
5/54 (9%) to normal; 24/54 
(44%) to IGBP
Reoperations 12/52 (23%) 23/54 (43%)
Stenosis 0 11 (20%)
Enlarged orifice 0 7 (13%)
Staple-line disruption 12 (23%) 2 (4%)
Clinical failure 0 2 (4%)
Stomal ulcere 7 (13%) 0
Abscess 0 1 (2%)
TABLE 24  Summary of results: gastric bypass versus vertical banded gastroplasty – complications and additional procedures (continued)DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 24  Summary of results: gastric bypass versus vertical banded gastroplasty – complications and additional procedures (continued)
GBP , gastric bypass; IGBP , isolated gastric bypass; LRYGBP , laparoscopic Roux-en-Y gastric bypass; LVBG, laparoscopic 
vertical banded gastroplasty; ns, not statistically significant; RYGBP , Roux-en-Y gastric bypass; SD, standard deviation; VBG, 
vertical banded gastroplasty.
a  For pre-existing gall bladder disease.
b  Perioperative complications in addition to conversions to open surgery and reoperations.
c  Agren and Naslund 198973, also included a third trial arm, non-adjustable gastric banding, that was not eligible for inclusion 
in this systematic review. The death may have occurred in any of the three trial arms.
d  Major complications required interventional management and hospitalisation of over 14 days.
e  RYGBP patients with stomal ulcer were among the 12 patients with staple-line disruption.
stopping rule. On measures of weight, participants 
who underwent gastric bypass had a better 
outcome, particularly at later time points, in five 
of the seven trials than those who underwent 
vertical banded gastroplasty (although a statistically 
significant difference was only reported in three 
of these trials). Only Lee and colleagues reported 
on QoL, which they found to be better for the 
gastric bypass group. Data on comorbidities were 
not assessed. Reporting of complications varied 
between studies. Evidence from two studies108,109,124 
suggests that the laparoscopic vertical banded 
gastroplasty surgery is quicker, and is associated 
with fewer early postoperative complications than 
laparoscopic gastric bypass surgery. However, 
two studies of open surgery121–123 report that after 
approximately three years, conversions to an 
alternative bariatric procedure occurred more often 
in the vertical banded gastroplasty groups, but 
neither study tested this for statistical significance.
Gastric bypass (non-banded) 
versus banded gastric bypass
One RCT118 compared non-banded long limb 
gastric bypass with banded long limb gastric bypass 
in participants with BMI greater than 50. Banded 
gastric bypass (which is not undertaken in the UK) 
is considered separately in this review, although 
there is some disagreement among surgeons 
about whether it constitutes a distinct procedure, 
or whether it is a variation of the standard gastric 
bypass procedure. 
Weight change
At one and two years follow-up, Bessler and 
colleagues118 reported per cent excess weight loss 
was greater for participants undergoing banded 
than non-banded long limb gastric bypass, but 
the differences were not statistically significant 
(Table 25). After three years, the per cent excess 
weight loss was statistically significantly higher in 
the banded gastric bypass group compared with 
the non-banded gastric bypass group (p < 0.05). 
There is however an uncertain risk of bias for 
this outcome as the paper reports that this was 
based on the small number of patients reaching 
the 36-month follow-up period (numbers not 
presented). The proportion achieving a BMI of less 
than 35 was higher in the banded gastric bypass 
groups than the non-banded gastric bypass groups 
at one and two years follow-up but the difference 
was not statistically significant. No rates were 
reported for the three-year follow-up.
Quality of life and comorbidities
Data on QoL were not assessed. Comorbidities 
were reported by Bessler and colleagues.118 
The study reported baseline values for stated 
comorbidities and the proportion with resolution 
of these comorbidities; however, the study does not 
state which follow-up period is being reported, or 
give any numerators and denominators for these 
calculations. 
The proportion of participants with resolution of 
their respective comorbidities was not shown to be 
statistically significantly different between the two 
interventions (Table 26).
Complications and additional 
operative procedures
There were no deaths reported in the study by 
Bessler and colleagues118 and no statistically 
significant differences between banded gastric 
bypass and non-banded gastric bypass in rates of 
any postoperative complications. Postoperative 
gastrointestinal symptoms were scored according 
to a subjective scale where 0 = none, 1 = mild, 
2 = moderate, 3 = severe. In this study only the 
scores for emesis were statistically significantly 
better (lower score) in the non-banded gastric 
bypass group than in the banded gastric bypass 
participants (0.35 versus 0.13 respectively, 
p = 0.0002) (Table 27). No other gastrointestinal 
symptoms were statistically significantly different 
between the two interventions. The proportion of Clinical effectiveness
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TABLE 25  Summary of results: gastric bypass (non-banded) versus banded gastric bypass – weight change
Bessler, 2007118 Banded GBP (n = 46) Non-banded GBP (n = 44) p-value
% EWL at 12 months 64 57.4 p = ns
% EWL at 24 months 64.2 57.2 p = ns
% EWL at 36 months 73.4 (small n, not reported) 57.7 (small n, not reported) p < 0.05
Achieving a BMI of < 35 at 12 months (%): 47.8 41.0
Achieving a BMI of < 35 at 24 months (%) 52.9 37.5
BMI, body mass index; EWL, excess weight loss; GBP , gastric bypass; ns, not statistically significant.
TABLE 26  Summary of results: gastric bypass (non-banded) versus banded gastric bypass – comorbidities
Bessler, 2007118 Banded GBP (n = 46) Non-banded GBP (n = 44) p-value
Resolution of hypertension (%) 79 90 p = ns
Resolution of diabetes (%) 92 98 p = ns
Resolution of hyperlipidaemia (%) 50 62 p = ns
Resolution of arthritis (%) 76 91 p = ns
Resolution of gastro-oesophageal reflux disease (%) 94 83 p = ns
Resolution of stress urinary incontinence (%) 83 93 p = ns
GBP , gastric bypass; ns, not statistically significant.
TABLE 27  Summary of results: gastric bypass (non-banded) versus banded gastric bypass – complications and additional procedures
Bessler, 2007118 Banded GBP (n = 46) Non-banded GBP (n = 44) p-value
Mortality 0 0
Total complications 12/46 (26%) 13/44 (29.5%) p = ns
Wound infection 7/46 (15.2%) 5/44 (11%) p = ns
Anastomotic leak 0 2/44 (4.8%) p = ns
Pneumonia 1/46 (2.1%) 1/44 (2.2%) p = ns
Pulmonary embolism 0 0
Small bowel obstruction 1/46 (2.1%) 1/44 (2.2%) p = ns
Band erosion/slippage/removal 0 n/a
Other 3/46 (6.5%) 4/44 (9.0%) p = ns
Gastrointestinal symptoms (average scores)
Dumping  0.12 0.05 p = ns
Emesis  0.35 0.13 p = 0.0002
Diarrhoea  0.11 0.13 p = ns
Constipation 0.07 0.08 p = ns
Flatulence  0.22 0.13 p = ns
Abdominal pain  0.04 0.06 p = ns
Food intolerance (%) 79 33 p < 0.05
GBP , gastric bypass; ns, not statistically significant.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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participants with food intolerance was higher in 
the banded gastric bypass group (79% versus 33%, 
p < 0.05). Care is required in the interpretation 
of these results, not only because of the subjective 
nature of these outcomes, but also because the 
study does not state which follow-up period is being 
reported or what the participant numbers were for 
these outcomes.
Summary
One study (with a low risk of selection bias but at 
high risk of bias through selective reporting) found 
similar weight loss after banded and non-banded 
gastric bypass in people with BMI greater than 
50. Although a statistically significant difference 
in BMI was found at 36 months follow-up, this was 
based on a small number of participants. Rates of 
improvement of existing comorbidities were not 
different between the two groups and complications 
were also generally similar. The evidence suggests 
that in these high BMI participants there is little 
added benefit from the addition of banding to the 
intervention.
Laparoscopic gastric bypass versus 
laparoscopic adjustable gastric banding
One RCT119compared laparoscopic Roux-en-Y 
gastric bypass with laparoscopic adjustable gastric 
banding.
Weight change
At one and three years of follow-up Angrisani and 
colleagues107 found that the per cent excess weight 
loss was greater for those undergoing laparoscopic 
Roux-en-Y gastric bypass than laparoscopic 
adjustable gastric banding, but no statistical 
significance was reported (Table 28). After 5 years 
of follow-up the per cent excess weight loss and 
mean weight were statistically significantly better 
for participants in the laparoscopic Roux-en-Y 
gastric bypass group compared with those in the 
laparoscopic adjustable gastric banding group 
(p < 0.001 for both outcomes). At one and three 
years follow-up the mean BMI was also lower in the 
laparoscopic Roux-en-Y gastric bypass group (but 
no p-values were reported) than the laparoscopic 
adjustable gastric banding group. After five years 
the mean BMI was statistically significantly better 
in the laparoscopic Roux-en-Y gastric bypass group 
than the laparoscopic adjustable gastric banding 
group (p < 0.001). The proportion classed as weight 
loss failures, defined as those with a BMI > 35 at 
5 years, were statistically significantly lower in the 
laparoscopic Roux-en-Y gastric bypass than the 
laparoscopic adjustable gastric banding group 
(p < 0.001) and the proportion with a BMI of less 
than 30 at 5 years were statistically significantly 
higher in the laparoscopic Roux-en-Y gastric 
bypass group (p < 0.001) than in the laparoscopic 
adjustable gastric banding group. 
Quality of life and comorbidities
QoL was not assessed by Angrisani and 
colleagues.107 Baseline rates of comorbidities 
were low in this study, with two participants in 
the laparoscopic Roux-en-Y gastric bypass group 
having hyperlipaemia, one hypertension and one 
Type 2 diabetes. In the laparoscopic adjustable 
gastric banding group three participants had 
hypertension and one sleep apnoea. The study 
reports that at five years there was resolution of the 
diabetes and hyperlipaemia (in the laparoscopic 
Roux-en-Y gastric bypass group) and the sleep 
apnoea (in the laparoscopic adjustable gastric 
banding group) (Appendix 8).
Complications and additional 
operative procedures
No deaths were noted in either group of the 
Angrisani and colleagues study119 (Table 29). 
Operative time for laparoscopic adjustable 
gastric banding was significantly shorter than 
for laparoscopic Roux-en-Y gastric bypass [mean 
60 (SD 20) minutes versus mean 220 (SD 100) 
minutes, p < 0.001]. Four (15.2%) participants in 
the laparoscopic adjustable gastric banding group 
underwent a reoperation (two pouch dilatation, 
two band removal because of inadequate weight 
loss: one of these was converted to biliopancreatic 
diversion, three waiting list for laparoscopic 
Roux-en-Y gastric bypass) and three (12.5%) 
from the laparoscopic Roux-en-Y gastric bypass 
group underwent a reoperation (for potentially 
lethal complications not further specified). Early 
complications requiring surgery in the laparoscopic 
Roux-en-Y gastric bypass group occurred in two 
(8.4%) [one posterior pouch leak intraoperatively 
causing conversion to open surgery, one (4.2%) 
sepsis caused by jejunal perforation (sutured 
and intestine resected)]. No early complications 
requiring surgery were noted in the laparoscopic 
adjustable gastric banding group. One participant 
undergoing laparoscopic Roux-en-Y gastric bypass 
had a late complication (small bowel obstruction as 
the result of internal hernia) and two participants 
undergoing laparoscopic adjustable gastric 
banding had gastric pouch dilatation (which was 
treated by band removal). No significance testing 
was undertaken for reoperation rates, or early or 
late complication rates between groups. Mean 
hospital stay was statistically significantly longer in 
the laparoscopic Roux-en-Y gastric bypass group 
than the laparoscopic adjustable gastric banding 
group [4 days (SD 2) versus 2 days (SD 1) for the Clinical effectiveness
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TABLE 28  Summary of results: laparoscopic gastric bypass versus laparoscopic adjustable gastric banding – weight change 
Angrisani, 2007107 LAGB (n = 27) LRYGBP (n = 24) p-value
% excess weight loss at 12 months 34.7 51.3
% excess weight loss at 36 months 47.3 67.3
% excess weight loss at 5 years  
(range 60–66 months)
47.5 66.6 p < 0.001
Mean weight (kg) at 12 months 102.4 92.8
Mean weight (kg) at 36 months 98.7 83.5
Mean weight (kg) at 5 years (range 60–66 months) 97.9 84  p < 0.001
Mean BMI at 12 months 38.7  35.4 
Mean BMI at 36 months 35.6  29.1 
Mean BMI at 5 years (range 60–66 months) 34.9  29.8  p < 0.001
Weight loss failure (BMI > 35 at 5 years) 9/26 (34.6%) 1/24 (4.2%) p < 0.001
BMI < 30 at 5 years 3/26 (11.5%) 15/24 (62.5%) p < 0.001
BMI, body mass index; LAGB, laparoscopic adjustable gastric banding; LRYGBP , laparoscopic Roux-en-Y gastric bypass.
TABLE 29  Summary of results: laparoscopic gastric bypass versus laparoscopic adjustable gastric banding – complications and 
additional procedures
Angrisani, 2007107 LAGB (n = 27) LRYGBP (n = 24) p-value
Mortality 0 0
Reoperationa 4/26 (15.2%) 3/24 (12.5%)
Gastric pouch dilatation 2
Unsatisfactory weight loss (band removal) 2
Early complications (with reoperation) 0 2 (8.4%)
Posterior pouch leak 1 (conversion to open)
Sepsis (jejunal perforation) 0  1
Late complication 2/26 (7.6%) 1/24 (4.2%)
Small bowel obstruction due to internal 
hernia
1
Pouch dilatation (band removal) 2
Hospital stay, days [mean (SD)] 2 (± 1) 4 (± 2) p < 0.05
Operative time, mins [mean (SD)] 60 (± 20) 220 (± 100) p < 0.001
LAGB, laparoscopic adjustable gastric banding; LRYGBP , laparoscopic Roux-en-Y gastric bypass; SD, standard deviation.
a  LAGB group: one conversion to biliopancreatic diversion, other three went on to waiting list for LRYGBP . LRYGBP 
reoperations were each for a potentially lethal complication (unspecified).
two groups respectively, p < 0.05], although one 
participant in the laparoscopic Roux-en-Y gastric 
bypass group required an intensive care stay of 
40 days (Appendix 8).
Summary
On a variety of measures of weight this small 
study showed that laparoscopic Roux-en-Y 
gastric bypass was superior to laparoscopic 
adjustable gastric banding. Reoperation rates 
were similar between the two interventions, 
and comorbidities were similar and few. Early 
complications requiring reoperation were seen 
in more participants undergoing laparoscopic 
Roux-en-Y than laparoscopic adjustable gastric 
banding, but the numbers were small and not 
tested for statistical significance. The risk of bias 
for this study is uncertain, although the risk of bias DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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from incomplete outcome data for weight loss and 
comorbidities is likely to be low.
Laparoscopic gastric bypass versus 
laparoscopic sleeve gastrectomy
One RCT compared laparoscopic Roux-en-Y gastric 
bypass with laparoscopic sleeve gastrectomy.125
Weight loss
There were no statistically significant differences in 
BMI or weight loss between the two procedures at 
12 months follow-up. However, laparoscopic sleeve 
gastrectomy led to a greater per cent excess weight 
loss at 12 months [69.7% (SD 14.6) versus 60.5% 
(SD 10.7), p = 0.05] in this small RCT (Table 30). 
Quality of life and comorbidities
QoL was not assessed by this study. Two patients 
had diabetes at baseline (both in the laparoscopic 
Roux-en-Y gastric bypass group); this was resolved 
at 12 months in both patients. The outcome 
of other comorbidities noted at baseline (see 
Appendix 9) was not reported. 
Complications and additional 
operative procedures
Karamanakos and colleagues reported that there 
were no conversions to open surgery and no 
intraoperative and postoperative complications. No 
further details were reported. 
Summary
In this small RCT with uncertain risk of bias, BMI 
and weight loss at 12 months follow-up were similar 
between laparoscopic Roux-en-Y gastric bypass 
and sleeve gastrectomy. Per cent excess weight loss 
was greater with sleeve gastrectomy at 12 months 
(p = 0.05).
Vertical banded gastroplasty versus 
adjustable gastric banding
One study126 compared open vertical banded 
gastroplasty with open adjustable gastric banding, 
one study110 compared laparoscopic vertical banded 
gastroplasty with laparoscopic adjustable silicone 
gastric banding, and one study127,128 compared 
open vertical banded gastroplasty with laparoscopic 
adjustable banding.
Weight change
At one year follow-up, Nilsell and colleagues126 
found that weight loss was greater for the vertical 
banded gastroplasty group, but these patients 
then began to regain weight. The patients with 
adjustable gastric banding experienced lower 
initial weight loss, but this continued over five 
years resulting in a weight reduction of 43 kg at 
five years compared with 35 kg for vertical banded 
gastroplasty (statistical significance not given) 
(Table 31). 
When comparing laparoscopic procedures, Morino 
and colleagues110 also found significantly lower 
BMI with vertical banded gastroplasty at one year 
follow-up (30.1 versus 35.5, p < 0.05), but at two 
and three years follow-up the difference was not 
statistically significant (two years: 29.7 versus 34.8; 
three years: 30.7 versus 35.7). A similar result 
was seen in terms of percentage excess weight 
loss which was significantly greater with vertical 
banded gastroplasty at one year follow-up (62.3% 
versus 39.2%, p < 0.05), but was not statistically 
significantly different at later follow-up (two years: 
63.5% versus 41.4%, three years: 58.9% versus 
39.0%, p-values not reported). At three years follow-
up, 25% of patients with laparoscopic adjustable 
silicone gastric banding and 63% of patients with 
laparoscopic vertical banded gastroplasty had an 
excellent or good result (residual excess weight 
< 50%, p = 0.056). 
Van Dielen and colleagues127,128 reported a 
comparison of open vertical banded gastroplasty 
and laparoscopic adjustable gastric banding at one 
and two years follow-up, with data at a mean of 
84 months follow-up reported in a recent abstract128 
(Table 31). At one year, mean BMI was lower in the 
open vertical banded gastroplasty group than in 
the laparoscopic adjustable gastric banding group 
[31.1 (SD 6.2) versus 35.0 (SD 6.3), no p-value 
reported] and statistically significantly lower at the 
two-year follow-up [31.0 (SD 6.0) versus 34.6 (SD 
6.5), p ≤ 0.002]. Percentage excess weight loss was 
statistically significantly greater in the open vertical 
banded gastroplasty group in comparison to the 
laparoscopic adjustable gastric banding group at 
both one and two years [one year: 71.1% (SD 24.0) 
versus 53.3% (SD 21.2), p ≤ 0.001; two years: 70.1% 
(SD 25.5) versus 54.9% (SD 23.3), p ≤ 0.001]. The 
difference was maintained at a mean of 84 months 
follow-up (per cent excess BMI loss 68.8% versus 
56.9%, respectively).128 However, it should be noted 
that at this time point 59% of vertical banded 
gastroplasty participants had been converted to 
gastric bypass, and 11% of laparoscopic adjustable 
gastric banding participants had been converted to 
another procedure. From the limited information 
presented in the abstract reporting these results128 
it is not clear whether this has been taken into 
consideration.Clinical effectiveness
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TABLE 30  Summary of results: laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy – weight change
Karamanakos, 2008125 LRYGBP (n = 16) LSG (n = 16) p-value
BMI at 12 months 31.5 (± 3.4) 28.9 (± 3.6) p = 0.41
% EWL at 12 months  60.5 (± 10.7) 69.7 (± 14.6) p = 0.05
Weight loss at 12 months (kg) 40.0 (± 8.3) 43.6 (± 11.7) p = 0.322
BMI, body mass index; EWL, excess weight loss; LRYGBP , laparoscopic Roux-en-Y gastric bypass; LSG, laparoscopic sleeve 
gastrectomy.
All mean (± SD).
Quality of life and comorbidities
One study assessed patient satisfaction126 and 
one study reported on comorbidities,127 whereas 
one study did not report QoL or comorbidity 
outcomes.110 At five years follow-up, patients were 
asked if they were satisfied with, or regretted 
having undergone, the operation.126 Only 56% 
of vertical banded gastroplasty patients were 
satisfied with the result of the operation, while 
81% of the patients with adjustable gastric 
banding were satisfied (statistical significance not 
given). The comparison of open vertical banded 
gastroplasty and laparoscopic adjustable gastric 
banding127 revealed that although the overall 
number of patients with comorbidity in both 
groups significantly decreased following surgery 
at one and two years follow-up, no differences in 
comorbidities were observed between groups (open 
vertical banded gastroplasty: 82% at baseline, 
30.4% at one year, 47.9%, at two years, p ≤ 0.001 
versus baseline; laparoscopic adjustable gastric 
banding 78% at baseline, one year 37.5% at one 
year, 40% at two years, p ≤ 0.001 versus baseline) 
(Table 32). Significant improvements in both 
groups were seen in joint problems (p ≤ 0.001 
compared with preoperative), pulmonary problems 
(p ≤ 0.05 compared to preoperative) and diabetes 
mellitus (p ≤ 0.05 compared with preoperative). No 
improvement in either group was observed between 
the percentage of patients with preoperative 
and postoperative hypertension, cardiovascular 
problems, hypercholesterolaemia, reflux disease, 
sleep apnoea or neurological problems (Appendix 
10). After a mean of 84 months follow-up 
comorbidities had all significantly decreased 
except for gastro-oesophageal reflux disease 
(GERD), which increased in both groups, although 
no numerical data are provided in the abstract 
reporting these results.128
Complications and additional 
operative procedures
Van Dielen and colleagues127 report that two deaths 
(4%) occurred, both in the open vertical banded 
gastroplasty group, one from sepsis in the first 
postoperative week, and one as the result of a pre-
existing pneumonia that had not been reported 
to the surgeon preoperatively. No postoperative 
deaths occurred in the other two studies,110,126 and 
although one patient from each group died during 
follow-up in the study by Nilsell and colleagues,126 
these deaths are reported to be unrelated to the 
surgery (Table 33). 
Operative time was shorter with laparoscopic 
adjustable silicone gastric banding than 
laparoscopic vertical banded gastroplasty 
[65.4 minutes (35–120) versus 94.2 minutes (40–
270), p < 0.05], as was hospital stay [3.7 days (2 to 
6), versus 6.6 days (3 to 58), p < 0.05] in the Morino 
and colleagues study.110 Hospital stay was also 
shorter for laparoscopic adjustable gastric banding 
than open vertical banded gastroplasty [mean 
3.5 days (SD 1.5), range 2–9 days, versus mean 
6.8 days (SD 10.4) days, range 2–56 days; p < 0.001] 
in the study by van Dielen and colleagues.127
One reoperation on the third postoperative day 
because of an anastomotic leak in the vertical 
banded gastroplasty group is reported by Nilsell 
and colleagues.126 Morino and colleagues110 found 
that early morbidity was similar between the two 
laparoscopic procedures (laparoscopic adjustable 
gastric banding 6.1% versus laparoscopic vertical 
gastric banding 9.8%, p = 0.754) and there were 
no conversions to open surgery. One patient 
experienced early postoperative band slippage 
(laparoscopically repositioned). There was also 
one port infection and one haematoma at the port 
site in the laparoscopic adjustable gastric banding 
group. In the vertical banded gastroplasty group 
there was one fistula at the staple line (treated with 
open gastric bypass), two instances of prolonged 
postoperative pyrexia, and two respiratory 
failures without evidence of pulmonary embolism. 
Van Dielen and colleagues127 reported that two 
conversions to open surgery were necessary in 
the laparoscopic adjustable banding group, and DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 31  Summary of results: vertical banded gastroplasty versus adjustable gastric banding – weight change
Nilsell, 2001126 VBG (n = 30) AGB (n = 29) p-value
Mean weight (kg) baseline (SEM) 123 (30) 124 (29)
Mean weight (kg) 1 year (SEM)a 82 (25) 98 (28)
Mean weight (kg) 2 year (SEM)a 85 (29) 88 (23)
Mean weight (kg) 3 year (SEM)a 90 (15) 85 (13)
Mean weight (kg) 4 year (SEM)a 95 (15) 86 (17)
Mean weight (kg) 5 years (SEM) 88 (16) 81 (16)
Morino, 2003110 LVBG (n = 51) LAGB (n = 49)
BMI 1 year 30.1 35.5 p < 0.05
BMI 2 years 29.7 34.8 p = ns
BMI 3 years 30.7 35.7 p = ns
% excess weight loss 1 year 62.3 39.2 p < 0.05
% excess weight loss 2 years 63.5 41.4 p = ns
% excess weight loss 3 years 58.9 39.0 p = ns
Patients with an excellent or good resultb 2 
years
74% 35% p < 0.001
Patients with an excellent or good result 3 
years
63% 25% p = 0.056
van Dielen, 2005127,128 Open VBG (n = 50) LAGB (n = 50) p-value
Mean BMI at 1 year (± SD) 31.1 (± 6.2) 35.0 (± 6.3)
Mean BMI at 2 years (± SD) 31.0 (± 6.0) 34.6 (± 6.5) p ≤ 0.002
% excess weight loss at 1 year (± SD) 71.1 (± 24.0) 53.3 (± 21.2) p ≤ 0.001
% excess weight loss at 2 years (± SD) 70.1 (± 25.5) 54.9 (± 23.3) p ≤ 0.001
% excess BMI loss at mean 84 months  68.8% 56.9%
BMI, body mass index; AGB, adjustable gastric banding; LAGB, laparoscopic adjustable gastric banding; LVBG, laparoscopic 
vertical banded gastroplasty; ns, not statistically significant; open, open surgery; SD, standard deviation; VBG, vertical banded 
gastroplasty.
a  Data from figure 2 within Nilsell, 2001.126
b  Patients with an excellent or good result defined as residual excess weight < 50%.
in an additional patient a conversion to gastric 
bypass was necessary. In the open vertical banded 
gastroplasty group nine patients experienced 
immediate postoperative complications: leakage 
in three patients required reoperation, two 
splenectomies were performed, and in two patients 
an obstruction that necessitated gastroscopy 
occurred. There were no infections in the 
laparoscopic adjustable banding group, but there 
were seven infections in five patients (including the 
two patients who died) in the open vertical banded 
gastroplasty group.
Nilsell and colleagues126 reported that late 
reoperations were necessary in a third of vertical 
banded gastroplasty patients because of staple-line 
disruption with rapid weight regain or strictures 
of the stoma with vomiting or intolerance of solid 
food. The total incidence of staple-line disruption 
was 18.5% (five patients), but three patients were 
not reoperated on for various reasons.126 Three 
(11.5%) adjustable gastric banding patients were 
reoperated; two as the result of dilatation of the 
gastric pouch, and one patient requested that 
their band be removed for reasons that were 
unclear. Morino and colleagues,110 found that 
late complications were more common following 
laparoscopic adjustable silicone gastric banding 
(32.7% versus 14%, p < 0.05). However, no patients 
with laparoscopic vertical banded gastroplasty 
required late reoperation, whereas 24.5% of 
patients required late reoperation following 
laparoscopic adjustable silicone gastric banding 
(p < 0.001), most commonly because of bands 
slipping. The percentage of late complications 
occurring in the open vertical banded gastroplasty Clinical effectiveness
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TABLE 32  Summary of results: vertical banded gastroplasty versus adjustable gastric banding – comorbidities
van Dielen, 2005127 Open VBG (n = 50) LAGB (n = 50) p-value
Preoperative patients with comorbidity 41 (82%) 39 (78%)
Joint problems 29 (58%) 28 (56%)
Pulmonary problems 8 (16%) 9 (18%)
Hypertension 10 (20%) 7 (14%)
Diabetes mellitus 7 (14%) 5 (10%)
Cardiovascular problems 3 (6%) 2 (4%)
Hypercholesterolaemia 2 (4%) 2 (4%)
Reflux disease 2 (4%) 3 (6%)
Sleep apnoea 1 (2%) 1 (2%)
Neurological problems 0 (0%) 1 (2%)
At 1 year patients with comorbidity 14 (30.4%)a 18 (37.5%)a
Joint problems 7 (15.2%)a 10 (20.8%)a
Pulmonary problems 3 (6.5%)b 3 (6.3%)b
Hypertension 8 (17.4%) 5 (10.4%)
Diabetes mellitus 1 (2.2%)b 1 (2.1%)b
Cardiovascular problems 2 (4.3%) 2 (4.2%)
Hypercholesterolaemia 1 (2.2%) 2 (4.2%)
Reflux disease 0 (0%) 0 (0%)
Sleep apnoea 0 (0%) 0 (0%)
Neurological problems 0 (0%) 1 (2.1%)
At 2 years patients with comorbidity 23 (47.9%)a 20 (40%)a
Joint problems 13 (27.1%)a 12 (24%)a
Pulmonary problems 3 (6.3%)b 1 (2%)b
Hypertension 7 (14.6%) 5 (10%)
Diabetes mellitus 1 (2.1%)b 1 (2%)b
Cardiovascular problems 1 (2.1%) 3 (6%)
Hypercholesterolaemia 1 (2.1%) 1 (2%)
Reflux disease 0 (0%) 0 (0%)
Sleep apnoea 0 (0%) 0 (0%)
Neurological problems 1 (2.1%) 1 (2%)
LAGB, laparoscopic adjustable gastric banding; open, open surgery; VBG, vertical banded gastroplasty.
a  p ≤ 0.001 compared to preoperative.
b  p ≤ 0.05 compared to preoperative.
group and the laparoscopic gastric bypass group 
appear similar in van Dielen and colleagues127 (no 
statistical comparison reported). Revisional surgery 
(conversion to gastric bypass) was necessary in 36% 
of those who had undergone open vertical banded 
gastroplasty, in most cases (15/18) this was the 
result of vertical staple-line disruption. A further 
eight (16%) patients required a surgical repair of 
an incisional hernia. Six patients (12%) required 
gastroscopy at least once for outlet stenosis or 
obstruction. In the laparoscopic adjustable gastric 
banding group, 40% of participants required 
reoperation. The majority of reoperations (16/20) 
were major reoperations for pouch dilatation or 
slippage, band leakage, or band erosion. At a mean 
of 84 months follow-up, the authors reported that 
long-term complications ‘were mainly’ staple-line 
disruption (51%) and incisional hernia (27%) for 
patients with open vertical banded gastroplasty, 
and pouch dilatation (24%) and anterior slippage DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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(15%) for patients with laparoscopic adjustable 
gastric banding.128 Major reoperation was required 
in 59% of vertical banded gastroplasty patients, 
who required conversions to gastric bypass, 
and in 46% of laparoscopic adjustable gastric 
banding patients, who required refixation or band 
replacements (35%) or conversion to another 
procedure (11%).128
GERD was slightly more common in patients 
with vertical banded gastroplasty (14.8%) than 
adjustable gastric banding (11.5%) in the study by 
Nilsell and colleagues.126
Summary
Three studies were included: one had a low risk 
of selection bias and two were of uncertain risk of 
bias for several items, although missing outcome 
data for weight loss were adequately addressed. 
Weight loss results were inconclusive. One study 
found that weight loss was initially greater with 
vertical banded gastroplasty, but weight regain 
meant that by three years patients with adjustable 
gastric banding had a lower mean weight, and 
this was still the case at five years (statistical 
significance not reported). The second study 
found lower BMI and greater per cent excess 
weight loss following laparoscopic vertical banded 
gastroplasty, but this was statistically significant 
only at year one and not at years two or three. 
The third study found statistically significant lower 
BMI and greater per cent excess weight loss at 
one and two years following open vertical banded 
gastroplasty, and greater per cent excess BMI loss 
seven years after open vertical banded gastroplasty 
(statistical significance not reported). However, 
the impact of participants being converted to 
another procedure in this study is unclear. More 
patients who had undergone adjustable gastric 
banding reported being satisfied with the results 
at five years, but this apparent superiority was not 
tested statistically. Resolution of comorbidities 
was similar in the two groups in the only study 
that reported on this outcome.127 It is difficult to 
draw conclusions regarding complications and 
additional operative procedures because one 
study compared two open procedures, one two 
laparoscopic procedures, and one compared an 
open procedure with a laparoscopic procedure. 
In the comparison of open procedures more 
reoperations were necessary following open vertical 
banded gastroplasty than open adjustable gastric 
banding, but a statistical comparison was not 
reported. Laparoscopic adjustable gastric banding 
was associated with a statistically shorter operative 
time and hospital stay than laparoscopic vertical 
banded gastroplasty, but there were statistically 
more late complications and reoperations. The 
third comparison found laparoscopic adjustable 
gastric banding was associated with a statistically 
significant shorter hospital stay while open vertical 
banded gastroplasty led to more infections. 
Late complications requiring further surgery 
were similar but a statistical comparison was not 
reported.
Laparoscopic adjustable gastric 
banding versus laparoscopic 
isolated sleeve gastrectomy
One RCT129 compared laparoscopic adjustable 
gastric banding with laparoscopic isolated sleeve 
gastrectomy. 
Weight loss
In this study Himpens and colleagues129 report 
that the proportion of excess weight loss was 
statistically significantly greater in participants in 
the laparoscopic isolated sleeve gastrectomy group 
than the laparoscopic adjustable gastric banding 
group at one year (57.7% versus 41.4%, p = 0.0004) 
and three years (66% versus 48% p = 0.0025) 
(Table 34). Weight loss (three years: 29.5 kg versus 
17 kg, p < 0.0001) and reduction in BMI (three 
years: 27.5 versus 18, p < 0.0001) were statistically 
significantly improved in laparoscopic isolated 
sleeve gastrectomy participants in comparison 
with the laparoscopic adjustable gastric banding 
participants. All of these data were presented by 
the trial authors as median and range so care 
should be taken when interpreting the results.
Quality of life and comorbidities
QoL was not assessed in this study. At baseline 
in the Himpens and colleagues129 study GERD 
requiring drug therapy with proton pump 
inhibitors was a problem for 15% (6/40) of 
the laparoscopic adjustable gastric banding 
participants and 20% (8/40) of the participants in 
the laparoscopic isolated sleeve gastrectomy group. 
After one year GERD had disappeared in 83% 
and 75% of these participants in the two groups 
respectively, and this remained the same at three 
years. Statistical significance was not reported. In 
those without GERD at baseline, no statistically 
significant differences in rates of appearance of 
GERD between the intervention groups were 
observed at one year [laparoscopic adjustable 
gastric banding 3/34 (8.8%), versus laparoscopic 
isolated sleeve gastrectomy 7/32 (21.8%), p = ns] or 
three years [laparoscopic adjustable gastric banding 
7/34 (20.5%) versus laparoscopic isolated sleeve 
gastrectomy 1/32 (3.1%), p = ns] (Appendix 11). Clinical effectiveness
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TABLE 33  Summary of results: vertical banded gastroplasty versus adjustable gastric banding – complications and additional procedures
Nilsell, 2001126 VBG (n = 30) AGB (n = 29) p-value
Postoperative deaths 0 0
Deaths 1 1
Reoperation: anastomotic leak (n) 1 0
Late reoperations 10/27 (37%) 3/26 (11.5%)
Removal of band 4 1
Gastrogastrostomy 3 0
Longer band 1 0
Gastric banding 2 0
Replacement of band 0 2
Gastro-oesophageal reflux disease 4/27 (14.8%) 3/26 (11.5%)
Staple-line disruption 5/27 (18.5%)
Morino, 2003110 LVBG (n = 51) LAGB (n = 49)
Mortality 0 0
Operative time, minutes [mean (range)] 94.2 (40–270) 65.4 (35–120) p < 0.05
Hospital stay, days [mean (range)] 6.6 (3–58) 3.7 (2–6) p < 0.05
Conversion to open surgery 0 0
Associated procedures
Cholecystectomies
Lymph node biopsy
5 (10%)
4
1
5 (10%)
5
0
Early morbidity 5/51 (9.8%) 3/49 (6.1%) p < 0.754
Band slippage 1
Port infection 1
Haematoma at port site 1
Fistula at staple line 1
Prolonged postoperative pyrexia 2
Respiratory failures 2
Late complications 7/50 (14%)  16/49 (32.7%) p < 0.05
Band slippage 9
Symptomatic reflux disease 4 3
Complete food intolerance 1
Poor compliance 1
Port infection 1
Port twisted 1
Pouch dilatation 1
Asymptomatic pouch to fundus fistula 1
Gastric bezoar 1DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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Morino, 2003110 LVBG (n = 51) LAGB (n = 49)
Late reoperations 0/50 12/49 (24.5%) p < 0.001
Band removed 8
For slipping 6
For severe reflux oesophagitis 1
For poor compliance 1
Slipped band replaced laparoscopically 1
Gastric bypass (due to food intolerance) 1
Port repositioned 1
Port removed 1
van Dielen, 2005127 Open VBG (n = 50) LAGB (n = 50)
Mortality 2/50 (4%)  0
Mean length of hospital stay, days (± SD; 
range)
6.8 (± 10.4; 2–56) 3.5(± 1.5; 2–9) p < 0.001
Conversion to open surgery n/a 2 (4%) to open procedure; 
1 (2%) to gastric bypass
Immediate postoperative complications 9/50 (18%) 3 conversions as noted 
above
Leakage (reoperation required) 3
Splenectomy 2
Obstruction (gastroscopy required) 2
Infections 7 in 5 (10%) patients 0
Sepsisa 3
Urinary tract infection 1
Pneumoniaa 3
Wound infection 1
Late complications requiring further surgery 
(detailed below)
26/50 (52%)b 20/50 (40%)c
Revisional surgery (conversion to gastric 
bypass)
18/50 (36%)
Due to vertical staple-line disruption 15
Due to narrow outlet 2
Due to insufficient weight loss 1
Surgical repair of incisional hernia 8/50 (16%)
Major reoperations 16 (32%)
Pouch dilatation/pouch slippage 12
Band leakage 2
Band erosion 2
Minor reoperations 4/50 (8%)
Outlet stenosis or obstruction requiring 
gastroscopy
6/50 (12%)
AGB, adjustable gastric banding; LAGB, laparoscopic adjustable gastric banding; LVBG, laparoscopic vertical banded 
gastroplasty; open, open surgery; VBG, vertical banded gastroplasty.
a  A patient with sepsis and a patient with pneumonia account for the two VBG patients who died.
b  Proportion who had undergone a major reoperation after a mean follow-up of 84 months had increased to 59%
c  Proportion who had undergone a major reoperation after a mean follow-up of 84 months had increased to 46%
TABLE 33  Summary of results: vertical banded gastroplasty versus adjustable gastric banding – complications and additional procedures 
(continued)Clinical effectiveness
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TABLE 34  Summary of results: laparoscopic adjustable gastric banding versus laparoscopic isolated sleeve gastrectomy – weight change
Himpens, 2006129 LAGB (n = 40) LISG (n = 40) p-value
% EWL at 1 year (median, range) 41.4 (– 11.8 to 130.5) 57.7 (0 to 125.5) p = 0.0004
% EWL at 3 years (median, range) 48 (0 to 124.8) 66 (– 3.1 to 152.4) p = 0.0025
Weight loss at 1 year (kg, median, range) 14 (– 5 to 38) 26 (0 to 46) p < 0.0001
Weight loss at 3 years (kg, median, range) 17 (0 to 40) 29.5 (1 to 48) p < 0.0001
BMI decrease at 1 year (median, range) 15.5 (5 to 39) 25 (0 to 45) p < 0.0001
BMI decrease at 3 years (median, range) 18 (0 to 39) 27.5 (0 to 48) p = 0.0004
BMI, body mass index; EWL, excess weight loss; LAGB, laparoscopic adjustable gastric banding; LISG, laparoscopic isolated 
sleeve gastrectomy.
Complications and additional 
operative procedures
No early postoperative complications were seen 
in the laparoscopic adjustable gastric banding 
group of the Himpens and colleagues129 study, two 
participants in the laparoscopic isolated sleeve 
gastrectomy group had an early postoperative 
complication, both required revisional surgery, 
in one this was a total gastrectomy for gastric 
ischaemia (Table 35). Late complications requiring 
surgery were observed in the laparoscopic 
adjustable gastric banding participants, with three 
TABLE 35  Summary of results: laparoscopic adjustable gastric banding versus laparoscopic isolated sleeve gastrectomy – complications 
Himpens, 2006129 LAGB (n = 40) LISG (n = 40)
Early postoperative complications (requiring surgery) 0 2/40 (5%)
Intraperitoneal bleed requiring laparoscopy 1
Gastric ischaemia requiring total gastrectomy 1
Late complications requiring surgery 7/40 (17.5%) 0
Pouch dilatation leading to band removal 2
Pouch dilatation leading to conversion to RYGBP 1
Gastric erosion leading to conversion to RYGBP 1
Port disconnections, reconnected 3
Conversion due to insufficient weight loss 2/40 (5%) to RYGBP 2/40 (5%) to laparoscopic 
duodenal switch
Complications at 1 year (not requiring surgery)
Shoulder pain 3/40 (7.5%)
Frequent vomiting 6/40 (15%) 1/40 (2.5%)
Poor choice of alimentation 2/40 (5%)
Gastric pain 2/40 (5%)
Mineral deficiency 2/40 (5%)
Complications at 3 years (not requiring surgery)a
Shoulder pain 3 (8.5%)
Frequent vomiting 10 (28.5%) 5 (16.6%)
Poor choice of alimentation 17 (48.5%) 8 (26.6%)
Gastric ulcer 1 (2.8%)
Mineral deficiency 3 (10%)
LAGB, laparoscopic adjustable gastric banding; LISG, laparoscopic isolated sleeve gastrectomy; RYGBP , Roux-en-Y gastric 
bypass.
a  To achieve these percentage values the number of participants (denominator) contributing data to the 3-year follow-up for 
LAGB would have been 35, and for LISG 30.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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pouch dilatations (treated with band removal in 
two and conversion to Roux-en-Y gastric bypass in 
one); one gastric erosion (treated with Roux-en-Y 
gastric bypass) and three disconnections of the port 
(treated with reconnection). There were no late 
complications requiring surgery in the laparoscopic 
isolated sleeve gastrectomy group. Complications 
not requiring surgery that were observed at one 
and three years can be seen in Table 35. There 
appeared to be higher frequencies of complications 
in the laparoscopic adjustable gastric banding 
group than in the laparoscopic isolated sleeve 
gastrectomy group but this is based on observation 
of the data only, no statistical analysis was 
undertaken. 
In addition, two participants in each group had 
‘insufficient weight loss’ noted as a complication 
in the Himpens and colleagues129 study. The two 
participants in the laparoscopic adjustable gastric 
banding group were converted to Roux-en-Y gastric 
bypass and the two participants in the laparoscopic 
isolated sleeve gastrectomy group were converted 
to laparoscopic duodenal switch. 
Summary
On measures of weight, participants undergoing 
laparoscopic isolated sleeve gastrectomy showed 
more improvement than participants undergoing 
laparoscopic adjustable gastric banding in one 
study with an uncertain risk of bias. Rates of 
complications were observed to be lower in 
the laparoscopic isolated sleeve gastrectomy 
group, apart from rates of early postoperative 
complications. 
Open versus laparoscopic gastric bypass 
Three RCTs compared open gastric bypass with 
laparoscopic gastric bypass113,114,130,131 and another 
RCT compared open gastric bypass with hand-
assisted laparoscopic gastric bypass.112
Weight change
Puzziferri and colleagues113,114 demonstrated a 
slightly higher percentage of excess body weight 
loss following laparoscopic gastric bypass (one year: 
68%, SD 15) compared with open gastric bypass 
(one year: 62%, SD 14), but the difference was 
not statistically significant at one year (p = 0.07) 
or at the three-year or four-year follow-ups114 
(Table 36). Similarly, a non-significant difference 
in reduction of BMI was found at one year by 
Westling and Gustavsson131 [laparoscopic 14 (SD 
3), open 13 (SD 3)], Sundbom and Gustavsson112 
(BMI reduction of 15 in both groups, BMI: 
laparoscopic 29, open 30) and at three years 
follow-up by Lujan and colleagues130 (laparoscopic 
31, open 35.5). Incomplete weight loss outcome 
data were adequately addressed by Westling and 
Gustavsson131 and by Sundbom and Gustavsson.112 
However, the risk of bias from incomplete weight 
loss data was uncertain in the studies by Lujan and 
colleagues130 and Puzziferri and colleagues.113,114 
Quality of life and comorbidities
The one- to six-month QoL outcomes for Puzziferri 
and colleagues113 have been tabulated and 
discussed previously,15 and can be seen in Appendix 
12. In brief, early differences in some components 
of the SF-36 score (at one month) and Moorehead–
Ardelt quality of life questionnaire (MAQoL) (at 
three months) were no longer significant at three 
months or six months respectively. At the three-
year follow-up there continued to be no significant 
difference in MAQoL scores, and there was also 
no significant difference in the proportion of 
participants with Bariatric Analysis and Reporting 
Outcome System (BAROS) scores of good, very 
good or excellent (Table 37).
Westling and Gustavsson131 reported that 92% of 
all patients described themselves as ‘very satisfied’ 
with the result of the operation after one year, 
while the remaining patients described themselves 
as ‘satisfied’. The authors report no significant 
difference between the groups, but data were not 
provided.
Only one study reported on comorbidities.114 
At the three-year follow-up the improvement of 
obesity-related comorbidities was significantly 
different between the two groups for only two 
of the reported comorbidities: osteoarthritis 
symptoms improved more in the laparoscopic 
gastric bypass group than the open gastric bypass 
group (p < 0.05), whereas the open gastric bypass 
group experienced a greater improvement of 
dyslipidaemia (p < 0.01). For other obesity-related 
comorbidities improvements were not statistically 
significantly different between the groups (Table 
38).
Complications and additional 
operative procedures
One postoperative death in the laparoscopic 
gastric bypass group was reported by Westling 
and Gustavsson;131 this was the result of malignant 
hyperthermia which developed during surgery 
leading to the death of the patient one week 
later. Lujan and colleagues130 reported three 
postoperative deaths. Two occurred in the 
laparoscopic group, one on postoperative day 32, Clinical effectiveness
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TABLE 36  Summary of results: open versus laparoscopic surgery – weight change
Open versus laparoscopic gastric bypass
Puzziferri, 2006113,114 Open RYGBP (n = 76) LRYGBP (n = 79) p-value
% excess body weight loss 12 months 62 (± 14) (n = 25) 68 (± 15) (n = 29) p = 0.07
% excess body weight loss 3 years  67 (± 21) (n = 33) 77 (± 22) (n = 30) p = ns
% excess body weight lost 4 years  71 (± 25) (n = 18) 76 (± 19) (n = 22) p = ns
Westling and Gustavsson, 2001131 Open RYGBP (n = 21) LRYGBP (n = 30)
BMI 1 year 30.6 (± 4) 27 (± 4)
Change in BMI 1 year 13 (± 3) 14 (± 3) p = ns
Lujan, 2004130 Open GBP (n = 51) LGBP (n = 53)
BMI 12 months (estimated from figure) 37 33 p = ns
BMI 18 months (estimated from figure) 36 31 p = ns
BMI 24 months (estimated from figure) 35 32 p = ns
BMI 36 months (estimated from figure) 35.5 31 p = ns
Sundbom, 2004112 Open RYGBP (n = 25) Hand-LRYGBP (n = 25)
Weight reduction at 1 year, median (range)  41 kg (26–57) 39 kg (23–57)
BMI at 1 year, median 30 29
Reduction in BMI 15 15
Open versus laparoscopic vertical banded gastroplasty
Davila-Cervantes, 2002111 Open VBG (n = 14) LVBG (n = 16) p-value
Excess body weight loss at 12 months 55% (30–88) 47% (22–97)
BMI at 12 months, median (estimated from 
figure)
33 33
Open versus laparoscopic adjustable silicone gastric banding
de Wit, 1999132 Open AGB (n = 25) LAGB (n = 25) p-value
Mean weight loss (12 months) 34.4 kg 35 kg p = ns
BMI reduction (12 months) 10.6 11.6 p = ns
AGB, adjustable gastric banding; BMI, body mass index; GBP , gastric bypass; hand-LRYGBP , hand-assisted laparoscopic Roux-
en-Y gastric bypass; LAGB, aparoscopic adjustable gastric banding; LGBP , laparoscopic gastric bypass; LRYGBP , laparoscopic 
Roux-en-Y gastric bypass; LVBG, laparoscopic vertical banded gastroplasty; ns, not statistically significant; open, open surgery; 
RYGBP , Roux-en-Y gastric bypass; VBG, vertical banded gastroplasty.
All mean ± SD unless stated.
and the other (unrelated to surgery) six months 
after surgery. One death occurred in the open 
surgery group within the first 30 postoperative 
days. No postoperative deaths occurred in the 
open versus laparoscopic113,114 or open versus hand-
assisted laparoscopic112 gastric bypass studies (Table 
39).
Conversion from laparoscopy to open procedure 
occurred in 2.5%,113 8% (all in the first 20 
patients),130 and 23% of patients.131 None of the 
patients with hand-assisted laparoscopy required 
conversion.112 Reoperation was required in 4%,112 
7.6%113 and 20%131 of laparoscopy patients, and 
none112 to 6.6%113 of patients with open gastric 
bypass.
In two of the studies, operative time was longer for 
laparoscopy [225 minutes (SD 40)113 to 245 minutes 
(range 135–190)131] than open gastric bypass 
(100 minutes (range 70–150)131 to 195 minutes (SD 
41), p < 0.001113]. This was also the case for hand-DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
67
TABLE 37  Summary of results: open versus laparoscopic surgery – quality of life
Open versus laparoscopic gastric bypass
Puzziferri, 2006114 Open RYGBP (n = 22) LRYGBP (n = 22) p-value
MAQoL scores 3 years
Self-esteem 0.88 0.89 p = ns
Physical activity 0.36 0.40 p = ns
Social life 0.33 0.34 p = ns
Labour or work conditions 0.25 0.33 p = ns
Sexual interest/activity 0.24 0.20 p = ns
BAROS scores (%) 3 years
Fair 9.1% 4.5%
Good, very good or excellent 86.4% 95.5% p = ns
BAROS, Bariatric Analysis and Reporting Outcome System; LRYGBP , laparoscopic Roux-en-Y gastric bypass; MAQoL, 
Moore-Ardelt Quality of Life; open, open surgery; RYGBP , Roux-en-Y gastric bypass.
assisted laparoscopy112 (150 minutes, 110–265; 
open 85 minutes, 60–150, p < 0.01]. However, 
Lujan and colleagues130 found operative time was 
longer for open (201.7 minutes, 129–310) than for 
laparoscopic gastric bypass (186.4 minutes, 125–
290), p < 0.05.
Puzziferri and colleagues113 found significantly 
less blood loss with laparoscopy (137 ml, SD 79 
versus 395 ml, SD 284, p < 0.001), whereas Westling 
and Gustavsson131 found only a slight reduction 
in blood loss [250 ml (50–1500) versus 300 ml 
(200–500), p = ns), and Sundbom and Gustavsson112 
found no difference between hand-assisted 
laparoscopy [median 250 ml, (0–1300)] and open 
surgery [median 250 ml (0–900)].
When excluding patients who were converted 
to open procedures, Westling and Gustavsson131 
found significant reductions in postoperative pain 
indicated by morphine dose, hospital stay and sick 
leave with laparoscopy, although the observations 
were not significant when using ITT analysis. 
Similarly, Sundbom and Gustavsson112 found no 
difference in the median LOS between open and 
hand-assisted laparoscopic gastric bypass [open 
six days (range 3–7), laparoscopy six days (range 
4–14)], and the amount of morphine required 
during the first three days was similar for the two 
procedures. Total sick leave was slightly higher 
following open surgery [hand-assisted laparoscopy 
30 days (15–59), open 37 days (19–95)]. Puzziferri 
and colleagues,113 however, found significant 
reductions in the proportion requiring intensive-
care unit (ITU) stay (7.6% versus 21.1%, p = 0.03), 
median LOS {three days [inter quartile range, 
(IQR), 1] versus four days (IQR 2), p < 0.001}, days 
to return to activities of daily living [8.4 days (SD 
8.6) versus 17.7 days (SD 19.1), p < 0.001], and 
days to return to work [32.2 days (SD 19.8) versus 
46.1 days (SD 20.6), p = 0.02] following laparoscopy. 
Lujan and colleagues130 also found a shorter mean 
hospital stay following laparoscopy [5.2 days (1–13) 
versus 7.9 days (2–28), p < 0.05].
The reporting of complications varied between 
studies, but in all studies most complications 
affected a small proportion of patients. Early 
major complications reported by Puzziferri and 
colleagues113 occurred in 9.2% of open gastric 
bypass patients and 7.6% of laparoscopy patients 
(p = 0.78). The most common complication in 
the laparoscopic group was jejunojejunostomy 
obstruction (3.8%) with other patients experiencing 
either an anastomotic leak (1.3%), hypopharyngeal 
perforation (1.3%), or gastrointestinal bleeding 
(1.3%). Participants receiving open surgery 
experienced wound infection (2.6%), anastomotic 
leak (1.3%), gastric pouch outlet obstruction 
(1.3%), pulmonary embolism (1.3%), respiratory 
failure and a retained laparotomy sponge (1.3%). 
Early minor complications, were similar following 
the open procedure (11.8% versus 7.6%, p = 0.42), 
although minor wound infections were more 
common following the open procedure (six patients 
versus one patient). Late complications were also 
similar (open: 15.8% versus laparoscopic: 18.9%, 
p = 0.52). Among the late complications reported 
by Puzziferri and colleagues113 anastomotic stricture 
occurred more often after laparoscopic gastric Clinical effectiveness
68
TABLE 38  Summary of results: open versus laparoscopic surgery – comorbidities
Open versus laparoscopic gastric bypass
Puzziferri, 2006114  Open RYGBP (n = 57) LRYGBP (n = 59)
Osteoarthritis
Baseline 31 (54%) 30 (51%) p = ns
Improvement/resolution at 3 years 19 (61%) 24 (80%) p < 0.05
Hypertension
Baseline 28 (49%) 18 (31%) p = ns
Improvement/resolution at 3 years 28 (100%) 15 (83%) p = ns
Depression
Baseline 17 (30%) 17 (29%) p = ns
Improvement/resolution at 3 years 12 (71%) 13 (76%) p = ns
Gastro-oesophageal reflux
Baseline 21 (37%) 14 (24%) p = ns
Improvement/resolution at 3 years 21 (100%) 14 (100%) p = ns
Dyslipidaemia
Baseline 14 (25%) 8 (14%) p = ns
Improvement/resolution at 3 years 14 (100%) 7 (88%) p < 0.01
Sleep apnoea
Baseline 15 (26%) 5 (8%) p < 0.05
Improvement/resolution at 3 years 12 (86%) 5 (100%) p = ns
Diabetes mellitus
Baseline 8 (14%) 5 (8%) p = ns
Improvement/resolution at 3 years 7 (88%) 5 (100%) p = ns
Infertility
Baseline 5 (9%) 7 (12%) p = ns
Improvement/resolution at 3 years 2 (40%) 2 (29%) p = ns
Urinary incontinence
Baseline 4 (7%) 8 (14%) p = ns
Improvement/resolution at 3 years 4 (100%) 7 (88%) p = ns
Lower extremity oedema
Baseline 3 (5%) 2 (3%) p = ns
Improvement/resolution at 3 years 3 (100%) 1 (50%) p = ns
LRYGBP , laparoscopic Roux-en-Y gastric bypass; ns, not statistically significant; open, open surgery; RYGBP , Roux-en-Y gastric 
bypass. 
bypass than open surgery but the difference was 
not statistically significant (laparoscopy 8.9% versus 
open 2.4%, p = 0.06), whereas ventral hernia was 
statistically significantly more frequent in the 
open surgical group (laparoscopy 0%, open 7.9%, 
p = 0.01). The difference in occurrence of hernias 
was still apparent at the three-year follow-up, which 
reports statistically significantly more patients in 
the open gastric banding group developed an 
incisional hernia than in the laparoscopic gastric 
banding group [22 (39%) versus 3 (5%), p < 0.001]. 
In addition, significantly more participants in the 
laparoscopic group required a cholecystectomy 
[12/43 (28%) versus 2/40 (5%), p = 0.03]. At three 
years the late complication of incisional hernia was 
still statistically significantly more frequent in the 
open surgical group (laparoscopy 5%, open 39%, 
p < 0.01), but there were no significant differences 
in the other complications reported at three 
years, and there were no late deaths (Table 39). DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 39  Summary of results: open versus laparoscopic surgery – complications and additional procedures
Open versus laparoscopic gastric bypass
Puzziferri, 2006113,114 Open RYGBP (n = 76) LRYGBP (n = 79) p-value
Perioperative deaths 0 0
Late deaths 0 0
Conversion from LGBP to GBP  n/a 2.5% 
Operative time (minutes) 195 (± 41) 225 (± 40) p < 0.001
Estimated blood loss (ml) 395 (± 284) 137 (± 79) p < 0.001
Intraoperative transfusion 3.9% 0
Proportion requiring intensive-care unit stay 21.1% 7.6% p = 0.03
Median length of hospital stay (days) 4 (IQR 2) 3 (IQR 1) p < 0.001
Reoperation 6.6% 7.6% p = ns
Return to activities of daily living (days) 17.7 (± 19.1) 8.4 (± 8.6) p < 0.001
Return to work (days) 46.1 (± 20.6) 32.2 (± 19.8) p = 0.02
Early major complications (total) 9.2% 7.6% p = 0.78
Anastomotic leak 1 1
Gastric pouch outlet obstruction 1 0
Hypopharyngeal perforation 0 1
Jejunojejunostomy obstruction 0 3
Pulmonary embolism 1 0
Respiratory failure 1 0
Gastrointestinal bleeding 0 1
Wound infection 2 0
Retained laparotomy sponge 1 0
Early minor complications (total) 11.8% 7.6% p = 0.42
Ileus 0 1
Clostridium difficile colitis 0 1
Gastrogastric fistula 1 0
Leak (asymptomatic) 1 0
Gastrointestinal bleeding 0 2
Wound infection 6 1
Deep venous thrombosis 1 1
Late complications (total)113 15.8% 18.9% p = 0.52
Anastomotic stricture 2 9 p = 0.06
Prolonged nausea vomiting 2 1
Small bowel obstruction 0 1
Cholelithiasis 0 3
Ventral hernia 6 0 p = 0.01
Anaemia 2 0
Protein-calorie malnutrition 0 1
Late complications at 3 years114 Open RYGBP (n = 57) LRYGBP (n = 59)
Incisional hernia 22 (39%) 3 (5%) p < 0.01
Anaemia 3 (5%) 8 (14%) p = ns
continuedClinical effectiveness
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Vitamin B12 deficiency 6 (11%) 3 (5%) p = ns
Chronic nausea vomiting 2 (4%) 3 (5%) p = ns
Chronic abdominal pain 1 (2%) 2 (3%) p = ns
Marginal ulcer 1 (2%) 0 p = ns
Small bowel obstruction 1 (2%) 2 (3%) p = ns
Cholecystectomy (excludes those with previous 
Cholecystectomy)
2/40 (5%) 12/43 (28%) p = ns
Late deaths 0 0 p = 0.03
Westling and Gustavsson, 2001131 Open RYGBP (n = 21) LRYGBP (n = 30)
Deaths 1/30 (3%)
Conversions to open surgery n/a 7/30 (23%)
Duration (minutes), median (range) 100 (70–150) (n = 21) 245 (135–390) (n = 30)
Preoperative bleeding (ml), median (range) 300 (200–500) (n = 21) 250 (50–1500) (n = 30)
Pain – morphine dose (mg) 140 (± 90) (n = 21) 98 (± 71.5) (n = 29); 
conversions excluded 
69 (± 46.4) (n = 22)
(p = ns); 
p < 0.005
Hospital stay (days) 6 (± 3.8) (n = 21) 4.5 (± 1.2) (n = 29); 
conversions excluded  
4 (± 0.8) (n = 22)
p = ns; 
p = 0.025
Sick leave (weeks) 5 (± 3.3) (n = 14) 3.9 (± 2.1) (n = 24); 
conversions excluded 
2.8 (± 1.8) (n = 18)
p = ns; 
p = 0.025
Reoperations 1/21 (4.8%)a 6/30 (20%)b
Gastrointestinal symptoms (dumping, vomiting, 
diarrhoea)
5% of all patients
Complications (n)
Incisional hernia 1
Small embolus 1
Colicky pain and vomiting 6b
Leakage 1a
Jejunal ulcers 2 3 p = ns
Stricture in gastrojejunostomy 1
Superficial wound infection 3
Readmission 1/21 (4.8%) 3/30 (10%)
Unexplained fever 1
Pneumonia 1
Epigastric pain and/or vomiting 2
Lujan, 2004130 Open GBP (n = 51) LGBP (n = 53)
Postoperative mortality 1/51 (2%) 2 (3.8%)(1 unrelated to 
surgery)
Conversions to laparotomy n/a 4/53 (8%)
Intraoperative complications 4/51 (8%)
Splenectomies 3
Splenic vein tear requiring suture 1
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Mean operating time, minutes 201.7 (129–310) 186.4 (125–290) p < 0.05
Mean hospital stay, days 7.9 (2–28) 5.2 (1–13) p < 0.05
Early complications (< 30 days) 15 (29.4%) 12 (22.6%) p = ns
Intestinal subocclusions 3
Asymptomatic leaks 2
Intra-abdominal bleeding 2
Upper gastrointestinal haemorrhage 2 3
Lower gastrointestinal haemorrhage 1
Thrombophlebitis 1
Stenosis of gastro-entero-anastomosis 1
Subphrenic abscess 4
Wound infection 4
Respiratory infection 3
Eviscerationc 1
Late complications (> 30 days) 12 (24%) 6 (11%) p < 0.05
Intestinal obstructionc 3 (1 reoperation) 1 (reoperation)
Pancreatitis/cholecystectomy 2
Sudden death (possible pulmonary 
thromboembolism)
1
Eventration 10
Subphrenic abscess 1
Sundbom, 2004112 Open RYGBP (n = 25) Hand-LRYGP (n = 25)
Deaths within 30 days postoperative 0 0
Laparoscopic conversions to laparotomy n/a 0
Duration of surgery, minutes [Median (range)] 85 (60–150) 150 (110–265) p < 0.001
Peroperative bleeding, ml [Median (range)] 250 (0–900) 250 (0–1300)
Intra-abdominal bleeding (oozing) 3
Intense intraluminal bleeding 2
Patients requiring blood transfusion due to post 
operative anaemia
1 (2 units) 1 (2 units)
Patients with postoperative respiratory symptoms 
requiring prolonged antibiotic treatment and 
physiotherapy treatment
5 8
Postoperative deep venous thrombosis, pulmonary 
embolism, or wound dehiscence
0 0
Length of hospital stay, days [Median (range)] 6 (3–7) 6 (4–14)
Morphine requirement, mg:
Day 1 [Median (range)] 32 (6–150) (n = 25) 48 (12–148) (n = 25)
Day 2 [Median (range)] 30 (12–118) (n = 22) 36 (14–123) (n = 20)
Day 3 [Median (range)] 25 (10–62) (n = 11) 28 (12–99) (n = 16)
Total days 1–3 [Median (range)] 66 (6–318) 98 (12–370)
Reoperation 0 1/25 (4%)
continued
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Complications at 1 month follow-up, (n)
Dysphagia (various grades) 18 (group not stated)
Narrow anastomosis 4 2
Wound infection with pus 0 1
Abnormal secretions 4 (group not stated)
Total sick leave, days, median (range). (10 patients 
retired or on long-term sick leave excluded)
37 (19–95) 30 (15–59)
Complications at 1-year follow-up, (n)
Anaemia requiring intensive treatment 2 (group not stated)
Symptomatic incisional hernia 1 0
Short-term treatment with proton pump inhibitor 3 3
Small stomal ulcer 1 0
Open versus laparoscopic vertical banded gastroplasty
Davila-Cervantes, 2002111 Open VBG (n = 14) LVBG (n = 16) p-value
Surgical details (median, min-max)
Surgical time 1.45 hours (1.1–2.5) 2.1 hours (1.5–4.0) p < 0.002
Blood transfusions 0 0
Conversion to open surgery n/a 0
Hospitalisationd 4 days (3–42) 4 days (3–97) p = ns
Complications (number of patients)
Wound problems (seroma, dehiscence or 
infection)
6 1
Pulmonary atelectasis requiring physical therapy 1
Number of extra doses of analgesics: (median,  
min.–max.)
1st postoperative day 2 (0–3) 1 (0–2) p = 0.04
2nd postoperative day 1 (0–1) 2 (0–2) p = 0.78
3rd postoperative day 1 (0–1) 0 (0) p = 0.46
12 months follow-up
Number with pathological scare 12 5 p = 0.002
Developed abdominal wall hernias 2 0
Open versus laparoscopic adjustable silicone gastric banding
de Wit, 1999132 Open AGB (n = 25) LAGB (n = 25)
Conversions Lap to open procedure: 
8%
Surgical time 76 minutes (SD 20) 150 minutes (SD 48) p < 0.05
Mean days in hospital 7.2 (range 5–13) 5.9 (range 4–10) p < 0.05
Early postoperative complications (lap vs open)
Cholecystectomy 5/25 (20%) 2/25 (8%)
Adhesiolysis 1/25 (4%)
Gall bladder puncture (to obtain samples for study 
purposes)
7/25 (28%) 0
Pulmonary complications 2/25 (8%) 2/25 (8%)
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Urinary infection 0 2/25 (8%)
Rhabdomyolysis 0 1/25 (4%)
Neurological complication (neuropraxis) 1/25 (4%) 1/25 (4%)
Perforation pouch 1/25 (4%) 0
Wound abscess 1/25 (4%) 0
Fever 2/25 (8%) 0
Gout 1/25 (4%) 0
First year surgical complications 
Incisional hernia 7 (28%), in 3 (12%) 
patients
0 p = ns
Migration band 1/24 (4%) 0 p = ns
Umbilical hernia 0%, 1/25 (4%) p = ns
Access port complications 6 (24%) in 5 (20%) patients 7 (28%), in 5 (20%) 
patients
p = ns
Readmissions
Patients 7/24 (28%) 5/25 (20%) p = ns
Total readmissions 15/24 6/25 p < 0.05
Overall length of hospital stay in the first year, days 11.8 (SD 10.5) 7.8 (SD 6) p < 0.05
AGB, adjustable gastric banding; GBP , gastric bypass; hand-LRYGBP , hand-assisted laparoscopic Roux-en-Y gastric bypass; 
IQR, inter quartile range; LAGB, laparoscopic adjustable gastric banding; LGBP , laparoscopic gastric bypass; LRYGBP , 
laparoscopic Roux-en-Y gastric bypass; LVBG, laparoscopic vertical banded gastroplasty; n/a, not applicable; n/s, not 
statistically significant; open, open surgery; RYGBP , Roux-en-Y gastric bypass; SD, standard deviation; VBG, vertical banded 
gastroplasty.
All mean (± SD) unless stated.
a  The patient in the open surgery group who required reoperation was the only patient with an obvious leakage.
b  Six patients were reoperated on: five due to narrow stricture of the tunnel through the mesocolon and one due to a 
herniated Roux limb.
c  This complication led to one patient death.
d  One patient in each group developed fistula at gastric partition requiring reoperation and prolonged hospital stay.
e  Pathological scar is a term used to describe particular types of abnormal/severe scar.
TABLE 39  Summary of results: open versus laparoscopic surgery – complications and additional procedures (continued)
In contrast to Puzziferri and colleagues,113 Lujan 
and colleagues130 reported four intraoperative 
complications in the open gastric bypass group 
and none in the laparoscopic group. They also 
found that while there was no significant difference 
between early complications (laparoscopy 22.6%, 
open 29.4%), late complications (> 30 days) were 
more common following open gastric bypass 
(11% versus 24%, p < 0.05). The most common 
early complications for laparoscopy included 
intestinal subocclusions (5.7%), asymptomatic 
leaks (3.8%), intra-abdominal bleeding (3.8%) 
and upper gastrointestinal haemorrhage (3.8%). 
For open surgery these included subphrenic 
abscesses (7.8%), wound infections (7.8%), 
upper gastrointestinal haemorrhage (5.9%) 
and respiratory infection (5.9%). The most 
common late complications reported by Lujan 
and colleagues130 included intestinal obstructions 
(5.7% of laparoscopy patients) and eventrations 
(protrusion of intestines through wound) (19.6% 
of open surgery patients). Late complications led 
to two reoperations, one in each group. Sundbom 
and Gustavsson112 reported that postoperative 
respiratory symptoms requiring prolonged 
antibiotic treatment and physiotherapy treatment 
occurred in 32% of hand-assisted laparoscopy 
patients and 20% of open surgery patients. 
Other complications included various grades of 
dysphagia (36% of patients, group not stated), 
narrow anastomosis (hand-assisted laparoscopy 
8%, open 16%), and short-term treatment with 
a proton pump inhibitor (12% of each group). 
Westling and Gustavsson131 did not report early and 
late postoperative complications separately. The 
most commonly reported complications occurring 
after surgery were reoperations (discussed earlier), 
most often as the result of stricture of the tunnel 
through the mesocolon causing colicky pain and 
vomiting, jejunal ulcers (laparoscopy 10.3%, open Clinical effectiveness
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9.5%), and superficial wound infection (open 
14.3%). There were four readmissions in the first 
year (laparoscopy 10.3%, open 4.7%) and one 
participant (4.7%) who had received open surgery 
developed an incisional hernia (Table 39).
Gastrointestinal symptoms reported at one year, 
such as dumping, vomiting or diarrhoea, were 
experienced by 5% of all patients in Westling and 
Gustavsson.131 
Summary
Four trials were included. The risk of selection bias 
was high in one trial, low in one trial and uncertain 
in two trials, and the risk of bias from other 
sources was mostly uncertain as many factors were 
not reported. Weight loss and QoL were similar 
between open and laparoscopic gastric bypass. 
Only one study reported on comorbidities and 
improvements were similar between the procedures 
except for two of the comorbidities. Statistically 
significant differences were found in favour 
of laparoscopic gastric bypass for a number of 
operative characteristics, particularly hospital stay 
in some studies. Complications in the two groups 
were in general reported to be not significantly 
different or were reported without a statistical 
comparison having been made.
Open versus laparoscopic 
vertical banded gastroplasty 
One RCT compared open vertical banded 
gastroplasty with laparoscopic vertical banded 
gastroplasty.129
Weight change
Davila-Cervantes and colleagues111 reported similar 
excess weight loss at 12 months (open 55% versus 
laparoscopic 47%, statistical significance not 
reported), resulting in a median BMI of 33 in both 
groups. In addition data were presented by the trial 
authors as median and range so care should be 
taken when interpreting the results (Table 36).
Quality of life and comorbidities
Data on QoL or comorbidities were not assessed. 
The median patient satisfaction score at 12 months 
was higher among the patients undergoing 
laparoscopic surgery [median score 2 (0–2) versus 1 
(0–2), p = 0.006].
Complications and additional 
operative procedures
There were no conversions from laparoscopic 
to open surgery. Surgical time was longer with 
laparoscopy [median 2.1 hours (1.5–4.0) versus 
1.45 hours (1.1–2.5), p < 0.002], but there was no 
statistically significant difference in LOS (median 
four days in both groups). Patients undergoing 
open surgery required more extra doses of 
analgesics on the first postoperative day [open 
median 2 (0–3), laparoscopic median 1 (0–2), 
p = 0.04], but not the second or third day. Wound 
problems such as seroma (accumulation of fluid), 
dehiscence (opening of wound) or infection 
were experienced by 43% of the open surgery 
group, whereas 6% of the laparoscopy group 
experienced wound infection and 6% experienced 
pulmonary atelectasis requiring physical therapy. 
One patient in each group developed a fistula at 
the gastric partition which required reoperation 
and prolonged hospital stay. Fewer laparoscopic 
patients had a pathologic scar at 12 months (five 
patients versus 12 patients, p = 0.002). Two patients 
(14%) with open surgery developed abdominal wall 
hernias (Table 39).
Summary
Similar excess weight loss occurred following open 
and laparoscopic vertical banded gastroplasty 
and LOS  was not significantly different between 
the two groups. Operative time was statistically 
significantly shorter for the open surgery group 
but after surgery fewer laparoscopic patients had 
wound problems and at 12 months fewer had a 
pathological scar. Laparoscopic patients had a 
higher patient satisfaction score at 12 months. This 
small RCT has an uncertain risk of bias as many 
factors were not reported.
Open versus laparoscopic adjustable 
silicone gastric banding 
One RCT compared open adjustable silicone 
gastric banding with laparoscopic adjustable 
silicone gastric banding.132
Weight change
De Wit and colleagues132 demonstrated no 
significant difference in weight loss between 
the procedures 12 months after surgery (p = ns). 
However, both laparoscopic and open adjustable 
silicone gastric banding were associated with a 
significant reduction in weight compared with 
baseline (35 kg and 34.4 kg respectively, p < 0.05) 
(Table 36). 
Quality of life and comorbidities
Data on QoL or comorbidities were not assessed.
Complications and additional 
operative procedures
Surgical complications and access port 
complications did not differ significantly between 
the two procedures, although patients undergoing DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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the open procedure had higher proportions of 
incisional hernia complications compared with 
laparoscopy (12% versus 0%, p = ns). Similarly early 
postoperative complications differed little between 
open and laparoscopic adjustable silicone gastric 
banding, although there were greater proportions 
of cholecystectomy among those undergoing open 
procedures (20% versus 8%). Readmissions (15 
among 7/24 open patients versus six among 5/25 
laparoscopic surgical patients, p < 0.05) following 
open and laparoscopic surgery, respectively, and 
mean overall LOS in the first year (11.8 days versus 
7.8 days, p < 0.05) were significantly higher in 
those undergoing open compared to laparoscopic 
procedures (Table 39).
Two (8%) patients were converted from 
laparoscopic to open procedure because of 
an inability to obtain a pneumoperitoneum. 
Laparoscopic surgery was rated as more difficult 
than open surgery (p < 0.05), and took longer to 
perform [150 minutes (SD 48) versus 76 minutes 
(SD 20), p < 0.05] (Table 39). Difficulty of surgery 
was rated on a subjective scale from 1 = easy 
to 10 = could not be performed or had to be 
converted, and therefore the finding should be 
treated with some caution.
Summary
Open and laparoscopic surgeries to fit adjustable 
silicone gastric banding led to similar degrees 
of significant weight loss. Operative time was 
statistically significantly shorter for the open 
surgery group. However, participants undergoing 
open procedures had a significantly longer 
hospital stay and were significantly more likely 
to be readmitted to hospital. Early postoperative 
complications were similar between the groups, but 
incisional hernia complications were experienced 
by 12% of patients who received the open 
procedure and by none of the laparoscopic surgical 
group. This study had a low risk of selection bias 
and a low risk of bias from incomplete weight loss 
data.
Summary of clinical 
effectiveness
Many of the included RCTs had an uncertain risk 
of bias because the reporting was unclear. Just five 
RCTs reported adequate allocation concealment 
and were, therefore, at low risk of selection bias. 
Most studies did not mention whether outcomes 
assessors were blinded to intervention assignments. 
The reporting of incomplete outcome data for 
weight loss, QoL or comorbidity was unclear for 
almost half of the studies. Other sources of bias 
included the use of block randomisation in non-
blinded trials, making it possible to predict future 
assignments. The included cohort studies were of 
variable size and quality. Most study participants 
were women so it is uncertain how generalisable 
the results are to men. All the studies included 
in this review were conducted in countries other 
than the UK. It is difficult to determine how 
generalisable the results of the included studies are 
to the ethnically diverse population within the UK.
Clinical effectiveness of surgery 
versus non-surgical interventions
Three RCTs and three cohort studies contributed 
evidence on the comparison of surgical versus non-
surgical interventions for obesity. All the studies 
reported that surgery results in greater weight 
loss than a non-surgical weight loss intervention 
even though they varied in the types of surgery 
undertaken, the non-surgical comparator, and 
the participants included. Two RCTs focused 
on participants at the lower side of the obesity 
continuum, one was judged to have a high risk of 
selection bias, and the other a low risk of selection 
bias, but at an uncertain risk of other sources 
of bias. These trials reported mean percentage 
excess weight loss at two years of 62.5% and 87.2% 
following surgery, but only 4.3% and 21.8% excess 
weight loss in participants in the non-surgical 
groups of these trials. The third RCT, judged to 
have an uncertain risk of bias, focused on people 
with morbid obesity, but again weight loss in men 
and women participants was greater one year 
following surgery (35 kg and 52 kg) than following 
diet (7 kg and 9 kg). Bias is inherently more likely 
within cohort studies than RCTs for a variety of 
reasons, but chiefly because there is a risk that 
confounding factors (both known and unknown) 
are distributed unevenly between the cohorts and 
the lack of randomisation provides an opportunity 
for selection bias to take place. The possible effect 
of these biases must therefore be kept in mind 
when interpreting the results of such studies. 
As noted above all the included cohort studies 
reported greater weight loss following surgical 
intervention than a non-surgical alternative. One 
of the three cohort studies, the large SOS study, 
has also reported the longest follow-up of all the 
included studies and therefore provides some 
evidence for the maintenance of the difference in 
weight loss for as long as 10 years.
Quality of life characteristics were reported by 
one of the RCTs and two of the cohort studies. 
The RCT provided evidence for an improvement Clinical effectiveness
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in some aspects of QoL at two years in patients 
who had undergone surgery, whereas one of the 
cohort studies found that after 3.2 years there were 
no significant differences between the groups. In 
contrast the larger SOS cohort study reported that 
all HRQoL measures were improved at 10 years 
compared with baseline for the surgery group, but 
for the conventional group some had improved 
while others had worsened.
One of the RCTs focused on participants at the 
lower side of the obesity continuum who also had 
Type 2 diabetes. In this study, remission of Type 
2 diabetes at two years was significantly higher in 
the surgery group than in the conventional therapy 
group and surgically treated participants were 
less likely to have metabolic syndrome. The other 
RCT focusing on participants at the lower end of 
the obesity continuum also reported a statistically 
significant reduction in the proportion of surgically 
treated participants with metabolic syndrome at 
two years. The SOS cohort study again provides 
evidence that improvements in comorbidities such 
as Type 2 diabetes and metabolic syndrome can be 
maintained at least for 10 years. Another weight-
related comorbidity, hypertension, was improved in 
one of the RCTs at two years and in the SOS study 
at 10 years, but the difference was not statistically 
significant at these time points.
Two of the RCTs reported that there were adverse 
events associated with both surgical and non-
surgical interventions and the SOS cohort study 
reported on complications and adverse events for 
the surgical group only, as well as overall mortality 
for both groups. The SOS study reported five 
deaths (0.25%) within 90 days of surgery in the 
surgical group in comparison with two deaths 
(0.10%) that occurred during the same period in 
the non-surgical group. During long-term follow-
up (of mean duration 10.9 years) 5% of the surgical 
group died in comparison with 6.3% of the non-
surgical group.
Clinical effectiveness of different 
surgical interventions
The clinical effectiveness of different surgical 
interventions was assessed by 20 RCTs which 
between them focused on nine different 
comparisons: six comparisons of different types 
of bariatric surgery and three comparisons of 
open and laparoscopic approaches to bariatric 
surgery. Among the six comparisons of different 
types of bariatric surgery there were three 
comparisons of procedures combining restrictive 
and malabsorption components with restrictive 
procedures (gastric bypass versus vertical banded 
gastroplasty; gastric bypass versus adjustable gastric 
band, and gastric bypass versus laparoscopic sleeve 
gastrectomy), two comparisons between restrictive 
procedures (vertical banded gastroplasty versus 
adjustable gastric band, and adjustable gastric band 
versus laparoscopic isolated sleeve gastrectomy), 
and one comparison between unbanded gastric 
bypass and banded gastric bypass.
Four comparisons included gastric bypass 
compared with either vertical banded gastroplasty 
(seven RCTs), banded gastric bypass (one 
RCT), adjustable gastric banding (one RCT), 
or laparoscopic sleeve gastrectomy (one RCT). 
On measures of weight change gastric bypass, 
which combines restrictive and malabsorption 
components, was superior to the purely restrictive 
procedures of vertical banded gastroplasty, and 
laparoscopic adjustable gastric banding. The 
comparison with laparoscopic sleeve gastrectomy 
was inconclusive. For people with a BMI over 50, 
banded gastric bypass was similar to non-banded 
gastric bypass. 
The comparisons between restrictive procedures 
included three RCTs which contributed evidence 
on the comparison between vertical banded 
gastroplasty and adjustable gastric banding, and 
the results were inconclusive. All studies found 
greater initial weight loss following vertical banded 
gastroplasty, but one study found no statistically 
significant difference at two or three years 
follow-up, one study found that vertical banded 
gastroplasty patients regained weight, so that at 
three to five years follow-up weight loss was greater 
following adjustable gastric banding (statistical 
significance not reported), and one study found 
that per cent excess BMI loss was greater with 
vertical banded gastroplasty at the seven-year 
follow-up (statistical significance not reported). 
The final comparison of different types of bariatric 
surgery, laparoscopic adjustable gastric banding 
versus laparoscopic isolated sleeve gastrectomy 
(both restrictive procedures) was assessed by only 
one RCT that reported weight-related outcomes 
at one and three years. All the data were reported 
as median and range and at both time points 
the participants who had received isolated sleeve 
gastrectomy showed more improvement than 
participants who had received adjustable gastric 
banding.
The comparisons of open versus laparoscopic 
gastric bypass (four RCTs), open versus DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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laparoscopic vertical banded gastroplasty (one 
RCT), and open versus laparoscopic adjustable 
silicone gastric banding (one RCT) all found that 
there were no significant differences in weight 
loss outcomes between the open and laparoscopic 
surgical approaches, both groups lost similar 
amounts of weight.
Only two RCTs comparing surgical procedures 
assessed QoL. One RCT reported that following 
surgery QoL was better in the gastric bypass group 
than in the vertical banded gastroplasty group on 
some items. The other RCT assessed people who 
had received either open or laparoscopic gastric 
bypass and found that there was no significant 
difference between the groups in QoL measures.
Five of the 20 RCTs assessing the clinical 
effectiveness of different surgical interventions 
reported on changes in comorbidities after surgery. 
In general comorbidities improved in all groups 
with no significant differences in improvements 
observed between different surgical interventions.
Reporting of adverse events, complications and 
operative variables varied greatly between studies 
and statistical comparisons between the groups 
were not often made. In general, adverse events 
and complications affected few participants. 
Fourteen of the 20 RCTs reported no deaths during 
or shortly after surgery and the remaining six 
RCTs reported very few deaths. Where deaths were 
reported separately for each trial arm, mortality 
ranged from 2% (one death within the first 30 
postoperative days among 51 patients receiving 
open gastric bypass surgery) to 10% (two deaths 
among 20 patients receiving open Roux-en-Y 
gastric bypass; one on the fourth postoperative day 
and one after 13 months). 
Two studies provided evidence that laparoscopic 
vertical banded gastroplasty surgery is quicker, 
and is associated with fewer early postoperative 
complications than laparoscopic gastric bypass 
surgery. However, approximately three years 
following open surgery to provide a vertical 
banded gastroplasty, conversions to an alternative 
bariatric procedure occurred more often than after 
open gastric bypass, but neither of the two studies 
reporting this comparison tested the outcome 
for statistical significance. Complications were 
generally similar for banded and unbanded gastric 
bypass apart from emesis and food intolerance, 
which were statistically significantly worse in the 
banded gastric bypass group. Laparoscopic gastric 
bypass was associated with a similar level of early 
complications and reoperations as laparoscopic 
adjustable gastric banding in the one RCT that 
compared these procedures. A further small 
RCT that compared laparoscopic gastric bypass 
with laparoscopic sleeve gastrectomy reported 
no intraoperative or postoperative complications 
in either group. Operative time was shorter for 
laparoscopic adjustable gastric banding than for 
laparoscopic vertical banded gastroplasty and 
hospital stay was also shorter than for laparoscopic 
or open vertical banded gastroplasty. However, 
there were statistically significantly more late 
complications following laparoscopic adjustable 
gastric banding than laparoscopic vertical 
banded gastroplasty in the trial that reported this 
comparison. Open vertical banded gastroplasty was 
associated with more infections than laparoscopic 
adjustable gastric banding. In the RCT that 
compared laparoscopic isolated sleeve gastrectomy 
with laparoscopic adjustable gastric banding there 
were more early postoperative complications with 
laparoscopic isolated sleeve gastrectomy, but late 
complications were higher in the laparoscopic 
adjustable gastric banding group. The comparisons 
of open and laparoscopic procedures in general 
favour the laparoscopic procedure for a number 
of operative characteristics, particularly hospital 
stay, and with fewer laparoscopic patients 
experiencing wound problems or incisional hernia 
complications.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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Introduction
The aim of this section is to assess the cost-
effectiveness of multiple types of surgical 
treatments for adults with morbid obesity (i.e. 
with BMI > 40), compared with non-surgical 
treatments, as well as a comparison of surgical 
treatments to each other. The cost-effectiveness of 
surgical treatment of obese patients (i.e. with BMI 
more than 35, but less than 40) with significant 
comorbidities is also analysed. The definition of 
the obese population here is consistent with the 
definition in the NICE Guidelines9 and with the 
general criteria of eligibility for bariatric surgery, 
as used in the cost-effectiveness studies138–142 
presented below. The obese population here is 
therefore defined according to narrower criteria 
than those used for clinical effectiveness (see 
Chapter 3, Inclusion criteria).
The following types of surgical intervention 
treatments were included:
•	 open gastric bypass
•	 laparoscopic gastric bypass
•	 vertical banded gastroplasty
•	 laparoscopic adjustable gastric banding
•	 biliopancreatic diversion and duodenal switch.
Results
Results of the literature search
A total of 448 reports of studies on the economics 
of surgical treatments were identified from which 
36 citations were retrieved as potentially eligible 
for inclusion and the full papers were obtained. 
Two systematic reviews51,143 of economic analyses of 
surgical interventions and five original economic 
evaluations138–142 that met the inclusion/exclusion 
criteria described in Chapter 3, Inclusion criteria 
were identified from the full reports (listed 
below). The reasons for excluding 29 studies after 
examination of the full papers can be seen in 
Appendix 17.
Included systematic reviews of cost-
effectiveness of bariatric surgery
1.  Relevant parts of Chapter 4 in the ‘Systematic 
review of the long-term effects and economic 
consequences of treatments for obesity and 
implications for health improvement’ by 
Avenell and colleagues.51
2.  ‘Are bariatric surgical outcomes worth their 
cost? A systematic review’ by Salem and 
colleagues.143
The two systematic reviews listed above were used 
as sources for economic evaluations published since 
searches were undertaken in 2001 for the previous 
review published in 2002.15 The final search for 
economic evaluation studies in the systematic 
review by Avenell and colleagues51 does not include 
any reports published after 2001. The systematic 
review by Salem and colleagues143 identified 
only three publications that reported the cost-
effectiveness of bariatric surgery as cost per QALY, 
including our previous 2002 systematic review and 
economic evaluation.15 Only one of these three 
economic evaluation studies140 was published after 
2001. This study is included in the list below of 
five newly identified original economic evaluations 
published after 2001. In addition to this study,140 
four other original economic evaluations that met 
the inclusion/exclusion criteria were identified and 
appraised. 
Original economic evaluations of bariatric 
surgeries included in the current review
1.  Ackroyd R, Mouiel J, Chevallier JM, Daoud 
F. ‘Cost-effectiveness and budget impact of 
obesity surgery in patients with type-2 diabetes 
in three European countries’.138
2.  van Mastrigt GA, van Dielen FM, Severens JL, 
Voss GB, Greve JW. ‘One-year cost-effectiveness 
of surgical treatment of morbid obesity: vertical 
banded gastroplasty versus Lap-Band’.139
3.  Craig BM, Tseng DS. ‘Cost-effectiveness of 
gastric bypass for severe obesity’.140
4.  Jensen C, Flum DR. ‘The costs of nonsurgical 
and surgical weight loss interventions: is an 
ounce of prevention really worth a pound of 
cure?’.141
Chapter 5 
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5.  Salem L, Devlin A, Sullivan SD, Flum DR. 
‘Cost-effectiveness analysis of laparoscopic 
gastric bypass, adjustable gastric banding, and 
nonoperative weight loss interventions’.142
Four of the identified studies were designed to 
estimate the cost-effectiveness of bariatric surgery 
in comparison with non-surgical treatment138,140–142 
and one study, by van Mastrigt and colleagues139, 
conducted a head-to-head comparison of clinical 
and economic effectiveness of two surgical 
alternatives. The study by van Mastrigt and 
colleagues139 is an economic evaluation alongside 
a clinical trial conducted over a one-year time 
interval. In this study the utility values were directly 
obtained from the trial participants. The four other 
studies are based on a decision analytic model 
that extrapolated the time horizon beyond the 
duration of clinical trials used as a source of clinical 
effectiveness and transformed an intermediate 
outcome (a body-weight reduction) into the final 
outcome (QALY or LY). Three out of the four 
modelled economic evaluations140–142 have a 
lifetime horizon and one138 has a five-year horizon. 
The studies differ with respect to: characteristics 
of the populations included in economic models 
(e.g. the baseline age, BMI and presence of 
comorbidities); perspectives of the evaluations 
(i.e. of a health-care system, a payer’s or a 
societal perspective); and, the source of clinical 
and epidemiological evidence. The study by van 
Mastrigt and colleagues139 has been undertaken 
from the societal perspective (the Netherlands). 
The only other study conducted from the societal 
(the USA) perspective is Jensen and Flum.141 This 
and two other studies140–142 use the same published 
US clinical, epidemiological and economic data.144 
Only one study, by Ackroyd and colleagues,138 
used UK data along with data from Germany and 
France. These issues are further elaborated in 
subsequent sections.
Description of the 
identified studies
Table 40 shows a list of surgical and non-surgical 
interventions from the identified studies and 
maps them across the list of surgical interventions 
included in the economic evaluation undertaken 
for this report. 
Table 40 shows that none of the economic 
evaluations involved the whole range of treatment 
alternatives for obesity. None of the identified 
studies included biliopancreatic diversion and 
duodenal switch, so this type of bariatric surgery 
was excluded from further consideration. Two 
studies, Craig and Tseng140 and Jensen and Flum,141 
compared open gastric bypass with non-surgical 
treatment, although the definitions of non-surgical 
treatment differ in these two studies. Two other 
studies, by Ackroyd and colleagues138 and Salem 
and colleagues,142 reported pair-wise comparisons 
of laparoscopic gastric bypass with a no-treatment 
strategy and laparoscopic adjustable gastric 
banding with a no-treatment strategy respectively. 
These studies differ with respect to the population 
included (only patients with Type 2 diabetes 
were included in Ackroyd and colleagues138) and 
the health-care systems where the intervention 
took place. Ackroyd and colleagues138 conducted 
economic evaluations using data from three 
European countries – the UK, Germany and France 
– whereas Salem and colleagues142 used clinical, 
epidemiological, cost and economic outcomes 
data from the USA. The only study that conducted 
a head-to-head comparison of two alternative 
surgical interventions was an economic evaluation 
alongside a clinical trial undertaken in a single 
Netherlands hospital.139 
The studies were summarised and critically 
appraised according to the methods described 
in Chapter 3, Quality assessment. The studies 
are characterised by large variations across the 
characteristics of the population, the interventions 
and the countries where the interventions took 
place so no formal quantitative systematic analysis 
of the results is possible. However, the strengths 
and weaknesses of the studies are presented in 
the Summary section of this chapter and the 
appraisal allowed us to make some judgements 
about the credibility of reported results and 
recommendations that the authors of identified 
studies had made. 
Table 41 provides a summary of the characteristics 
of the five included published economic 
evaluations of surgical treatment alternatives for 
obesity (see Appendix 15 for full data extractions 
and critical appraisal of each study). 
The target population. 
The studies presented in Table 41 are consistent 
with respect to the definition of the obese 
population for whom a surgical intervention is 
recommended according to NICE guidelines:9 
patients with BMI ≥ 40 or with BMI between 35 
and 40 and with a significant disease such as Type 
2 diabetes or high blood pressure. At the same 
time the studies differ with respect to baseline 
characteristics of the target population such as age DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 40  Surgical and non-surgical interventions included in the identified studies
Type of treatment strategies
Study
Non-surgical 
treatment 
(description)
Open gastric 
bypass (Open 
GBP)
Laparoscopic 
gastric bypass 
(LGBP)
Open vertical 
banded 
gastroplasty 
(VBG) 
Laparoscopic 
adjustable gastric 
banding (LAGB) 
Ackroyd and 
colleagues138,a
Conventional 
treatment for 
obese Type 2 
diabetes patientsb
X X
van Mastrigt and 
colleagues139
– X X
Craig and Tseng140 No treatmentc X
Jensen and Flum141 Diet and exercise  X
Salem and 
colleagues142,a
Non-operative 
weight loss 
interventionsd
X X
a  The studies by Ackroyd and colleagues and Salem and colleagues do not include a direct comparison between the 
alternative surgical interventions (contrary to the statement made in the latter). Only pair-wise comparisons of each 
surgery with a non-surgical intervention are reported. 
b  The conventional treatment was identified as either ‘annual follow-up watchful waiting’ or ‘continuation of the second 
year of a medically guided dieting’ that is assumed to be undertaken in the first year. 
c  It is not clear whether a ‘no-treatment’ comparator arm means no surgical treatment or no other interventions like 
dieting, exercise, behaviour therapy and pharmacotherapy. In either case a zero clinical effectiveness in terms of weight 
loss
d  Not elaborated, however assumed to be associated with a zero clinical effectiveness in terms of weight loss.
(ranging from 35 to 55 years old) and the presence 
or absence of comorbidities. Craig and Tseng140 
and Salem and colleagues142 have assumed that 
the population of obese patients with BMI ≥ 40 
have no comorbidities at baseline, which may 
not be a realistic assumption and would limit the 
generalisability of results. Likewise, the outcomes 
reported in Ackroyd and colleagues138 are only 
applicable to the population of obese patients with 
Type 2 diabetes. The outcomes reported in Jensen 
and Flum141 are applicable only to white female 
patients who were obese at the age of 18 with 
BMI ≥ 33 (or 35) (see Table 41, footnote d). The 
population enrolled in the study by van Mastrigt 
and colleagues139 appears to be the closest to the 
population typically presented in (European) 
clinical practice for bariatric surgery as it consists 
of both male and female patients with a mix of 
obesity-related comorbidities.
Sources of clinical evidence for 
weight reduction used in the 
modelled economic evaluations. 
Four modelled economic evaluations138,140–142 used 
the primary clinical end point of reduction in BMI 
(or per cent excess weight loss converted into BMI 
values). In all four studies the BMI values were 
taken from the published evidence; however, it 
does not appear that a systematic literature search 
and evidence synthesis was conducted in these 
studies. The economic analysis reported in Craig 
and Tseng140 and Jensen and Flum141 was based on 
bariatric surgery outcomes obtained from a single 
published source of evidence (a case series study 
by Pories and colleagues148 and a case–control 
longitudinal study by Sjostrom and colleagues,89 
respectively). The likelihood of a biased estimate 
of clinical outcomes is the highest in the case of 
a single and/or uncontrolled clinical study, which 
potentially affects validity of the estimate of the 
differential weight loss and generalisability of the 
results.
Primary and secondary clinical 
outcome(s) used in the modelled 
economic evaluations. 
The short-term intervention period (which is 
defined differently across the studies) is also 
characterised by the likelihood of an operative 
mortality and possible immediate and subsequent 
complications, some of which may result in surgical 
revisions (see Assumptions of economic evaluations, 
this chapter). Differential operative mortality rates 
(including mortality in revision and/or reversal Assessment of cost-effectiveness
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surgeries) are translated into the different life 
expectancy in the intervention and the comparator 
arms. Some patients also require reversal surgery 
(e.g. a band removal after laparoscopic adjustable 
gastric banding). The study by Jensen and Flum141 
includes only immediate (unspecified) postsurgical 
complications and associated mortality. The 
studies by Ackroyd and colleagues,138 Craig and 
Tseng,140 and Salem and colleagues142 include 
a fairly complete list of both immediate and 
subsequent complications (e.g. cholecystectomy, 
abdominoplasty). 
The study by Ackroyd and colleagues138 seems 
to have implicitly assumed a zero mortality rate 
(i.e. operative mortality, all-cause mortality 
and mortality associated with obesity-specific 
comorbidities, were all assumed to be zero) in all 
treatment options over the entire five years of 
the modelled time interval. It effectively implies 
that the differential operative mortality in the 
interventions (laparoscopic adjustable gastric 
banding and laparoscopic gastric bypass) and the 
comparator arms (non-surgical treatment) do not 
have an effect on the estimates of LYs and QALYs. 
The same also applies to the differential rates of 
postsurgical complications, including revision and 
reversal surgeries. These implicit assumptions do 
not seem to be reasonable and may potentially 
affect the validity of the estimate of the LYs gained 
and the generalisability of the results.
All modelled economic evaluations applied a 
discounting rate to both costs and outcomes 
although Jensen and Flum141 did not specify the 
value of the discounting rate.
Critical appraisal of 
economic evaluations
Table 42 outlines the approaches used in 
the identified cost-effectiveness studies. For 
completeness, the only economic evaluation that 
was not based on a decision analytic model139 is also 
included.
The economic evaluation alongside a clinical 
trial reported by van Mastrigt and colleagues139 
and the deterministic models reported in the 
other studies138,140–142 are two different methods 
of assessing the cost-effectiveness of bariatric 
surgery, and therefore cannot be directly compared 
across the whole range of criteria used for 
critical appraisal of decision analytic models.77 
Nevertheless, as reported below, some selected 
criteria can be used across the entire range of the 
identified economic evaluations. 
Assumptions of economic 
evaluations
Time horizon
The time horizon of the economic evaluation in 
van Mastrigt and colleagues139 is only one year. 
The authors have acknowledged the short-term 
horizon as one of the limitations of the study. 
In particular, the two types of bariatric surgery 
(laparoscopic adjustable gastric banding and 
vertical banded gastroplasty) compared in the study 
are characterised by the differential speed at which 
patients lose weight during the first 12 months. 
This is because the laparoscopic adjustable gastric 
banding patients need to undertake a few band 
adjustments in the first year following surgery, 
therefore losing weight in a more gradual fashion. 
The authors suggested that it is reasonable to 
expect that the patients in the laparoscopic 
adjustable gastric banding arm will continue to 
lose weight in the following postoperative years 
(up to five years), while the weight loss trend in 
the vertical banded gastroplasty arm will reach a 
plateau or even reverse after the first year.126 
The five-year time interval, as opposed to one 
year, was recommended in Clegg and colleagues15 
as appropriate for assessing the (short-term) 
effectiveness of a surgical intervention. This 
statement was used as a rationale for selecting a 
five-year time horizon in the model reported by 
Ackroyd and colleagues.138 However, the long-term 
consequences of weight loss may extend beyond the 
five-year time interval, and result in reduced rates 
of lifetime mortality and morbidity.153 Therefore, 
the lifetime horizon in the models reported in 
Craig and Tseng,140 Jensen and Flum141 and Salem 
and colleagues142 is more appropriate for assessing 
the long-term benefits of bariatric surgery. 
However, as explained below, these models differ 
with respect to assumptions about the short-term 
consequences of bariatric surgery.
Baseline cohort
Van Mastrigt and colleagues139 reported the 
baseline characteristics (gender, age, BMI and 
comorbidities) of the population enrolled in 
the clinical trial that provided evidence for the 
economic evaluation of open vertical banded 
gastroplasty as compared with laparoscopic 
adjustable gastric banding. Although the 
population is reasonably well matched across 
the arms with respect to most of the clinical 
parameters, there are differences (possibly 
statistically significant) in relation to the proportion 
of people in paid employment and (conversely) 
on disability benefits. In particular, the number DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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u
r
g
e
r
y
 
a
t
 
t
h
e
 
a
g
e
 
o
f
 
4
0
 
a
n
d
 
B
M
I
 
o
f
 
≥
 
4
0
.
 
D
i
e
t
 
a
n
d
 
e
x
e
r
c
i
s
e
 
g
r
o
u
p
:
 
w
h
i
t
e
 
w
o
m
e
n
;
 
a
g
e
 
1
8
 
y
e
a
r
s
;
 
b
a
s
e
l
i
n
e
 
B
M
I
 
o
f
 
3
3
 
(
o
r
 
3
5
)
b
A
 
s
e
t
 
o
f
 
I
C
E
R
 
e
s
t
i
m
a
t
e
s
 
c
o
m
p
a
r
i
n
g
 
L
G
B
P
 
w
i
t
h
 
n
o
-
t
r
e
a
t
m
e
n
t
 
a
n
d
 
L
A
G
B
 
w
i
t
h
 
n
o
-
t
r
e
a
t
m
e
n
t
 
h
a
v
e
 
b
e
e
n
 
c
o
n
d
u
c
t
e
d
 
s
e
p
a
r
a
t
e
l
y
 
f
o
r
 
c
o
h
o
r
t
s
 
o
f
 
m
e
n
 
a
n
d
 
w
o
m
e
n
:
 
a
g
e
d
 
3
5
 
w
i
t
h
 
B
M
I
 
=
 
4
0
;
 
a
g
e
d
 
4
5
 
w
i
t
h
 
B
M
I
 
=
 
5
0
;
 
a
g
e
d
 
5
5
 
w
i
t
h
 
B
M
I
 
=
 
6
0
A
s
s
u
m
p
t
i
o
n
,
 
m
a
i
n
 
c
l
i
n
i
c
a
l
 
o
u
t
c
o
m
e
s
 
a
n
d
 
h
o
w
 
t
h
e
 
i
n
t
e
r
m
e
d
i
a
t
e
 
o
u
t
c
o
m
e
s
 
a
r
e
 
t
r
a
n
s
l
a
t
e
d
 
i
n
t
o
 
t
h
e
 
fi
n
a
l
 
o
u
t
c
o
m
e
s
O
u
t
c
o
m
e
s
 
o
f
 
b
a
r
i
a
t
r
i
c
 
s
u
r
g
e
r
y
 
a
r
e
 
a
s
s
e
s
s
e
d
 
i
n
 
t
e
r
m
s
 
o
f
 
w
e
i
g
h
t
 
l
o
s
s
 
a
n
d
 
T
y
p
e
 
2
 
d
i
a
b
e
t
e
s
 
r
e
m
i
s
s
i
o
n
.
 
T
h
e
 
p
r
o
b
a
b
i
l
i
t
y
 
o
f
 
d
e
v
e
l
o
p
i
n
g
 
o
t
h
e
r
 
o
b
e
s
i
t
y
-
r
e
l
a
t
e
d
 
c
o
m
o
r
b
i
d
i
t
i
e
s
 
a
n
d
 
c
o
r
r
e
s
p
o
n
d
i
n
g
 
c
h
a
n
g
e
s
 
i
n
 
l
i
f
e
 
e
x
p
e
c
t
a
n
c
y
 
a
r
e
 
i
m
p
l
i
c
i
t
l
y
 
a
s
s
u
m
e
d
 
t
o
 
b
e
 
t
h
e
 
s
a
m
e
 
a
s
 
i
n
 
t
h
e
 
n
o
n
-
s
u
r
g
i
c
a
l
 
t
r
e
a
t
m
e
n
t
 
a
r
m
.
 
O
p
e
r
a
t
i
v
e
,
 
a
l
l
 
c
a
u
s
e
 
a
n
d
 
c
o
m
o
r
b
i
d
i
t
y
-
r
e
l
a
t
e
d
 
m
o
r
t
a
l
i
t
y
 
r
a
t
e
s
 
a
r
e
 
i
m
p
l
i
c
i
t
l
y
 
a
s
s
u
m
e
d
 
t
o
 
b
e
 
z
e
r
o
.
 
 
I
n
 
e
a
c
h
 
y
e
a
r
 
i
n
 
e
a
c
h
 
a
r
m
 
o
f
 
t
h
e
 
m
o
d
e
l
 
t
h
e
 
T
y
p
e
 
2
 
d
i
a
b
e
t
e
s
 
o
u
t
c
o
m
e
 
i
s
 
i
n
d
e
p
e
n
d
e
n
t
l
y
 
a
s
s
e
s
s
e
d
 
a
s
 
a
 
c
h
a
n
g
e
 
f
r
o
m
 
t
h
e
 
b
a
s
e
l
i
n
e
 
i
n
 
p
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
 
f
r
e
e
 
o
f
 
T
y
p
e
 
2
 
d
i
a
b
e
t
e
s
.
 
T
h
i
s
 
i
s
 
c
a
l
l
e
d
 
a
n
 
‘
a
n
n
u
a
l
 
m
a
r
g
i
n
a
l
 
T
y
p
e
 
2
 
d
i
a
b
e
t
e
s
-
f
r
e
e
-
y
e
a
r
 
g
a
i
n
e
d
 
a
t
 
a
 
p
a
r
t
i
c
u
l
a
r
 
y
e
a
r
’
.
I
n
 
t
h
i
s
 
n
o
n
-
m
o
d
e
l
l
e
d
 
e
c
o
n
o
m
i
c
 
e
v
a
l
u
a
t
i
o
n
 
t
h
e
 
E
Q
-
5
D
c
 
u
t
i
l
i
t
y
 
v
a
l
u
e
s
 
w
e
r
e
 
c
o
l
l
e
c
t
e
d
 
f
r
o
m
 
e
a
c
h
 
s
u
r
v
i
v
i
n
g
 
p
a
t
i
e
n
t
 
a
t
 
t
h
e
 
b
a
s
e
l
i
n
e
,
 
a
n
d
 
a
t
 
3
,
 
6
 
a
n
d
 
1
2
 
m
o
n
t
h
s
.
 
T
o
 
o
b
t
a
i
n
 
a
 
Q
A
L
Y
 
f
o
r
 
e
a
c
h
 
p
a
t
i
e
n
t
 
t
h
e
 
E
Q
-
5
D
 
s
c
o
r
e
s
 
w
e
r
e
 
m
u
l
t
i
p
l
i
e
d
 
b
y
 
t
h
e
 
d
u
r
a
t
i
o
n
 
o
f
 
t
i
m
e
 
t
o
 
w
h
i
c
h
 
t
h
e
s
e
 
s
c
o
r
e
s
 
r
e
l
a
t
e
d
.
 
T
h
e
 
m
e
a
n
 
Q
A
L
Y
 
v
a
l
u
e
s
 
f
o
r
 
e
a
c
h
 
o
f
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
a
l
t
e
r
n
a
t
i
v
e
s
 
a
r
e
 
u
s
e
d
 
i
n
 
t
h
e
 
I
C
E
R
.
 
 
T
h
e
 
d
i
r
e
c
t
 
a
n
d
 
i
n
d
i
r
e
c
t
 
m
e
d
i
c
a
l
 
c
o
s
t
 
d
a
t
a
 
w
e
r
e
 
c
o
l
l
e
c
t
e
d
 
f
r
o
m
 
t
h
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
 
u
n
d
e
r
t
a
k
e
n
 
t
o
 
e
s
t
i
m
a
t
e
 
t
h
e
 
c
o
s
t
 
o
f
 
s
u
r
g
e
r
i
e
s
,
 
t
h
e
 
h
o
s
p
i
t
a
l
’
s
 
b
i
l
l
i
n
g
 
s
y
s
t
e
m
,
 
a
n
d
 
p
a
t
i
e
n
t
s
’
 
d
i
a
r
i
e
s
.
 
I
n
 
t
h
e
 
n
o
-
t
r
e
a
t
m
e
n
t
 
a
r
m
 
o
f
 
t
h
e
 
m
o
d
e
l
 
i
t
 
w
a
s
 
a
s
s
u
m
e
d
 
t
h
a
t
 
p
a
t
i
e
n
t
s
 
d
o
 
n
o
t
 
l
o
s
e
 
o
r
 
g
a
i
n
 
w
e
i
g
h
t
,
 
i
.
e
.
 
t
h
e
y
 
r
e
m
a
i
n
 
a
t
 
t
h
e
 
b
a
s
e
l
i
n
e
 
B
M
I
.
 
 
L
i
f
e
 
e
x
p
e
c
t
a
n
c
y
 
d
e
p
e
n
d
s
 
o
n
:
 
(
1
)
 
B
M
I
 
v
a
l
u
e
 
(
r
e
d
u
c
e
d
 
a
s
 
a
 
r
e
s
u
l
t
 
o
f
 
a
 
s
u
c
c
e
s
s
f
u
l
 
s
u
r
g
e
r
y
 
a
n
d
 
s
t
a
b
i
l
i
s
e
d
 
a
t
 
fi
v
e
 
y
e
a
r
s
 
a
f
t
e
r
 
s
u
r
g
e
r
y
,
 
o
r
 
r
e
v
e
r
s
e
d
 
t
o
 
t
h
e
 
b
a
s
e
l
i
n
e
 
v
a
l
u
e
 
a
s
 
a
 
r
e
s
u
l
t
 
o
f
 
a
 
r
e
v
e
r
s
a
l
 
s
u
r
g
e
r
y
)
;
 
(
2
)
 
g
e
n
d
e
r
;
 
a
n
d
 
(
3
)
 
t
h
e
 
a
g
e
 
a
t
 
w
h
i
c
h
 
t
h
e
 
s
u
r
g
e
r
y
 
w
a
s
 
u
n
d
e
r
t
a
k
e
n
.
 
L
i
f
e
 
e
x
p
e
c
t
a
n
c
y
 
w
a
s
 
a
d
j
u
s
t
e
d
 
f
o
r
 
t
h
e
 
e
s
t
i
m
a
t
e
d
 
o
p
e
r
a
t
i
v
e
 
m
o
r
t
a
l
i
t
y
.
 
 
U
t
i
l
i
t
y
 
v
a
l
u
e
s
 
(
a
l
s
o
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
 
b
y
 
B
M
I
,
 
g
e
n
d
e
r
,
 
a
n
d
 
a
g
e
)
 
a
r
e
 
a
p
p
l
i
e
d
 
t
o
 
t
h
e
 
e
s
t
i
m
a
t
e
d
 
L
Y
s
 
s
p
e
n
t
 
w
i
t
h
 
t
h
e
 
e
v
e
n
t
u
a
l
 
B
M
I
 
t
o
 
o
b
t
a
i
n
 
Q
A
L
Y
s
.
 
L
i
f
e
 
e
x
p
e
c
t
a
n
c
y
 
d
e
p
e
n
d
s
 
o
n
 
t
h
e
 
B
M
I
,
 
w
h
i
c
h
 
i
n
c
r
e
a
s
e
s
 
w
i
t
h
 
a
g
e
,
 
f
o
l
l
o
w
i
n
g
 
a
 
t
r
a
j
e
c
t
o
r
y
 
o
f
 
t
h
e
 
o
b
e
s
e
 
p
o
p
u
l
a
t
i
o
n
 
(
a
t
 
t
h
e
 
r
a
t
e
 
o
b
s
e
r
v
e
d
 
i
n
 
g
e
n
e
r
a
l
 
U
S
A
 
p
o
p
u
l
a
t
i
o
n
 
i
n
 
t
h
e
 
9
5
t
h
 
p
e
r
c
e
n
t
i
l
e
 
f
o
r
 
w
e
i
g
h
t
)
.
 
I
n
 
t
h
e
 
b
a
s
e
 
c
a
s
e
 
t
h
i
s
 
r
a
t
e
 
i
s
 
a
p
p
l
i
e
d
 
t
o
 
a
l
l
 
s
u
r
v
i
v
i
n
g
 
p
a
t
i
e
n
t
s
 
i
n
 
e
a
c
h
 
b
r
a
n
c
h
 
o
f
 
t
h
e
 
d
e
c
i
s
i
o
n
 
t
r
e
e
.
 
H
o
w
e
v
e
r
,
 
t
h
e
 
B
M
I
 
r
e
d
u
c
t
i
o
n
 
o
b
t
a
i
n
e
d
 
a
s
 
a
 
r
e
s
u
l
t
 
o
f
 
t
h
e
 
G
B
P
 
(
a
t
 
t
h
e
 
a
g
e
 
o
f
 
4
0
)
 
o
r
 
a
 
d
i
e
t
 
a
n
d
 
e
x
e
r
c
i
s
e
 
p
r
o
g
r
a
m
m
e
 
(
a
s
 
a
 
r
e
s
u
l
t
 
o
f
 
a
 
o
n
e
-
 
y
e
a
r
 
p
r
o
g
r
a
m
m
e
 
u
n
d
e
r
t
a
k
e
n
 
a
t
 
t
h
e
 
a
g
e
 
o
f
 
1
8
)
 
i
s
 
r
e
t
a
i
n
e
d
 
f
o
r
 
l
i
f
e
.
 
A
s
 
a
 
r
e
s
u
l
t
 
t
h
e
 
B
M
I
 
i
n
 
s
u
c
h
 
p
a
t
i
e
n
t
s
,
 
a
l
t
h
o
u
g
h
 
i
n
c
r
e
a
s
i
n
g
 
a
t
 
t
h
e
 
a
b
o
v
e
 
r
a
t
e
,
 
i
s
 
a
l
w
a
y
s
 
r
e
d
u
c
e
d
 
b
y
 
t
h
e
 
i
n
c
r
e
m
e
n
t
a
l
 
B
M
I
 
v
a
l
u
e
 
o
b
s
e
r
v
e
d
 
a
f
t
e
r
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
.
 
I
n
 
t
h
e
 
n
o
-
t
r
e
a
t
m
e
n
t
 
a
r
m
 
o
f
 
t
h
e
 
m
o
d
e
l
 
i
t
 
w
a
s
 
a
s
s
u
m
e
d
 
t
h
a
t
 
p
a
t
i
e
n
t
s
 
d
o
 
n
o
t
 
l
o
s
e
 
o
r
 
g
a
i
n
 
w
e
i
g
h
t
,
 
i
.
e
.
 
t
h
e
y
 
r
e
m
a
i
n
 
a
t
 
t
h
e
 
b
a
s
e
l
i
n
e
 
B
M
I
.
 
 
L
i
f
e
 
e
x
p
e
c
t
a
n
c
y
 
d
e
p
e
n
d
s
 
o
n
:
 
(
1
)
 
B
M
I
 
v
a
l
u
e
 
(
r
e
d
u
c
e
d
 
a
s
 
r
e
s
u
l
t
 
o
f
 
a
 
s
u
c
c
e
s
s
f
u
l
 
s
u
r
g
e
r
y
 
a
n
d
 
s
t
a
b
i
l
i
s
e
d
 
a
t
 
t
h
r
e
e
 
y
e
a
r
s
 
a
f
t
e
r
 
s
u
r
g
e
r
y
,
 
o
r
 
r
e
v
e
r
s
e
d
 
t
o
 
t
h
e
 
b
a
s
e
l
i
n
e
 
v
a
l
u
e
 
a
s
 
a
 
r
e
s
u
l
t
 
o
f
 
a
 
r
e
v
e
r
s
a
l
 
s
u
r
g
e
r
y
)
;
 
(
2
)
 
g
e
n
d
e
r
;
 
a
n
d
 
(
3
)
 
t
h
e
 
a
g
e
 
a
t
 
w
h
i
c
h
 
t
h
e
 
s
u
r
g
e
r
y
 
w
a
s
 
u
n
d
e
r
t
a
k
e
n
.
 
L
i
f
e
 
e
x
p
e
c
t
a
n
c
y
 
w
a
s
 
a
d
j
u
s
t
e
d
 
f
o
r
 
t
h
e
 
e
s
t
i
m
a
t
e
d
 
o
p
e
r
a
t
i
v
e
 
m
o
r
t
a
l
i
t
y
.
 
U
t
i
l
i
t
y
 
v
a
l
u
e
s
 
(
a
l
s
o
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
 
b
y
 
B
M
I
,
 
g
e
n
d
e
r
 
a
n
d
 
a
g
e
)
 
a
r
e
 
a
p
p
l
i
e
d
 
t
o
 
t
h
e
 
e
s
t
i
m
a
t
e
d
 
L
Y
s
 
s
p
e
n
t
 
w
i
t
h
 
t
h
e
 
e
v
e
n
t
u
a
l
 
B
M
I
 
t
o
 
o
b
t
a
i
n
 
Q
A
L
Y
s
.
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o
n
t
i
n
u
e
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A
u
t
h
o
r
A
c
k
r
o
y
d
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
1
3
8
v
a
n
 
M
a
s
t
r
i
g
t
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
1
3
9
C
r
a
i
g
 
a
n
d
 
T
s
e
n
g
1
4
0
J
e
n
s
e
n
 
a
n
d
 
F
l
u
m
1
4
1
S
a
l
e
m
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
1
4
2
T
h
e
 
c
u
m
u
l
a
t
i
v
e
 
T
y
p
e
 
2
 
d
i
a
b
e
t
e
s
-
f
r
e
e
 
y
e
a
r
s
 
a
r
e
 
c
a
l
c
u
l
a
t
e
d
 
b
y
 
a
g
g
r
e
g
a
t
i
n
g
 
t
h
e
 
p
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
 
f
r
e
e
 
f
r
o
m
 
T
y
p
e
 
2
 
d
i
a
b
e
t
e
s
 
i
n
 
e
a
c
h
 
y
e
a
r
 
o
v
e
r
 
5
 
y
e
a
r
s
.
a
 
U
t
i
l
i
t
y
 
w
e
i
g
h
t
s
 
a
r
e
 
d
e
r
i
v
e
d
 
f
r
o
m
 
t
h
e
 
l
i
n
e
a
r
 
c
o
m
b
i
n
a
t
i
o
n
 
o
f
 
B
M
I
 
v
a
l
u
e
s
 
a
n
d
 
t
h
e
 
T
y
p
e
 
2
 
d
i
a
b
e
t
e
s
 
s
t
a
t
u
s
.
 
Q
A
L
Y
s
 
a
r
e
 
o
b
t
a
i
n
e
d
 
b
y
 
a
g
g
r
e
g
a
t
i
n
g
 
t
h
e
 
e
s
t
i
m
a
t
e
d
 
u
t
i
l
i
t
y
 
v
a
l
u
e
s
 
(
a
c
c
o
r
d
i
n
g
 
t
o
 
t
h
e
 
B
M
I
 
a
n
d
 
%
 
o
f
 
T
y
p
e
 
2
 
d
i
a
b
e
t
e
s
-
f
r
e
e
 
p
a
t
i
e
n
t
s
 
o
b
s
e
r
v
e
d
 
i
n
 
e
a
c
h
 
y
e
a
r
)
 
o
v
e
r
 
fi
v
e
 
y
e
a
r
s
.
T
h
e
 
p
r
o
d
u
c
t
i
v
i
t
y
 
l
o
s
s
 
w
a
s
 
e
s
t
i
m
a
t
e
d
 
u
s
i
n
g
 
t
h
e
 
f
r
i
c
t
i
o
n
 
c
o
s
t
 
m
e
t
h
o
d
 
(
n
o
t
 
e
l
a
b
o
r
a
t
e
d
)
.
 
T
h
e
 
t
o
t
a
l
 
c
o
s
t
 
f
o
r
 
e
a
c
h
 
p
a
t
i
e
n
t
 
w
a
s
 
c
a
l
c
u
l
a
t
e
d
 
a
s
 
d
i
r
e
c
t
 
a
n
d
 
i
n
d
i
r
e
c
t
 
m
e
d
i
c
a
l
 
c
o
s
t
 
a
n
d
 
t
h
e
 
m
e
a
n
 
t
o
t
a
l
 
c
o
s
t
s
 
f
o
r
 
e
a
c
h
 
o
f
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
a
l
t
e
r
n
a
t
i
v
e
s
 
a
r
e
 
u
s
e
d
 
i
n
 
t
h
e
 
I
C
E
R
.
T
h
e
 
a
r
b
i
t
r
a
r
y
 
a
s
s
i
g
n
e
d
 
u
t
i
l
i
t
y
 
v
a
l
u
e
s
 
a
r
e
 
a
p
p
l
i
e
d
 
t
o
 
t
h
e
 
p
e
r
i
o
d
 
o
f
 
t
i
m
e
 
s
p
e
n
t
 
i
n
 
t
h
e
 
h
o
s
p
i
t
a
l
 
a
n
d
 
i
n
 
r
e
c
o
v
e
r
i
n
g
.
 
I
t
 
w
a
s
 
a
l
s
o
 
a
s
s
u
m
e
d
 
t
h
a
t
 
t
h
e
 
p
a
t
i
e
n
t
s
 
w
h
o
 
u
n
d
e
r
w
e
n
t
 
t
h
e
 
r
e
v
e
r
s
a
l
 
s
u
r
g
e
r
y
 
h
a
v
e
 
‘
n
e
v
e
r
 
[
p
s
y
c
h
o
l
o
g
i
c
a
l
l
y
]
 
r
e
c
o
v
e
r
e
d
 
c
o
m
p
l
e
t
e
l
y
’
.
 
A
 
5
0
%
 
r
e
d
u
c
t
i
o
n
 
i
n
 
u
t
i
l
i
t
y
 
w
e
i
g
h
t
s
 
w
a
s
 
a
p
p
l
i
e
d
 
t
o
 
t
h
e
s
e
 
p
a
t
i
e
n
t
s
 
f
o
r
 
t
h
e
 
r
e
s
t
 
o
f
 
t
h
e
i
r
 
l
i
v
e
s
.
U
t
i
l
i
t
y
 
v
a
l
u
e
s
 
(
a
s
 
a
 
f
u
n
c
t
i
o
n
 
o
f
 
B
M
I
)
 
a
r
e
 
t
a
k
e
n
 
f
r
o
m
 
t
h
e
 
p
u
b
l
i
s
h
e
d
 
l
i
t
e
r
a
t
u
r
e
.
1
5
2
U
t
i
l
i
t
y
 
v
a
l
u
e
s
 
a
r
e
 
a
s
s
i
g
n
e
d
 
a
c
c
o
r
d
i
n
g
 
t
o
 
t
h
e
 
B
M
I
 
o
b
s
e
r
v
e
d
 
i
n
 
e
a
c
h
 
y
e
a
r
 
t
o
 
o
b
t
a
i
n
 
Q
A
L
Y
s
.
T
h
e
 
v
a
l
u
e
s
 
a
r
e
 
t
a
k
e
n
 
d
i
r
e
c
t
l
y
 
f
r
o
m
 
t
h
e
 
s
t
u
d
y
 
b
y
 
C
r
a
i
g
 
a
n
d
 
T
s
e
n
g
,
 
2
0
0
2
.
1
4
0
S
t
r
u
c
t
u
r
e
 
o
f
 
t
h
e
 
m
o
d
e
l
 
N
o
t
 
r
e
p
o
r
t
e
d
.
 
I
t
 
a
p
p
e
a
r
s
 
t
h
a
t
 
t
h
e
 
c
o
s
t
 
a
n
d
 
e
f
f
e
c
t
i
v
e
n
e
s
s
 
p
a
r
a
m
e
t
e
r
s
 
a
r
e
 
a
s
s
i
g
n
e
d
 
t
o
 
e
a
c
h
 
y
e
a
r
 
i
n
d
e
p
e
n
d
e
n
t
l
y
 
a
n
d
 
t
h
e
n
 
a
g
g
r
e
g
a
t
e
d
 
o
v
e
r
 
fi
v
e
 
y
e
a
r
s
 
p
r
o
d
u
c
i
n
g
 
e
i
t
h
e
r
 
y
e
a
r
s
 
f
r
e
e
 
f
r
o
m
 
T
y
p
e
 
2
 
d
i
a
b
e
t
e
s
 
o
r
 
Q
A
L
Y
s
.
 
T
h
e
 
c
o
s
t
 
d
a
t
a
 
w
e
r
e
 
c
o
l
l
e
c
t
e
d
 
f
r
o
m
 
t
h
e
 
p
u
b
l
i
s
h
e
d
 
l
i
t
e
r
a
t
u
r
e
 
a
n
d
 
e
x
p
e
r
t
 
o
p
i
n
i
o
n
 
a
n
d
 
a
s
s
i
g
n
e
d
 
t
o
 
t
h
e
 
fi
r
s
t
 
y
e
a
r
 
(
i
n
t
e
r
v
e
n
t
i
o
n
)
.
N
o
t
 
a
p
p
l
i
c
a
b
l
e
T
h
e
 
o
p
e
n
 
G
B
P
 
a
r
m
 
o
f
 
t
h
e
 
d
e
c
i
s
i
o
n
 
t
r
e
e
 
m
o
d
e
l
 
a
s
s
u
m
e
s
 
f
o
u
r
 
s
u
r
g
e
r
y
 
o
u
t
c
o
m
e
s
 
t
h
a
t
 
o
c
c
u
r
 
i
n
 
t
h
e
 
fi
r
s
t
 
i
n
s
t
a
n
c
e
:
 
s
u
c
c
e
s
s
f
u
l
 
s
u
r
g
e
r
y
,
 
r
e
v
i
s
i
o
n
 
s
u
r
g
e
r
y
,
 
r
e
v
e
r
s
a
l
 
s
u
r
g
e
r
y
 
a
n
d
 
d
e
a
t
h
.
 
R
e
v
i
s
i
o
n
 
s
u
r
g
e
r
y
 
a
n
d
 
r
e
v
e
r
s
a
l
 
s
u
r
g
e
r
y
 
a
r
e
 
i
n
 
t
u
r
n
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
p
r
o
b
a
b
i
l
i
t
y
 
o
f
 
a
 
p
o
s
t
s
u
r
g
i
c
a
l
 
d
e
a
t
h
,
 
w
h
i
l
e
 
t
h
e
 
f
o
r
m
e
r
 
m
a
y
 
b
e
 
f
o
l
l
o
w
e
d
 
b
y
 
a
 
s
u
b
s
e
q
u
e
n
t
 
r
e
v
e
r
s
a
l
 
s
u
r
g
e
r
y
,
 
w
h
i
c
h
 
i
s
 
a
l
s
o
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
t
h
e
 
p
r
o
b
a
b
i
l
i
t
y
 
o
f
 
d
e
a
t
h
.
 
I
t
 
i
s
 
i
m
p
l
i
c
i
t
l
y
 
a
s
s
u
m
e
d
 
t
h
a
t
 
t
h
e
 
i
n
i
t
i
a
l
 
a
n
d
 
s
u
b
s
e
q
u
e
n
t
 
i
n
t
e
r
v
e
n
t
i
o
n
s
 
t
a
k
e
 
p
l
a
c
e
 
w
i
t
h
i
n
 
fi
v
e
 
y
e
a
r
s
 
a
f
t
e
r
 
w
h
i
c
h
 
t
h
e
 
r
e
d
u
c
e
d
 
p
o
s
t
s
u
r
g
i
c
a
l
 
B
M
I
 
i
s
 
e
i
t
h
e
r
 
s
t
a
b
i
l
i
s
e
d
 
o
r
 
r
e
v
e
r
s
e
d
 
t
o
 
t
h
e
 
b
a
s
e
l
i
n
e
 
v
a
l
u
e
 
i
n
 
t
h
e
 
u
n
s
u
c
c
e
s
s
f
u
l
 
s
u
r
v
i
v
i
n
g
 
p
a
t
i
e
n
t
s
.
 
T
h
e
 
o
p
e
n
 
G
B
P
 
a
r
m
 
o
f
 
t
h
e
 
d
e
c
i
s
i
o
n
 
t
r
e
e
 
m
o
d
e
l
 
a
s
s
u
m
e
s
 
t
w
o
 
o
u
t
c
o
m
e
s
 
o
f
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
:
 
s
u
r
g
e
r
y
 
w
i
t
h
 
i
m
m
e
d
i
a
t
e
 
c
o
m
p
l
i
c
a
t
i
o
n
s
 
(
u
n
d
e
fi
n
e
d
)
,
 
a
n
d
 
s
u
r
g
e
r
y
 
w
i
t
h
o
u
t
 
i
m
m
e
d
i
a
t
e
 
c
o
m
p
l
i
c
a
t
i
o
n
s
.
 
B
o
t
h
 
o
u
t
c
o
m
e
s
 
a
r
e
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
p
r
o
b
a
b
i
l
i
t
y
 
o
f
 
d
e
a
t
h
.
 
T
h
e
 
s
u
r
v
i
v
i
n
g
 
p
a
t
i
e
n
t
s
 
m
a
y
 
h
a
v
e
 
a
 
r
e
d
u
c
e
d
 
B
M
I
 
o
r
 
r
e
m
a
i
n
 
w
i
t
h
 
t
h
e
i
r
 
i
n
i
t
i
a
l
 
B
M
I
.
 
T
h
e
 
d
i
e
t
 
a
n
d
 
e
x
e
r
c
i
s
e
 
a
r
m
 
o
f
 
t
h
e
 
d
e
c
i
s
i
o
n
 
t
r
e
e
 
m
o
d
e
l
 
a
s
s
u
m
e
s
 
t
h
a
t
 
n
o
 
p
a
t
i
e
n
t
 
e
x
p
e
r
i
e
n
c
e
s
 
c
o
m
p
l
i
c
a
t
i
o
n
s
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
d
e
a
t
h
.
 
T
h
e
 
s
u
r
v
i
v
i
n
g
 
p
a
t
i
e
n
t
s
 
f
r
o
m
 
t
h
e
 
c
o
n
t
r
o
l
 
a
r
m
 
f
o
l
l
o
w
 
t
h
e
 
p
a
t
h
w
a
y
 
c
o
r
r
e
s
p
o
n
d
i
n
g
 
t
o
 
t
h
e
 
n
o
-
c
o
m
p
l
i
c
a
t
i
o
n
 
b
r
a
n
c
h
 
i
n
 
t
h
e
 
o
p
e
n
 
G
B
P
 
a
r
m
 
o
f
 
t
h
e
 
d
e
c
i
s
i
o
n
 
t
r
e
e
.
B
o
t
h
 
s
u
r
g
e
r
y
 
i
n
t
e
r
v
e
n
t
i
o
n
 
a
r
m
s
 
o
f
 
t
h
e
 
m
o
d
e
l
 
a
s
s
u
m
e
 
t
w
o
 
o
u
t
c
o
m
e
s
 
t
h
a
t
 
o
c
c
u
r
 
i
n
 
t
h
e
 
fi
r
s
t
 
i
n
s
t
a
n
c
e
:
 
s
u
c
c
e
s
s
f
u
l
 
s
u
r
g
e
r
y
,
 
a
n
d
 
d
e
a
t
h
.
 
I
n
 
t
h
e
 
L
G
B
P
 
a
r
m
 
t
h
e
 
s
u
r
v
i
v
i
n
g
 
p
a
t
i
e
n
t
s
 
m
a
y
 
n
e
e
d
 
t
o
 
u
n
d
e
r
g
o
 
a
 
r
e
v
i
s
i
o
n
 
s
u
r
g
e
r
y
,
 
w
h
i
c
h
 
c
a
n
 
b
e
 
s
u
c
c
e
s
s
f
u
l
 
o
r
 
c
a
n
 
r
e
s
u
l
t
 
i
n
 
t
h
e
 
d
e
a
t
h
 
o
f
 
a
 
p
a
t
i
e
n
t
.
 
I
n
 
t
h
e
 
L
A
G
B
 
a
r
m
 
t
h
e
 
s
u
r
v
i
v
i
n
g
 
p
a
t
i
e
n
t
s
 
m
a
y
 
n
e
e
d
 
t
o
 
u
n
d
e
r
g
o
 
a
 
r
e
v
e
r
s
a
l
 
s
u
r
g
e
r
y
 
(
b
a
n
d
 
r
e
m
o
v
a
l
)
,
 
w
h
i
c
h
 
i
s
 
n
o
t
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
t
h
e
 
r
i
s
k
 
o
f
 
d
e
a
t
h
.
 
A
l
l
 
s
u
r
v
i
v
i
n
g
 
p
a
t
i
e
n
t
s
 
i
n
 
b
o
t
h
 
a
r
m
s
 
(
e
x
c
e
p
t
 
t
h
o
s
e
 
w
h
o
 
u
n
d
e
r
w
e
n
t
 
a
 
r
e
v
e
r
s
a
l
 
s
u
r
g
e
r
y
)
 
a
c
h
i
e
v
e
 
w
e
i
g
h
t
 
l
o
s
s
 
s
p
e
c
i
fi
c
 
t
o
 
t
h
e
 
t
y
p
e
 
o
f
 
s
u
r
g
e
r
y
.
 
T
A
B
L
E
 
4
2
 
M
o
d
e
l
 
s
t
r
u
c
t
u
r
e
/
a
s
s
u
m
p
t
i
o
n
s
 
f
o
r
 
c
o
s
t
-
e
f
f
e
c
t
i
v
e
n
e
s
s
 
o
f
 
a
l
t
e
r
n
a
t
i
v
e
 
t
r
e
a
t
m
e
n
t
s
 
o
f
 
o
b
e
s
i
t
y
 
(
c
o
n
t
i
n
u
e
d
)DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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A
u
t
h
o
r
A
c
k
r
o
y
d
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
1
3
8
v
a
n
 
M
a
s
t
r
i
g
t
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
1
3
9
C
r
a
i
g
 
a
n
d
 
T
s
e
n
g
1
4
0
J
e
n
s
e
n
 
a
n
d
 
F
l
u
m
1
4
1
S
a
l
e
m
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
1
4
2
P
a
r
a
m
e
t
e
r
s
 
u
s
e
d
 
i
n
 
s
e
n
s
i
t
i
v
i
t
y
/
s
c
e
n
a
r
i
o
 
a
n
a
l
y
s
i
s
 
(
i
f
 
a
n
y
)
S
i
m
u
l
t
a
n
e
o
u
s
l
y
 
B
M
I
 
r
e
d
u
c
t
i
o
n
;
 
%
 
p
a
t
i
e
n
t
s
 
f
r
e
e
 
o
f
 
T
y
p
e
 
2
 
d
i
a
b
e
t
e
s
;
 
(
b
y
 
i
m
p
l
i
c
a
t
i
o
n
 
t
h
e
 
u
t
i
l
i
t
y
 
w
e
i
g
h
t
s
 
h
a
v
e
 
a
l
s
o
 
c
h
a
n
g
e
d
)
.
O
n
l
y
 
c
o
s
t
 
e
s
t
i
m
a
t
e
s
 
w
e
r
e
 
s
u
b
j
e
c
t
e
d
 
t
o
 
t
h
e
 
s
e
t
 
o
f
 
o
n
e
-
w
a
y
 
s
e
n
s
i
t
i
v
i
t
y
 
a
n
a
l
y
s
e
s
.
 
T
h
e
s
e
 
w
e
r
e
:
 
o
p
e
r
a
t
i
o
n
 
r
o
o
m
 
p
e
r
s
o
n
n
e
l
 
c
o
s
t
 
p
e
r
 
m
i
n
u
t
e
 
a
n
d
 
u
n
i
t
 
p
r
i
c
e
 
o
f
 
a
n
 
i
n
p
a
t
i
e
n
t
 
d
a
y
.
%
 
o
f
 
e
x
c
e
s
s
 
w
e
i
g
h
t
 
l
o
s
t
;
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
r
a
t
e
;
 
l
i
f
e
t
i
m
e
 
m
e
d
i
c
a
l
 
c
o
s
t
;
 
l
i
f
e
 
e
x
p
e
c
t
a
n
c
y
 
(
i
t
 
w
a
s
 
a
s
s
u
m
e
d
 
t
h
a
t
 
l
i
f
e
 
e
x
p
e
c
t
a
n
c
y
 
i
s
 
n
o
t
 
a
f
f
e
c
t
e
d
 
b
y
 
t
h
e
 
w
e
i
g
h
t
 
l
o
s
s
 
–
 
i
.
e
.
 
t
h
e
 
e
s
t
i
m
a
t
e
 
t
h
a
t
 
c
o
r
r
e
s
p
o
n
d
s
 
t
o
 
t
h
e
 
b
a
s
e
l
i
n
e
 
w
e
i
g
h
t
 
w
e
r
e
 
a
p
p
a
r
e
n
t
l
y
 
u
s
e
d
)
;
 
r
e
g
r
e
s
s
i
o
n
 
c
o
e
f
fi
c
i
e
n
t
s
 
i
n
 
t
h
e
 
(
u
n
r
e
p
o
r
t
e
d
)
 
m
u
l
t
i
p
l
e
 
r
e
g
r
e
s
s
i
o
n
 
e
q
u
a
t
i
o
n
 
f
o
r
 
t
h
e
 
u
t
i
l
i
t
y
 
v
a
l
u
e
s
 
w
e
r
e
 
d
e
c
r
e
a
s
e
d
 
b
y
 
2
5
%
;
 
o
p
e
r
a
t
i
v
e
 
m
o
r
t
a
l
i
t
y
;
 
c
o
m
p
l
i
c
a
t
i
o
n
 
r
a
t
e
s
.
 
I
n
 
t
h
e
 
t
w
o
-
w
a
y
 
s
e
n
s
i
t
i
v
i
t
y
 
a
n
a
l
y
s
i
s
 
t
h
e
 
d
i
s
c
o
u
n
t
 
r
a
t
e
 
w
a
s
 
i
n
c
r
e
a
s
e
d
 
f
r
o
m
 
3
%
 
t
o
 
5
%
 
w
h
i
l
e
 
t
h
e
 
l
i
f
e
t
i
m
e
 
m
e
d
i
c
a
l
 
c
o
s
t
 
w
a
s
 
a
s
s
u
m
e
d
 
t
o
 
b
e
 
z
e
r
o
.
 
A
n
o
t
h
e
r
 
t
w
o
-
w
a
y
 
s
e
n
s
i
t
i
v
i
t
y
 
a
n
a
l
y
s
i
s
 
v
a
r
i
e
d
 
t
h
e
 
e
s
t
i
m
a
t
e
 
o
f
 
w
e
i
g
h
t
 
l
o
s
s
 
a
n
d
 
t
h
e
 
m
e
d
i
c
a
l
 
c
o
s
t
 
a
d
j
u
s
t
e
d
 
f
o
r
 
t
h
e
 
d
i
f
f
e
r
e
n
t
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
r
a
t
e
s
.
A
 
s
e
r
i
e
s
 
o
f
 
o
n
e
-
w
a
y
 
s
e
n
s
i
t
i
v
i
t
y
 
a
n
a
l
y
s
e
s
 
w
e
r
e
 
p
e
r
f
o
r
m
e
d
 
(
t
h
e
 
l
i
s
t
 
o
f
 
p
a
r
a
m
e
t
e
r
s
 
t
e
s
t
e
d
 
w
a
s
 
n
o
t
 
p
r
o
v
i
d
e
d
)
.
 
T
h
e
 
r
e
s
u
l
t
s
 
p
r
o
v
e
d
 
t
o
 
b
e
 
s
e
n
s
i
t
i
v
e
 
t
o
 
t
h
e
 
e
s
t
i
m
a
t
e
d
 
c
o
s
t
 
o
f
 
c
o
m
p
l
i
c
a
t
i
o
n
s
 
(
t
h
e
 
r
a
n
g
e
 
t
e
s
t
e
d
 
i
n
 
t
h
e
 
s
e
n
s
i
t
i
v
i
t
y
 
a
n
a
l
y
s
i
s
 
w
a
s
 
n
o
t
 
r
e
p
o
r
t
e
d
)
 
a
n
d
 
t
h
e
 
d
i
s
c
o
u
n
t
 
r
a
t
e
 
(
n
e
i
t
h
e
r
 
t
h
e
 
v
a
l
u
e
 
n
o
r
 
t
h
e
 
r
a
n
g
e
 
w
e
r
e
 
r
e
p
o
r
t
e
d
)
.
 
%
 
o
f
 
e
x
c
e
s
s
 
w
e
i
g
h
t
 
l
o
s
t
;
 
c
o
s
t
 
o
f
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of patients claiming disability benefits at baseline 
was four times higher in the open vertical 
banded gastroplasty than in the laparoscopic 
adjustable gastric banding arm. There appears 
to be a statistically significant difference in the 
baseline utility values in favour of the laparoscopic 
adjustable gastric banding arm that may reflect the 
difference in the level of disability observed at the 
baseline.
The clinical effectiveness data in the two arms of 
the model presented in Jensen and Flum141 were 
collected from populations of different ages and 
from different countries.89,150 It is not clear whether 
the data for the open gastric bypass arm of the 
model came from the subgroup of the open GBP 
patients or from patients who underwent any type 
of bariatric surgery.89 The authors acknowledged 
that the strong assumption of the model is that 
18-year-old women with BMI > 33 (or 35) (see 
Table 41, footnote d) are the same individuals who 
continue gaining weight until they reach BMI > 40 
at the age of 40, at which point they undergo open 
GBP. 
In the study by Craig and Tseng140 the baseline 
cohort is described as non-smoking adults without 
a CVD, drug addiction or major psychological 
disorder and who failed conservative therapies 
consisting of dieting, exercise, behaviour therapy 
and pharmacotherapy. The age of the patients is 
said to be between 35 and 55 years and BMI > 40 
and < 50. However, the clinical evidence for the 
open gastric bypass arm was obtained from a single 
case series study involving 608 obese patients 
with BMI ≥ 40 or BMI ≥ 35 with comorbidities 
such as diabetes, arthritis or cardiopulmonary 
failure.148 The age of the patients in this study 
ranged from 14 to 64 (mean age at the time of 
surgery was 37.3 years). This inconsistency between 
the definition of the target population for whom 
bariatric surgery is typically recommended and 
characteristics of the population used as a source of 
clinical evidence is likely to undermine the internal 
validity of the results of the study.
Both Craig and Tseng140 and Salem and 
colleagues142 assumed that patients in the non-
surgical treatment arm retain the baseline weight 
for life. The same assumption, beginning from the 
second year, was also made in the model reported 
in Ackroyd and colleagues.138 This may not be a 
realistic assumption because patients in the non-
treatment arm are likely to continue gaining weight 
during their lifetime, as assumed in the model 
reported by Jensen and Flum.141 The assumption of 
zero weight gain over the modelled time interval in 
patients in the non-surgical treatment arm is likely 
to bias the cost-effectiveness estimates although the 
direction of the potential bias is uncertain.
Assumptions about the short-
term and long-term consequences 
of surgical interventions
The immediate consequences of surgical 
interventions are associated with the risk of 
operative death and complications that may occur 
during the postsurgery recovery such as deep 
venous thrombosis and wound infection, which 
do not typically require a surgical intervention. 
Other complications such as staple-line disruption 
or dehiscence may require a revision or even a 
reversal surgery. Reversal surgery is also required 
when patients cannot restrict their diets sufficiently 
following surgery and develop intractable dumping 
syndrome. In addition, nearly a quarter of patients 
require treatment for incisional hernia within 
two years after hospital discharge. Some patients 
require treatment for cholelithiasis two years after 
discharge and abdominoplasty five years after 
discharge.140 
Ackroyd and colleagues138 do not model the 
differential rates of postsurgical complications 
for laparoscopic adjustable gastric banding, 
open gastric bypass and non-surgical treatment 
(where they are, by definition, zero). However, the 
differential use of resources is included in the cost 
side of the cost-effectiveness estimate. The decision 
analytic models reported by Jensen and Flum,141 
Salem and colleagues,142 and Craig and Tseng140 
all include differential probabilities associated with 
operative mortality and complications, especially 
those that require surgical interventions and are 
associated with the risk of death. Jensen and 
Flum141 only include immediate (unspecified) 
complications while Salem and colleagues142 
and Craig and Tseng142 model postoperative 
complications over three-year and five-year 
time intervals, respectively. In these studies the 
operative mortality is factored into calculations of 
LY estimates. 
The postoperative complications in surviving 
patients are likely to result in a temporary 
reduction in QoL. The study by Craig and Tseng 
was the only one that attributed disutility values 
to patients who experienced postoperative 
complications, but only to those complications 
that required a surgical intervention (see section 
on Translation of short-term outcomes into final 
outcomes, this chapter). Other modelled economic DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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evaluations do not fully incorporate the differential 
rate of postoperative complications in surviving 
patients. 
The long-term outcomes of bariatric surgery 
include the reduced probability of developing an 
obesity-related disease. In particular, remission of 
Type 2 diabetes is frequently observed in obese 
patients who successfully underwent bariatric 
surgery. In Ackroyd and colleagues,138 which 
includes only patients with Type 2 diabetes at 
baseline, the clinical effectiveness data for each of 
the five years appear to have been extracted from 
the various studies with different cut-off points and 
different characteristics of the obese population. It 
appears that the implicit assumption of the model 
is that for each patient the probability of Type 2 
diabetes remission in each year does not depend 
on the Type 2 diabetes status in the previous 
year or on the BMI. This assumption may not be 
reasonable.
Jensen and Flum,141 Salem and colleagues142 
and Craig and Tseng140 do not explicitly model 
the differential probabilities of developing an 
obesity-related disease. However, the gender- 
and age-specific life expectancy estimates used 
in these studies are taken from the published 
model by Thompson and colleagues144 that 
includes the lifetime risks of hypertension, 
hypercholesterolemia, Type 2 diabetes, coronary 
heart disease (CHD) and stroke in relation to BMI. 
Translation of short-term 
outcomes into final outcomes 
Typically, to obtain final outcomes such as QALYs 
the duration of time that a patient spends in a 
particular health state is ‘weighted’ using a utility 
estimate (typically ranging from 0 = death to 1 =  
perfect health) that corresponds to this health 
state. This approach was used in assessing the 
cost-effectiveness of pharmacotherapies for obesity 
treatment as compared to non-pharmaceutical 
treatment options.154 
The modelled economic evaluations of bariatric 
surgery do not explicitly define health states in 
terms of disease progression but either derive 
the utility estimates from the regression analysis 
that estimated the relationship between utility 
[measured in European Quality Of Life-5 
Dimensions (EQ-5D) values] and BMI values while 
accounting for the Type 2 diabetes status,138 or 
used the published utility estimates for the general 
population,155 and for the overweight population.152 
The utility weights are then applied to the cohort 
of surviving obese patients as they progress through 
the modelled time interval.
The second component (life expectancy) that 
is required to calculate QALYs in the modelled 
economic evaluations with a lifetime horizon140–142 
was obtained from a single published source,144 
which reports life expectancy for the US population 
categorised by age and BMI.
Estimation of utility values
There are variations between the studies in the 
methods adopted for estimating utility values.
In van Mastrigt and colleagues139 the EQ-5D utility 
values were collected from each surviving patient 
at the baseline, and at three, six and 12 months. 
To obtain a QALY for each patient the EQ-5D 
scores were multiplied by the duration of time (as a 
proportion of the 12-month time interval) to which 
these scores related. The mean QALY values for 
each of the treatment alternatives were used in the 
denominator of the ICER.
Ackroyd and colleagues138 utility values were 
estimated using the empirical data on the 
representative sample of the UK population 
(n = 13,500), that included both obese and non-
obese individuals.156 The data were used to estimate 
a linear relationship between the EQ-5D values and 
BMI values. The authors do not justify the linearity 
assumption in their estimate of the relationship 
between the observed utility and BMI values. As is 
evident from Figure 1 in Ackroyd and colleagues,138 
while this assumption may be true in the general 
UK population, in relation to the obese population 
with BMI > 35, a more complex form of regression 
equation may be more appropriate. 
It appears that at first the coefficients in the linear 
regression of utility values on BMI values were 
estimated separately for Type 2 diabetes and non-
Type 2 diabetes subgroups. The authors then 
assumed that there was no statistically significant 
difference in the estimated regression coefficients 
(slopes) in these two equations. Therefore the 
alternative (not reported) regression equations 
were used to estimate utility values in both 
subgroups. It seems that the modified regression 
equations have different constant terms (from the 
original equations), but the same slope equal to 
the weighted average of the slopes in regression 
equations for two separate subgroups. This is not 
a correct way of deriving utility estimates that 
may vary with respect to both BMI and Type 2 Assessment of cost-effectiveness
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diabetes. A multiple regression of utility values 
on BMI values and Type 2 diabetes status and an 
interaction term (BMI × Type 2 diabetes) would be 
more appropriate. 
The QALY outcomes in the study by Ackroyd and 
colleagues138 were obtained by combining the utility 
estimates for the mean BMI reduction observed 
in any particular year in Type 2 diabetes and non-
Type 2 diabetes patients and then aggregating the 
calculated values over the five-year time interval. 
Craig and Tseng140 do not report clearly the 
method used for obtaining utility values for 
the specified cohorts of men and women in the 
different age categories and baseline BMI values. 
From their reference it can be deduced that utility 
values might have been elicited using the published 
algorithm which employed data from the 1997 
USA National Health Interview Survey.155 The 
population-based mean values describing the 
Activity Limitations and Perceived Health Status 
were then interpreted as single attribute scores 
of a two-dimensional generic QoL instrument. A 
modelling technique was used to obtain the missing 
multiple attribute scores (e.g. for the combination 
of Activity Limitations and Perceived Health Status 
values). The resulting utility values are assumed 
to reflect HRQoL in the US general population. 
These values were not available for the population 
categorised by age, gender and BMI, which 
limited the possibility of using the estimates of life 
expectancy for the general population categorised 
by gender, age and BMI values.144
It is not clear whether Craig and Tseng140 fully 
replicated the complex modelled calculations 
reported in Erickson and colleagues155 with respect 
to the population data stratified by age, gender 
and BMI. It is possible that some methodological 
shortcomings were overlooked in the process. For 
example, Erickson and colleagues estimated that 
in the US general population of 35–40 years old 
the utility value is 0.89. According to Craig and 
Tseng,140 the overweight 35-year-old men and 
women (i.e. with BMI of 25) have utility values 
of 0.93 and 0.91 respectively. It then follows that 
the overweight population in this age group has a 
higher HRQoL than the general US population. 
This contradicts the authors’ statement that their 
findings indicate that there is a negative relation 
between HRQoL and BMI. 
Nevertheless, the newly estimated utility values 
were then applied to the estimated age/gender/
BMI-specific life expectancy144 to obtain QALYs. 
The shortcoming of this approach is that first, the 
utility weights were not obtained using one of the 
conventional techniques for eliciting population-
based health preferences (standard gamble or time 
trade-off) and second, that the utility weights were 
not elicited from the obese population, whose 
health-related preferences may be different from 
those of the general population.
The study by Craig and Tseng140 was the only 
one among the identified modelled economic 
evaluations that attempted to incorporate the 
differential rates of surgical complications on 
both the cost and the effectiveness sides of the 
ICER. It was reasonably assumed that there is 
a reduction in QoL (disutility) associated with 
postsurgical complications. In the absence of 
published evidence, Craig and Tseng140 assigned 
some arbitrary utility values to the period of time 
spent in hospital and in postsurgery recovery. It was 
implicitly assumed that non-surgical complications 
are not associated with a reduction in QoL. For the 
period of a hospital admission the corresponding 
age/gender/BMI-specific utility value was reduced 
by 200% (assuming that being in hospital is 
equivalent to a health state which is significantly 
‘worse than death’). The utility value associated 
with the recovery time was 50% of the applicable 
utility value. The utility weights which apply to the 
remaining years of life in patients who underwent 
a reversal surgery were also reduced by 50% (it is 
assumed that patients never recovered completely 
from reversal surgery because of its psychological 
effects). No justification for the choice of these 
values was provided.
Salem and colleagues142 replicated the method 
of converting the intermediate clinical outcomes 
(weight reduction) into QALYs introduced by Craig 
and Tseng140 and used the utility values from their 
study. Therefore the methodological shortcomings 
that characterise the study by Craig and Tseng140 
also apply to the study by Salem and colleagues.142 
In both studies by Craig and Tseng140 and by 
Salem and colleagues142 the gender-specific utility 
weights change over time as the age of the cohort 
increases. However, utility weights do not change 
with respect to the BMI value that remained fixed 
at the baseline level in the non-surgical treatment 
arm, and in the surgery arm, at the level achieved 
when the postsurgical interventions (e.g. band 
adjustments, revision and reversal surgeries) are 
completed.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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In contrast, the study by Jensen and Flum141 does 
not make an assumption about the BMI values 
remaining unchanged during the patients’ lifetime. 
The trajectory of weight increase was estimated 
from the data on the BMI distribution in the US 
white female population stratified by age.157 In the 
base-case scenario BMI values increase from one 
year to another at the rate observed in the general 
USA population in the 95.6th percentile for weight 
(a cut-off point for BMI > 40, which corresponds 
to 4.4% of the population at age 40). In the base 
case this rate is applied to all surviving patients 
in each branch of the decision tree. However, the 
BMI reduction obtained as a result of the open 
GBP or a diet and exercise programme is retained 
for life. As a result, the BMI in such patients, 
although increasing at the above rate, is always 
reduced by the incremental BMI value observed 
after the intervention. Utility values used in this 
study were obtained from the study by Hakim 
and colleagues,152 who estimated a utility gain 
associated with each unit of BMI lost. The utility 
values were then combined with life expectancy 
data.144 QALYs gained in each arm of the model 
are totalled each year. The authors commented 
that this yearly calculation, rather than assigning 
a single estimate of the life expectancy based on 
the BMI observed at the end of the intervention 
period, is necessary because the interventions take 
place at different times and BMI is assumed to be 
increasing over time.141
Life expectancy and lifetime 
medical cost estimates
As was mentioned before, all modelled economic 
evaluations with the lifetime horizon140–142 applied 
utility values to the life expectancy estimates for 
the US population categorised by age, gender 
and BMI.144 Thompson and colleagues144 reported 
both the life expectancy estimates and the lifetime 
medical cost estimates that were also used in all 
modelled economic evaluations. The estimates 
are based on the USA Third National Health 
and Nutrition Examination Survey (1988–94) 
that was provided separately for men and women 
categorised by age groups from 35 to 64 years in 
10-year increments. However, Thompson and 
colleagues144 report the life expectancy estimates 
only up to BMI of 37.5, which is below the range 
of BMI values assessed in the modelled economic 
evaluations. 
Craig and Tseng140 and Salem and colleagues142 
applied what they described as ‘a simple linear 
approximation’ to obtain life expectancy for 
the BMI values beyond the range reported in 
Thompson and colleagues.144 Although no further 
details were provided, it appears that the method 
was insufficient to obtain reliable estimates of 
life expectancy. For example, Thompson and 
colleagues144 reported life expectancy of men 
aged 59.5 years (midpoint in the age group of 
55–64 years) with BMI of 37.5 to be 18.3 years. It 
is reasonable to assume that the life expectancy of 
men aged 55 with BMI of 37.5 is likely to be higher 
than this.
According to the calculations by Craig and Tseng,140 
life expectancy of 55 year old men with BMI of 40 
from the ‘no treatment’ arm is 16.15 years. This 
implies that the additional weight of 2.5 BMI is 
associated with the loss of at least 2.15 years of life. 
According to Thompson and colleagues144 for men 
in the 55–64-year age group the additional weight 
gain of five BMI units (from 32.5 to 37.5 kg/m2) is 
associated with the loss of just 0.5 years of life (from 
18.8 to 18.3 years). Although it is possible that the 
lesser increments in weight gain when applied 
to the higher BMI values are associated with the 
accelerated loss of years of life, the difference in 
the estimates of additional LYs lost as the result 
of obesity is too large to be plausible and is more 
likely to relate to a deficiency in the methods used 
by Craig and Tseng140 to extrapolate life expectancy 
values to the higher BMI categories. It is therefore 
likely that the study by Craig and Tseng140 has 
produced biased estimates of the final outcomes. 
Salem and colleagues142 do not report the 
estimated life expectancy values obtained by 
method of ‘a simple linear approximation’, so it is 
not possible to assess their validity.
Jensen and Flum141 also used a ‘linear 
approximation’ to obtain life expectancy for 
each BMI value not reported in Thompson and 
colleagues.144 The linear regression equation that 
relates the remaining years of life to the BMI 
value is provided. It appears that only a subset of 
the data reported in Thompson and colleagues144 
(i.e. the life expectancy data for women in 
the 45–54-year-old category) was used in the 
regression. How accurate the linear fit is in relation 
to other subgroups of the female population is not 
clear.
The final outcomes (LYs and QALYs) reported in 
the identified economic evaluations are presented 
in Tables 45 to 47 in the section on Results reported 
in the identified economic evaluations of bariatric 
surgeries in this chapter.Assessment of cost-effectiveness
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Structure of the models
The structure of the decision tree models reported 
in the studies by Craig and Tseng,140 Jensen and 
Flum141 and Salem and colleagues142 are presented 
in a graphical format. The study by Ackroyd 
and colleagues138 does not explicitly present the 
structure of their deterministic model. 
Craig and Tseng140 have assumed that in the first 
instance four alternative outcomes of open gastric 
bypass can occur simultaneously: a successful 
surgery, a revision surgery, a reversal surgery 
and death. Revision surgery and reversal surgery 
are in turn associated with the probability of 
a postsurgical death, while the former may be 
followed by a subsequent reversal surgery, which 
is also associated with the probability of death. 
Although it may be reasonable to assume that in 
some patients revision surgery may be undertaken 
immediately to correct the complications arising 
in the course of the initial surgery, other surgical 
interventions (e.g. abdominoplasty) may occur 
over a period of three to five years. It is not clear 
how these later surgeries are incorporated into the 
model. Also, the decision to undertake a reversal 
surgery may be separated in time from the initial 
surgery. The modelling assumptions in Craig and 
Tseng140 may not correspond to current clinical 
practice. 
The structure of the model presented in Salem 
and colleagues142 seemed to be an improvement in 
comparison to the structure of the model presented 
in Craig and Tseng.140 Salem and colleagues142 have 
assumed that the immediate outcome of bariatric 
surgery is either survival or death, therefore the 
probabilities of revision or reversal surgeries apply 
only to the surviving patients. 
The decision tree model reported in Jensen and 
Flum141 has the following options: ‘Intervention 
with immediate complications’; ‘Intervention 
without immediate complications’; ‘Death’; ‘Alive 
with reduced BMI’; and ‘Alive with baseline 
BMI’. The probability values associated with each 
outcome are not reported. No details on the types 
of immediate complications are provided. It is 
reasonably assumed in the diet and exercise arm 
of the decision tree that no patient experiences 
complications associated with death. The surviving 
patients in both arms of the model may have a 
reduced BMI or remain with their initial BMI. 
The shortcoming of the model is the exclusion 
of non-immediate complications, which among 
other things, rules out the probability of revision 
surgeries that occur later in time and are also 
associated with the risk of death. Therefore the 
modelling assumptions in Jensen and Flum141 may 
not correspond to current clinical practice.
Estimation of costs within 
economic evaluations
Cost of bariatric surgeries
A comprehensive itemised list of health-care 
resources used and the corresponding unit costs 
were not provided in the identified studies on 
economic evaluation of bariatric surgery. The most 
detailed account of health-care resources used 
in laparoscopic gastric bypass and laparoscopic 
adjustable gastric banding is reported in Ackroyd 
and colleagues.138 It seems that for each type of 
surgical intervention the range of resource items 
was identified, checked with experts and multiplied 
by the corresponding unit costs. However, the list 
of resource components in natural units does not 
include the itemised cost of complications. It is not 
clear how the cost of postsurgical complications was 
estimated. 
Ackroyd and colleagues138 employed different 
methods for producing the cost estimates in 
relation to three European countries, which makes 
the comparison of cost data across these countries 
problematic. Therefore, only the UK cost data as 
reported in Ackroyd and colleagues138 are included 
in this section.
Van Mastrigt and colleagues139 estimated resources 
used in laparoscopic adjustable gastric banding and 
open vertical banded gastroplasty in natural units 
by conducting an observational study of 10 surgical 
procedures of both types of surgery. Other hospital 
costs were obtained from the hospital’s billing 
system. Health-resource items used outside the 
hospital (e.g. medications used during the follow-
up) were obtained from the patients’ cost-diaries. 
The cost of each of the postsurgical complications 
was not reported. However, the aggregated 
mean cost of rehospitalisations is provided and is 
likely to relate to the number and seriousness of 
postsurgical complications associated with each 
surgery. 
Table 43 summarises the cost data in terms of 
the natural units and the corresponding unit 
costs because this is a conventional approach to 
reporting cost data. Cost data by unit costs for the 
selected cost items are reported in Ackroyd and 
colleagues138 and in van Mastrigt and colleagues139 
along with other cost data that are reported in 
more aggregated cost categories. These are also 
included for completeness. DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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Craig and Tseng140 and Salem and colleagues142 
reported aggregated cost categories for bariatric 
surgery, postsurgical complications, revision and 
reversal surgery using the US Healthcare Cost and 
Utilisation project database (1997).158 The costs 
were then adjusted for inflation using a medical-
care component of the consumer price index. No 
further details were reported. 
Jensen and Flum141 used the published cost data 
from a single study comparing open gastric bypass 
with laparoscopic gastric bypass.113 The missing 
estimate of the cost(s) of complications was set to 
be $5000 per complication, which appears to be 
an underestimate. The costs were then adjusted 
for inflation to 2004 US prices using the Bureau 
of Labour Statistics Inflation calculator. It is not 
clear whether this method is an equivalent to the 
correct method of using a medical-care component 
of the consumer price index as in the other US 
studies.140,142 Costs for the comparator treatment – a 
one-year programme of diet and exercise – were 
taken from the US case–control longitudinal study 
by Heshka and colleagues.150 Health-care resources 
and the corresponding unit costs are reported only 
for the comparator arm of the model and no direct 
medical costs of bariatric surgery are reported, 
therefore this study is excluded from the cost data 
analysis presented below. 
It should be noted that although in different 
studies the same name may be used to identify 
an aggregated cost component, the health-care 
resources included under this category may 
be quite different. Therefore, no meaningful 
comparison across the studies with respect to the 
individual cost items can be made. Comparisons 
with respect to the total costs are also limited 
because of differences in the nature of the health-
care systems (i.e. private versus public) and because 
of differences in the currencies in which costs are 
reported (see Table 41). 
According to Ackroyd and colleagues,138 the direct 
medical costs of laparoscopic gastric bypass and 
laparoscopic adjustable gastric banding over five 
years do not appear to be different. Likewise, van 
Mastrigt and colleagues139 found no statistically 
significant difference in the mean costs of 
laparoscopic adjustable gastric banding and vertical 
banded gastroplasty over a one-year time interval. 
Only a very limited number of cost components, 
(i.e. those reported in natural units) are available 
for direct comparison between the studies. 
According to Ackroyd and colleagues,138 the 
mean LOS for the initial surgery is not very 
different between laparoscopic gastric bypass and 
laparoscopic adjustable gastric banding and is 
about five days. The study by van Mastrigt and 
colleagues139 reported the mean estimate of the 
LOS for the initial laparoscopic adjustable gastric 
banding as 5.56 days, which is about 0.5 days 
longer than the corresponding LOS reported in 
Ackroyd and colleagues.138 However, van Mastrigt 
and colleagues139 found that the median LOS was 
only four days, which is one day shorter than the 
mean LOS reported in Ackroyd and colleagues.138 
The discrepancy between the mean and median 
LOS reported in van Mastrigt and colleagues139 
is likely to have resulted from the relatively small 
sample of the population participating in the study 
(50 patients in each arm). The sample size used in 
the LOS estimate in Ackroyd and colleagues138 was 
not reported. It is therefore uncertain which of the 
estimates is more accurate. The same concern also 
applies to the duration of the operating theatre 
time to conduct laparoscopic adjustable gastric 
banding surgery, which is reported as 1.9 hours 
and 3.26 hours, respectively, in the studies by 
Ackroyd and colleagues138 and van Mastrigt and 
colleagues.139 
Table 44 summarises the cost data as reported in 
two US studies by Craig and Tseng140 and by Salem 
and colleagues.142 In comparison to Ackroyd and 
colleagues138 and van Mastrigt and colleagues,139 
the US studies140,142 provide a more elaborate 
list of postsurgical complications and associated 
direct medical costs. Direct comparison of the 
cost estimates across these studies is not possible 
because they do not involve a common surgical 
intervention and employ different formats for 
reporting cost estimates: Craig and Tseng140 
report the costs by gender categories while Salem 
and colleagues142 do not differentiate the costs 
by gender. Both studies140,142 report health-care 
resources used in bariatric surgery by aggregated 
cost categories, the only resource reported in 
natural units is the number of follow-up visits, 
which is three times a year for three years for open 
gastric bypass according to Craig and Tseng140 and 
twice a year for three years for laparoscopic gastric 
bypass according to Salem and colleagues.142 The 
latter study also reported that the expected number 
of band adjustments over three years following 
laparoscopic adjustable gastric banding is 10. Both 
studies report only point estimates without a 95% 
CI, which limits the possibility of establishing the 
statistical significance of the difference in costs of 
bariatric surgeries. Assessment of cost-effectiveness
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TABLE 44  Health-care resources used in bariatric surgery as reported by Craig and Tseng140 and Salem and colleagues142
Resource 
category 
Type of resources 
by aggregated cost 
categories 
Cost estimate of 
resources used in 
open GBP (Craig and 
Tseng140) (US$2001)
Cost estimate of 
resources used 
in LGBP (Salem 
and colleagues142) 
(US$2004)
Cost estimate of 
resources used 
in LAGB (Salem 
and colleagues142) 
(US$2004)
Men Women Obese population Obese population
Cost of surgery $26,100 $20,500 $27,560 $16,200
Band adjustment n/a $150 per visit × 10 
visits over 3 years 
Cost of immediate 
complications 
requiring surgery
Revision surgery $38,500 $25,600 $10,000 $5000
Reversal surgery (band 
removal)
n/a n/a n/a $6000
Reversal surgery GBP $38,500 $25,600 N/R n/a
Cost of 
subsequent 
complications 
Minor wound infection $192 $192 $204 $204
Major wound infection $20,600 $19,200 $11,236 $11,236
Deep venous thrombosis $8700 $8100 $9222 $9222
Pulmonary embolism $14,700 $13,900 $15,582 $15,582
Leak non-operative n/r n/r $50,000 n/a
Cholecystectomy $27,100 $22,700 $16,000 $16,000
Incisional hernia $13,200 $12,500 $14,416 $14,416
Abdominoplasty $13,600 $12,200 $13,992 $13,992
Postoperative death $27,600 $29,000 n/r n/r
Follow-up cost $150 per 
visit × 3 
visits a 
year
$150 per 
visit × 3 
visits a 
year
$159 per visit × 2 
visits a year
None required 
except for the 
scheduled band 
adjustment visits
Lifetime cost of 
pharmaceuticals
$68 $68 $72 $0
GBP , gastric bypass (as applicable in the context of open GBP or LGBP); LAGB, laparoscopic adjustable gastric banding; 
LGBP , laparoscopic gastric bypass; n/a, not applicable; n/r, not reported.
Neither Craig and Tseng140 nor Salem and 
colleagues142 report the estimated cost of bariatric 
surgery that would apply to the general population. 
The total cost estimates are available only with 
respect to the subgroups of the population with 
the selected combination of gender/age/BMI value 
and no comorbidities at the baseline. Craig and 
Tseng140 reported that sex-specific cost estimates 
were consistently higher in men than in women 
except for postoperative death, but did not offer 
any explanation as to the possible reason for the 
observed cost differences.
The US cost estimates in Table 44 are not consistent 
with the cost data presented in Table 43 in that 
the mean total cost of laparoscopic gastric bypass 
appears to be higher than the mean total cost of 
laparoscopic adjustable gastric banding although 
whether this difference reaches the level of 
statistical significance is uncertain. 
There is a large difference in costs of revision 
surgeries with open gastric bypass revision in men 
being four times more expensive than laparoscopic 
gastric bypass revision and eight times more 
expensive than laparoscopic adjustable gastric 
banding revision.140,142 The cost difference is likely 
to be the result of the differences between the open 
and laparoscopic surgeries, and other differences 
in surgical techniques employed across the bariatric 
surgeries. DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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Cost of non-surgical 
treatment (comparator)
It appears that Craig and Tseng140 and Salem 
and colleagues142 have implicitly assumed that 
the short-term cost of non-surgical treatment 
alternatives (such as diet and exercise) is zero. This 
assumption, although it may not be realistic, is 
conservative and is likely to bias the ICER in favour 
of the comparator. 
Jensen and Flum141 provided a detailed account 
of the health-care resources in natural units and 
the corresponding unit costs for the comparator 
treatment – a one-year diet and exercise 
programme. However, the cost of a single privately 
run diet and exercise programme undertaken by 
predominantly white females residing in the USA 
may be of limited generalisability. 
Ackroyd and colleagues138 provided a fairly 
comprehensive list of health-care resources used in 
the comparator arm – a conventional treatment that 
typically involves dieting (see Table 40, footnote 
b). The resource use is reported in natural units 
(e.g. number of GP and dietitian consultations; 
number of district and practice nurse consultations; 
number of laboratory assessments and number of 
food substitutes) and the corresponding unit costs 
as well as in aggregated cost-categories (an annual 
cost of outpatient visits, pharmaceuticals and 
hospital admissions). 
The study by Ackroyd and colleagues138 was 
the only one among the modelled economic 
evaluations that explicitly modelled the prevalence 
of Type 2 diabetes in non-surgical and surgical 
treatment arms. The cost of treatment of obesity-
related Type 2 diabetes was taken from the CODE-
2 (The Cost of Diabetes in Europe – Type II) survey 
which used the 1999 prices,159 while the cost of 
surgical interventions is expressed in 2005 prices. It 
does not appear likely that the cost of a comparator 
in terms of treatment of Type 2 diabetes was 
converted into 2005 prices using the health price 
index. This approach is likely to produce a bias in 
the cost-effectiveness estimate in favour of surgical 
treatments.
Long-term costs
The studies by van Mastrigt and colleagues139 and 
by Ackroyd and colleagues138 limited their time 
horizons to one year and five years, respectively, 
and did not include any long-term costs and the 
outcomes of bariatric surgeries. 
Three other studies140–142 used the same published 
source of the lifetime medical costs for the different 
subgroups of the US population categorised by 
age/gender/BMI.144 These costs were applied to 
both the surgical and non-surgical treatments. As 
already mentioned in the section on Translation 
of short-term outcomes into final outcomes, this 
chapter, Thompson and colleagues144 reported 
the lifetime medical cost estimates separately for 
men and women categorised by age groups from 
35 to 64 years old in 10-year increments. However, 
the published lifetime medical-cost estimates are 
available only up to BMI of 37.5 which is below 
the range of BMI values assessed in the modelled 
economic evaluations. All authors used a linear 
extrapolation method to obtain the estimates of 
the lifetime medical cost for BMI values above the 
range reported in Thompson and colleagues.144 
Although no actual values of the estimated lifetime 
medical cost are reported in the studies, the same 
concerns about the methods used in extrapolating 
life expectancy estimates, that were outlined earlier 
may also apply to extrapolating lifetime medical 
costs.
Results reported 
in the identified 
economic evaluations 
of bariatric surgeries
Tables 45 to 47 present the estimated costs, 
outcomes and ICERs as reported in the 
identified studies. Three tables were designed 
to accommodate the inconsistency in the format 
of reporting incremental costs and incremental 
outcomes across the studies. Some studies (most 
notably Jensen and Flum141) do not report costs 
and outcomes separately for each treatment 
alternative.
Results reported in Ackroyd 
and colleagues138 and van 
Mastrigt and colleagues139
Table 45 presents results reported in Ackroyd and 
colleagues138 and van Mastrigt and colleagues139 
with respect to costs and outcomes expressed 
in QALYs. These two studies adopt different 
perspectives: Ackroyd and colleagues138 adopted 
a payer’s perspective (i.e. the NHS in the case of 
UK) and van Mastrigt and colleagues139 adopted a 
societal perspective. The costs in van Mastrigt and 
colleagues139 were reduced by us by the amount of 
non-direct costs to make the results of these two Assessment of cost-effectiveness
98
TABLE 45  Cost-effectiveness estimates of bariatric surgeries as compared to the alternative treatment strategy as reported in Ackroyd 
and colleagues138 and van Mastrigt and colleagues139
Type of 
treatment 
strategies Results
Intervention 
and 
comparator
Cost of the 
interventiona
Cost of the 
comparatora
QALYs 
interventiona
QALYs 
comparatora
ICER (Incremental 
cost over incremental 
outcome)
LGBP vs 
conventional 
treatment138
£9121b £7083b 3.34b 2.00b 2033/1.34 = £1517/
QALY
LAGB vs 
conventional 
treatment138
£9072b £7088b 3.03b 2.00b 1984/1.03 = £1929/
QALY
VBG vs LAGB 
(assumed to be a 
comparator)139
€8105c  €7336c 0.76d (SD = 0.2) 0.81d (SD = 0.13) LAGB dominates open 
VBG
ICER, incremental cost-effectiveness ratio; LAGB, laparoscopic adjustable gastric bypass; LGBP , laparoscopic gastric bypass; 
LYs, life years; QALY, quality-adjusted life-year; SD, standard deviation; VBG, vertical banded gastroplasty.
a  Cumulative discounted cost/outcome over the horizon of the model or the time interval used in the economic evaluation
b  See table 13 in Ackroyd and colleagues138 for the total discounted (at 3.5%) costs accumulated over five years. There is a 
discrepancy in the costs reported for the first year by Ackroyd and colleagues in table 13 and tables 6 and 7.138
c  See Table 43 above and Table 2 in van Mastrigt and colleagues.139 Discounting rates do not apply. 
d  The mean difference of 0.05 utility scores between LAGB and open VBG is not statistically significant (p = 0.138).
studies comparable (see Table 43, footnote e). Both 
studies undertook cost-effectiveness analyses (CEA) 
in addition to cost–utility analyses (CUA). These 
are discussed below.
Ackroyd and colleagues138 reported that in 
comparison to non-surgical treatment laparoscopic 
gastric bypass is associated with an incremental cost 
of £1517 per QALY, and laparoscopic adjustable 
gastric banding is associated with an incremental 
cost of £1929 per QALY. Both costs and outcomes 
are discounted at 3.5%. With respect to diabetes 
mellitus outcome, laparoscopic gastric bypass 
is associated with an additional 2.6 years free 
of Type 2 diabetes or incremental cost of £776 
per Type 2 diabetes-free year, and laparoscopic 
adjustable gastric banding is associated with an 
additional 2.5 years free of Type 2 diabetes or 
incremental cost of £810 per Type 2 diabetes-free 
year. The outcomes in terms of the Type 2 diabetes 
prevalence observed over five years were not 
discounted. It is not clear whether discounted or 
undiscounted costs were used in calculating ICERs 
with respect to the Type 2 diabetes prevalence. 
Ackroyd and colleagues138 suggested that at five-
year follow-up both laparoscopic gastric bypass 
and laparoscopic adjustable gastric banding are 
cost-effective in comparison to a non-surgical 
treatments in patients with Type 2 diabetes and a 
baseline BMI > 35.
Van Mastrigt and colleagues139 used the 
observational data collected alongside an RCT 
involving 100 patients undertaking either 
laparoscopic adjustable gastric banding or open 
vertical banded gastroplasty and reported the 
12-month outcomes in terms of % excess weight 
loss (EWL) and QALYs. A bootstrap analysis of 
the joint distribution of incremental costs and 
outcomes involving 1000 replications identified 
that in 86% of trials laparoscopic adjustable gastric 
banding was both less effective and less expensive 
in comparison to open vertical banded gastroplasty, 
and in 14% of trials it was less effective and more 
expensive (i.e. dominated by open vertical banded 
gastroplasty). The authors erroneously claimed that 
moving from open vertical banded gastroplasty 
to laparoscopic adjustable gastric banding would 
involve an additional amount of €105.80 per 
each additional % EWL. In fact, this amount is 
what society would be spending for choosing not 
to switch from open vertical banded gastroplasty 
to laparoscopic adjustable gastric banding, i.e. 
replacing open vertical banded gastroplasty with 
laparoscopic adjustable gastric banding would 
involve a saving of €105.80 for each per cent of 
extra weight retained.
With respect to the outcomes expressed in QALYs 
a different (and somewhat contradictory) result was 
reported: laparoscopic adjustable gastric banding DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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appears to be both less expensive and more 
effective than open vertical banded gastroplasty 
(i.e. a dominant strategy). A bootstrap analysis 
showed that in 79% of trials laparoscopic adjustable 
gastric banding was both more effective and less 
expensive in comparison to open vertical banded 
gastroplasty (i.e. dominant); and in 14% of trials it 
was more effective but also more expensive. There 
was a negligible probability of open vertical banded 
gastroplasty being dominant (3%) or being both 
less effective and less expensive (4%).
The authors suggested that the difference 
in QALYs at 12 months after surgery was not 
statistically significant between the open vertical 
banded gastroplasty and laparoscopic adjustable 
gastric banding arms. Although the observed 
utility scores at 12 months do appear very similar 
between the arms these values do not reflect the 
baseline difference (see discussion in section 
on Assumptions of economic evaluations, this 
chapter). The absolute utility values were not 
reported, but as is evident from Figure 3 in van 
Mastrigt and colleagues,139 the incremental utility 
gain over 12 months appears to be larger in the 
open vertical banded gastroplasty arm. Without 
the long-term data it is not possible to say whether 
the larger incremental gain associated with open 
vertical banded gastroplasty would extend beyond 
the first year. However, these considerations 
undermine the long-term validity of the authors’ 
conclusions of no incremental gain in QALYs 
between the open vertical banded gastroplasty and 
laparoscopic adjustable gastric banding and the 
laparoscopic adjustable gastric banding dominance 
with respect to open vertical banded gastroplasty. 
Inconsistently with the results of their CEA the 
authors concluded that at 12 months the costs 
and QALYs outcomes of two alternative surgical 
interventions were found to be equal.139 Therefore 
the selection of the procedure should be based on 
the clinical aspects, efficacy and safety at one year. 
Results reported in the 
US studies by Jensen and 
Flum,141 Craig and Tseng140 
and Salem and colleagues142
Table 46 presents results reported in Jensen and 
Flum.141 The studies by Craig and Tseng140 and 
Salem and colleagues142 are reported separately in 
Table 47.
On the basis of the results reported in Jensen 
and Flum,141 open gastric bypass appears to be 
cost-effective at the incremental cost of $7126 per 
QALY, although the incremental effect is reported 
in terms of additional LYs gained rather than 
QALYs. The ICER reported by Jensen and Flum141 
comparing open bastric bypass undertaken by 
white females at the age of 40 (BMI > 40) with a 
diet and exercise programme undertaken at the 
age of 18 [BMI > 33(or 35); see Table 41, footnote 
d] falls within the range of ICERs reported by 
Craig and Tseng for the subgroups of females aged 
35 or 55 and with the baseline BMI of 40 or 50 (see 
Table 47).
Table 47 presents results reported in Craig and 
Tseng140 and Salem and colleagues.142 The 
results are reported with respect to subgroups 
of population with the specified baseline 
characteristics of gender/age/BMI.
The results reported by Craig and Tseng140 are 
characterised by large variability with respect to 
baseline demographic characteristics of the obese 
population. The ICER varies from US$5400 per 
QALY in 55-year-old females with BMI of 50 to 
US$35,600 per QALY in 55-year-old males with a 
baseline BMI of 40. 
Salem and colleagues142 do not report the 
results across the same subgroups as Craig and 
Tseng,140 which makes it impossible to compare 
variability of estimates of incremental cost-
TABLE 46  Cost-effectiveness estimates of bariatric surgeries as compared to the alternative treatment strategy Jensen and Flum141
Type of treatment 
strategies Results: Open GBP vs non-surgical treatment
Incremental cost
Incremental outcome 
(additional LY gained)a ICER
Open GBP vs diet and 
exercise141
US$4600 0.61 US$7126/QALY
GBP , gastric bypass; ICER, incremental cost-effectiveness ratio; LY, life year; QALY, quality-adjusted life-year.
a  Jensen and Flum 2005141 do not report incremental QALYs accumulated over patients’ lifetimeAssessment of cost-effectiveness
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TABLE 47  Cost-effectiveness estimates of bariatric surgeries as compared to the alternative treatment strategy as reported in Craig 
and Tseng140 and Salem and colleagues142
Subgroup
Cost of 
intervention 
(Open GBP)
Cost of 
comparator 
(non-surgical 
treatment)
QALY 
interventiona
QALY 
comparator
(non-surgical 
treatment) ICER 
Results: Open GBP vs non-surgical treatment140
Men 35 years;  
BMI 40
US$68,600 US$38,500 19.56 18.51 US$28,600/QALY
Men 35 years;  
BMI 50
US$75,000 US$53,200 18.87 16.83 US$10,700/QALY
Men 55 years;  
BMI 40
US$77,600 US$47,900 13.32 12.48 US$35,600/QALY
Men 55 years;  
BMI 50
US$85,300 US$63,500 12.81 11.17 US$13,300/QALY
Women 35 years; 
BMI 40
US$59,000 US$35,300 19.82 18.21 US$14,700/QALY
Women 35 years; 
BMI 50
US$64,800 US$48,500 18.88 16.03 US$5700/QALY
Women 55 years; 
BMI 40
US$69,600 US$48,200 13.94 12.62 US$16,100/QALY
Women 55 years 
BMI 50 
US$77,000 US$64,100 13.23 10.88 US$5400/QALY
Results: LGBP vs non-surgical treatment142
Men 35 years;  
BMI 40
US$27,560 n/r n/r n/r US$18,543/QALY
Women 35 years; 
BMI 40
US$27,560 n/r n/r n/r US$14,680/QALY
Results: LAGB vs non-surgical treatment142
Men 35 years;  
BMI 40
US$16,200 n/r n/r n/r US$11,604/QALY
Women 35 years; 
BMI 40
US$16,200 n/r n/r n/r US$8878/QALY
BMI, body mass index; GBP , gastric bypass; ICER, incremental cost-effectiveness ratio; LAGB, laparoscopic adjustable gastric 
banding; LGBP , laparoscopic gastric bypass; n/r= not reported; QALY, quality-adjusted life-year.
a  QALY intervention was open GBP , LGBP or LAGB, as indicated.
effectiveness in various subgroups of the obese 
population. However, the authors reported that 
both bariatric procedures in comparison to non-
surgical treatment were cost-effective at < $25,000 
per QALY for all base-case scenarios (i.e. the 
combinations of baseline age of either 35, 45, or 
55 years and BMI of either 40, 50 or 60). 
Salem and colleagues142 concluded that 
laparoscopic adjustable gastric banding is more 
cost-effective than laparoscopic gastric bypass for 
all base-case scenarios. However, this conclusion 
is based on the ICERs individually comparing 
laparoscopic gastric bypass with non-surgical 
treatment and laparoscopic adjustable gastric 
banding with non-surgical treatment, whereas 
the direct comparison of these two surgical 
interventions in terms of incremental costs and 
QALYs was not reported. Therefore this conclusion 
may not be true for every subgroup of the obese 
population.
Sensitivity analysis
Eight one-way sensitivity analyses undertaken by 
van Mastrigt and colleagues139 were undertaken DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
101
to test the sensitivity of the outcomes associated 
with variability of cost estimates used in CEA (with 
outcomes expressed in % EWL) and CUA. The cost 
of operating-theatre personnel time (€2.96 per 
minute) was substituted in turn for the maximum 
and minimum values of €3.56 and €2.66 per 
minute respectively. Also the per diem cost 
(€332 per day in hospital) was substituted for the 
maximum and minimum values of €432 and €232 
per day respectively. The results reported in terms 
of the outcomes of bootstrapping analyses of joint 
distribution of incremental costs and outcomes are 
very robust with respect to variations in unit cost 
estimates. A scenario analysis from the alternative 
health-care system perspective (rather than the 
societal perspective used in the original economic 
evaluation) was also undertaken. With respect 
to the QALY outcome exclusion of non-medical 
costs, that represent 39% and 35% of open vertical 
banded gastroplasty and laparoscopic adjustable 
gastric banding costs, respectively, has reduced 
the probability of laparoscopic adjustable gastric 
banding being a dominant strategy (from 79% to 
68%) and increased the probability of laparoscopic 
adjustable gastric banding being more effective and 
more expensive (from 14% to 27%). van Mastrigt 
and colleagues139 did not test the uncertainty 
associated with clinical effectiveness or utility 
estimates observed in the RCT. 
Ackroyd and colleagues138 do not seem to test 
the variability in cost estimates using a sensitivity 
analysis. Instead the authors conducted a two-
way sensitivity analysis where clinical effectiveness 
of laparoscopic adjustable gastric banding and 
laparoscopic gastric bypass with respect to both 
BMI reduction and Type 2 diabetes prevalence was 
reduced by 20% in each arm of the model, which 
is equivalent to assigning zero Type 2 diabetes 
benefits from a non-surgical treatment in the first 
year. The ICER for laparoscopic adjustable gastric 
banding compared with non-surgical treatment 
changed from £1929 to £3251 per QALY. The 
ICER for laparoscopic gastric bypass compared 
to non-surgical treatment changed from £1517 to 
£2599 per QALY. The ICERs appear to be very 
sensitive to variability in clinical effectiveness 
estimates. The sensitivity of results to the variations 
in utility estimates was not tested in this study. 
Jensen and Flum141 conducted a series of one-
way sensitivity analyses and the outcomes are 
reported to be sensitive to the estimated cost 
of complications (although the range was not 
reported) and the discount rate (neither the value 
nor the range were reported). 
Craig and Tseng140 conducted a series of one-way 
sensitivity analyses that varied the short-term 
clinical effectiveness parameters (% EWL, mortality 
rates and complication rates) and the long-term 
outcomes (LYs lost as the result of the elevated 
BMI). Another sensitivity analysis was conducted to 
assess the impact of variability in utility estimates. 
However, instead of varying the utility values, the 
regression coefficients in the (unreported) multiple 
regression equation (see the section on Translation 
of short-term outcomes into final outcomes, 
this chapter) used to obtain utility values were 
decreased by 25%. It is not clear how the actual 
utility values were affected. 
Two-way sensitivity analysis varying both the 
lifetime medical cost and the discount rate was 
undertaken by Craig and Tseng.140 Another two-way 
sensitivity analysis varied the estimated % EWL and 
the reimbursement rates for the insured patients. 
These parameters were also used in the threshold 
analysis for the subgroup of insured 55-year-old 
men with the baseline BMI of 40 with the ICER 
of $50,000 per QALY as a threshold. The results 
indicated that under the base-case assumptions 
about the 67% reimbursement rate, the loss of 
excess weight greater than 46% is sufficient for 
the incremental cost per incremental QALY to be 
below US$50,000. The threshold analysis implicitly 
assumed the change of the perspective of the 
economic evaluation from that of the health-care 
system (where the cost of medical care is covered by 
both the third party and the patients’ copayments) 
to the perspective of the individually insured 
patients. It was also implicitly assumed that for any 
payer (Government, the third party or an insured 
individual) the same criterion of value for money is 
applied (i.e. the threshold of $50,000 per QALY). 
This may not be a reasonable assumption.
Craig and Tseng140 concluded that the results 
reported in Table 47 appear to be robust to 
all parameter variations for the subgroups of 
women and younger more obese men. An open 
gastric bypass may not be cost-effective for some 
subgroups of older and less obese men as the ICER 
exceeds US$50,000 per QALY when the base-
case assumptions about some clinical effectiveness 
parameters are varied.
Salem and colleagues142 investigated the 
uncertainty associated with parameter estimates 
in the model, but the source of the ranges in 
parameter estimates, and the methods used to 
derive them, were not clear. A series of one-way 
sensitivity analyses were performed and results Assessment of cost-effectiveness
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are said to be sensitive to the value of the primary 
clinical outcome (% EWL), cost of the surgical 
procedure, number of times the band adjustment 
was required for the laparoscopic adjustable gastric 
banding procedure and the estimated rate of 
operative mortality for laparoscopic gastric bypass. 
To summarise, none of the identified studies 
undertook a probabilistic sensitivity analysis. The 
rationale for choosing the model parameters and 
the ranges included in the sensitivity analysis is 
not clear in some studies.138,139 In other studies 
results of the sensitivity analyses are not fully 
reported.140,141 Nevertheless, based on the reported 
set of one-way and two-way sensitivity analyses, the 
results in the identified economic evaluations of 
bariatric surgeries appear to be fairly robust with 
respect to the variation in (the tested) parameter 
estimates. 
Summary of the results reported 
in economic evaluations 
of bariatric surgeries
As discussed in the previous sections, all identified 
studies138–142 are characterised by various 
methodological shortcomings that undermine 
the validity and generalisability of the reported 
results. Most importantly, the natural disease 
progression was not explicitly modelled in terms 
of probabilities of obesity-related diseases. Only 
one study138 has modelled a Type 2 diabetes 
outcome explicitly and accounted for it in the 
final outcomes (QALYs); however, this model 
is limited to the five-year horizon and has 
numerous methodological problems and results 
are only relevant to the obese population with 
Type 2 diabetes at the baseline. Other modelled 
economic evaluations138,140–142 are based on the 
lifetime horizon, but do not incorporate separate 
differential probabilities of developing/reversing 
obesity-related diseases. Instead, the published 
estimates of life expectancy and lifetime costs for 
the US population categorised by age, gender and 
BMI (up to 37.5) were used.144 As discussed in the 
section on Translation of short-term outcomes 
into final outcomes (this Chapter) extrapolation 
of the life expectancy and lifetime cost estimates 
to include BMI values higher than 37.5 is likely 
to have produced unreliable estimates. Also, the 
unspecified method of deriving utility estimates, 
which was reported by Craig and Tseng140 and 
replicated in Salem and colleagues,142 may not be 
of sufficient methodological rigour to produce 
reliable estimates of QALYs. Other assumptions 
also appear not to correspond to the clinical 
evidence. In particular, the assumptions of no 
weight gain in the comparator arm140,142 does not 
seem to be realistic. 
It appears that none of the identified modelled 
economic evaluations has provided a reliable and 
generalisable estimate of the incremental cost-
effectiveness of bariatric surgeries in comparison 
to a non-surgical treatment. However, some of the 
assumptions in the identified studies are reasonable 
and need to be considered in the future economic 
evaluations:
•	 differential time in gaining full benefits from 
the different types of bariatric surgery139 
•	 differential rates of short-term mortality and 
morbidity associated with different types of 
bariatric surgery140 
•	 postsurgical interventions may be required 
immediately after the surgery140,141 and over the 
longer time interval (up to five years)138,142 
•	 differential rate of regaining the lost weight 
over the lifetime associated with the bariatric 
surgery and the non-surgical treatment141
•	 differential probabilities of developing/
reversing obese-related diseases as a function 
of changes in BMI140–142
•	 use of utility weights that relate to the changes 
in BMI.141
To summarise, none of the identified studies 
undertook an economic evaluation across the 
entire range of bariatric surgery. All modelled 
economic evaluations138–142 found the bariatric 
surgery evaluated to be cost-effective in comparison 
to non-surgical treatment, although the variability 
in estimates of costs and outcomes is large. 
The choice and the range of model parameter 
estimates used in the sensitivity analyses were not 
justified. Nevertheless, with respect to the selected 
parameters the results appear to be robust to 
parameter variations in most of the CEA. The only 
exception, as reported by Craig and Tseng,140 are 
some subgroups of older and less obese men for 
whom an open gastric bypass may not be cost-
effective (i.e. exceeding US$50,000 per QALY) 
when the base-case assumptions about some clinical 
effectiveness parameters are varied. 
It should also be noted that numerous 
methodological shortcomings discussed in the 
previous sections are likely to have resulted 
in biased estimates of the incremental cost-
effectiveness of bariatric surgeries in comparison 
with the non-surgical treatment. The head-to-
head RCT of two bariatric surgical procedures,139 
although being methodologically sound, was 
nevertheless compromised by the discrepancies DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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in the baseline characteristics of the population 
randomised to the laparoscopic adjustable gastric 
banding and open vertical banded gastroplasty 
that resulted in the difference in the baseline utility 
values in two intervention groups. This difference is 
likely to be the major reason for the contradicting 
results of the CEA and CUA undertaken within this 
study. 
Uncertainties and the 
source of biases within 
economic evaluations 
of bariatric surgery
Clinical evidence used to 
obtain the primary outcomes 
(weight reduction)
In all four studies the BMI values were taken 
from the published evidence; however, it does 
not appear that any study conducted a systematic 
literature search and evidence analysis. Two studies, 
Craig and Tseng140 and Jensen and Flum,141 used 
the outcomes from a single published source of 
evidence which may affect validity of the estimate 
of the differential weight loss in the alternative 
treatments and the generalisability of results. 
Generalisability of results is also impaired by the 
choice of evidence that applies only to a subgroup 
of the obese population: the population of obese 
patients with Type 2 diabetes as in Ackroyd and 
colleagues138 and white female patients who were 
obese at the age of 18 with BMI > 33 (or 35) (see 
Table 41, footnote d) as in Jensen and Flum.141 
Assumptions about the 
target population
Craig and Tseng140 and Salem and colleagues142 
have assumed that the cohort of obese patients with 
BMI > 40 have no comorbidities at the baseline, 
which may not be a realistic assumption. 
Assumptions about the 
outcomes of bariatric surgeries
Ackroyd and colleagues138 implicitly assumed 
that there is no differential operative mortality 
and postoperative morbidity between the 
two surgical treatments and the non-surgical 
treatment comparator. This is not likely to be a 
realistic assumption. The same is also true with 
respect to the assumption of a zero weight gain 
over the modelled time horizon in patients in 
the non-surgical treatment arm in Ackroyd and 
colleagues,138 Craig and Tseng140 and Salem and 
colleagues.142
Utility estimates 
Utility estimates reported in Ackroyd and 
colleagues138 were also used in Craig and Tseng140 
and Salem and colleagues.142 However, these 
are not likely to be unbiased estimates of the 
HRQoL because of the multiple methodological 
shortcomings in the way they were derived from 
the available data. In addition, the source data 
relate to the general population whose health-
related preferences may differ from those of the 
obese population. 
SHTAC economic model
Statement of the decision 
problem and perspective for 
the cost-effectiveness analysis
We developed a model to estimate the cost-
effectiveness of bariatric surgery comparing 
surgical procedures against each other and against 
non-surgical comparators, for a UK cohort of 
adults meeting the NICE criteria for bariatric 
surgery. The perspective of the CEA is that of the 
NHS and Personal Social Services (PSS).
Strategies/comparators
Interventions included in the economic model 
are gastric bypass and gastric banding. Surgical 
procedures are compared with a non-surgical 
comparator. For patients with morbid obesity the 
non-surgical comparator, as in the previous report15 
consists primarily of monitoring rather than active 
treatment, because NICE guidance9 specifies that 
patients offered bariatric surgery should have failed 
to achieve (or maintain) an adequate and clinically 
beneficial weight loss for at least six months on all 
appropriate non-surgical alternatives. We assume 
that procedures are performed laparoscopically, 
where possible, but that conversion to open 
procedures may be required. 
Methods 
Summary of methods and results 
of economic modelling in the 
previous assessment report15
The previous assessment report15 presented 
estimates of the cost-effectiveness of gastric 
bypass, vertical banded gastroplasty and adjustable 
silicone gastric banding using a simple economic Assessment of cost-effectiveness
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model. Surgical procedures were compared with 
each other, as well as a non-surgical comparator. 
It has not been possible to repeat all of the 
methodological detail of the model here. Readers 
are therefore encouraged to consult the original 
report which is freely available for download 
(http://www.ncchta.org/fullmono/mon612.pdf).
The model in the previous report was not 
developed as a state transition model. However, 
conceptually it contained four health states: no 
comorbidity, remission of comorbidity, Type 2 
diabetes and death. The remission of comorbidity 
health state was included in the model to allow 
for the fact that people with Type 2 diabetes may 
revert to normoglycaemia following successful 
treatment for obesity. Comorbidities other than 
Type 2 diabetes, such as myocardial infarction, 
angina and stroke, were not included. The model 
was used to extrapolate long-term outcomes (in 
terms of QALYs up to 20 years following surgery) 
and lifetime costs (in terms of costs of managing 
diabetes in addition to intervention costs) based 
on intermediate outcomes reported in the clinical 
effectiveness review (per cent weight reduction, 
operative mortality, percentage of people with Type 
2 diabetes reverting to normoglycaemia, diabetes 
incidence in surgical and non-surgical patients).
In the model it was assumed that weight reduction 
(36% with gastric bypass, 25% to 17% for vertical 
banded gastroplasty, 20% to 33% with adjustable 
silicone gastric banding) occurred over five years 
following surgery, but that patients then reverted 
to their baseline weight of 135 kg. Operative 
mortality was based on a combination of trial 
evidence and expert opinion and was assumed to 
be 1% for gastric bypass, 0.5% for vertical banded 
gastroplasty and 0% for adjustable silicone gastric 
banding. Baseline diabetes prevalence in the model 
was 10%. Based on evidence from the Adelaide 
study149 it was assumed that 75% of people with 
diabetes revert to normoglycaemia and remain 
off medication for eight years (based on follow-up 
from the SOS study89,90) – after eight years these 
patients revert to medication. Different diabetes 
incidence rates were applied to surgical and non-
surgical patients (2.3% per annum for non-surgical 
and 0.45% per annum for surgical patients) 
based on data from the SOS study89,90 – after eight 
years surgical patients revert to the incidence 
rate for non-surgical patients. Reversion to 
normoglycaemia and incidence rates were applied 
on the basis of whether patients had or had not 
undergone surgery and were not directly related to 
their weight loss or assumed BMI.
HRQoL in the model was entirely dependent 
on BMI (using data from an unpublished study). 
There were no adjustments to these utility values 
for patients who developed Type 2 diabetes or 
for people with Type 2 diabetes who reverted to 
normoglycaemia.
Intervention costs for non-surgical management 
consisted of primary-care and dietitian contacts, 
with a VLCD (for 12 weeks) every three years. 
This continued for all patients for the model time 
horizon. Intervention costs for surgery consisted 
of preoperative assessment (including outpatient 
and dietitian appointments as well as psychological 
assessment), surgery (based on theatre time, 
length of ward stay, admission to an ITU or 
high-dependency unit (HDU), and percentage 
of reoperations) and postdischarge management 
(consisting of outpatient follow-up, community 
dietitian contacts, psychology consultations and 
primary care). Disease management costs in 
the model were limited to those associated with 
diabetes, using the assumptions on diabetes 
prevalence, reversion to normoglycaemia and 
diabetes incidence for surgical and non-surgical 
patients described earlier. Annual cost per person 
with Type 2 diabetes was taken from the CODE-2 
study.160
The model had a 20-year time horizon and the 
analysis adopted the perspective of the NHS and 
personal social services. The baseline cohort in the 
model was 90% female, had an average age of 40, 
average body weight of 135 kg and an average BMI 
of 45. The baseline model assumed no change in 
life expectancy and only included postoperative 
mortality; all-cause or disease-specific mortality was 
not included in the model.
Table 48 reports the base-case cost-effectiveness 
estimates from the previous report.15 On the basis 
of these results the report concluded that surgery 
was a cost-effective alternative to non-surgical 
management and that gastric bypass may be the 
preferred option. The conclusion, that surgery was 
cost-effective was robust to changes in a series of 
scenario analyses. However, the report cautioned 
against interpreting these results as conclusive 
given limited data available for some of the surgical 
options.
Summary of findings of current review 
and implications for economic model
This update has identified:
•	 The model developed for the previous 
assessment report15 based QoL entirely on DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 48  Base case from previous report15
Intervention
VBG AGB GBP
Comparator Non-surgical £2663; 0.26 QALY; 
£10237
£3831; 0.45 QALY; 
£8527
£2800; 0.45 QALY; 
£6289
Vertical banded 
gastroplasty
Adjustable silicone 
gastric band
£1168; 0.19 QALY; 
£6,176
Gastric bypass £137; 0.19 QALY; 
£742
£1031; 0.004 QALY; 
£256,856
AGB, adjustable silicone gastric banding; GBP , gastric bypass; ICER, incremental cost-effectiveness ratio; QALY, quality-
adjusted life-year; VBG, vertical banded gastroplasty;  
Results are presented for each intervention (columns in table) relative to comparators (row in table) with incremental cost in 
the first line of each cell, incremental QALY on the second line of each cell and the ICER (incremental cost per QALY gained) 
on the bottom line of each cell.
BMI and took no account of the effect of 
comorbidity on QoL. Since the publication of 
the previous assessment report15 a systematic 
review on patient utilities related to body 
weight and a number of additional models 
has been published, in some cases suggesting 
a larger reduction in QoL in relation to BMI. 
For this report we intend adopting an estimate 
of the impact of BMI on utility, and including 
additional state-specific utility decrements for 
patients experiencing comorbidities (Type 2 
diabetes and CVD).
•	 The model developed for the previous 
assessment report15 included Type 2 diabetes as 
the only comorbidity of obesity. This was based 
on evidence from included studies that weight 
loss following bariatric surgery was associated 
with:
  – reversion to normoglycaemia or cessation 
of medication for patients with pre-existing 
Type 2 diabetes;89,149,161
  – reduced incidence of diabetes [0% versus 
4.7% at two years (corresponding to annual 
incidence of 0% versus 2.41% using the 
declining exponential approximation to 
life expectancy, or DEALE, method162) 
and 3.6% versus 18.5% at eight years 
(corresponding to annual incidence of 
0.45% versus 2.56% using the DEALE 
method) for surgical and control patients 
respectively];89
  – transient effect on hypertension.89,149,161
•	 Adopting a deliberately conservative approach 
the previous review limited the scope of 
comorbidities considered to Type 2 diabetes. As 
discussed earlier, the impact of Type 2 diabetes 
was limited to the cost impact, no estimate of 
the impact on QoL was included in the model. 
For the analysis in this report we adopt a set 
of BMI-specific Type 2 diabetes incidence 
estimates and include estimates of cardiovascular 
comorbidities, where trial data support such 
estimates (see section on Data sources, Effectiveness 
data, this chapter, for details and discussion).
•	 Costings developed for the previous assessment 
report15 were predominantly based on expert 
opinion, in terms of preoperative assessments, 
surgical costs and postdischarge management. 
Since the publication of the previous 
assessment report15 a number of economic 
evaluations have been published reporting 
costs or resource use assumptions for different 
types of bariatric surgery. For this report 
we intend updating the cost assumptions in 
relation to bariatric surgery, where published 
evidence or expert opinion suggests there have 
been substantial changes since the publication 
of the previous assessment report.15
•	 Methodological guidance and accepted 
practice in discounting have changed since 
the publication of the previous assessment 
report,15 where costs and outcomes were each 
discounted at 6%. Updated estimates, using 
the original model, are presented in Appendix 
18 using the current practice of discounting 
both costs and outcomes each at 3.5%. Where 
this has a substantial impact on the results 
of the analysis, this will be discussed in the 
conclusions of this report.Assessment of cost-effectiveness
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FIGURE 2  State transition diagram. CHD, coronary heart disease.
Model type and rationale for 
the model structure
For this report we have sought to expand the 
conceptual model adopted for the previous 
assessment report, to include CHD and stroke. 
Figure 2 shows the state transition diagram for the 
model developed for this review. In this diagram 
ellipses indicate health states and arrows indicate 
allowable transitions. Patients may enter the 
model in any of the grey-shaded ellipses – i.e. they 
may have already developed Type 2 diabetes as a 
result of their obesity, they may resolve diabetes 
(temporarily or permanently) as a result of 
treatment for their obesity or they may enter the 
model free of diabetes. We assume that patients 
are free of CHD and have not experienced stroke 
before treatment.
The primary outcomes reported for clinical trials 
included in this review are typically related to 
change in body weight (total weight change from 
baseline, change in excess weight or change in 
BMI) so data to model transitions between health 
states would ideally be based on a standardised, 
weight-related measure such as BMI. However, 
body weight may not be an ideal parameter for 
predicting some comorbidities associated with 
obesity – for example, CHD and stroke are more 
typically modelled using blood pressure and lipid 
measurements rather than BMI. The reporting of 
these additional measures is not complete in all 
studies. Where these additional parameters are 
not available in trial reports it may not be possible 
to apply the full model described before – in that 
situation a more limited model, similar to that 
adopted for the previous report will be used.
The models have a maximum time horizon of 
20 years, as adopted in the previous assessment 
report, to allow for some extrapolation of trends 
in weight loss beyond the end of trial follow-up. 
This time horizon represents a trade-off between 
allowing the benefits of continued weight reduction 
(compared with baseline) to accrue and the limited 
long-term follow-up data, uncertainty over its 
applicability to current clinical practice and surgical 
technology (including the absence of reliable data 
on long-term reoperation rates and conversions). 
In the analyses conducted using the updated model 
cost-effectiveness results are presented for three 
time horizons – trial-only (two years), intermediate 
extrapolation (to five years) and a longer term 
extrapolation (to 20 years). The purpose of 
this is to identify how far the extrapolation of 
benefits, beyond the trial period, affects the cost-
effectiveness estimates. DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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Baseline cohort of patients 
with morbid obesity
The baseline cohort consists of patients with 
morbid obesity, with a BMI of 45, 90% of which 
are female, with a mean age of 40, and all have 
failed to achieve or maintain adequate, clinically 
beneficial weight loss for at least six months using 
appropriate non-surgical measures. This is similar 
to the baseline cohort for the previous report and 
is consistent with current NICE guidance.9 It is 
estimated that 10% of morbidly obese patients, 
eligible for treatment, have Type 2 diabetes before 
the start of treatment with surgical or non-surgical 
treatment to promote weight loss.
Additional analyses will be undertaken for a cohort 
of obese patients, mean BMI of 37 with Type 2 
diabetes (adopting the baseline characteristics 
of the trial reported by Dixon and colleagues117). 
Treatment outcomes from the trial reported by 
Dixon and colleagues107 will be applied to estimate 
the cost-effectiveness of bariatric surgery in this 
group of patients. These patients meet the NICE 
criteria in having a BMI greater than 35 and other 
significant disease (Type 2 diabetes) that could be 
improved if they lost weight. However, it is not 
clear from the trial report whether these patients 
had previously failed to achieve or maintain weight 
loss with non-surgical interventions. Analyses will 
also be presented based on characteristics and 
clinical outcomes for patients recruited to the 
trial reported by O’Brien and colleagues,115 which 
selected patients with moderate obesity (baseline 
BMI between 30 and 35) and are therefore outside 
the scope of the NICE guideline.
Data sources
Effectiveness data
Effectiveness – percentage weight reduction
We have reported on the findings from our 
systematic review on the clinical effectiveness 
of bariatric surgery (see Chapter 4, Assessment 
of clinical effectiveness evidence) and also the 
findings of the review of natural history models 
and clinical effectiveness data used in economic 
evaluations of interventions included in this report 
(Results, this chapter). The clinical effectiveness 
review concluded that it was not appropriate to 
conduct a meta-analysis because of the limited 
number of studies for comparison of surgical 
procedures, differences in surgical and non-surgical 
comparators, heterogeneity of patient populations, 
and poor reporting (no reporting of standard 
deviations or equivalent measures of variation). In 
the absence of formally analysed, robust estimates 
of the relative effectiveness of surgical and non-
surgical approaches, based on all relevant studies 
included in the clinical effectiveness review, the 
effectiveness data for this economic evaluation have 
been derived from five sources:
1.  effectiveness estimates adopted in the previous 
assessment report15
2.  a prospective randomised trial of laparoscopic 
adjustable gastric banding and laparoscopic 
Roux-en-Y gastric bypass107
3.  an RCT of laparoscopic adjustable gastric 
banding and conventional therapy for patients 
with BMI of greater than 30 and less than 40, 
with Type 2 diabetes117
4.  an RCT of laparoscopic adjustable gastric 
banding and an intensive medical programme 
for patients with BMI of greater than 30 and 
less than 35115
5.  trends in weight reduction for surgical patients 
and non-surgical controls, over 10 years, from 
the SOS study.97
Percentage  weight  reduction  in  morbidly  obese 
subjects15,97,107
The previous assessment report estimated a 
percentage weight reduction for bariatric surgery 
procedures separately, with an underlying 
assumption that long-term weight loss was very 
unlikely to occur in patients undergoing non-
surgical management, based on data from the SOS 
study. The baseline assumption for Roux-en-Y 
gastric bypass, on the basis of a visual inspection of 
the percentage weight loss from baseline in eight 
studies, was that patients lose 36% of initial weight 
and that this weight loss is maintained for five years 
following surgery. There was more limited evidence 
on weight reduction following adjustable gastric 
banding – the baseline assumption corresponded 
to the percentage weight loss reported in an RCT 
of adjustable gastric banding and vertical banded 
gastroplasty.126
Table 49 reports the baseline weight (or BMI where 
weight reduction was not reported) for included 
trials of gastric bypass and the absolute change in 
weight or BMI reported for each year of follow-up 
in the trial.
Table 50 reports the percentage weight reduction 
(or percentage reduction in BMI where weight 
reduction was not reported) calculated from 
the values reported in Table 49. The baseline 
assumption of a 36% reduction in weight for gastric 
bypass, adopted in the previous assessment report, 
is at the upper extreme of the values reported in 
Table 50.Assessment of cost-effectiveness
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TABLE 49  Absolute weight reduction and reduction in BMI following gastric bypass, reported in included studies
Study Baseline Year 1 Year 2 Year 3 Year 4 Year 5
Absolute weight reduction (kg)
Howard120 154 55 53 54   50
Sugerman123 132 44 44 41    
Angrisani107 118 25   35   34
Absolute reduction in BMI (kg/m2)
Stoeckli102 43.6   10.7      
Olbers108 42.7 13.7 14.7      
Lee124 43.18 13.6 14.7      
BMI, body mass index.
TABLE 50  Per cent weight reduction and percentage reduction in BMI following gastric bypass, reported in included studies
Study Year 1 Year 2 Year 3 Year 4 Year 5
Percentage weight reduction
Howard120 36% 34% 35%   32%
Sugerman123 33% 33% 31%    
Angrisani107 21%   29%   29%
Percentage reduction in BMI
Stoeckli102   25%      
Olbers108 32% 34%      
Lee124 31% 34%      
BMI, body mass index.
For consistency, the percentage weight reduction 
adopted in the previous report will be used in this 
evaluation – these represent the most optimistic 
assumptions for weight reduction following gastric 
bypass. A second set of effectiveness estimates, 
based on percentage weight reduction reported by 
Angrisani and colleagues,107 will also be reported. 
These represent the least optimistic assumptions 
for weight reduction following gastric bypass.
Table 51 reports the baseline weight (or BMI where 
weight reduction was not reported) for included 
trials of adjustable gastric banding and the absolute 
change in weight or BMI reported for each year of 
follow-up in the trial.
Table 52 reports the percentage weight reduction 
(or percentage reduction in BMI where weight 
reduction was not reported) calculated from values 
reported in Table 51. The baseline assumption 
of an initial 20% reduction in weight in the 
first year rising to a 33% weight reduction at 
five years, adopted in the previous assessment 
report, is the most optimistic set of assumptions 
for weight reduction following adjustable gastric 
banding and contrasts starkly with the results of 
the trial reported by Angrisani and colleagues.107 
For consistency the percentage weight reduction 
adopted in the previous report will be used in this 
evaluation. However a second set of effectiveness 
estimates, based on percentage weight reduction 
reported by Angrisani and colleagues107 will also 
be reported, representing the least optimistic 
assumptions for weight reduction following 
adjustable gastric banding.
Data on trends in weight reduction for surgical 
patients and non-surgical controls, over 10 years, 
from the SOS study97 are used to extrapolate 
beyond five years of follow-up. Percentage weight 
reduction for gastric bypass patients was estimated 
to decline by 17.7% from five to 10 years of follow-
up (estimated from Sjostrom and colleagues97, see 
Figure 1of their article). The equivalent decline for DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 51  Absolute weight reduction and reduction in BMI following adjustable gastric banding, reported in included studies
Study Baseline Year 1 Year 2 Year 3 Year 4 Year 5
Absolute weight reduction (kg)
Angrisani107 117 15   19   19
Nilsell126 124 26 36 39 38 43
De Wit132 152 35        
Absolute reduction in BMI (kg/m2)
Stoeckli102 41.7 8.0 8.5      
Morino110 44.7 9.2 9.9 9.0    
Van Dielen127 46.7 11.7 12.1      
BMI, body mass index.
TABLE 52  Per cent weight reduction and percentage reduction in BMI following adjustable gastric banding, reported in included studies
Study Year 1 Year 2 Year 3 Year 4 Year 5
Percentage weight reduction
Angrisani107 13%   16%   16%
Nilsell126 21% 29% 31% 31% 35%
De Wit132 23%        
Percentage reduction in BMI
Stoeckli102 19% 20%      
Morino110 21% 22% 20%    
Van Dielen127 25% 26%      
BMI, body mass index.
adjustable gastric banding patients was estimated 
to be 14.7%.
Table 53 reports the percentage weight reduction 
applied in the model for each intervention and 
comparator for morbidly obese patients. Where 
values were not reported for each year (Angrisani 
and colleagues reported trial outcomes at year 1, 
year 3 and year 5) values were estimated by linear 
interpolation.
Percentage weight reduction in obese subjects with 
Type 2 diabetes117
Table 54 reports the weight loss from baseline for 
patients followed up for two years following surgery 
using laparoscopic adjustable gastric banding 
compared with conventional diabetes care with a 
focus on weight loss by lifestyle change in the trial 
reported by Dixon and colleagues.117
For the base-case analysis it is assumed that the 
reduction in BMI occurs from entry to the study 
and persists for two years with reversion to baseline 
BMI of 37 kg/m2 at the end of the study period 
(two years). An additional analysis will be reported, 
extrapolating the percentage weight reduction over 
10 years using data on trends in weight reduction 
for patients undergoing gastric banding from the 
SOS study,97 which suggest that the percentage 
weight reduction from baseline reduces by one-
third from two to 10 years following surgery.
Percentage  weight  reduction  in  moderately  obese 
subjects115
Table 55 reports the percentage weight loss from 
baseline at four observation points for moderately 
obese patients followed up for two years following 
surgery using laparoscopic adjustable gastric 
banding compared with a non-surgical programme 
using behaviour modification, VLCDs and 
pharmacotherapy.
For the base-case analysis it is assumed that the 
reduction in BMI follows the pattern described by Assessment of cost-effectiveness
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TABLE 53  Percentage weight reduction over ten years for morbidly obese patients undergoing non-surgical or surgical management, 
applied in the base-case economic model
Time (years)
Non-surgical 
management
Gastric bypass Adjustable gastric banding
Optimistic Pessimistic Optimistic Pessimistic
0 0.0 0.0 0.0 0.0 0.0
1 0.0 – 36.0 – 21.4 – 21.0 – 12.6
2 0.0 – 36.0 – 25.3 – 29.0 – 14.4
3 0.0 – 36.0 – 29.2 – 31.5 – 16.2
4 0.0 – 36.0 – 29.0 – 30.6 – 16.3
5 0.0 – 36.0 – 28.8 – 34.7 – 16.4
6 0.0 – 34.7 – 27.8 – 33.7 – 15.9
7 0.0 – 33.5 – 26.8 – 32.6 – 15.4
8 0.0 – 32.2 – 25.8 – 31.6 – 15.0
9 0.0 – 30.9 – 24.7 – 30.6 – 14.5
10 0.0 – 29.6 – 23.7 – 29.6 – 14.0
Gastric bypass
Optimistic values from one to five years are taken from the previous assessment report. Percentage weight loss at 10 years 
is based on 17.7% decline in percentage weight loss observed from five to 10 years in the SOS study.97 Values between five 
and 10 years estimated by linear interpolation.
Pessimistic values from one to five years are taken from Angrisani and colleagues.107 Values for two and four years were 
not reported and are estimated by linear interpolation. Percentage weight loss at 10 years is based on 17.7% decline in 
percentage weight loss observed from five to 10 years in the SOS study.97 Values between five and 10 years estimated by 
linear interpolation
Adjustable gastric banding
Optimistic values from one to five years are taken from Nilsell and colleagues126. Percentage weight loss at 10 years is based 
on 14.7% decline in percentage weight loss observed from five to 10 years in the SOS study.97 Values between five and 
10 years estimated by linear interpolation.
Pessimistic values from one to five years are taken from Angrisani and colleagues.107 Values for two and four years were 
not reported and are estimated by linear interpolation. Percentage weight loss at 10 years is based on 14.7% decline in 
percentage weight loss observed from five to 10 years in the SOS study.97 Values between five and 10 years estimated by 
linear interpolation
TABLE 54  Absolute weight loss and estimated BMI, from a 
baseline BMI of 37, for obese subjects with Type 2 diabetes117
Intervention
Weight loss 
(standard error) BMI
Surgical 21.1 (1.9170) 29.6
Non-surgical 1.5 (0.9859) 36.6
BMI, body mass index.
the solid lines in Figure 3, showing the estimated 
BMI over time for surgical and non-surgical 
cohorts. This figure reproduces Figure 3 from the 
original trial report115 except that it plots estimated 
BMI (reported in Table 54), rather than per cent 
weight loss from baseline. For the base-case analysis 
both cohorts revert to baseline BMI at the end 
of two years, i.e. applying data from the clinical 
trial report with no extrapolation of effect beyond 
the trial duration. Inspection of Figure 3 suggests 
that BMI for the non-surgical cohort is already 
reverting toward the baseline level at two years, 
whereas for the surgical cohort the BMI appears 
to be stabilising around a value 20% below the 
baseline level.
An additional scenario is considered:
•	 As illustrated using the dashed lines in Figure 
3, a linear extrapolation has been estimated 
using the final two BMI values (month 18 and 
month 24) for the non-surgical cohort. This 
suggests that BMI is reverting to its baseline 
value at a rate of 0.106 points per month. 
On this basis the estimated BMI reverts to its 
baseline value 18 months after the end of the 
two-year study period. Applying the same rate 
of increase for the surgical cohort implies that 
BMI reverts to its baseline value 68 months 
(52/3 years) after the end of the two-year study 
period.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 55  Percentage weight loss and estimated BMI, from a baseline BMI of 33.5  kg/m2, for moderately obese subjects115
Intervention
6 months 12 months 18 months 24 months
Weight 
loss (%) BMI
Weight 
loss (%) BMI
Weight 
loss (%) BMI
Weight 
loss (%) BMI
Surgical 14.1 28.8 19.7 26.9 20.8 26.5 21.6 26.3
Non-surgical 13.9 28.8 10.0 30.1 7.5 31.0 5.6 31.6
BMI, body mass index.
BMI has been estimated using the percentage weight loss from baseline, reported in the previous column, against a baseline 
BMI of 33.5 kg/m2
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FIGURE 3  Estimated BMI for moderately obese subjects over two years surgical and non-surgical treatment. BMI, body mass index.
Effectiveness – diabetes resolution
The previous assessment report estimated the 
proportion of morbidly obese patients with existing 
Type 2 diabetes who revert to normoglycaemia 
following bariatric surgery as 75%, based on the 
proportion of patients who were off medication 
at three years reported by Hall and colleagues.149 
Similar proportions have been reported for 
patients with Type 2 diabetes in the SOS study 
(72% recovery from diabetes at two years)97 
and Dixon and colleagues117 (73% remission 
of diabetes in surgical patients versus 13% in 
conventionally treated patients, though these 
were patients with a lower BMI of between 30 
and 40). At 10 years of follow-up the SOS study97 
reported that 36% of patients who had had Type 
2 diabetes at baseline, were in remission following 
bariatric surgery. For the base case we adopt the 
assumption that 75% of prevalent Type 2 diabetes 
cases revert to normoglycaemia up to two years 
following bariatric surgery and that 36% are in 
recovery at 10 years – the percentage of patients 
for intermediate years is estimated using linear 
interpolation. The proportion of patients in 
the control cohort in the SOS study97 is used to 
estimate recovery from Type 2 diabetes with non-
surgical management. These values are 21% at two 
years and 13% at 10 years – as with the surgically 
managed patients the values for intermediate years 
are estimated using linear interpolation.
Diabetes  resolution  in  obese  subjects  with  Type  2 
diabetes117
Table 56 reports the percentage of patients with 
Type 2 diabetes at baseline, who were in remission 
at two years following surgery using laparoscopic 
adjustable gastric banding compared with 
conventional diabetes care in the trial reported by 
Dixon and colleagues.117Assessment of cost-effectiveness
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Change in blood pressure and lipids in moderately 
obese subjects115
Table 58 reports the change in systolic blood 
pressure and change in the ratio of total to HDL-
cholesterol from baseline at four observation 
points for moderately obese patients followed up 
for two years following surgery using laparoscopic 
adjustable gastric banding compared with a non-
surgical programme using behaviour modification, 
VLCDs and pharmacotherapy.
For the base-case analysis it is assumed that the 
change in systolic blood pressure (from a baseline 
of 131 mmHg) and change in ratio of total to 
HDL-cholesterol (from a baseline ratio of 4.3) 
occurs from entry to the study and persists for two 
years with reversion to baseline values at the end 
of the study period (two years). For the alternative 
scenarios – where reduction in BMI below baseline 
levels is assumed to persist beyond two years (up 
to 18 months for non-surgical and 68 months for 
the surgical cohort in the first scenario, and up 
to 14 months for the second) – the same duration 
of effect is assumed for changes in systolic blood 
pressure and ratio of total to HDL-cholesterol. 
Values between the observed changes at two years 
and the assumed date of reversion to baseline are 
estimated by linear interpolation.
Diabetes incidence by BMI
The Description of health problem section 
in chapter 1 of this report briefly reviewed 
epidemiological evidence for the association 
between BMI and Type 2 diabetes, indicating 
an approximate doubling of the odds of Type 2 
diabetes for obese subjects compared with those 
with a BMI less than 25. Targeted searches were 
undertaken to identify studies reporting diabetes 
incidence by BMI. Economic evaluations of 
interventions to promote weight reduction were 
also identified and searched for data relating BMI 
and diabetes incidence.
TABLE 56  Percentage of obese subjects with Type 2 diabetes 
patients resolving diabetes117
Intervention
Per cent of patients resolving 
diabetes (standard error)
Surgical 73.3 (0.0811)
Non-surgical 13.3 (0.0614)
For the base-case analysis it is assumed that the 
resolution of diabetes occurs from entry to the 
study and persists for two years with reversion to 
Type 2 diabetes at the end of the study period (two 
years).
Effectiveness – change in blood pressure and lipids
The effect of bariatric surgery on blood pressure 
and lipids is not included in the model for 
morbidly obese patients because the baseline 
ratio of total to HDL-cholesterol and change from 
baseline over time was not reported in any of the 
included studies. Hence the model for morbidly 
obese patients does not include an estimate of 
the effect of bariatric surgery on cardiovascular 
morbidity or mortality.
Change in blood pressure and lipids in obese subjects 
with Type 2 diabetes117
Table 57 reports the change in systolic blood 
pressure and change in the ratio of total to HDL-
cholesterol from baseline for patients followed up 
for two years following surgery using laparoscopic 
adjustable gastric banding compared with 
conventional diabetes care in the trial reported by 
Dixon and colleagues.117
For the base-case analysis it is assumed that the 
change in systolic blood pressure (from a baseline 
value of 135 mmHg) and change in ratio of total 
to HDL-cholesterol (from a baseline ratio of 4.4) 
occurs from entry to the study and persists for two 
years with reversion to baseline values at the end of 
the study period (two years).
TABLE 57  Change in systolic blood pressure, from a baseline of 135 mmHg, and change in the ratio of total to HDL-cholesterol, from a 
baseline ratio of 4.4, for obese subjects with Type 2 diabetes107
Intervention
Change in systolic blood pressure, mmHg 
(standard error)
Change in the ratio of total to HDL-cholesterol 
(standard error)
Surgical – 6.0 (3.2681) – 0.82 (0.3469)
Non-surgical – 1.7 (2.5926) – 0.14 (0.1899)
HDL, high-density lipoprotein.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 58  Change in systolic blood pressure, from a baseline of 131 mmHg, and change in the ratio of total to HDL-cholesterol, from a 
baseline ratio of 4.3, for obese subjects with Type 2 diabetes115
Intervention
Change in systolic blood pressure %  
(standard error)
Change in the ratio of total to HDL- 
cholesterol % (standard error)
Surgical – 10.8 (1.7294) – 21.3 (2.4019)
Non-surgical – 7.2 (1.7422) – 8.0 (2.8198)
HDL, high-density lipoprotein.
Column two of Table 59 reports estimates of 
diabetes incidence by BMI, derived by Warren and 
colleagues.163 These are based on data reported by 
Colditz and colleagues164 (column one Table 59), 
which reported diabetes incidence by bounded 
categories, up to a BMI value of 34.9, with the 
final incidence rate applied to an unbounded BMI 
category of 35 and over. Warren and colleagues163 
extrapolated for values beyond 35 kg/m2 using data 
from Sjostrom and colleagues,88 which reported 
two-year incidence in control patients (who did 
not lose weight and had average BMI of 40) of 
6.3% versus a diabetes incidence of 0.2% in treated 
patients, who achieved an average weight reduction 
of 27.8 kg (reducing average BMI from 42.1 to 
32.4 kg/m2).
Comparing the incidence rates estimated by 
Warren and colleagues163 with those adopted in the 
previous report [2.3% without surgery (BMI of 45) 
and 0.45% with surgery (BMI between 29 and 38)] 
suggests that adopting these BMI-specific values 
would estimate a greater difference in diabetes 
incidence than would be the case with the original 
model. For example, the original model predicted 
that, in cohorts of 100 patients with an initial BMI 
of 45, an initial Type 2 diabetes prevalence of 
10%, and a reduction in BMI of 16 points (over 
five years) following surgery compared with no 
reduction for non-surgical management, 43% 
treated non-surgically and 35% treated with gastric 
bypass would have Type 2 diabetes after 20 years. 
The equivalent values using the same baseline 
assumptions as in the original model, but using 
the BMI-specific incidences, are 53% and 41% 
respectively. The difference in diabetes incidence 
between the two cohorts is therefore 9% in the 
original model and 12% using the incidence rates 
adopted by Warren and colleagues.163
An alternative method for estimating BMI-specific 
diabetes incidence for values of BMI beyond 35 
would be to fit a regression line. Table 59 reports 
the results of fitting a polynomial regression, using 
the mid-points of the BMI categories, to the age-
standardised incidences for the bounded categories 
up to 34.9. The regression equation is then used 
to extrapolate values beyond BMI of 35. This gives 
an estimated incidence of 2.5% for a BMI of 45, 
which is more consistent with values adopted for 
the model used in the previous report.15 Repeating 
the comparison described earlier, in cohorts of 100 
patients with an initial BMI of 45, an initial Type 
2 diabetes prevalence of 10%, and a reduction in 
BMI of 16 points (over five years) following surgery 
compared with no reduction for non-surgical 
management, 46% treated non-surgically and 36% 
treated with gastric bypass would have Type 2 
diabetes after 20 years. The difference in diabetes 
incidence between the two cohorts is therefore 
9% in the original model and 10% using the 
polynomial regression for extrapolation.
We adopt the extrapolation based on the 
polynomial regression for the base case in the 
model, applying the values estimated by Warren 
and colleagues163 in a sensitivity analysis.
Coronary heart disease
Targeted searches failed to find reliable published 
estimates relating CHD [acute myocardial 
infarction (AMI) or angina] to BMI alone. 
Where data were identified they related to CHD 
mortality165–167 rather than incidence or CHD 
events and used BMI categories that were of little 
benefit in populating the model (e.g. upper BMI 
categories set at greater than or equal to 32 or 
greater than or equal to 35).
To estimate CHD for patients with and without 
diabetes the Framingham Heart Study (FHS) 
accelerated failure time risk equations are used,168 
which predict first cardiovascular events. The 
hazard of CHD events is estimated based on sex, 
age, systolic blood pressure, smoking status, total 
cholesterol to HDL-cholesterol ratio (TC : HDL). 
These equations are typically used to derive 10-
year risks. However, a reparameterisation, as 
proposed by Caro and colleagues169 has been 
adopted to estimate hazards for each model cycle 
(see Appendix 19 for details). Assessment of cost-effectiveness
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TABLE 59  Diabetes incidence by BMI
BMI
Colditz and colleagues164 
Age standardised risk per 
100,000 persons
Warren and colleagues163 
% annual incidence
Polynomial regression using 
estimates of Colditz and 
colleagues164 
22–22.9 37.4 0.04 0.04
23–23.9 54.9 0.05 0.05
24–24.9 62.9 0.06 0.07
25–26.9 103.5 0.10 0.11
27–28.9 200.4 0.20 0.21
29–30.9 354.5 0.35 0.34
31–32.9 521.2 0.52 0.51
33–34.9 703.6 0.70 0.71
35–36.9 1190.5a 1.19 0.95
37–38.9 1.55 1.23
39–40.9 2.00 1.55
41–42.9 2.50 1.90
43–44.9 3.15 2.28
BMI, body mass index.  
Polynomial regression diabetes incidence = 2.18627 – (0.19792 × BMI) + (0.00455 × BMI2)
a  This value applied to the group of individuals with BMI ≥ 35 in the study reported by Colditz and colleagues and is 
therefore likely to overestimate the incidence for the group with BMI 35 to 36.9, although this is taken as the rate for that 
category by Warren and colleagues163
The Framingham equation for myocardial 
infarction only, is used in the model, therefore the 
model does not predict angina in the modelled 
cohorts.
To apply the FHS risk equations, information on 
baseline systolic blood pressure and TC : HDL 
and also changes from baseline are required for 
included clinical trials. These data are not available 
for all trials and therefore predictions of CHD 
risk may not be available for all comparisons. In 
that situation a more limited version of the model, 
similar to that adopted for the previous report,15 
will be used.
Stroke
Targeted searches identified studies describing 
associations between total stroke risk (also broken 
down by ischaemic and haemorrhagic stroke) 
by BMI for both men170 and women.171 Both 
studies found significantly higher stroke risk for 
participants with greater BMI. The relative risk 
was 2.00 (95% CI 1.48 to 2.71) for total stroke, 
1.95 (95% CI 1.398 to 2.72) for ischaemic stroke 
and 2.25 (95% CI 1.01 to 5.01) for haemorrhagic 
stroke in men with BMI of 30 or more compared 
with those with a BMI less than 23. In women the 
relative risks of ischaemic stroke were 1.75 (95% 
CI 1.17 to 2.59) for BMI of 27 to 28.9, 1.90 (95% 
CI 1.28 to 2.82) for BMI of 29 to 31.9 and 2.37 
(95% CI 1.60 to 3.50) for BMI of 32 or more, 
compared with those with a BMI less than 21. 
For haemorrhagic stroke, in women, there was a 
non-significant inverse association between risk 
and obesity. However, as with studies reporting 
associations between BMI and CHD mortality, the 
BMI categories reported in these studies were of 
little benefit in populating the model (e.g. upper 
BMI categories set at greater than or equal to 30 
or greater than or equal to 32). In addition, the 
reported relative risks did not distinguish between 
subjects with or without diabetes.
As for CHD, stroke risk for patients with and 
without diabetes will be estimated using the FHS 
risk equations,168 which predict first stroke events, 
based on sex, age, systolic blood pressure, smoking 
status and TC : HDL. The same reparameterisation, 
as adopted for CHD, will be used for predicting 
stroke risk. However, there is no adjustment for 
BMI applied in calculating the stroke risks.
As discussed earlier, where baseline systolic blood 
pressure and TC : HDL and also changes from 
baseline are not reported for the included clinical 
trials these risks cannot be computed and a more DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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limited version of the model, similar to that 
adopted for the previous report,15 will be used.
Health state values/utilities
A targeted search was conducted to identify 
published utility estimates for the BMI values 
relevant to the obese population included in the 
models. The search aimed to identify estimates 
of the change in utility scores based on the unit 
change in BMI values. Utility estimates were 
only considered where they used a validated, 
multiattribute utility scale (e.g. EQ-5D) or 
appropriate methodology (e.g. standard gamble 
or time trade-off techniques) and provided a clear 
definition of utility scores anchors 0 and 1 (Table 
60). Utility values within a broader scope than is 
relevant to the current economic model can be 
found in a recent systematic review of the impact 
of body weight on patient utilities with or without 
Type 2 diabetes.172 This systematic review does not 
include utility estimates associated with specific 
surgical interventions. Critical appraisal of utility 
estimates used in economic evaluations of bariatric 
surgeries is presented in the Translation of short-
term outcomes into final outcomes section in this 
chapter. A systematic review of published utility 
estimates in the obese population,173 published in 
2004, identified only one study that assessed the 
change in utility scores as a function of change in 
BMI.152 This study is described below.
Some of the identified studies indicated that 
obesity is an independent predictor of the health-
related preferences with the utility scores as a 
function of BMI decreasing (in absolute values) 
as the number of covariates included in the 
model increases.174,175 The search failed to identify 
the change in utility values specific to an obese 
population with CHD. However, some studies 
estimated the change in utility scores in obese 
populations with and without diabetes.152,179 For 
example, Hakim and colleagues152 found that a 
one-unit decrease in BMI, over a period of one 
year, was associated with a gain of 0.017, which 
was independent of age or gender. However, 
overweight patients with Type 2 diabetes appear to 
have the greatest gain in utility for a given change 
in BMI over one year (0.0285).
There is a large variation in the estimated change 
in utility with the unit change in BMI. This is likely 
to relate to the differences in characteristics of the 
population and the number of covariates included 
in the analysis. Recent cost-effectiveness studies 
in obesity141,176 have employed the utility values 
reported by Hakim and colleagues152 as these are 
derived from the obese (rather than overweight) 
population, have a time-frame of one year (which 
is consistent with the typical cycle duration used in 
the model) and explicitly control for baseline utility 
values. The disadvantage of these values is that the 
assumption of the linear relationship between the 
change in utility and the change in BMI may have 
produced biased estimates of utility gain over the 
range of extreme BMI values.
We adopt the values reported by Hakim and 
colleagues152 in this report, as they represent the 
most methodologically sound estimates derived 
from subjects across a wide range of obesity levels. 
The sensitivity of cost-effectiveness estimates to 
alternative assumptions regarding health-state 
utility is tested in a sensitivity analysis.
Cost data
Costs in the model were developed in two 
stages. First the additional resource use, in 
terms of preoperative assessments, hospital 
admissions for surgery, managing adverse 
events and postdischarge care were identified 
based on estimates developed for the previous 
review,15 published literature, discussion with 
surgical specialists and a costing developed 
for Aberdeen specialist obesity services (U. 
Kulkarni, NHS Grampian, 2008, personal 
communication). Resource use associated with 
non-surgical interventions was estimated using 
a similar approach. The resource use estimates 
were combined with unit costs provided by the 
finance department at Southampton University 
Hospital Trust, and from routine published 
sources,177 to provide estimates of the costs of 
surgical and non-surgical weight loss programmes. 
These are described below as intervention costs. 
Second, literature describing the costs of health 
states associated with obesity was reviewed and 
appropriate estimates, applicable to the UK setting, 
were extracted and used in the analysis. These are 
described below as health-state costs.
Intervention costs
Resource use associated with bariatric surgery 
procedures has been estimated based on estimates 
developed for the previous review,15 duration of 
operative procedures and total length of stay used 
in published economic evaluations, in addition to 
clinical studies reviewed in Chapter 4, Assessment 
of clinical effectiveness evidence and discussion 
with surgical specialists. These are reported in 
Table 61. In the base case we estimate costs for each 
procedure assuming that they will be conducted 
laparoscopically wherever possible, using the Assessment of cost-effectiveness
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TABLE 60  Change in utility values associated with a unit change in BMI
Men Women
People  
with  
diabetes
People 
without 
diabetes
Tool 
used Source and comments
Change in 
utility per 
one unit 
change in 
BMI
0.01665 0.0264 0.0285 0.017 TTO  Hakim and colleagues152 derived utility 
values from the data on the cohort 
of 621 patients predominantly female 
(78%) and white (91%) with the 
mean age of 42 years and mean BMI 
of 35 kg/m2 controlling for age, gender 
and the health preference value at the 
beginning of the year
Change in 
utility per 
one unit 
change in 
BMI
With no 
diabetes-related 
complications: 
0.01; with 
diabetes-related 
complications: 
0.016
EQ-5D Currie and colleagues178 derived utility 
values from the hospitalised patients 
with mean BMI of 29 kg/m2 controlling 
for age and peripheral neuropathy
Change in 
utility per 
one unit 
change in 
BMI
0.0168 Dixon and colleagues173 derived 
utility values from 13,152 inpatients 
and outpatients. Mean BMI was not 
reported for the entire sample. The 
results are estimated for patients with 
BMI> 25 kg/m2
Change in 
utility per 
one unit 
change in 
BMI
0.01 0.0079 EQ-5D Lee and colleagues179 derived utility 
values from regression analysis 
controlling for age but not for gender. 
The data on inpatients and outpatients 
included 24,250 people without and 
2575 patients with Type 2 diabetes 
with mean age of 59 and 68 in patients 
without and with Type 2 diabetes, 
respectively. The patients were 
predominantly white (>95%) with 
mean BMI of 26 kg/m2 and 29 kg/m2 
in patients without and with Type 2 
diabetes, respectively.
BMI, body mass index; EQ-5D, EuroQoL-five dimensions generic, preference-based instrument; TTO, time trade-off 
technique.
breakdown of open and laparoscopic procedures as 
in the previous review (see Table 62).
The resource use estimates differ from those 
adopted for the previous review.15 Duration of 
surgery and length of stay for laparoscopic gastric 
bypass and laparoscopic gastric banding are lower 
than the previous values [235 minutes and six days 
for laparoscopic gastric bypass (operating time and 
total length of stay, respectively) and 150 minutes 
and six days for laparoscopic adjustable gastric 
banding]. The costings adopted here assume 
a lower use of high-dependency care following 
surgery. In the previous review all patients were 
assumed to spend one day in either HDU or ITU, 
whereas clinical advice for this update suggested 
that patients undergoing laparoscopic procedures 
typically recover on the ward unless they 
experience perioperative complications requiring 
admission to ITU. Patients undergoing open 
operations are estimated to spend one day in HDU 
following surgery.
In contrast to the costings developed for the 
previous review, gastric bypass is estimated to 
cost more than adjustable gastric banding. The 
previously estimated values for gastric bypass 
were £3286 and £3174 for laparoscopic and open 
procedures, respectively (using values for the 
1999/2000 financial year). The equivalent values 
for adjustable gastric banding were £3751 and 
£3645.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 61  Resource use and cost estimates for bariatric surgery
Resource use Unit cost Open Laparoscopic
Gastric bypass
Time in theatre (minutes) £16 per minute 180 180
Surgeons operating time (per hour) Consultant: £87.11 2 2
Anaesthetists time (per hour) Consultant: £72.64 3 3
High cost consumables £2040 per procedure 1 1
Days on ward £261 per day 5 5
Days in ITU £1986 per day 21.1% 7.5%
Days in HDU £497 per day 78.9% 0
Specialist dietitian £32 per hour 2 2
Physiotherapy £38 per hour 1 1
Total cost gastric bypass £7705 £7042
Adjustable gastric banding
Time in theatre (minutes) £16 per minute 120 120
Surgeons operating time (per hour) Consultant: £87.11 1 1
Anaesthetists time (per hour) Consultant: £72.64 2 2
High cost consumables £1440 per procedure 1 1
Days on ward £261 per day 5 2
Days in ITU £1986 per day 0 0
Days in HDU £497 per day 100% 0
Specialist dietitian £32 per hour 2 2
Physiotherapy £38 per hour 1 1
Total cost adjustable gastric banding £5584 £4304
HDU, high-dependency unit; ITU, intensive-care unit.
Anaesthetist’s time is assumed to reflect 30 minutes preparation before surgery and 30 minutes recovery following surgery.
It is assumed that two consultant surgeon operators are present for each laparoscopic procedure.
High-cost consumables for gastric bypass are: staples (£1500) and other single-use items (£200). High-cost consumables for 
adjustable gastric banding are: gastric bands (£1000) and other single-use items (£200). A trust overhead of 20% has been 
applied to the total high-cost items for both gastric bypass and adjustable gastric banding.
Unit costs applied to the resource use estimates 
were provided by the finance department at 
Southampton University Hospital Trust. The ITU, 
HDU and ward unit costs are based on 2006/7 
Reference Costs uprated to 2007/8 values. Ward 
unit costs are based on the excess cost per bed 
day for general surgery. Staff costs are based on a 
consultant anaesthetist with discretionary points, 
consultant surgeon with discretionary points 
(MC10) and a specialist registrar (MN25). There 
is a large difference in the unit cost for theatre 
time in this review (£960 per hour) compared 
with the previous review15 which estimated theatre 
time at £335 per hour (approximately £470 
per hour at 2007/8 prices, uprated using the 
Hospital and Community Health Services Pay and 
Prices Index177). Specialist dietitian and hospital 
physiotherapist unit costs were taken from the Unit 
costs of Health and Social Care.177
The included clinical trials provide little additional 
information on conversion from laparoscopic to 
open surgery. Moreover it is difficult to generalise 
the results from clinical trials, which are likely to be 
undertaken in more specialist centres, with more 
experience which may be less likely to convert to 
open procedures than would be the case in other 
centres. The proportion of cases converting to 
open procedures is 0%108 to 23%131 for laparoscopic 
Roux-en-Y gastric bypass. For laparoscopic 
adjustable gastric banding the range in trials 
reporting conversions is narrower: 0%110 to 4%.127 Assessment of cost-effectiveness
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TABLE 62  Additional assumptions
Gastric bypass
Adjustable 
gastric banding
Proportion open 
procedures 
10% 8%
Given the limited additional data on the rate of 
conversion from laparoscopic to open procedures 
reported in the included trials, we used the values 
adopted in the previous review, see Table 62.
Resource use assumptions for costing non-surgical 
management of morbidly obese patients have been 
taken from the previous review,15 see Table 63. Unit 
costs have been updated using Unit Costs of Health 
and Social Care.177
Resource use assumptions for moderately 
obese patients undergoing the non-surgical 
weight reduction programme were based on the 
description of the programme in the clinical 
trial report by O’Brien and colleagues.115 The 
programme consisted of an intensive six-month 
period of VLCD and pharmacotherapy as well 
as specialist dietary advice. The resource use 
assumptions extracted from the clinical trial report 
and the unit costs applied to the resource estimates 
are reported in Table 64.
The frequency of patients attendance for hospital 
or primary care, associated with each intervention, 
was based on estimates developed for the previous 
review,15 published literature, discussion with 
surgical specialists and a costing developed for 
Aberdeen specialist obesity services (U. Kulkarni, 
NHS Grampian, 2008, personal communication). 
All new patients are evaluated in the outpatient 
department and receive an electrocardiogram. In 
the previous review the preoperative assessment 
TABLE 63  Resource use and cost estimates for non-surgical management of morbidly obese patients
Resource use Unit cost Contacts per year
General practitioner £30 4
Community dietitian £48 2
Practice nurse £9 2
District nurse £24 2
Total cost of non-surgical management £282
Add cost of 12 weeks of very-low-calorie diet, every three years (£201.60, two ready-mixed Slimfast shakes everyday for 
12 weeks)
schedule assumed that, for every patient 
undergoing surgery, four patients are screened for 
eligibility and two undergo workup (by VLCD) to 
assess suitability for treatment, based on figures 
reported in Andersen and colleagues.180 This 
corresponded to seven outpatient visits, four 
dietitian consultations and one session with a 
psychologist. The unit costs and estimated cost per 
patient undergoing surgery are listed in Table 65.
Based on the costing developed in Aberdeen, it 
was assumed that patients undergoing adjustable 
gastric banding would make four additional 
attendances for the initial fill and band adjustments 
and that they would have additional specialist 
dietitian consultations associated with these 
band adjustments. These additional attendances 
add £428 to the costs of follow-up for patients 
undergoing adjustable gastric banding.
The costs of managing adverse events were taken 
into account in our analyses by identifying the 
proportion of patients having major perioperative 
complications requiring ITU admission, and the 
proportion of patients having early reoperation 
(within 30 days) because of failure of the original 
operation (typically band slippage for patients 
undergoing adjustable gastric band procedures 
or bleeding, stenosis or leakage in patients 
undergoing gastric bypass). Revision surgery was 
estimated to cost the same as the original surgical 
procedure. Complications requiring admission 
to ITU were costed using the estimated length 
of ITU admission and the per diem cost (£1986) 
reported in Table 61. The costs were applied to the 
proportion of patients experiencing perioperative 
complications requiring ITU admission (7.5% of 
laparoscopic gastric bypass patients113,124) and to the 
proportion of patients requiring surgical revision 
(2% for laparoscopic adjustable gastric bypass110 
and 13.5% for gastric bypass107,108).DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 64  Resource use and cost estimates for non-surgical weight loss programme for moderately obese (BMI ≥ 30 and < 35) patients
Resource category Phase of programme Unit cost Contacts per period
Contact with physician (in out-patients, 
every two weeks for intensive phase and 
every six weeks for remainder)
Intensive phase  
(0 – 6 months)
First visit: £144
Subsequent: £99
1
13a
Months 7–12  £99 4b
Months 13–24  £99 9b
Total cost of medical management for non-surgical weight loss programme £2718
Resource category Phase of programme Unit cost Resource Use
Intensive management (diet and 
pharmacotherapy)
Very-low-calorie diet  
(0–12 weeks)
£1.27
(1 packet optifast)
168 
(2 per day)
Transition phase  
 (weeks 13–16)
£1.27
(1 packet optifast)
£0.40
(120 mg orlistat)
28
(1 per day)
28
(1 per day)
Pharmacotherapy only 
(weeks 17–26)
£0.40
(120 mg orlistat)
210
(3 per day)
Postintensive management Months 7–24 £0.40
(120 mg orlistat)
1057c
(3 per day)
Total cost of very-low-calorie diet and pharmacotherapy for non-surgical weight loss programme £767
Optifast is a liquid, very-low-calorie diet developed by Novartis Medical Nutrition Corporation and is available in the USA, 
Canada, New Zealand and Australia. This product was used in the trial reported by O’Brien and colleagues,115 hence the 
costings developed here are based on the use of this product. The price per packet reported in this table has been derived 
from the quoted price for USA and converted to UK pounds using currency conversion rates.
a  Estimated on the basis that clinical trial report states that patients were seen every two weeks during the intensive phase.
b  Estimated on the basis that the clinical trial report states that patients were seen every four to six weeks following the 
intensive phase. All patients were seen at least every six weeks.
c  Estimated as three 120 mg tablets per day for 78 weeks, adjusted for the fact that 25.8% of non-surgical patients could 
not tolerate orlistat and a further 9.7% chose not to use it.
Patients are likely to undergo a number of 
additional surgical procedures as a result of 
undergoing bariatric surgery, even when the 
original operation was successful. Expert opinion 
suggested that 5% of patients undergoing 
laparoscopic gastric bypass would require an 
additional operation for repair of internal hernia. 
Additionally, patients undergoing active weight 
reduction are at risk of developing gallstones, and 
may require cholecystectomy. It has been suggested 
that 35–38% of patients with morbid obesity 
develop gallstones as they lose weight following 
bariatric surgery181–183 (which has led some surgeons 
to advocate performing cholecystectomy during 
bariatric surgery). Miller and colleagues184 observed 
12 cholecystectomies in 60 placebo-treated 
patients during two years follow-up in their trial 
of prophylaxis against gallstone formation for 
patients following vertical banded gastroplasty 
and adjustable gastric banding (patients had a 
mean preoperative BMI of 44.3 and were 85% 
female). De Wit and colleagues reported 8% of 
patients having a cholecystectomy within one year 
of bariatric surgery.132 In the model we assume 
that 20% of morbidly obese patients undergo 
cholecystectomy within two years of a bariatric 
procedure (8% in the first year and 12% in the 
second, reflecting the observation that the peak 
incidence of symptomatic gallstones is 16 months 
after surgery).
Health-state costs
The model, as described in the section Model type 
and rationale for the model structure, this chapter, Assessment of cost-effectiveness
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TABLE 65  Preoperative and postoperative resource use and costs
Category of 
resource use Frequency Unit cost (£) Total cost 
Preoperative 
assessment
7 outpatient visits 4 × 144; 3 × 99 £1114
4 dietitian consultationsa 32 per hour
4 dietitian consultationsb 32 per hour
1 session with a psychologistc  67 per hour
Postdischarge Primary care in 
month following 
discharge
6 GP visits 32 per visit £306
2 practice nurse visits 9 per visit
4 district nurse visits 24 per visit
Follow-up care Year 1 4 outpatient visits 99 per visit £849
12 community dietitian contactsd 48 per hour
2 psychology consultations 67 per hour
Year 2 4 outpatient visits 99 per visit £636
4 community dietitian contactsd 48 per hour
2 psychology consultations 67 per hour
Year 3 and 
beyond
2 outpatient visits 99 per visit £318
2 community dietitian contactsd 48 per hour
1 psychology consultations 67 per hour
Unit costs for outpatient visits are taken from 2006/07 NHS Reference Costs.185 The remaining costs are taken from Unit 
costs of Health and Social Care.177
a  Assumed duration 30 minutes
b  Assumed duration 20 minutes
c  Assumed duration two hours
d  Assumed duration 30 minutes. Add £2.60 pr visit for travel.
consists of five health states (excluding death). 
Costs for the health state labelled ‘no comorbidity’ 
in the state transition diagram, Figure 2, consists 
only of ongoing monitoring for postsurgical 
patients, or routine follow-up for patients receiving 
non-surgical intervention. No additional, state-
specific, costs are applied to this state. The same 
assumption holds for the ‘remission of comorbidity’ 
health state.
Table 66 reports the health-state costs adopted in 
the model. The Type 2 diabetes cost is based on 
the CODE-2 UK160 estimate of health-care resource 
use and costs applied in the economic model 
developed for the previous report. The average 
cost per patient year (£1505) reported for CODE-2 
UK, with a cost year of 1998–9, has been inflated to 
2007–8 prices using the Hospital and Community 
Health Services (HCHS) Pay and Prices Index.177 
The breakdown of costs reported for CODE-2 UK 
was that 36.2% of costs were attributable to hospital 
admissions and 37.7% to ambulatory care, with the 
remainder attributable to drug treatment (22.5%) 
and insulin (3.5%).
Health-state costs for AMI were based on inputs 
to the Southampton CHD treatment model (K. 
Cooper, University of Southampton, 2008, personal 
communication). The acute costs are based on 
NHS Reference Costs for non-elective inpatient 
admission with AMI. Costs for the post-MI health 
state are based on daily dosage and estimated 
use of a range of drugs (statins, calcium channel 
blockers, beta blockers, acetylcholinesterase 
inhibitors and nitrates) combined with unit costs 
from the British National Formulary, as well as 
health-care utilisation data from the Health Survey 
for England17 combined appropriate unit costs.177 All 
costs were estimated for the 2005–6 financial year 
and have been inflated to 2007–8 prices using the 
HCHS Pay and Prices Index.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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TABLE 66  Health-state costs applied in the economic model
Health state Acute (£) Chronic (£) Source
Diabetes 2197 Williams and colleagues160
AMI 1613 565 Southampton CHD treatment model
Stroke 9540a 2565 Ward and colleagues186
AMI, acute myocardial infarction; CHD, coronary heart disease.
a  Applies for year following stroke.
Health-state costs for stroke were based on 
costs applied in a recent HTA of statins for the 
prevention of coronary events.186 These were 
derived from a published study187 estimating the 
economic burden of stroke in the UK. The acute 
cost of a stroke was estimated using the cost of 
acute events reported by Youman and colleagues187 
(mild stroke £5099, moderate stroke £4816 and 
severe stroke £10,555), weighted by the distribution 
of severity of strokes. The costs reported by Ward 
and colleagues186 were for the financial year 2004–5 
and have been inflated to 2007–8 prices using the 
HCHS Pay and Prices Index.
Discounting of future costs and benefits
A discount rate of 3.5% has been applied to future 
costs and benefits in line with current guidance. 
Discount rates of 0% and 6% for costs and 0% 
and 1.5% for outcomes have been applied in the 
sensitivity analyses.
Presentation of results
We report findings on the cost-effectiveness of 
interventions based on analysis of a cohort of 
patients having baseline age, sex and weight 
characteristics, as discussed earlier. Surgical 
procedures are compared with appropriate non-
surgical comparators.
We report the results of these comparisons in 
terms of the incremental gain in QALYs and 
the incremental costs determined in the cohort 
analysis.
Assessment of uncertainty in the 
SHTAC analysis (sensitivity analysis)
Parameter uncertainty in the updated model is 
addressed using probabilistic sensitivity analysis. 
Probability distributions are assigned to the 
point estimates used in the base-case analysis. 
Appendix 20 reports the variables included in 
the probabilistic sensitivity analyses, the form of 
distribution used for sampling and the parameters 
of the distribution.
In the absence of a robust, pooled estimate of 
treatment effect (with associated estimate of 
variability) we felt it was inappropriate to undertake 
probabilistic sensitivity analysis using the original 
model. In both models deterministic sensitivity 
analysis is used to address particular areas of 
uncertainty in the model related to:
•	 model structure
•	 methodological assumptions
•	 parameters around which there is considerable 
uncertainty or which may be expected, a priori, 
to have disproportionate impact on study 
results.
The purpose of this analysis is to identify clearly 
the impact of this uncertainty and to test the 
robustness of the cost-effectiveness results to 
variation in structural assumptions and parameter 
inputs.
SHTAC cost-effectiveness model 
– summary of methods
•	 The model developed for the previous 
assessment report was assessed against other 
published models for completeness and 
relevance, and the conceptual model was 
extended to include CHD and stroke. The 
ability to include these additional health 
states in the economic model depends on the 
methods adopted to estimate transitions to 
these states, which are not typically based on 
weight-related measures (such as BMI), but use 
blood pressure and lipid measurements. Where 
such measurements are reported, the expanded 
version of the model may be relevant. We 
propose using the FHS equations to model 
cardiovascular risks for the expanded model, 
which require values for blood pressure (systolic 
or diastolic) and the TC : HDL ratio as well as 
patients’ age, sex, smoking status and whether 
they have developed diabetes. However, not all 
studies will report changes in blood pressure 
and lipid measurements, hence the expanded 
model may not be applicable to all studies.Assessment of cost-effectiveness
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•	 The analysis was developed for three patient 
populations covered by studies included in the 
clinical effectiveness review:
  – patients with morbid (Class III, BMI ≥ 40) 
obesity undergoing adjustable gastric 
banding or gastric bypass – as in the 
previous review
  – patients with severe (Class II, BMI ≥ 30 and 
< 40) obesity with significant comorbidity 
at baseline (Type 2 diabetes) undergoing 
adjustable gastric banding, based on data 
from a single trial117
  – patients with moderate (Class I, BMI ≥ 30 
and < 35) obesity undergoing adjustable 
gastric banding, based on data from a 
single trial.115
•	 The clinical effectiveness review concluded 
that meta-analysis was not appropriate, 
hence the model for patients with morbid 
obesity is not based on robust data synthesis 
of effectiveness – there was no statistically 
pooled estimate of each surgical procedure 
on weight loss and no robust estimate of 
variability. As a result, the economic model 
adopted two estimates of the effect of gastric 
bypass and adjustable gastric banding on 
weight loss – these were identified as ‘optimistic’ 
estimates (based on the previous assessment 
report) and an alternative ‘pessimistic’ estimate 
(based on a recently published trial comparing 
gastric bypass and adjustable gastric banding). 
Outcomes, in terms of weight loss at five years 
following surgery, were extrapolated using data 
from the SOS study.97
•	 Included trials for patients with morbid obesity 
did not report change in both blood pressure 
and suitable lipid measurements – hence the 
model developed for the previous assessment 
report has been used for this population, 
with updated assumptions on costs, diabetes 
incidence, permanency of diabetes remission 
following surgery and on the impact of BMI on 
health-state utility.
•	 The clinical trials reporting the use of 
adjustable gastric banding for severely obese 
(BMI ≥ 30 and < 40) patients with Type 2 
diabetes and for moderately obese (BMI 
≥ 30 and < 35) patients reported sufficient 
information, up to two years of follow-up, to 
apply the new model. The analysis for these 
patients will initially be undertaken for the 
period of the trial follow-up only, and will then 
use extrapolations based on data from the SOS 
study, where relevant, or on the basis of data 
reported in the trial.
•	 In the absence of a robust, pooled estimate 
of treatment effect (with associated estimate 
of variability) we felt it was inappropriate to 
undertake probabilistic sensitivity analysis 
using the original model. The robustness of 
the model results to variation in assumptions 
and parameter values was assessed using 
deterministic sensitivity analysis. Probabilistic 
sensitivity analysis would be used for the 
updated model, but would primarily address 
uncertainty in parameter values – uncertainty 
over model structure and methods for 
extrapolating trial results would be addressed 
using deterministic sensitivity analysis.
Results
The first of the next eight section reports results for 
the base-case analysis of adjustable gastric banding 
and gastric bypass compared with non-surgical 
management for patients with morbid obesity (BMI 
≥ 40), using baseline characteristics described in 
the section Baseline cohort of patients with morbid 
obesity, this chapter. Total costs for all management 
strategies are reported, as are the total QALYs 
under the optimistic and pessimistic assumptions 
regarding weight loss. ICERs are reported for 
both surgical procedures relative to non-surgical 
management. The principal differences between 
the results of this analysis and the previous 
assessment report are identified and explanations 
provided. The deterministic sensitivity analysis 
of adjustable gastric banding and gastric bypass 
compared with non-surgical management for 
patients with morbid obesity is then discussed. 
In the absence of a robust, pooled estimate of 
treatment effect (with associated estimate of 
variability) we felt it was inappropriate to undertake 
probabilistic sensitivity analysis using the original 
model.
The third section reports on results for the 
base-case analysis of adjustable gastric banding 
compared with non-surgical management for 
patients with moderate-to-severe obesity (BMI ≥ 30 
and < 40) and Type 2 diabetes, based on the trial 
reported by Dixon and colleagues.117 The following 
two sections report the deterministic sensitivity 
analysis and a probabilistic sensitivity analysis of 
adjustable gastric banding compared with non-
surgical management for patients with moderate-
to-severe obesity (BMI ≥ 30 and < 40) and Type 
2 diabetes. The probabilistic sensitivity analysis 
primarily addresses uncertainty in parameter 
values – uncertainty over model structure and DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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methods for extrapolating trial results is addressed 
using deterministic sensitivity analysis.
Results for the base-case analysis of adjustable 
gastric banding compared with an intensive 
management programme for patients with 
moderate obesity (BMI ≥ 30 and < 35) are 
reported, based on the trial reported by O’Brien 
and colleagues.115 Finally, the deterministic 
sensitivity analysis and a probabilistic sensitivity 
analysis are reported. As stated above, the 
probabilistic sensitivity analysis primarily addresses 
uncertainty in parameter values – uncertainty over 
model structure and methods for extrapolating 
trial results is addressed using deterministic 
sensitivity analysis.
Cost-effectiveness of bariatric 
surgery (gastric bypass or adjustable 
gastric banding) for morbid obesity 
(BMI ≥ 40) – base-case analysis
Table 67 reports the total costs and total QALYs 
for the baseline cohort of morbidly obese patients 
undergoing gastric bypass, adjustable gastric 
banding and non-surgical management, using the 
updated assumptions with regard to surgery cost, 
efficacy (in terms of weight reduction, impact on 
diabetes incidence and on remission of Type 2 
diabetes) and health-state utility. The model has 
been estimated over a 20-year time horizon, as 
in the previous assessment report. All costs and 
outcomes are discounted at 3.5%. 
Surgical management of obesity is estimated to be 
more costly than non-surgical management, but 
results in improved outcomes (in terms of QALYs) 
over the modelled 20-year time horizon. Two 
scenarios are modelled that effect outcomes, but 
not cost. Assumptions on weight loss, up to five 
years, adopted in the previous assessment report 
have been extrapolated to 10 years using data for 
gastric bypass and gastric banding from the SOS 
study.97 An alternative scenario was constructed 
using data, with five years follow-up, from the trial 
reported by Angrisani and colleagues107 with a 
similar extrapolation to 10 years using data from 
the SOS study.97 This gave generally less favourable 
estimates in terms of weight loss, particularly for 
gastric banding.
Compared with the previous assessment report, 
total QALYs associated with non-surgical 
management are lower, while the total QALYs 
for surgical management are higher. This is the 
result of changes in discounting practice, updated 
assumptions on duration of weight reduction and 
alternative assumptions regarding the health gain 
associated with weight loss. The effect of change 
in discounting practice, alone, would be to reduce 
the QALYs associated with each treatment strategy 
by approximately 1.7 QALYs. Extrapolating 
weight loss assumptions up to 10 years, alone, 
increases the total QALYs associated with surgical 
intervention by approximately 4% (with no impact 
on outcomes for non-surgical management because 
the baseline assumption is that patients receiving 
non-surgical management neither gain nor lose 
weight). Updated assumptions on the utility gain 
associated with weight loss increases the total 
QALYs associated with non-surgical management 
by approximately 13% and increases the total 
QALYs associated with surgical management by 
approximately 18%.
Total costs of non-surgical management and 
gastric bypass are approximately double the 
estimates included in the previous assessment 
report, while costs for adjustable gastric banding 
are approximately 60% higher. The increase in 
total costs is the result of a combination of changes 
in discounting practice, updated assumptions 
regarding incidence and remission of Type 2 
diabetes in patients undergoing surgery and 
receiving non-surgical management and updated 
TABLE 67  Total discounted costs and total discounted QALYs for surgical and non-surgical management of morbid obesity (BMI 
≥ 40), using updated assumptions, based on weight reduction adopted for previous assessment report188 and based on weight reduction 
reported by Angrisani and colleagues107
Treatment Total cost (£) QALYsa QALYsb
Non-surgical management 13,561 10.80 10.80
Adjustable gastric banding 17,126 12.68 11.72
Gastric bypass 19,824 12.78 12.32
QALYs, quality-adjusted life-years.
a  ‘optimistic’ – based on weight reduction estimates developed for previous assessment report.188
b  ‘pessimistic’ – based on weight reduction reported by Angrisani and colleagues.107Assessment of cost-effectiveness
124
costing assumptions. For non-surgical management 
36% of the difference can be attributed to changes 
in discounting practice alone and 44% to changes 
in costs alone, whereas for gastric bypass 22% of 
the difference can be attributed to changes in 
discounting practice and 73% to changes in costing 
assumptions. Aside from the general increase in 
the estimated total costs for each strategy, the other 
main difference from the previous assessment 
report is that total costs for gastric bypass are 
approximately £2600 higher than for adjustable 
gastric banding, whereas total costs for adjustable 
gastric banding were approximately £1000 higher 
than for gastric bypass in the previous report. This 
is primarily the result of the shorter duration of 
surgery for adjustable gastric banding (60 minutes 
versus 120 minutes for laparoscopic gastric bypass) 
and shorter LOS (two days for adjustable gastric 
banding versus five days for gastric bypass).
Table 68 reports the incremental cost-effectiveness 
of gastric bypass and adjustable gastric banding 
each compared with non-surgical management.
Surgical management of morbid obesity, using 
adjustable gastric banding or gastric bypass 
provides additional QALYs at additional cost under 
both scenarios – extrapolating weight reduction 
to 10 years based on data from the previous 
assessment report188 and the trial reported by 
Angrisani and colleagues.1107 The ICERs range 
between £1897 and £4127 per QALY gained, 
which are within the range conventionally deemed 
as cost-effective from an NHS decision-making 
perspective.
The incremental cost for gastric bypass is around 
60% greater than for adjustable gastric banding, 
which contrasts with the previous assessment 
report, where gastric bypass was less costly than 
adjustable gastric banding. This is largely the result 
of changes in assumptions over duration of surgery, 
which have affected adjustable gastric banding 
disproportionately (duration of laparoscopic 
adjustable gastric banding was assumed to be 
60 minutes, in contrast with 150 minutes in the 
previous report, whereas duration of laparoscopic 
gastric bypass was assumed to be 120 minutes, in 
contrast with 235 minutes in the previous report) 
and length of stay (length of stay for laparoscopic 
adjustable gastric banding was assumed to be two 
days, in contrast with five days in the previous 
report, whereas length of stay for laparoscopic 
gastric bypass was assumed to be five days, in 
contrast with six days in the previous report).
The QALY gain associated with surgical 
management of morbid obesity is approximately 
two, when based on assumptions on weight 
reduction adopted in the previous report and 
between 1 and 1.5 when based on the results of the 
trial reported by Angrisani and colleagues. These 
QALY gains are larger than those estimated in the 
previous report (0.45 QALYs when compared with 
non-surgical management). These differences are 
primarily the result of extrapolating the weight 
reduction assumptions up to 10 years (resulting in 
an approximate doubling of the QALY gain) and 
updated assumptions on the utility gain associated 
with reduction in BMI. The impact of alternative 
assumptions on the utility gain associated with 
reduction in BMI is explored in a deterministic 
sensitivity analysis.
Cost-effectiveness of bariatric surgery 
(gastric bypass or adjustable gastric 
banding) for morbid obesity (BMI 
≥ 40) – deterministic sensitivity analysis
A series of one-way sensitivity analyses were 
conducted using the updated model. These are 
reported in Table 69, which also includes results for 
some scenario analyses presented in the previous 
TABLE 68  Incremental cost-effectiveness of gastric bypass and adjustable gastric banding compared with non-surgical management
‘Optimistic’ weight reduction from 
previous assessment report188
‘Pessimistic’ weight reduction from 
Angrisani and colleagues107
Intervention
Incremental cost 
(£)
Incremental 
QALYs ICER (£)
Incremental 
QALYs ICER (£)
AGB 3566 1.88 1897 0.92 3863
GBP 6263 1.98 3160 1.52 4127
AGB, adjustable gastric banding; GBP , gastric bypass, ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted 
life-years.
Incremental cost and incremental QALYs for both AGB (adjustable gastric banding) and GBP (gastric bypass) are estimated 
relative to non-surgical management.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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assessment report (for example, Scenario five from 
the previous report which examined the impact of 
involving surgeons with less experience of bariatric 
surgery on the cost-effectiveness of surgical 
management of morbid obesity – see rows titled 
‘Surgeon experience’ in Table 69). Other scenarios 
considered in the sensitivity analysis include:
•	 altering assumptions for operative mortality 
from 1% to 0.5% for gastric bypass and from 
0% to 0.05% for adjustable gastric banding
•	 reducing the change in utility associated with a 
unit change in BMI (from 0.0166 to 0.0075)
•	 applying BMI-specific incidence of Type 2 
diabetes, rather than values for the surgical 
(all surgery, not specific to gastric bypass or 
adjustable gastric banding) and non-surgical 
cohorts from the SOS study97
•	 allowing band adjustments in the second and/
or third year rather than four only in year one
•	 considering the impact of surgeon 
inexperience – on duration of surgery, on 
revision rates and on outcome (in terms of 
weight reduction)
•	 increasing elements of surgical cost by 20%
•	 varying costs of health-service contacts for 
patients on the intensive programme
•	 consider the cost impact of a higher rate of 
abdominoplasty following surgically-induced 
weight loss and including cost impact of 
complications of abdominoplasty.
In general the results are robust to changes in 
assumptions, reported in Table 69, and in all cases 
the ICERs remain within the range conventionally 
deemed as cost-effective from an NHS decision-
making perspective. However, changes in some 
key assumptions produce less favourable cost-
effectiveness estimates than the base case adopted 
for this analysis:
•	 Adopting a lower utility gain for reductions 
in BMI has a large impact on the QALY 
gain associated with surgical management; 
reducing from 1.88 to 0.85 for adjustable 
gastric banding and from 1.98 to 0.85 for 
gastric bypass, for the optimistic assumption 
on weight reduction, when the utility gain per 
unit BMI reduction is reduced from 0.017 to 
0.0075. Equivalent values using pessimistic 
assumptions are a reduction from 0.92 to 0.42 
and from 1.52 to 0.64 for adjustable gastric 
banding and gastric bypass respectively.
•	 Using BMI-specific incidence of Type 2 
diabetes has a greater impact on incremental 
costs for adjustable gastric banding when using 
weight reduction from the trial reported by 
Angrisani and colleagues107 than is the case 
for gastric bypass (or for either approach to 
surgical management when using assumptions 
for weight reduction adopted in the previous 
assessment report). The effect of using BMI-
specific diabetes incidence is to increase 
incremental costs for adjustable gastric banding 
by approximately £1750 so that the ICER rises 
from £3863 to £5749.
•	 Increasing operative costs by 20% increases 
incremental costs for adjustable gastric banding 
by approximately £1000 and gastric bypass by 
approximately £1500. This increases the ICER 
for adjustable gastric banding from £1897 to 
£2416 using assumptions for weight reduction 
adopted in the previous assessment report, and 
from £3863 to £4921 based on the trial results 
reported by Angrisani and colleagues.107 The 
equivalent changes for gastric bypass are from 
£3160 to £3963, and from £4127 to £5176.
•	 Increasing postoperative costs by 20% increases 
incremental costs by between £1200 and £1300. 
This increases the ICER for adjustable gastric 
banding to £2579 using assumptions for weight 
reduction adopted in the previous assessment 
report, and to £5252 based on the trial results 
reported by Angrisani and colleagues.107 The 
equivalent changes for gastric bypass are an 
increase to £3758, and to £4908.
•	 Increasing all surgery-related costs by 20% 
leads to a higher proportionate increase for 
adjustable gastric banding, with incremental 
costs increasing by approximately £2500 
(70% increase). The equivalent value for 
gastric bypass is approximately £3000 (48% 
increase). The ICER for adjustable gastric 
banding increases to £3217 using assumptions 
for weight reduction adopted in the previous 
assessment report, and to £6551 based on 
the trial results reported by Angrisani and 
colleagues.107 The equivalent changes for 
gastric bypass are an increase to £4674, and to 
£6103.
•	 Repeating the scenario analysis, presented 
in the previous assessment report, for 
surgical experience leads to increased costs 
(because of increased duration in surgery 
and increases in the rate of revision) and 
poorer outcomes (i.e. reduced QALYs because 
of increased operative mortality and lower 
weight reduction). The effect of these altered 
assumptions is shown cumulatively, with the 
effects on costs considered first. Increasing 
duration of surgery and revision rates leads to 
similar proportionate increases in incremental Assessment of cost-effectiveness
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TABLE 69  Deterministic sensitivity analysis for cost-effectiveness of surgical management (gastric bypass or adjustable gastric banding) 
of morbid obesity (BMI ≥ 40)
‘Optimistic’ weight 
reduction from previous 
assessment report188
‘Pessimistic’ weight 
reduction from Angrisani 
and colleagues107
Incremental 
cost (£)
Incremental 
QALYs ICER (£)
Incremental 
QALYs ICER (£)
Base case AGB 3566 1.88 1897 0.92 3863
GBP 6263 1.98 3160 1.52 4127
Operative mortality
(AGB = 0.05%; GBP = 0.5%)
AGB 3559 1.87 1906 0.91 3905
GBP 6293 2.05 3075 1.58 3983
Health-state utility
(0.0075 gain per unit BMI reduction)
AGB 3566 0.85 4215 0.42 8584
GBP 6263 0.85 7412 0.64 9845
Use BMI-specific incidence of Type 2 
diabetes (see Table 59)
AGB 3873 1.88 2060
GBP 6297 1.98 3177
AGB 5307 0.92 5749
GBP 6814 1.52 4490
Increase cost of preoperative 
assessment by 20%
AGB 3788 1.88 2015 0.92 4104
GBP 6486 1.98 3272 1.52 4273
Increase operative costs by 20% AGB 4542 1.88 2416 0.92 4921
GBP 7855 1.98 3963 1.52 5176
Increase postoperative costs by 20% AGB 4848 1.88 2579 0.92 5252
GBP 7448 1.98 3758 1.52 4908
Increase all costs by 20% AGB 6048 1.88 3217 0.92 6551
GBP 9262 1.98 4674 1.52 6103
Band adjustments in second year 
(four)
AGB 3965 1.88 2109 0.92 4295
GBP 6263 1.98 3160 1.52 4127
Band adjustments in second year 
(four) and third year (two)
AGB 4152 1.88 2208 0.92 4497
GBP 6263 1.98 3160 1.52 4127
Late reoperations for AGB continue 
over 10 years (6%)
AGB 5240 1.88 2787 0.92 5676
GBP 6263 1.98 3160 1.52 4127
Late reoperations for AGB continue 
over 10 years (2.5%)
AGB 3957 1.88 2105 0.92 4286
GBP 6263 1.98 3160 1.52 4127
Surgeon experience: increase duration 
of surgery (50%) and double revision 
rates
AGB 5685 1.88 3024 0.92 6159
GBP 9588 1.98 4838 1.52 6318
Surgeon experience: double operative 
mortality; (GBP = 2% AGB = 0%)
AGB 5685 1.88 3024 0.92 6159
GBP 9528 1.85 5143 1.39 6839
Surgeon experience: reduce estimated 
weight loss by 25% 
AGB 5685 1.41 4019 0.70 8091
GBP 9528 1.34 7135 0.99 9631
Cost cholecystectomy as a day case AGB 3445 1.88 1833 0.92 3732
GBP 6143 1.98 3099 1.52 4048
Cost abdominal hernia procedures as 
day case
AGB 3566 1.88 1897 0.92 3863
GBP 6205 1.98 3131 1.52 4088DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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‘Optimistic’ weight 
reduction from previous 
assessment report188
‘Pessimistic’ weight 
reduction from Angrisani 
and colleagues107
Incremental 
cost (£)
Incremental 
QALYs ICER (£)
Incremental 
QALYs ICER (£)
Adjust abdominoplasty cost for 
complications (25% with intermediate 
complication and 5% with major 
complication)
AGB 3589 1.88 1909 0.92 3888
GBP 6286 1.98 3172 1.52 4142
Higher rate of apronectomy AGB 3901 1.88 2075 0.92 4226
GBP 6599 1.98 3330 1.52 4348
Patients recover in HDU (1 day) 
rather than on ward
AGB 3766 1.88 2003 0.92 4079
GBP 6426 1.98 3243 1.52 4234
Include conversion to open 
procedures
AGB 3677 1.88 1956 0.92 3983
GBP 6329 1.98 3194 1.52 4170
AGB, adjustable gastric banding; BMI, body mass index; GBP , gastric bypass; HDU, high-dependency unit; ICER, incremental 
cost-effectiveness ratio; QALYs, quality-adjusted life-years.
costs [increase of approximately £2200 (59% 
increase) for adjustable gastric banding and 
£3325 (54% increase) for gastric bypass]. The 
ICER for adjustable gastric banding increases 
to £3024 using assumptions for weight 
reduction adopted in the previous assessment 
report, and to £6159 based on the trial results 
reported by Angrisani and colleagues.107 The 
equivalent changes for gastric bypass are an 
increase to £4838, and to £6318. Doubling 
operative mortality has no effect on adjustable 
gastric banding (because operative mortality 
was assumed to be zero), but reduces the QALY 
gain for gastric bypass to 1.85 using weight 
loss assumptions from the previous report and 
1.39 using assumptions based on Angrisani 
and colleagues.107 Reducing estimated weight 
loss by 25% reduces the QALY for surgical 
management by around 0.5 QALYs (using 
weight loss assumptions from the previous 
report) resulting in an ICER of £4019 for 
adjustable gastric banding and £7135 for 
gastric bypass. The equivalent values using 
assumptions based on Angrisani and colleagues 
are £8091 for adjustable gastric banding and 
£9631 for gastric bypass.
Cost-effectiveness of bariatric surgery 
(adjustable gastric banding) for moderate 
to severe obesity (BMI ≥ 30 and < 40), 
with Type 2 diabetes – base-case analysis
Table 70 reports the total costs and total QALYs 
for the baseline cohort of moderately-to-severely 
obese patients (BMI ≥ 30 and < 40) undergoing 
adjustable gastric banding and non-surgical 
management – see section on Baseline cohort of 
patients, this chapter, with morbid obesity for the 
assumptions made for this cohort. All costs and 
outcomes are discounted at 3.5%.
The estimated cost of surgery is based on the 
assumptions outlined in Table 61, with regard 
to operating time, length of stay and costs of 
consumables. Costs associated with reoperations 
as the result of failure of the initial surgery or 
reoperation because of late complications were 
based on complication rates reported for the 
trial population (3.3% reoperations caused by 
initial failures and 6.7% reoperation for late 
complications).117 Costs for the conventional-
therapy programme were based on the trial report, 
which stated that patients met with a member of 
the team (general physician, dietitian, nurse or 
diabetes educator) every six weeks throughout the 
two years of the trial. It was assumed, as with the 
postdischarge routine for surgical patients, that 
non-surgical patients would have more frequent 
consultations with dietitians than with general 
medical support – hence it was assumed that the 
conventional therapy programme consisted of six 
additional consultations with a dietitian and three 
additional outpatient visits. The components of the 
programme that were related to patients’ diabetes 
care was assumed to be included in the health-state 
costs for diabetes. 
TABLE 69  Deterministic sensitivity analysis for cost-effectiveness of surgical management (gastric bypass or adjustable gastric banding) 
of morbid obesity (BMI ≥ 40) (continued)Assessment of cost-effectiveness
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TABLE 70  Total discounted and incremental costs, total discounted and incremental QALYs and ICERs for surgical (adjustable gastric 
banding) and non-surgical management of moderate-to-severe obesity (BMI ≥ 30 and < 40), with Type 2 diabetes, adopting varying 
model time horizons
Model time horizon
2 years 5 years 20 years
Non-
surgical Surgical Difference
Non-
surgical Surgical Difference
Non-
surgical Surgical Difference
Cost (£) 4842  9874  5032  10,628  13,425  2796  31,683  33,182  1500 
QALYs 1.47 1.74 0.27 3.48 4.09 0.61 10.39 11.49 1.10
ICER (£) 18,930  4580  1367 
ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life-years.
Table 70 reports results for three time horizons:
•	 two years, which corresponds to the duration of 
the clinical trial report117
•	 five years, where outcomes reported in the 
clinical trial have been extrapolated beyond 
two years, based on data on trends in weight 
reduction over time reported for the gastric 
banding cohort in the SOS study97 and on 
reported durability of diabetes remission 
reported for all surgically managed patients in 
the SOS study (discussed in the Effectiveness – 
diabetes resolution section, this chapter)
•	 twenty years, where outcomes reported in 
the clinical trial have been extrapolated up 
to 10 years following surgery using trends 
reported for the SOS study,97 as discussed 
above. At 10 years following surgery it is 
assumed that weight, blood pressure and lipid 
measurements return to their baseline levels. It 
is also assumed that all patients who previously 
resolved Type 2 diabetes, either following 
surgery or through conventional treatment, 
and remained in the postdiabetic state up to 
10 years would then relapse and return to the 
diabetic health state.
Surgical management of moderate-to-severe 
obesity (BMI ≥ 30 and < 40) in patients with Type 
2 diabetes is estimated to be more costly, but also 
results in improved outcomes (in terms of QALYs) 
over each of the modelled time horizons. Costs for 
the surgical cohort are approximately double the 
costs for the non-surgical cohort, when adopting 
a two-year time horizon. However, as the time 
horizon increases, the proportionate difference and 
the absolute difference in costs between the surgical 
and non-surgical cohorts decreases. This is largely 
because of the dominant effect of diabetes-related 
costs for the non-surgical cohort, where only 13% 
of the cohort achieve remission of Type 2 diabetes 
in contrast with 73% of the surgically-treated 
cohort, and where 83% of total costs are associated 
with the diabetes health state cost. As a result of 
this, total costs for the non-surgical cohort increase 
by over 100% moving from the two-year to the five-
year time horizon, whereas the increase is around 
36% for the surgical cohort. The proportionate 
increase, when moving from the five-year to the 20-
year time horizon, is more similar between the two 
cohorts, because differences in diabetes resolution 
and weight loss are only extrapolated up to 10 years 
in the model – at that point patients in both cohorts 
are assumed to revert to baseline values.
The total discounted QALYs with surgical 
management are greater than with non-surgical 
management for each of the time horizons 
modelled, with the incremental gain increasing 
with increasing time horizon. The proportionate 
increase, for surgical over non-surgical 
management, is approximately the same for a two-
year and five-year time horizon (18.4% at two years 
and 17.5% at five years), but drops slightly for the 
20-year time horizon (10.6%). As with the costs, this 
reflects the fact that trial outcomes are extrapolated 
up to 10 years, with both cohorts reverting to 
baseline values at that point.
Cost-effectiveness of bariatric 
surgery (adjustable gastric banding) 
for moderate to severe obesity 
(BMI ≥ 30 and < 40), with Type 2 
diabetes – deterministic sensitivity analysis
A series of one-way sensitivity analyses were 
conducted for each time horizon. These are 
reported in Table 71. In all cases the least 
favourable ICERs are associated with the short 
model time horizon, ranging from around £19,000 
per QALY gained up to £35,000 per QALY gained. 
More favourable ICERs are found for the five-year 
and 20-year time horizons, ranging from around DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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£1300 per QALY gained up to £10,000 per QALY 
gained. In all scenarios, for longer time horizons, 
the ICERs remain within the range conventionally 
deemed as cost-effective from an NHS decision-
making perspective.
In general the sensitivity analyses are similar to 
those described in the previous section. However, 
some entries in Table 71 may require further 
explanation. The first entry in the table, labelled 
‘Gradual decline in weight’, tests the influence 
of the assumption that the weight reduction 
reported at two years following surgery occurs 
immediately following surgery. This assumption 
may not be realistic, given the data reported in 
Table 52 for percentage weight reduction following 
gastric banding over time (in trials of patients 
with morbid obesity) or the data reported in Table 
55 (percentage weight reduction following gastric 
banding over time in patients with moderate 
obesity) which show a gradual decline over the 
first year following surgery. To estimate this 
gradual decline, the proportion of total weight 
loss at six-month intervals (up to two years) was 
estimated from the trial reported by O’Brien and 
colleagues.115 These proportions were then applied 
to the total weight loss observed at two years in the 
trial reported by Dixon and colleagues,117 where 
patients with moderate obesity lost 21.6% of their 
baseline weight by two years. The proportion of 
total weight loss at six-month periods reported by 
O’Brien and colleagues115 was 65% at six months, 
91% at 12 months, 97% at 18 months and 100% 
at 24 months. The two different assumptions on 
percentage of weight lost are illustrated in Figure 4.
Other scenarios considered in the sensitivity 
analysis include:
•	 reducing the change in utility associated with a 
unit change in BMI (from 0.0166 to 0.0075)
•	 including a low operative mortality for surgery 
(0.05% rather than zero in the base case)
•	 allowing band adjustments in the second and/
or third year rather than four only in year one
•	 considering the impact of surgeon 
inexperience – on duration of surgery, on 
revision rates and on outcome (in terms of 
weight reduction).
In general the results are robust to changes 
in assumptions. However, changes in some 
key assumptions produce less favourable cost-
effectiveness estimates than the base case adopted 
for this analysis.
•	 Assuming a gradual decline in weight, rather 
than applying the reduction observed at two 
years immediately following surgery, has a large 
impact on the ICER at two years (by reducing 
the QALY gain with surgery by around 20%). 
However, the effect of this changed assumption 
is greatly reduced when longer time horizons 
are considered;
•	 Applying a lower utility gain for reduction 
in BMI has a large impact on the QALY gain 
associated with surgery, reducing from 0.27 
to 0.14 at two years (applying a utility gain 
per unit BMI reduction of 0.0075, the value 
adopted in the previous review). This effect is 
maintained over the varying time horizons of 
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the model, with the QALY gain being reduced 
by between 45% and 48%. The effect of this 
is to raise the ICER at two years to £35,000 
per QALY gained, above a cost-effectiveness 
threshold considered acceptable from an NHS 
decision-making perspective.
•	 Repeating the scenario analysis described 
earlier for surgical experience leads to 
increased costs (because of increased duration 
in surgery and increases in the rate of 
revision) and poorer outcomes (i.e. reduced 
QALYs because of lower weight reduction). 
The effect of these altered assumptions is 
shown cumulatively, with the effects on costs 
considered first. Increasing duration of surgery 
and revision rates leads to an increase in 
incremental costs of approximately £1900, an 
increase of 37% at two years and 125% increase 
at 20 years. The ICER increases to £25,958 
at two years and £3070 at 20 years. Reducing 
estimated weight loss by 25% reduces the 
QALY for surgical management by around 0.06 
QALYs at two years and 0.23 QALYs at 20 years 
(approximately 22% and 21% reduction, 
respectively) resulting in an ICER of £33,273 at 
two years and £3866 at 20 years.
•	 Increasing operative costs by 20% increases 
incremental costs for surgery by approximately 
£950 increasing the ICER at two years to 
£22,484 (£2228 at 20 years). Increasing 
postoperative costs by 20% increases 
incremental costs by approximately £350, 
increasing the ICER to £20,235 at two years 
and £2379 at 20 years. Increasing all surgery-
related costs by 20% leads to an increase in 
incremental costs increasing by approximately 
£1500, increasing the ICER to £24,627 at two 
years and £3443 at 20 years.
•	 The impact of decreasing the diabetes health 
state cost by 50% on incremental costs is larger 
as the model time horizon increases. The 
proportionate increase in incremental cost 
at two years is 23%, whereas at 20 years it is 
224%. This arises from the dominant effect of 
diabetes costs in the non-surgical cohort, in 
conjunction with the assumption that surgically 
treated patients who resolve Type 2 diabetes 
will achieve a maximum remission of 10 years.
Cost-effectiveness of bariatric 
surgery (adjustable gastric banding) 
for moderate to severe obesity 
(BMI ≥ 30 and < 40), with Type 2 
diabetes – probabilistic sensitivity analysis
In a probabilistic sensitivity analysis, where 
percentage weight loss, reduction in systolic 
blood pressure and TC : HDL ratio, proportion of 
patients with remission of Type 2 diabetes (and rate 
of relapse up to 10 years), health-state utility and 
health-state costs were sampled probabilistically, 
all simulations produced incremental cost-
effectiveness estimates that were in the north-
east quadrant of the cost-effectiveness map when 
adopting a two-year time horizon (Figure 5). That 
is, all simulations are associated with increased 
QALYs, but also increased costs. However, when 
the time horizon was extended to 20 years, while all 
simulations showed increased QALYs a proportion 
have negative incremental costs (total discounted 
costs for the surgical cohort are lower than for the 
non-surgical cohort). Simulations where costs for 
the surgically treated cohort are lower than for the 
non-surgical cohort are most likely to be associated 
with high proportions of patients with remission of 
Type 2 diabetes.
In this analysis surgical management with 
adjustable gastric banding had a probability of 
being cost-effective (compared with non-surgical 
management) of 17.5% at a willingness-to-pay 
threshold of £20,000 per QALY and 83.8% at 
a willingness-to-pay threshold of £30,000 per 
QALY for a time horizon of two years when 
assuming weight loss observed at two years 
occurs immediately after surgery (Figure 6). If the 
simulations are rerun assuming a gradual reduction 
in weight following surgery the probability of being 
cost-effective, with a two-year time horizon falls to 
2.5% at a willingness-to-pay threshold of £20,000 
per QALY and 50.6% at a willingness-to-pay 
threshold of £30,000 per QALY. In contrast, for a 
20-year time horizon, the probability of surgical 
management being cost-effective is 100% at both 
willingness-to-pay thresholds, irrespective of 
assumptions regarding the pattern of early weight 
loss (see Figure 6).
Cost-effectiveness of bariatric 
surgery (adjustable gastric banding) 
for moderate obesity (BMI ≥ 30 
and < 35) – base-case analysis
Table 72 reports the total costs and total QALYs 
for the baseline cohort of moderately obese (BMI 
≥ 30 and < 35) patients undergoing adjustable 
gastric banding and non-surgical management – see 
section Baseline cohort of patients with morbid 
obesity, this chapter, for assumptions on this 
cohort. All costs and outcomes are discounted 
at 3.5%. The estimated cost of surgery is based 
on assumptions outlined in Table 61, with regard 
to operating time, length of stay and costs of 
consumables. Costs associated with reoperations Assessment of cost-effectiveness
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FIGURE 6  Cost-effectiveness acceptability curves for adjustable gastric banding in patients with moderate to severe obesity (BMI ≥ 30 
and < 40), with Type 2 diabetes.
because of failure of the initial surgery or 
reoperation as the result of late complications 
were based on complication rates reported for the 
trial population [0 reoperations for initial failures 
and 10% (4/39, three in year 1 and one in year 2) 
reoperation rate because of late complications in 
the first and second year following surgery].115 In 
addition, one patient had an elective laparoscopic 
cholecystectomy in the second year following initial 
surgery.
Costs for the intensive medical programme 
were based on the trial report,115 which stated 
that patients were seen in outpatient setting by 
a physician every two weeks for the intensive 
phase (first six months) of the programme and 
every six weeks for the remainder of the two-
year intervention period. During the intensive 
phase patients initiated a VLCD for the first 
12 weeks, combined VLCD with initiation of 
pharmacotherapy with orlistat over the next four 
weeks, before transitioning to pharmacotherapy 
only (see Table 64 for costing assumptions). It was 
reported that eight patients could not tolerate 
orlistat and three others chose not to use it – the 
costs of pharmacotherapy in the postintensive DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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management phase of the programme have 
been adjusted to take account of this. The 
principal cost relating to adverse events in the 
non-surgical cohort relate to surgical procedures 
related to cholecystitis. The trial report stated 
that four non-surgical patients developed acute 
cholecystitis and underwent elective laparoscopic 
cholecystectomy (three in year one, and one in 
year two, corresponding to surgical rates of 10% 
and 3.7% respectively). It was assumed that non-
surgical patients reverted to standard non-surgical 
management (see Table 63) after two years on the 
weight loss programme.
Table 72 reports results for three time horizons:
•	 two years, which corresponds to the duration of 
clinical trial report115
•	 five years, where outcomes reported in the 
clinical trial have been extrapolated beyond 
two years, based on data on the trend in 
weight reduction observed in the non-surgical 
cohort, where BMI was tending to revert to the 
baseline value (see Figure 3)
•	 20 years, where outcomes reported in the 
clinical trial have been extrapolated using 
methods discussed above. By the 20-year 
time horizon all patients are assumed to have 
reverted to baseline weight and those patients 
who achieved remission of Type 2 diabetes will 
have relapsed.
Surgical management of moderately obese patients 
with adjustable gastric banding is estimated to be 
more costly, but also results in improved outcomes 
(in terms of QALYs) over each of the modelled 
time horizons. Adopting a two-year time horizon 
costs for the surgical cohort are more than double 
the costs for the non-surgical cohort. However, as 
the time horizon increases, the absolute difference 
in costs between the surgical and non-surgical 
cohorts remains more or less constant, and the 
proportionate difference reduces. Costs for the 
two cohorts increase, as the result of the need to 
maintain follow-up of both surgically and non-
surgically treated patients and also because of the 
increasing proportion of each cohort with Type 2 
diabetes. This was assumed to be approximately 
5%, based on BMI-specific prevalence of Type 
2 diabetes reported in the Health Survey for 
England 2003,17 where diabetes prevalence in the 
population with a BMI between 30 and 35 was 
7.21% for males and 4.71% for females. By the end 
of the 20-year time horizon prevalence of Type 2 
diabetes was estimated at 15.4% in the non-surgical 
cohort and 13.8% in the surgical cohort.
The total discounted QALYs with surgical 
management are greater than with non-surgical 
management for each of the time horizons 
modelled, with the incremental gain increasing 
with increasing time horizon. For the longest time 
horizon (20 years) the majority of the QALY gains 
for the surgical cohort are realised in the first 
10 years – these are the utility gains from reduced 
weight. In the base-case weight in the surgical 
cohort is assumed to revert to baseline level at 
around eight years following surgery – utility gains 
following this are the result of the lower proportion 
of patients with Type 2 diabetes and a lower 
proportion with CVD.
Cost-effectiveness of bariatric 
surgery (adjustable gastric banding) 
for moderate obesity (BMI ≥ 30 and 
< 35) – deterministic sensitivity analysis
A series of one-way sensitivity analyses were 
conducted for each time horizon. These are 
reported in Table 73. Scenarios considered in the 
sensitivity analysis include:
TABLE 72  Total discounted and incremental costs, total discounted and incremental QALYs and ICERs for bariatric surgery (adjustable 
gastric banding) and non-surgical management of moderate obesity(BMI ≥ 30 and < 35), adopting varying model time horizons
Model time horizon
2 years 5 years 20 years
Non-
surgical Surgical Difference
Non-
surgical Surgical Difference
Non-
surgical Surgical Difference
Cost (£) 3484  8403  4919  4503  9393  4890  9311  14,398  5087
QALY 1.62 1.70 0.08 3.74 4.03 0.30 11.12 11.52 0.40
ICER (£) 60,754  16,381  12,763
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.Assessment of cost-effectiveness
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•	 reducing the change in utility associated with a 
unit change in BMI (from 0.0166 to 0.0075)
•	 including a low operative mortality for surgery 
(rather than zero, as applied in the base case)
•	 allowing band adjustments in the second and/
or third year rather than four only in year one
•	 considering the impact of surgeon 
inexperience – on duration of surgery, on 
revision rates and on outcome (in terms of 
weight reduction)
•	 increasing elements of surgical cost by 20%
•	 varying costs of health-service contacts for 
patients on the intensive programme
•	 considering the impact on reducing health-
state costs for diabetes.
In all cases the least favourable ICERs are 
associated with a short model time horizon, 
ranging from around £45,000 per QALY gained 
up to £190,000 per QALY gained. More favourable 
ICERs are found for the five-year and 20-year time 
horizons, ranging from around £16,000 per QALY 
gained up to £40,000 per QALY gained for five-
year time horizon and from around £12,500 per 
QALY gained up to £33,000 per QALY gained for 
the 20-year time horizon. In some scenarios, even 
for longer time horizons, the ICERs are above the 
range conventionally deemed as cost-effective from 
an NHS decision-making perspective.
In general the results are robust to changes 
in assumptions. However, changes in some 
key assumptions produce less favourable cost-
effectiveness estimates than the base case adopted 
for this analysis.
•	 Applying a lower utility gain for reduction 
in BMI has a large impact on the QALY gain 
associated with surgery, reducing from 0.08 
to 0.04 at two years (applying a utility gain 
per unit BMI reduction of 0.0075, the value 
adopted in the previous review). This effect is 
maintained over the varying time horizons of 
the model, with the QALY gain being reduced 
by between 49% and 54%. The effect of this 
is to raise the ICER substantially so that it 
remains above conventionally acceptable cost-
effectiveness thresholds until the time horizon 
extends to 20 years.
•	 Repeating the scenario analysis, described 
earlier, for surgical experience leads to 
increased costs (because of increased duration 
in surgery and increases in the rate of revision) 
and poorer outcomes (i.e. reduced QALYs 
as the result of lower weight reduction). 
The effect of these altered assumptions is 
shown cumulatively, with the effects on costs 
considered first. Increasing duration of surgery 
and revision rates leads to an increase in 
incremental costs of approximately £2000. 
The ICER increases to £86,370 at two years 
and £17,967 at 20 years. Reducing estimated 
weight loss by 25% reduces the QALY for 
surgical management by around 0.04 QALYs 
at two years and 0.18 QALYs at 20 years 
(approximately 54% and 44% reduction 
respectively) resulting in an ICER of £188,545 
at two years and £33,058 at 20 years.
•	 Increasing operative costs by 20% increases 
incremental costs for surgery by approximately 
£1000, increasing the ICER at two years to 
£72,745 (£15,199 at 20 years). Increasing 
postoperative costs by 20% increases 
incremental costs by approximately £350, 
increasing the ICER to £65,040 at two years 
and £15,569 at 20 years. Increasing all surgery-
related costs by 20% leads to an increase in 
incremental costs increasing by approximately 
£1500, increasing the ICER to £79,783 at two 
years and £18,563 at 20 years.
•	 Variation in the cost of health service 
contacts for patients on the intensive medical 
programme has a relatively large impact 
on incremental costs as these comprise a 
substantial proportion of the total costs of 
the intensive medical programme. Reducing 
costs of contacts by 50% increases incremental 
costs by approximately £1300 and increases 
the ICER at two years to £76,254 (£15,955 
at 20 years). Conversely, increasing costs of 
contacts by 50% reduces incremental costs by 
approximately £1300 and reduces the ICER at 
two years to £45,255 (£9571 at 20 years).
Cost-effectiveness of bariatric 
surgery (adjustable gastric banding) 
for moderate obesity (BMI ≥ 30 and 
< 35) – probabilistic sensitivity analysis
In a probabilistic sensitivity analysis, where 
percentage weight loss, reduction in systolic 
blood pressure and TC : HDL ratio, proportion 
of patients with remission of Type 2 diabetes, 
health-state utility, health-state costs and costs of 
health service contacts for non-surgical patients 
during the intensive medical programme were 
sampled probabilistically, all simulations produced 
incremental cost-effectiveness estimates that were 
in the north-east quadrant of the cost-effectiveness 
map (Figure 7, which also shows the 95% confidence 
ellipses for the ICER).Assessment of cost-effectiveness
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FIGURE 7  Cost-effectiveness plane – incremental costs and incremental QALYs for patients with moderate obesity (BMI ≥ 30 and 
< 35), undergoing adjustable gastric banding compared with an intensive medical programme. QALYs, quality-adjusted life-years.
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FIGURE 8  Cost-effectiveness acceptability curve for adjustable gastric banding in patients with moderate obesity (BMI ≥ 30 and < 35) 
using a 20-year time horizon. QALY, quality-adjusted life-year.
In this analysis, surgical management with 
adjustable gastric banding had a probability of 
being cost-effective (compared with the intensive 
medical programme) of 64% at a willingness-to-
pay threshold of £20,000 per QALY and 98% at a 
willingness-to-pay threshold of £30,000 per QALY 
for a time horizon of 20 years (Figure 8). In contrast 
the probability of surgical management being 
cost-effective was zero at both willingness-to-pay 
thresholds, when adopting a time horizon of two 
years (i.e. when using data from the clinical trial 
report115 with no extrapolation of outcomes).
Discussion of cost-effectiveness
Summary of key results
•	 We reviewed the economic model developed 
for the previous assessment report and 
identified a number of potential updates that 
could be applied in this report:
  – The conceptual model (including health 
states for non-diabetic, postdiabetic and 
diabetic patients as well as death) was 
extended to include CHD and stroke. 
Methods relevant to modelling the 
incidence of CHD and stroke in obese DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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and Type 2 diabetes populations were 
investigated.
  – Updated estimates of the utility impact 
of weight reduction were incorporated, 
including estimates of the impact of 
comorbidity.
  – BMI-specific diabetes incidence estimates 
were incorporated into the model as well as 
estimates of the impact of weight reduction 
on the development of cardiovascular 
comorbidities.
  – Expert opinion suggested that resource 
use assumptions adopted in the previous 
report, for costing bariatric surgery, did not 
reflect current practice in the UK. Updated 
resource use assumptions were developed, 
based on review of the literature, discussion 
with surgical specialists and a costing 
developed by a specialist service.
  – While the conceptual model was extended 
to include CHD and stroke, it was 
recognised that appropriate parameter 
inputs to include these comorbidities 
may not be available for all modelled 
populations. In this situation an updated 
version of the model used in the previous 
assessment report (updated for cost and 
utility estimates) would be adopted.
•	 The analysis was developed for three patient 
populations covered by studies included in the 
clinical effectiveness review:
  – patients with morbid (Class III, BMI ≥ 40) 
obesity – as in the previous review;
  – patients with moderate to severe (Class I 
to Class II, BMI > 30 and < 40) obesity 
with significant comorbidity at baseline 
(Type 2 diabetes) undergoing laparoscopic 
adjustable gastric banding or receiving 
conventional therapy, based on data from a 
single trial117
  – patients with moderate (Class I, BMI ≥ 30 
and < 35) obesity undergoing laparoscopic 
adjustable gastric banding or an intensive 
medical programme, based on data from a 
single trial.115
•	 Included trials for patients with morbid obesity 
did not report measures of cardiovascular 
risks that were suitable for our new model. 
Hence the model developed for the previous 
assessment report was used for this population. 
The economic model adopted ‘optimistic’ 
estimates (based on the previous assessment 
report) and an alternative ‘pessimistic’ 
estimate (based on a recently published trial107 
comparing gastric bypass and gastric banding), 
as the clinical effectiveness review concluded 
that meta-analysis was not appropriate. Weight 
loss outcomes were extrapolated to 10 years 
following surgery based on long-term outcomes 
reported for the SOS study.97 In the absence of 
a robust, pooled estimate of treatment effect 
(with associated estimate of variability) we felt 
it was inappropriate to undertake probabilistic 
sensitivity analysis for the model applied to 
patients with morbid obesity.
•	 The clinical trials reporting the use of 
adjustable gastric banding for moderate-to-
severely obese (BMI ≥ 30 and < 40) patients 
with Type 2 diabetes and for moderately 
obese (BMI ≥ 30 and < 35) patients reported 
sufficient information, up to two years of 
follow-up, to apply the new model. The time 
horizon for these analyses was initially for the 
period of the trial follow-up only. However, 
extrapolations based on data from the SOS 
study (where relevant) or on the basis of data 
reported in the trial were undertaken.
Cost-effectiveness of bariatric surgery 
(gastric bypass or adjustable gastric 
banding) for morbid obesity (BMI ≥ 40)
•	 Surgical management of morbid obesity with 
gastric bypass or adjustable gastric banding is 
estimated to be more costly than non-surgical 
management, but results in improved outcomes 
(in terms of QALYs) over the modelled 20-year 
time horizon. Using the optimistic assumption 
on weight reduction up to five years following 
surgery the QALY gain for adjustable gastric 
banding is 1.88, while using the pessimistic 
assumption the QALY gain is 0.92. The 
equivalent values for gastric bypass are 1.98 
and 1.52 QALYs. These QALY gains are larger 
than those estimated in the previous report, 
because of extrapolation of effects over 10 years 
(rather than the assumption of immediate 
reversion to baseline weight at five years) 
and updated assumptions on the utility gain 
associated with a unit reduction in BMI. The 
ICERs range between £1897 and £4127 per 
QALY gained.
•	 The results were generally robust to changes 
in assumptions in the deterministic sensitivity 
analysis, and in all cases the ICERs remained 
within the range conventionally regarded as 
cost-effective from an NHS decision-making 
perspective. Some key assumptions produced 
less favourable cost-effectiveness estimates – in 
particular reducing the utility gain associated 
with a weight loss to the value used in the 
previous review, and adopting alternative, 
less favourable assumptions (longer duration Assessment of cost-effectiveness
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of surgery, higher revision rates and lower 
weight loss) that might be associated with less 
experienced surgical operators.
Cost-effectiveness of bariatric surgery 
(adjustable gastric banding) for moderate 
to severe obesity (BMI ≥ 30 and < 40) 
in patients with Type 2 diabetes
•	 Results were reported for three time horizons: 
two years (corresponding to the duration of 
the clinical trial report), five years and 20 years 
[by which time it was assumed all patients 
had reverted to baseline weight, systolic 
blood pressure and TC : HDL ratio, and that 
all patients who resolved Type 2 diabetes 
(following surgery or through conventional 
treatment) had relapsed]. For each time 
horizon, surgical management of moderate to 
severe obesity in patients with Type 2 diabetes 
is estimated to be more costly than non-
surgical management, but results in improved 
outcomes. The QALY gain of 0.27 at two years, 
increases to 1.10 for the 20-year time horizon. 
Incremental costs reduced from £5032 at two 
years to £1500 for the 20-year time horizon. 
The reduction in incremental cost arises from 
the difference in Type 2 diabetes resolution 
between the two modelled cohorts, with 73% 
of surgically treated patients resolving Type 2 
diabetes at two years of follow-up (relative risk, 
compared with non-surgical patients, of 5.5, 
95% CI 2.2 to 14.0).117 The ICER reduced with 
longer time horizon from £18,930 at two years 
to £1367 at 20 years.
•	 The results were generally robust to changes 
in assumptions in the deterministic sensitivity 
analysis. However, some key assumptions 
produced less favourable cost-effectiveness 
estimates – in particular reducing the diabetes 
health-state cost, assuming a gradual (rather 
than immediate) reduction in weight following 
surgery, reducing the utility gain associated 
with weight loss to the value used in the 
previous review, and adopting alternative, 
less favourable assumptions (longer duration 
of surgery, higher revision rates and lower 
weight loss) that might be associated with less-
experienced surgeons. The impact of these 
changed assumptions was particularly marked 
for the two-year time horizon.
•	 In the probabilistic sensitivity analysis all 
simulations were associated not only with 
increased QALYs, but also increased costs, 
when adopting a two-year time horizon. 
However, when the time horizon was extended 
to 20-years, while all simulations showed 
increased QALYs a proportion had negative 
incremental costs (total discounted costs for the 
surgical cohort were lower than for the non-
surgical cohort). These occurred in simulations 
where surgical treatment was associated with 
high proportions of patients with remission of 
Type 2 diabetes. With a two-year time horizon 
the probability of surgical management being 
cost-effective (compared with non-surgical 
management) was 2.5% at a willingness-to-pay 
threshold of £20,000 per QALY and 50.6% at 
a willingness-to-pay threshold of £30,000 per 
QALY, assuming a gradual reduction in weight 
following surgery. In contrast the probability of 
surgical management being cost-effective was 
100% at both willingness-to-pay thresholds, for 
a 20-year time horizon.
Cost-effectiveness of bariatric surgery 
(adjustable gastric banding) for 
moderate (BMI ≥ 30 and < 35) obesity
•	 Results were reported for three time horizons: 
two years (corresponding to the duration of 
the clinical trial report), five years and 20 years. 
For each time horizon, surgical management of 
moderate obesity is estimated to be more costly 
than non-surgical management, but results in 
improved outcomes. The QALY gain of 0.08 at 
two years, increases to 0.40 for the 20-year time 
horizon. Incremental costs are approximately 
£5000 for each time horizon. The ICER 
reduced with longer time horizon – from 
£60,754 at two years to £12,763 at 20 years.
•	 In the deterministic sensitivity analysis the least 
favourable ICERs were associated with short 
model time horizon, ranging from around 
£60,000 per QALY gained up to £190,000 per 
QALY gained. More favourable ICERs were 
found for the five and 20-year time horizons, 
ranging from around £16,000 per QALY 
gained up to £40,000 per QALY gained for 
the five-year time horizon and from around 
£12,500 per QALY gained up to £33,000 per 
QALY gained for the 20-year time horizon. In 
some scenarios, even for longer time horizons, 
the ICERs are above the range conventionally 
deemed as cost-effective from an NHS 
decision-making perspective – in particular 
reducing the utility gain associated with a 
weight loss to the value used in the previous 
review, and adopting assumptions that might 
be associated with less experienced surgeons 
were associated with high ICERs for all time 
horizons.
•	 In the probabilistic sensitivity analysis all 
simulations were associated with increased DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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QALYs but also increased costs, for all time 
horizons. With a 20-year time horizon the 
probability of surgical management being cost-
effective (compared with an intensive medical 
programme) was 64% at a willingness-to-pay 
threshold of £20,000 per QALY and 98% at 
a willingness-to-pay threshold of £30,000 per 
QALY. In contrast, the probability of surgical 
management being cost-effective was zero at 
both willingness-to-pay thresholds, for a two-
year time horizon.
Generalisability
•	 In general, the clinical trials used to model the 
effectiveness of bariatric surgery for morbidly 
obese (BMI ≥ 40) patients reflect the key 
characteristics of the population discussed in 
Chapter 1, Description of Health problem, 
with the majority of patients recruited to the 
trials being female. These trials also generally 
recruit patients meeting the eligibility specified 
by current NICE guidance, with inclusion 
criteria specifying a BMI > 40, or a BMI > 
35 for patients with significant comorbidity. 
An exception to this, is the trial reported by 
O’Brien and colleagues,115 which recruited 
patients with moderate obesity (BMI ≥ 30 
and < 35), below the threshold for weight 
loss surgery adopted in current clinical 
guidelines.9,146 The majority of patients 
recruited to the trial also seemed to be free of 
major comorbidities associated with obesity. 
In addition, in those trials recruiting patients 
meeting current clinical criteria for weight loss 
surgery (in terms of BMI) it is not always clear 
from the trial reports, what previous weight 
loss regimes the patients have undergone and 
whether they failed to achieve and maintain 
weight loss with non-surgical management (as 
specified in the NIH146 and NICE guidance9).
•	 Some of the included trials specified inclusion 
criteria in relation to patient age – for example 
Angrisani and colleagues107 recruited patients 
between the ages of 16 and 50 years, van 
Dielen and colleagues127 recruited patients 
between 18 and 60 years, Lee and colleagues124 
recruited patients between 18 and 59 years, 
while Howard and colleagues120 recruited 
patients below 50 years of age. The lower age 
criteria relate to distinctions between adult 
and adolescent/paediatric services. However, 
it is more likely that the upper age limits 
reflect issues in the design of the clinical 
trials (for example, to recruit patients whose 
comorbidities are more likely to be obesity-
related rather than age-related) rather than the 
expected patient group for bariatric surgery.
•	 The patient population in the trial reported 
by Angrisani and colleagues107 was 83% female 
with a BMI between 35 and 50, without 
specifying the presence of comorbidities and 
therefore had inclusion criteria wider than 
the current NICE guidance, whereas in the 
trial reported by Nilsell and colleagues126 the 
inclusion criteria specified a BMI of greater 
than 40, or greater than 37 with an obesity-
related comorbidity. Inclusion criteria for the 
trial reported by Dixon and colleagues117 were 
also wider than the current NICE guidance 
with moderate to severely obese patients with 
Type 2 diabetes – patients were included if their 
BMI was greater than 30 but less than 40.
•	 Clinical trials providing data used in the 
economic model were conducted in a variety 
of countries (Italy, Sweden and Australia). It is 
not clear how differences in clinical practice 
between countries are likely to influence the 
outcomes of procedures, nor the extent to 
which the results obtained in specialist centres 
conducting clinical trials can be generalised 
to other settings. Some of the included 
clinical trials (for example, Angrisani and 
colleagues107) refer directly to the impact of 
surgeon experience and the learning curve on 
patient outcomes – particularly with respect to 
the frequency of operative complications. To 
some extent this uncertainty is addressed in 
the analysis by considering a scenario where 
less-experienced surgeons are characterised by 
longer operative duration, higher operative 
mortality rates, higher rates of non-fatal 
complications and poorer outcomes (in terms 
of average weight loss).
•	 Expert opinion suggested that resource use 
estimates (in terms of duration of surgery and 
length of stay) extracted from included clinical 
trials were likely to overestimate resource use 
in the UK setting. Updated estimates were 
developed based on expert clinical opinion. 
However, these have not been validated 
against any external standard. Discussion 
with clinical experts suggested that there was 
likely to be considerable variation in surgical 
practice (for example, some centres may 
undertake prophylactic cholecystectomy on all 
patients, while others would not perform any 
cholecystectomies on bariatric surgery patients 
at the time of the initial operation) and in 
the involvement of clinical psychology (for 
example, some services may limit involvement 
to patients with documented psychological Assessment of cost-effectiveness
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illness). The costings in the report are based, 
as far as possible, on implementation of NICE 
guidance and therefore assume that all patients 
have a psychological evaluation and continuing 
psychological support following surgery.
•	 As far as possible the economic analyses 
have used routinely available unit cost 
estimates – NHS Reference Costs185 and Unit costs 
of health and social care.177 As no appropriate 
reference cost exists for bariatric surgery we 
developed a resource use protocol, which was 
refined by clinical experts (as discussed above) 
and costed in consultation with the costing unit 
at Southampton University Hospitals NHS 
Trust. Similarly, as no cost estimates existed 
for non-surgical management, protocols were 
developed – based on the previous assessment 
report, for morbidly obese patients, and on 
details in the clinical trial reports115,117 – and 
costed using appropriate UK unit costs. Details 
of the costing protocols are presented in the 
Data sources, Cost data section in this chapter. 
The accuracy and comprehensiveness of 
costing for non-surgical management in the 
trials reported by Dixon and colleagues117 and 
O’Brien and colleagues115 is dependent on the 
reporting of the interventions in the clinical 
trial reports.
Strengths and limitations
  – The model adopted for the economic 
evaluation in this review is based upon a 
previously published model, developed 
for assessing the cost-effectiveness of 
bariatric surgery in a UK setting. The 
model has been extended, where possible, 
to include cardiovascular comorbidity, and 
has been updated with respect to duration 
of weight loss following bariatric surgery, 
the estimated utility gain associated 
with reduction in BMI, remission (and 
durability of remission) of Type 2 diabetes, 
resource use and health-care costs.
  – Clinical evidence, in terms of weight 
reduction, revision rates and operative 
complications, were extracted from the 
RCTs included, and critically appraised 
in the clinical effectiveness review. Where 
necessary, these sources were supplemented 
with data from long-term cohort studies 
within the scope of the review. These were 
also critically appraised in the clinical 
effectiveness review. The main effectiveness 
parameter in the model, weight reduction, 
is an accepted primary aim of bariatric 
surgery, although not all included trials 
were powered on a measure of weight 
loss (where sample size calculations were 
reported). For example, the trial reported 
by Dixon and colleagues117 was powered 
to detect a 1% difference in HbA1c and 
also powered for diabetes remission rates 
(expected values 60% in the surgical group 
and 20% in conventional therapy).
  – The majority of the data included in the 
model are in the public domain. Where 
updated assumptions have been developed 
in the course of this review (for example, 
resource use assumptions) these have been 
clearly documented and are presented 
in the body of this report. The model 
structure, assumptions and data inputs 
are clearly presented in this report. This 
should facilitate replication and testing of 
model assumptions and analyses.
  – Patient utility was related to the main 
effectiveness parameter in the model 
using a published estimate of the change 
in utility associated with a unit change 
in BMI. The utility model was based on 
health-state preferences expressed by 
subjects in an RCT of pharmacotherapy 
and dietary modification for the treatment 
of obesity. Subjects covered a wide range 
of BMI, including 76 (of 621) categorised 
as morbidly (Class III) obese. Health-state 
preferences were assessed using a visual 
analogue scale (VAS; anchored at 0 for 
death and 100 for perfect health) to rank 
participants’ current health states. VAS 
scores were transformed to their equivalent 
time trade-off values using a published 
conversion method.189 These time trade-
off values were included in a multiple 
regression model to derive an estimate of 
the change in utility associated with a unit 
change in BMI, controlling for baseline 
utility age and sex. A review of health-
state preference values, related to changes 
in BMI, concluded that these were the 
most methodologically sound published 
estimates to include in the model. The 
robustness of the results to assumptions 
regarding utility were addressed in a 
sensitivity analysis.
  – Published economic evaluations of bariatric 
surgery for morbid obesity were reviewed 
to develop estimates of resource use 
associated with bariatric surgery. Duration 
of surgery, length of stay, ITU and/or HDU 
admissions were extracted from identified 
reports and compared with assumptions DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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developed for the previous report. 
Updated assumptions were discussed 
with clinical experts who felt that these 
overestimated the duration of surgery and 
length of stay in comparison with current 
UK practice. New resource use estimates 
were developed, based on expert opinion, 
and were costed in consultation with the 
costing unit at Southampton University 
Hospitals Trust.
  – A review of previous economic evaluations 
of surgery for morbid obesity identified 
factors that were likely to be particularly 
influential on cost and outcome estimates. 
The impact of these factors was tested in 
deterministic sensitivity analyses.
  – A weakness in the economic model is that 
we were not able to conduct a robust meta-
analysis on  outcomes. For the morbidly 
obese population the clinical effectiveness 
review concluded that meta-analysis was 
inappropriate because, for comparison 
of certain surgical procedures there was 
only one study, and where there was more 
than one RCT there was heterogeneity in 
patient groups, comparator treatments 
and in outcomes reported. An additional 
practical limitation was the fact that 
standard deviations (or data to calculate 
them) were not reported in the majority 
of studies. For moderate-to-severely 
obese (BMI ≥ 30 and < 40) patients with 
Type 2 diabetes and moderately obese 
(BMI ≥ 30 and < 35) patients there was 
only one included trial each, comparing 
adjustable gastric banding with non-
surgical management. These trials had 
limited follow-up periods – two years each, 
with some loss to follow-up [12.5% (5/40) 
of patients in the non-surgical group 
were reported as lost to follow-up at two 
years in the trial reported by O’Brien and 
colleagues115]. For the morbidly obese 
(BMI > 40) population the analysis is 
primarily based on three trials (for surgery 
outcomes, in terms of weight loss, the 
‘optimistic’ assumption uses data from 
one trial for adjustable gastric banding126 
and another for gastric bypass,120 while 
the pessimistic assumption uses both arms 
of the trial reported by Angrisani and 
colleagues107), whereas the effectiveness 
of non-surgical management is modelled 
through assumption based on the control 
cohort reported in the SOS study.97 In 
all cases the comprehensiveness of the 
analysis (for effects such as reoperation or 
complications) is dependent on quality and 
completeness of reporting. A similar caveat 
applies to the resource assumptions and 
costings based on clinical trial reports. 
  – The cost-effectiveness model applies utility 
values for reduction in BMI associated with 
surgical or non-surgical management of 
obesity, but takes no account of any utility 
impact of side effects or complications 
of interventions. The cost impact of 
complications resulting in admission to 
ITU or reoperation are estimated based 
on proportions reported in included 
trials – although, as noted in the clinical 
effectiveness review, reporting of adverse 
events and complications is variable 
between studies. Similarly, in the analysis 
of surgery versus non-surgical management 
of moderate obesity (BMI ≥ 30 and 
< 35), the impact of approximately 
30% of non-surgical patients being 
intolerant to VLCD or orlistat (reported 
by O’Brien and colleagues115) is included 
in cost calculations, but there is no 
assessment of the impact of side effects 
on utility. Reporting of long-term adverse 
effects – such as frequent vomiting or 
flatulence – following surgery is variable 
and of limited duration in included trials 
(up to three years postsurgery). However, 
where reported, the proportion of patients 
reporting such effects are non-trivial 
(28.5% frequent vomiting,129 13–25% 
emesis and 13–22% flatulence118). The 
likely duration of the side effects is not 
clear nor is it apparent how far the impact 
of these effects may offset any utility gains 
from reduction in BMI alone.
  – A potentially serious weakness in published 
utility models is an assumption of linear 
additivity, with respect to BMI or change 
in BMI – the effect of reduction in BMI 
(or absolute value of BMI in the model 
applied in the previous review) is assumed 
to be constant over the range of BMI 
values. Hakim and colleagues152 reported 
investigating more complex functional 
forms, but opted for a simple model on 
the grounds of parsimony and that the 
more complex specifications failed to add 
significant explanatory power (assessed 
using the adjusted R2). However, the 
simple linear model cannot exclude the 
possibility of estimating utility values 
outside the logical range (in particular Assessment of cost-effectiveness
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estimating values greater than one, where 
a large change in BMI is observed). An 
additional, implicit, assumption is that 
the utility change is independent of initial 
BMI or that it is independent of proximity 
to an ‘ideal’ or target BMI. Hakim and 
colleagues152 conducted a subgroup 
analysis re-estimating the regression on 
patients with a BMI greater than or equal 
to 30, but did not report any analysis of 
potential interactions between utility gain 
from reduction in BMI and baseline BMI, 
proximity to the non-obese range (i.e. 
to BMI below 30) or to a target or ‘ideal’ 
value (such as BMI of 25).
  – There is uncertainty over resource 
use and costs associated with surgical 
management. Costs associated with the 
surgical admission, used in the economic 
model, are based on resource use protocols 
developed using expert opinion. Published 
resource use protocols were regarded as 
overestimates, in terms of duration of 
surgery and length of stay, and as poor 
predictors of cost in the UK. However, 
it has not been possible to validate the 
updated cost assumptions against external 
standards, reflecting current UK practice. 
Similarly, assumptions over preoperative 
assessments and postsurgical follow-up 
have been based on protocols, informed 
by expert opinion. Costs for non-surgical 
comparators were based on brief resource 
use protocols included in clinical trial 
reports – as such, they are dependent on 
the comprehensiveness of coverage in the 
clinical trial reports.
  – A major source of uncertainty in the 
economic model relates to the absence 
of reliable, long-term data on the 
effectiveness (in terms of sustained 
weight loss) and the need for operative 
revision and conversion to alternative 
weight-loss methods. Data on long-term 
outcomes from the SOS study were used 
to extrapolate from clinical trial outcomes 
to longer term outcomes for patients with 
morbid obesity (BMI > 40) and also for 
patients with moderate-to-severe obesity 
(BMI ≥ 30 and < 40) and Type 2 diabetes. 
However, the validity of applying these 
data may be questioned – for example, 
in the clinical trial reported by Dixon 
and colleagues117 surgical patients were 
treated with adjustable gastric bands, 
while an unknown proportion of patients 
in the SOS study were treated with non-
adjustable bands. It is not clear how 
changes in surgical techniques (or indeed 
in non-surgical management of obese 
patients) occurring over the duration of 
long-term cohort studies may affect the 
outcomes observed. On the other hand, 
it is unlikely that clinical trials – powered 
to detect differences in outcomes within 
two years – will be able to provide robust 
data on longer-term outcomes, even 
assuming complete follow-up. Surgical 
experts providing advice during this review 
have been particularly concerned about 
the absence of data on the proportion of 
patients who initially undergo adjustable 
gastric banding, but who will require 
reoperation and ultimately undergo 
conversion to gastric bypass in the 
longer term – estimated at approximately 
30%. This has not been included in the 
economic evaluation because, while 
it would be relatively straightforward 
to include a range of possible costs 
for reoperation and conversion in the 
economic model, there are no data to 
model the effect on outcome of patients 
who undergo late conversion to gastric 
bypass following initial adjustable gastric 
banding.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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T
he prevalence of obesity is rising and the NICE 
commissioning guide for the bariatric surgical 
service68 has suggested that the average number 
of people receiving bariatric surgery (in line with 
NICE guidance) for a standard PCT population of 
250,000 should be 25 per year in five years time, 
which equates to more than a threefold increase 
compared with estimated levels in 2006. Expert 
opinion has suggested that this may be too low. 
Such increases may necessitate a step change in 
service provision.
It is likely that greater resources will be required 
in primary care because for people to meet NICE 
criteria for surgery they must first have tried all 
appropriate non-surgical measures, unless they 
have a BMI of 50 or over in which case surgery 
may be considered as a first-line option. Following 
surgery the management of any minor adverse 
events will also occur within primary care and 
GPs and practice nurses may need more training 
to recognise and manage some of these events 
appropriately.
Greater resources may be required to provide band 
adjustment services for people who have received 
a gastric band. At present, expert opinion suggests 
that the pattern of follow-up care is variable both in 
quality and quantity. Appropriate band adjustment 
may improve weight loss outcomes and have effects 
on utility and costs.
Chapter 6 
Assessment of factors relevant to 
the NHS and other parties DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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Statement of 
principal findings 
Clinical effectiveness
Surgery versus non-surgical interventions 
Weight loss
The surgical option has been shown to be the 
more effective intervention for weight loss in 
obese people in each RCT115–117,119 and cohort 
study102–104 comparing gastric bypass, adjustable 
gastric banding and biliopancreatic diversion 
with a non-surgical intervention, and in each 
cohort study82–101,105 where participants received 
a different mix of surgical options. A variety of 
measures were used to report weight outcomes 
over different time spans. One RCT117 reports 
a statistically significant difference in per cent 
initial weight lost after two years (laparoscopic 
adjustable gastric banding 20.0% (± 9.4) versus 
1.4% (± 4.9) in the conservative therapy group, 
p < 0.001) and in kg of weight lost at two years. The 
statistical significance of the reported reduction in 
BMI and per cent excess weight loss at two years 
is not reported. Another RCT with a maximum 
follow-up of two years115,116 reports statistically 
significant differences between the laparoscopic 
adjustable gastric banding and non-surgical group 
using four different outcome measures (weight in 
kg, BMI, per cent initial weight lost and per cent 
excess weight lost). In contrast, the third RCT119 
did not report a statistical comparison between 
biliopancreatic diversion and a dietary intervention 
but instead reported separately for men and 
women statistically significant reductions from 
baseline to one year for measures of weight, BMI, 
fat-free mass and fat mass in the biliopancreatic 
diversion group that were not apparent in 
the dietary group. The cohort study102–104 that 
compared adjustable gastric banding and gastric 
bypass with a non-surgical intervention reported 
that BMI was statistically significantly lower two 
years after surgery [laparoscopic adjustable gastric 
banding 33.2 (± 4.7) or open Roux-en-Y gastric 
bypass 32.9 (± 6.7) versus control 41.0 (± 3.4), 
p < 0.001]. Weight and total fat mass were also 
statistically significantly reduced in comparison 
to baseline in the laparoscopic adjustable gastric 
banding group whereas the reductions that 
occurred in the Roux-en-Y gastric bypass group 
were not statistically significantly different. In 
the control group small increases that were not 
statistically significant occurred in both these 
measures after two years. The remaining two 
studies both compared a cohort that received 
different surgical interventions with a no surgery 
cohort97,99,100,105 and reported a greater change in 
BMI after a mean of 3.2 years105 and 10 years97,99,100 
following surgery. Absolute mean BMI values, 
although lower in the surgical cohorts, were not 
reported to be statistically significantly different 
in one study105 and in the other a statistical 
comparison was not reported.97,99,100 One study105 
reported one further weight loss outcome, finding 
that surgery led to a statistically significantly 
greater per cent excess weight loss after 3.2 years 
of follow-up. The other study97,99,100 provides 
five further weight loss outcomes for this review 
update; surgery led to statistically significantly 
better outcomes in terms of per cent weight change 
and per cent BMI change after two years, and also 
weight and per cent weight change at 10 years. The 
difference in per cent weight change at 10 years 
was greater following surgery, but a statistical 
comparison with the control group is not reported.
HRQoL
There is evidence for improvement in some 
measures of HRQoL, particularly in the first couple 
of years following surgery. One RCT115,116 provided 
evidence for a statistically significant improvement 
in five of the eight domains of the SF-36 (physical 
function, physical role, general health, vitality 
and emotional role) two years after laparoscopic 
adjustable gastric banding. Over longer time 
periods (up to 10 years) there is mixed evidence 
from a large cohort study100 with statistically 
significantly greater change following surgery after 
10 years observed in some HRQoL measures but 
not others.
Comorbidities
Surgical interventions led to greater improvements 
in comorbidities than non-surgical interventions. 
One RCT117 specifically enrolled people with 
Type 2 diabetes and after two years found 
statistically significantly higher remission of the 
disease following laparoscopic adjustable gastric 
banding than conventional therapy (laparoscopic 
Chapter 7 
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adjustable gastric banding: 73% of participants 
with remission versus 13% in the conventional 
therapy group, p < 0.001) and statistically 
significantly fewer people with the metabolic 
syndrome. A large cohort study96,97,136 has reported 
that after 10 years a statistically significantly 
greater proportion of people who had received 
surgery had recovered from diabetes, hypertension, 
hypertriglyceridaemia, low HDL-cholesterol and 
hyperuricaemia. Furthermore, in those without 
the relevant comorbidities at baseline, the 
incidence of diabetes, hypertriglyceridaemia and 
hyperuricaemia (but not hypercholesterolaemia) 
was statistically significantly lower in the surgical 
cohort than the control cohort.
Mortality, adverse events 
and complications
The commonly reported adverse events associated 
with the non-surgical interventions were 
intolerance to prescribed medications such as 
orlistat and metformin, or intolerance to a VLCD 
or meal replacement. These events can be resolved 
by discontinuing treatment. A further complication 
of rapid weight loss, which is also observed 
following surgical interventions, is cholecystitis 
which occurred in a greater proportion of people 
receiving conventional therapy than those receiving 
laparoscopic adjustable gastric banding in the 
single RCT that reported this outcome. However, a 
cohort study96 reported that after two years obesity 
surgery statistically significantly increased the 
incidence of cholelithiasis and cholecystectomies 
in men, but that there was no difference in the 
incidence of these events among women.
Surgery versus other surgical interventions
Gastric bypass
Weight loss
Gastric bypass has been compared with four 
other surgical options and is reported to be 
more effective than adjustable gastric banding 
(one trial107), and more effective than vertical 
banded gastroplasty (statistically significant 
difference in three trials,108,109,120,123 greater 
weight loss in the remaining four trials either 
not statistically significantly different106,121,122 or 
no statistical comparison reported73,124). At five 
years, laparoscopic Roux-en-Y gastric bypass was 
statistically significantly better than adjustable 
gastric banding in terms of per cent excess weight 
loss, mean weight and mean BMI.107 There were 
also statistically significantly fewer weight loss 
failures and more participants with a BMI < 30 
following laparoscopic Roux-en-Y gastric bypass 
than adjustable gastric banding.107 In the seven 
trials that assessed gastric bypass and vertical 
banded gastroplasty surgery, greater weight loss was 
observed following gastric bypass using a variety of 
different measures. However, statistically significant 
differences in favour of gastric bypass were only 
reported by three trials,108,109,120,123 and in two of 
these trials the statistically significant difference 
only applied to the per cent excess weight loss 
outcomes.108,109,120 Statistical comparisons for the 
other weight loss outcomes were not reported. The 
trial comparing gastric bypass with laparoscopic 
sleeve gastrectomy125 was inconclusive. Adjustable 
gastric banding, vertical banded gastroplasty 
and laparoscopic isolated sleeve gastrectomy are 
restrictive procedures. Weight loss with gastric 
bypass was not significantly different to that 
with banded gastric bypass (one trial118). There 
were no differences in weight loss in the four 
trials reporting on the open and laparoscopic 
approaches to gastric bypass surgery (four 
trials112–114,130,131).
HRQoL
The HRQoL of people with gastric bypass has 
been compared with that of people with vertical 
banded gastroplasty (one trial124). Twelve months 
after surgery HRQoL as measured by the GIQLI 
had significantly improved for all patients but 
gastric bypass patients scored significantly better 
than vertical banded gastroplasty patients on 14 of 
the 36 individual items that make up the GIQLI. 
Vertical banded gastroplasty patients scored 
significantly better than gastric bypass patients on 
only one item. HRQoL following either open or 
laparoscopic gastric bypass has also been reported 
(1 trial113,114) and after three years there were 
no significant differences in MAQoL or BAROS 
outcome scores.
Comorbidities
Two studies comparing gastric bypass with 
adjustable gastric banding (one trial107) and 
banded gastric bypass (one trial118) reported 
comorbidities. The numbers of participants with 
comorbidities were low and unevenly dispersed 
between the groups in the small trial that 
compared gastric bypass and adjustable gastric 
banding. Therefore it is not possible to determine 
whether one procedure has a greater impact on 
comorbidities than the other. After gastric bypass 
and banded gastric bypass there was no statistically 
significant difference in the proportion of patients 
experiencing resolution of the six reported 
comorbidities. There was no statistically significant 
difference in the improvement or resolution of 
eight out of 10 comorbidities that were reported on DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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following either open or laparoscopic gastric bypass 
(one trial113,114). For the other two comorbidities 
a statistically significant difference was found in 
improvement/resolution of dyslipidaemia in favour 
of open gastric bypass, and in improvement/
resolution of osteoarthritis symptoms in favour of 
laparoscopic gastric bypass.
Mortality, adverse events and complications
Of the 10 studies comparing gastric bypass to 
another surgical option eight reported no deaths in 
either trial arm.106–109,118,120–122,124,125 In one study123 
two deaths occurred among the 20 patients in the 
Roux-en-Y gastric bypass group (10%) and none 
in the vertical banded gastroplasty group. In one 
trial73 one death occurred among the 77 patients 
enrolled in the study (1.3%), but the trial arm in 
which this death occurred is not stated (gastric 
bypass, or loop gastric bypass or gastric banding, 
the latter trial arm has not been reported in this 
review). Gastric bypass was associated with more 
early complications than laparoscopic adjustable 
gastric banding and vertical banded gastroplasty, 
but a level of late complications similar to vertical 
banded gastroplasty and similar or reduced 
reoperation rates compared to laparoscopic 
adjustable gastric banding or vertical banded 
gastroplasty respectively. There were no differences 
in complications between gastric bypass and 
banded gastric bypass. In the four trials that 
compared the open and laparoscopic approaches to 
gastric bypass surgery, two reported no deaths,112–114 
but deaths occurred in both the open (1/51, 
2%) and laparoscopic (2/53, 3.8% although one 
reported to be unrelated to surgery) groups in one 
trial,130 and in the laparoscopic arm of the fourth 
trial (1/30, 3%).131 Conversion to open surgery 
ranged from 0 to 23%. Anastomotic stricture and 
reoperations were more frequent following the 
laparoscopic approach, but wound infections and 
hernias were more common after open surgery.
Vertical banded gastroplasty
Weight loss
Vertical banded gastroplasty has been compared 
with two other surgical options and found to be less 
effective than gastric bypass as discussed above. 
The results from the trials comparing vertical 
banded gastroplasty to adjustable gastric banding 
(three trials110,126–128) do not enable a conclusion 
to be drawn regarding which procedure leads 
to greater weight loss. One year after surgery 
greater improvements in weight (reported by 
one trial126), per cent excess weight loss (reported 
by two trials110,127,128) and BMI (reported by two 
trials110,127,128) were evident for vertical banded 
gastroplasty. However, a statistical comparison was 
not presented for the one-year weight outcome126 
nor for one of the trials reporting one-year BMI 
outcomes.127,128 A statistically significant difference 
at one year was reported by both trials reporting 
per cent excess weight loss110,127,128 and one of the 
trials reporting one-year BMI.110 After two years 
statistically significant differences in BMI and 
per cent excess weight loss were only apparent in 
one of the two trials reporting these outcomes.127,128 
There were no differences in weight loss between 
the open and laparoscopic approaches to vertical 
banded gastroplasty surgery (one trial111).
HRQoL
The HRQoL of people with a vertical banded 
gastroplasty has been compared with that of people 
with a gastric bypass (one trial) as discussed above.
Comorbidities
Vertical banded gastroplasty has been compared 
with one other surgical option, adjustable gastric 
banding (one trial127,128). Although the overall 
number of patients with comorbidity significantly 
decreased following both vertical banded 
gastroplasty and adjustable gastric banding there 
were no significant differences in improvements in 
comorbidities between the groups.
Mortality, adverse events and complications
Of the 10 trials comparing vertical banded 
gastroplasty to another surgical option six reported 
no deaths106,108–110,120–122,124 and one reported no 
immediate deaths related to surgery.126 Deaths 
occurred in two trials comparing vertical banded 
gastroplasty with gastric bypass as discussed 
above, and in one trial comparing vertical banded 
gastroplasty to adjustable gastric banding where 
two of the 50 participants undergoing vertical 
banded gastroplasty died (4%), whereas there 
were no deaths in the adjustable gastric banding 
group.123,124 Vertical banded gastroplasty was 
associated with fewer early complications than 
gastric bypass and a similar or reduced level of late 
complications than gastric bypass and laparoscopic 
adjustable gastric banding respectively. There 
were fewer reoperations following vertical banded 
gastroplasty than with gastric bypass and adjustable 
gastric banding. GERD occurred more often after 
vertical banded gastroplasty than adjustable gastric 
banding. In the trial that compared the open 
and laparoscopic approaches to vertical banded 
gastroplasty there were no deaths. Surgery wound 
problems, pathological scars and hernias were 
more common following open surgery.Discussion 
148
Adjustable gastric banding
Weight loss
Adjustable gastric banding has been compared with 
three other surgical options and found to be less 
effective than gastric bypass (one trial) as discussed 
above, and less effective than laparoscopic isolated 
sleeve gastrectomy (one trial129) for the three weight 
loss outcomes reported: per cent excess weight loss, 
weight loss and BMI decrease. In the comparison 
of adjustable gastric banding with vertical banded 
gastroplasty (three trials) the results were equivocal 
as already stated above. There were no differences 
in weight loss between the open and laparoscopic 
approaches to adjustable gastric banding surgery 
(one trial132).
HRQoL
None of the studies reporting on adjustable gastric 
banding included an assessment of HRQoL. 
Comorbidities
Adjustable gastric banding has been compared with 
three other surgical options. Comorbidity outcomes 
in comparison with gastric bypass (one trial) 
and vertical banded gastroplasty (one trial) are 
discussed above. Only one comorbidity, GERD, was 
reported on in comparison to laparoscopic isolated 
sleeve gastrectomy (one trial129). At one year, GERD 
had resolved in a greater percentage of participants 
in the laparoscopic adjustable gastric banding 
group than the laparoscopic isolated sleeve 
gastrectomy group, but statistical significance was 
not reported.
Mortality, adverse events and complications
Of the five trials comparing adjustable gastric 
banding to another surgical option three reported 
no deaths and one reported no immediate deaths 
related to surgery. The only deaths reported 
occurred in one trial comparing adjustable gastric 
banding to vertical banded gastroplasty and these 
did not occur in the adjustable gastric banding 
group as noted above. Adjustable gastric banding 
was associated with more late complications 
and a greater level of revisional surgery than 
vertical banded gastroplasty. Adjustable gastric 
banding was also associated with gastrointestinal 
effects such as more frequent vomiting than in 
laparoscopic isolated sleeve gastrectomy. In the 
trial that compared the open and laparoscopic 
approaches to adjustable gastric banding there 
were no deaths. Open surgery for adjustable gastric 
banding involved a longer hospital stay and more 
readmissions than laparoscopic adjustable gastric 
banding. Incisional hernia also occurred following 
open adjustable gastric banding.
Laparoscopic sleeve gastrectomy
Weight loss
Laparoscopic sleeve gastrectomy was superior to 
adjustable gastric banding (one trial129), but similar 
to gastric bypass (one trial125), as noted above.
HRQoL
The studies reporting on laparoscopic sleeve 
gastrectomy did not include an assessment of 
HRQoL.
Comorbidities
Resolution of GERD following laparoscopic isolated 
sleeve gastrectomy was compared with adjustable 
gastric banding (one trial129) as reported above. 
Comorbidity was not fully assessed in the trial 
comparing laparoscopic sleeve gastrectomy with 
gastric bypass,125 although diabetes resolved in both 
the patients who had this comorbidity at baseline 
(both were in the gastric bypass group).
Mortality, adverse events and complications
Laparoscopic isolated sleeve gastrectomy led 
to generally fewer gastrointestinal effects than 
laparoscopic adjustable gastric banding and no 
deaths were reported. Similarly, the trial reporting 
on the comparison between laparoscopic sleeve 
gastrectomy and LGBP reported no conversions 
to open surgery and no intraoperative or 
postoperative complications.
Banded gastric bypass
Weight loss
Banded gastric bypass did not result in a 
significantly different weight loss to gastric bypass 
(one trial).
HRQoL
The study reporting on banded gastric bypass did 
not include an assessment of HRQoL.
Comorbidities
After gastric bypass and banded gastric bypass 
there was no statistically significant difference in 
the proportion of patients experiencing resolution 
of the six reported comorbidities.
Mortality, adverse events and complications
No deaths were reported. The only gastrointestinal 
symptom score that was statistically different 
between the groups was the score for emesis, 
which was statistically significantly better in the 
non-banded gastric bypass group. However, the 
proportion of participants with food intolerance 
was statistically significantly higher in this group.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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Cost-effectiveness
Published economic evaluations
Five original economic evaluations were assessed in 
this report. Four of these compared different types 
of bariatric surgeries with a non-surgical treatment 
138,140–142 and one was an economic evaluation 
alongside a clinical trial.139 All modelled economic 
evaluations138–142 found the evaluated bariatric 
surgeries to be cost-effective in comparison to 
non-surgical treatment although the variability 
in estimates of costs and outcomes is large. The 
results of the economic evaluation alongside a 
clinical trial139 were inconclusive.
The choice and the range of model parameter 
estimates used in sensitivity analyses were not 
justified. Nevertheless, with respect to the limited 
number of parameters used in the sensitivity 
analyses the results appear to be robust to 
parameter variations. However, Craig and Tseng140 
identified some subgroups of older and less obese 
men for whom an open gastric bypass may exceed 
the threshold of US$50,000 per QALY depending 
on the value of clinical effectiveness parameters. 
The reported results should be interpreted with 
care: 
•	 because the natural disease progression was not 
explicitly modelled in terms of probabilities of 
obesity-related diseases in any of the identified 
modelled economic evaluations 
•	 because of the various methodological 
shortcomings in modelled economic 
evaluations138,140–142 identified and explained in 
the relevant sections of Chapter 5.
•	 because of some of the assumptions used in 
modelled economic evaluations.
The most important concerns are summarised 
below:
•	 Clinical evidence used to obtain the primary 
outcomes (weight reduction).  In all four studies 
with modelled economic evaluations138,140–142 
the BMI values were taken from the published 
evidence; however, it does not appear that any 
study conducted a systematic literature search 
and evidence analysis. Two studies, Craig and 
Tseng140 and Jensen and Flum,141 used the 
outcomes from a single published source of 
evidence, which may affect the validity of the 
estimate of the differential weight loss in the 
alternative treatments and the generalisability 
of results. Generalisability of results is also 
impaired by the choice of evidence that applies 
only to a subgroup of the obese population: 
the population of obese patients with Type 2 
diabetes as in Ackroyd and colleagues138 and 
white female patients who were obese at the 
age of 18 as in Jensen and Flum.141 
•	 Assumptions about the target population.  Craig 
and Tseng140 and Salem and colleagues142 have 
assumed that the cohort of obese patients 
with BMI > 40 have no comorbidities at 
the baseline, which may not be a realistic 
assumption. 
•	 Assumptions about the outcomes of bariatric 
surgeries.  Ackroyd and colleagues138 implicitly 
assumed that there is no differential operative 
mortality and postoperative morbidity 
between the two surgeries and the non-surgical 
treatment comparator. This is not likely to be a 
realistic assumption. The same is also true with 
respect to the assumption of a zero weight gain 
over the modelled time horizon in patients in 
the non-surgical treatment arm in Ackroyd and 
colleagues,138 Craig and Tseng140 and Salem 
and colleagues.142
•	 Utility estimates.  Utility estimates reported 
in Ackroyd and colleagues,138 were also 
used in Craig and Tseng140 and Salem and 
colleagues.142 However, these are not likely to 
be unbiased estimates of the HRQoL because 
of the multiple methodological shortcomings 
in the way they were derived from the available 
data. In addition the source data relate to 
the general population whose health-related 
preferences may differ from those of the obese 
population. 
In summary, it appears that the identified studies 
have not provided reliable and generalisable 
estimates of the incremental cost-effectiveness of 
bariatric surgeries in comparison to non-surgical 
treatment.
SHTAC economic model
•	 The model developed for the previous 
assessment report was assessed against 
other published models for completeness 
and relevance, and the conceptual model 
was extended to include CHD and stroke. 
Cardiovascular risks are typically estimated 
using variables other than body weight or 
BMI (such as blood pressure and cholesterol 
measurements, as well as patients’ age, sex, 
smoking status), so the inclusion of these 
additional health states in the economic model 
depends on the methods adopted to estimate 
transitions to these states and the extent to Discussion 
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which appropriate measurements are reported 
in clinical studies.
•	 The analysis was developed for three patient 
populations covered by studies included in the 
clinical effectiveness review:
  – patients with morbid (Class III, BMI > 40) 
obesity – as in the previous review
  – patients with moderate to severe (Class I to 
Class II, BMI > 30 and < 40) obesity with 
significant comorbidity at baseline (Type 
2 diabetes), based on data from a single 
trial117
  – patients with moderate (Class I, BMI ≥ 30 
and < 35) obesity, based on data from a 
single trial.115
•	 All surgical patients in the latter two groups 
above underwent laparoscopic adjustable 
gastric banding. Therefore gastric bypass 
was only included in the economic model for 
patients with morbid obesity (BMI > 40).
•	 The relevance of the three populations to 
current clinical guidelines was considered. 
Patients in the first group (with morbid obesity) 
and a subgroup of the second group (those 
with BMI greater than 35 and significant 
comorbidity) are considered appropriate for 
weight loss surgery under current clinical 
guidelines9,146 if they have failed to achieve 
sustained weight loss using other methods. 
Some clinical opinion suggests that patients 
with less severe obesity (BMI between 30 and 
35) who have significant comorbidity that 
may respond to surgically induced weight loss 
(such as Type 2 diabetes), may be potential 
candidates for weight loss surgery. However, 
they emphasise that further research is 
required, with a clearer indication of the 
patient’s overall cardiovascular risk rather 
than relying on BMI.190 In all cases the clinical 
consensus seems to suggest that weight loss 
surgery would not be an appropriate option 
for patients with mild obesity in the absence 
of evidence of cardiovascular risk or other 
significant comorbidity (which appears to be 
the majority of the patient population in the 
trial reported by O’Brien and colleagues,115 
where, at baseline, no patients had coronary 
artery disease, 38% had metabolic syndrome 
and 20% had hypertension).
•	 Meta-analysis of included clinical data 
was considered inappropriate. This has 
implications for the economic model. We 
adopted two estimates of the effect of gastric 
bypass and gastric banding on weight loss 
for the morbidly obese population. The first 
was an ‘optimistic’ scenario (based on the 
previous assessment report) and the second 
a ‘pessimistic’ scenario (based on a recently 
published trial107 comparing gastric bypass 
and gastric banding). Outcomes, in terms of 
weight loss at five years following surgery, were 
extrapolated using data from the SOS study.97
•	 Effectiveness data, in terms of weight loss, from 
the clinical trials reporting the use of adjustable 
gastric banding for severely obese patients 
with Type 2 diabetes and for moderately obese 
patients were used directly in the model. The 
analysis was initially undertaken for the period 
of the trial follow-up only. Extrapolations of 
longer-term weight loss were undertaken based 
on data from the SOS study, where relevant, or 
on the basis of data reported in the trial.
•	 We reviewed recently published studies 
reporting estimates of change in utility 
associated with change in weight or change in 
BMI. There is large variation in the estimated 
change in utility associated with a unit change 
in BMI, which relates to differences in the 
characteristics of the populations studied, and 
may also relate to the number of covariates 
included in the analysis. For the base case 
in the economic model we adopted values 
estimated by Hakim and colleagues152 as 
these were derived from an obese (rather 
than an overweight) population, attempted 
to derive appropriate time trade-off values, 
and explicitly controlled for baseline utility. 
However, one potential problem with adopting 
this model is the assumption of a linear 
relationship between change in utility and 
change in BMI, that may produce biased 
or unfeasible estimates for large changes in 
BMI or at the extremes of the BMI range. 
The economic model does not include any 
utility adjustments for patients experiencing 
adverse effects associated with surgical or non-
surgical management, nor are any adjustments 
included for patients undergoing surgical 
revision of their initial procedure. A scenario 
is included in the deterministic sensitivity 
analysis to reduce the utility gain associated 
with reduction in BMI to the value adopted in 
the previous assessment report.
•	 Updated resource use assumptions, to reflect 
current UK practice, were developed, based 
on discussion with surgical specialists and a 
costing developed by a specialist service. These 
were costed in consultation with a local NHS 
costing unit, based within the Trust Finance 
Department.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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Cost-effectiveness of bariatric surgery 
for morbid obesity (BMI > 40)
•	 Surgical management with gastric bypass 
or adjustable gastric banding of morbid 
obesity was more costly than non-surgical 
management, but resulted in improved 
outcomes (in terms of QALYs) over the 
modelled 20-year time horizon. Differences 
between the optimistic and pessimistic 
scenarios were greater for adjustable gastric 
banding than for gastric bypass. Using the 
optimistic assumption on weight reduction 
up to five years following surgery the QALY 
gain for adjustable gastric banding is 1.88, 
while using the pessimistic assumption the 
QALY gain is 0.92. The equivalent values for 
gastric bypass are 1.98 and 1.52 QALYs. These 
QALY gains are larger than those estimated in 
the previous report, because of extrapolation 
of effects over 10 years (rather than the 
assumption of immediate reversion to baseline 
weight at five years) and updated assumptions 
on the utility gain associated with a unit 
reduction in BMI. The ICERs ranged between 
£1897 and £4127 per QALY gained.
•	 Some alternative scenarios considered in the 
deterministic sensitivity analysis produced 
less favourable cost-effectiveness estimates – in 
particular reducing the utility gain associated 
with a weight loss to the value used in the 
previous review, and adopting less favourable 
assumptions (in terms of duration of surgery, 
revision rates and weight loss) that might 
be associated with less experienced surgical 
operators. However, the results were generally 
robust to changes in assumptions in the 
deterministic sensitivity analysis, and in all 
cases the ICERs remained within the range 
conventionally regarded as cost-effective from 
an NHS decision-making perspective. 
Cost-effectiveness of adjustable 
gastric banding for moderate to 
severe obesity (BMI ≥ 30 and < 35) 
in patients with Type 2 diabetes
•	 Results were reported for time horizons of two 
years (corresponding to the duration of the 
clinical trial report), five years and 20 years. 
For each time horizon, surgical management 
of moderate to severe obesity in patients with 
Type 2 diabetes was more costly than non-
surgical management, but resulted in improved 
outcomes. The QALY gain of 0.27 at two 
years, increased to 1.10 for the 20-year time 
horizon. Incremental costs reduced from £5032 
at two years to £1500 for the 20-year time 
horizon, because of the difference in Type 2 
diabetes resolution between the two modelled 
cohorts. The ICER reduced with longer time 
horizon – from £18,930 at two years to £1367 at 
20 years.
•	 The results were generally robust to changes 
in assumptions in the deterministic sensitivity 
analysis. However, reducing the diabetes 
health-state cost, assuming a gradual (rather 
than immediate) reduction in weight following 
surgery, reducing the utility gain associated 
with weight loss to the value used in the 
previous review, and adopting less favourable 
assumptions (in terms of duration of surgery, 
revision rates and weight loss) that might be 
associated with less-experienced surgeons, 
produced less favourable cost-effectiveness 
estimates. The impact of these changed 
assumptions was particularly marked for the 
two-year time horizon.
•	 In the probabilistic sensitivity analysis all 
simulations were associated with increased 
QALYs, but also increased costs when adopting 
a two-year time horizon. However, when 
the time horizon was extended to 20 years 
a proportion of simulations had negative 
incremental costs (total discounted costs for the 
surgical cohort were lower than for the non-
surgical cohort). These occurred in simulations 
where surgical treatment was associated with 
high proportions of patients with remission of 
Type 2 diabetes. With a two-year time horizon 
the probability of surgical management being 
cost-effective (compared with non-surgical 
management) was 2.5% at a willingness-to-pay 
threshold of £20,000 per QALY and 50.6% 
at a willingness-to-pay threshold of £30,000 
per QALY, assuming a gradual reduction in 
weight following surgery. In contrast, for a 20-
year time horizon, the probability of surgical 
management being cost-effective was 100% at 
both thresholds.
Cost-effectiveness of adjustable 
gastric banding for moderate 
obesity (BMI ≥ 30 and < 35)
•	 Results were reported for time horizons of two 
years, five years and 20 years. For each time 
horizon, surgical management was estimated to 
be more costly than non-surgical management, 
but resulted in improved outcomes. The QALY 
gain of 0.08 at two years, increased to 0.40 
for the 20-year time horizon. Incremental 
costs were approximately £5000 for each time 
horizon. The ICER reduced with longer time Discussion 
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horizon – from £60,754 at two years to £12,763 
at 20 years.
•	 In the deterministic sensitivity analysis the least 
favourable ICERs were associated with short 
model time horizon, ranging from around 
£60,000 per QALY gained up to £190,000 per 
QALY gained. More favourable ICERs were 
found for the five and 20-year time horizons, 
ranging from around £16,000 per QALY 
gained up to £40,000 per QALY gained for 
the five-year time horizon and from around 
£12,500 per QALY gained up to £33,000 per 
QALY gained for the 20-year time horizon. In 
some scenarios, even for longer time horizons, 
the ICERs are above the range conventionally 
deemed acceptable from an NHS decision-
making perspective – in particular, reducing the 
utility gain associated with a weight loss to the 
value used in the previous review and adopting 
assumptions that might be associated with 
less-experienced surgeons were associated with 
high ICERs for all time horizons.
•	 In the probabilistic sensitivity analysis all 
simulations were associated not only with 
increased QALYs but also increased costs, for 
all time horizons. With a 20-year time horizon 
the probability of surgical management being 
cost-effective (compared with an intensive 
medical programme) was 64% at a willingness-
to-pay threshold of £20,000 per QALY and 
98% at a willingness-to-pay threshold of 
£30,000 per QALY. In contrast, for a two-
year time horizon, the probability of surgical 
management being cost-effective was zero at 
both thresholds.
Strengths and limitations 
of the assessment 
This review has the following strengths.
•	 It is independent of any vested interest.
•	 It has been undertaken following the principles 
for conducting a systematic review. The 
methods were set out in a research protocol 
(Appendix 1), which defined the research 
question, inclusion criteria, quality criteria, 
data extraction process and methods to be 
employed at different stages of the review. 
•	 An advisory group has informed the review 
from its initiation. The research protocol was 
informed by comments received from the 
advisory group and the advisory group has 
reviewed and commented on the final report.
•	 The review brings together the evidence for 
the clinical effectiveness and cost-effectiveness 
of bariatric surgery for obese people. This 
evidence has been critically appraised and 
presented in a consistent and transparent 
manner.
•	 An economic model has been developed de 
novo following recognised guidelines and 
systematic searches have been conducted to 
identify data for the economic model. The 
main results have been summarised and 
presented.
In contrast, this review also has certain limitations:
•	 Synthesis of the included studies was through 
narrative review. Although 26 eligible studies 
were identified either comparing surgery with 
no surgery or comparing different surgical 
procedures, in several cases only one study 
assessed a particular pair of interventions, 
for example gastric bypass versus adjustable 
gastric banding, or gastric bypass versus 
biliopancreatic diversion. 
•	 Meta-analysis was deemed inappropriate. In 
cases where the same procedures are compared 
by several studies, limitations in the literature 
prevented us from proceeding with meta-
analysis. The most common limitation in the 
literature is that SDs are not reported by the 
majority of studies. In addition, data such 
as exact p-values or CIs, which might have 
been used to calculate a standard deviation, 
are also not reported. Furthermore, there are 
often differences in the outcome measures 
reported by the studies, or differences in 
the patient groups. If these limitations had 
applied to a minority of the studies available 
for meta-analysis we would have considered 
using a standard technique to impute the 
missing standard deviations. For example, the 
comparison assessed by the greatest number 
of studies was gastric bypass versus vertical 
banded gastroplasty, which was assessed by 
seven RCTs. Five of these RCTs reported 
similar outcomes that could be combined in 
a meta-analysis, but only two reported any 
measure of variance. All five trials found 
greater weight loss with gastric bypass. Notably, 
the two studies that reported different outcome 
measures both found no statistically significant 
difference. To combine these five RCTs in a 
meta-analysis (if SDs could be obtained from 
the authors) would be inappropriate not only 
because a proportion of the evidence would be DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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ignored, but also because it would give undue 
weight to these procedures relative to other 
different surgical procedures that could not be 
combined in a meta-analysis.
•	 Despite conducting a wide ranging and 
systematic search of the literature we did not 
identify any studies that met the inclusion 
criteria and assessed bariatric surgery in young 
people. There were also only two studies that 
included adults with either Class I or Class II 
obesity (BMI ranges 30–34.99 and 35–39.99 
respectively).
•	 Deaths, adverse events and some complications 
are generally rare events and therefore it is not 
likely that evidence presented here provides 
reliable estimates of the incidence of these rare 
events because most of the studies, particularly 
the RCTs, were of a limited size and duration. 
The proportion of deaths reported by the 
included studies within surgical cohorts or 
single surgical trial arms ranged from 0.25 
to 10%. A recent systematic review and meta-
analysis of mortality in bariatric surgery 
reports meta-analysis of total mortality at 
30 days or less was 0.28% (95% CI 0.22 to 0.34) 
with restrictive operations having the lowest 
mortality.191 The limited size and duration of 
the RCTs may have led to an underestimate 
of some of the more frequently encountered 
complications such as failure of gastric bands, 
e.g. due to band slip or erosion, complications 
that usually necessitate band removal. The SOS 
cohort study which has been ongoing for over 
a decade provides data for greater numbers of 
participants but is vulnerable to various kinds 
of bias. In addition, some RCTs compared 
different procedures with open surgery 
being undertaken for one intervention, and 
laparoscopic surgery for the other.
•	 The included studies provided insufficient 
information on surgeon experience for 
learning curve effects to be assessed in the 
comparisons of open versus laparoscopic 
surgeries.
•	 Owing to the time constraints of this review 
we were unable to contact the authors of the 
primary studies to request additional data. 
Although this might have provided some 
additional useful information, we cannot be 
certain that sufficient data would have been 
forthcoming to enable a meta-analysis, and 
it is unlikely that further details would have 
changed our conclusions. 
•	 The utility model adopted for the base case 
maybe an over-simplification by assuming 
linear additivity, with respect to change in BMI. 
The utility gain associated with a reduction in 
BMI (or conversely the utility loss associated 
with an increase in BMI) is assumed to be 
constant over the range of BMI values and 
therefore cannot exclude the possibility of 
estimating utility values outside the logical 
range. Moreover, the model does not allow for 
interactions between baseline BMI or proximity 
to a target or ‘ideal’ value, that may modify the 
effect of change in BMI on utility.
•	 The economic model applies utility values to 
the reduction in BMI associated with surgical 
or non-surgical management of obesity, but 
takes no account of any utility impact of side 
effects or complications of interventions. 
Reporting of long-term adverse effects 
following surgery is variable and of limited 
duration in included trials. However, where 
reported, the proportion of patients reporting 
such effects is non-trivial. The likely duration 
of the side effects is not clear, nor is it apparent 
how far the impact of these effects may offset 
any utility gains from reduction in BMI alone.
•	 Costs associated with the surgical admission 
in the economic model are based on resource 
use protocols developed using expert 
opinion. Published resource use protocols 
were regarded as overestimates, in terms of 
duration of surgery and LOS, and as poor 
predictors of cost in the UK. However, it has 
not been possible to validate the updated 
cost assumptions against external standards, 
reflecting current UK practice. Similarly, 
assumptions over preoperative assessments 
and postsurgical follow-up have been based on 
protocols, informed by expert opinion. Costs 
for non-surgical comparators were based on 
brief resource use protocols included in clinical 
trial reports – as such, they are dependent on 
the comprehensiveness of coverage in the 
clinical trial reports.
•	 A major source of uncertainty in the economic 
model relates to the absence of reliable, 
long-term data on the effectiveness (in terms 
of sustained weight loss) and the need for 
operative revision and conversion to alternative 
weight loss methods. Data on long-term 
outcomes from the SOS study were used to 
extrapolate from clinical trial outcomes to 
longer-term outcomes. However, the validity 
of applying these data may be questioned – for 
example, a proportion of patients in the 
SOS study were treated with non-adjustable 
bands, which would not be considered an 
acceptable strategy in current practice. It is not Discussion 
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clear how changes in surgical techniques (or 
indeed in non-surgical management of obese 
patients) occurring over the duration of long-
term cohort studies may affect the outcomes 
observed.
Other relevant factors 
•	 This review updates a previous Technology 
Assessment Report15 and Cochrane review.70,71 
The criteria for this updated review were 
broadened to include adults and young people 
with Class I and Class II obesity, as well as 
those considered to be morbidly obese (Class 
III obesity). To maintain the relevance of 
the review to current practice the historical 
procedures of horizontal gastroplasty and 
jejunoileal bypass have been excluded from this 
updated review.
•	 The duration of the majority of the studies 
included in this review lay between one and 
three years with, in general, very few dropouts 
reported or apparent from the shortest studies. 
However, it was reported or apparent from the 
results of the few studies with durations of four 
to six years that only a half to one-quarter of 
the study population contributed outcome data 
at the final time points.
•	 Only five (three RCTs, two cohort studies) of 
the studies included in this review reported 
any assessment of QoL issues. It is therefore 
difficult to make any judgement about the 
impact of weight loss interventions on the 
quality of an obese person’s daily life.
•	 It was beyond the remit of this research to 
assess the impact of preintervention and 
postintervention education, counselling and 
support on the outcomes of the interventions. 
However, the majority of the studies included 
in this review did not provide such details, 
which may be important for understanding 
patient compliance with the lifestyle and diet 
modifications that are necessary for successful 
weight loss maintenance.
•	 Few studies included participants aged over 
60 years, so it is uncertain how generalisable 
these results are to older adults.
•	 Most study participants were women, so it is 
uncertain how generalisable the results are to 
men.
•	 All the studies included in this review were 
conducted in countries other than the UK. 
It is difficult to determine how generalisable 
the results of the included studies are to the 
ethnically diverse population within the UK.
•	 Only two RCTs assessed sleeve gastrectomy 
and none of the included studies assessed 
a two-stage approach to gastric surgery for 
obesity using sleeve gastrectomy before another 
bariatric procedure. We are therefore not able 
to draw any conclusion regarding the use of a 
two-stage approach.
•	 The relatively short duration of the majority of 
the RCTs available for inclusion in this review 
may mean that the impact of late complications 
(such as gastric ulcers, stomal stenosis and 
erosions, and band slippage) and the need for 
revisional surgery are underestimated. 
•	 Expert opinion indicates that vertical banded 
gastroplasty is almost never undertaken 
now. However, this procedure forms the 
bulk of the evidence base, reported by 11 
of 20 comparisons of surgical procedures 
and one of the six comparisons with non-
surgical interventions. Similarly, the bariatric 
procedures in common use are mainly 
undertaken laparoscopically now, but the 
available evidence includes a number of trials 
that include open procedures.
•	 In common with earlier versions15,70,71 of this 
review, bariatric surgery interventions were 
found to be more effective than any of the 
non-surgical interventions in terms of weight 
loss and improvements in comorbidities. The 
longer-term information from one cohort 
study that is now available on quality of life 
(up to 10 years) provides mixed evidence with 
some HRQoL measures showing significantly 
greater change after surgery, but not others. 
Only two comparisons, gastric bypass versus 
vertical banded gastroplasty, and vertical 
banded gastroplasty versus adjustable gastric 
banding, are common to both our previous 
reviews15,70,71 and this review. Gastric bypass 
continues to appear more effective for weight 
loss than vertical banded gastroplasty because 
three trials report statistically significant 
greater weight loss and greater weight loss is 
apparent in the remaining four trials although 
this loss is either not statistically different or 
no statistical comparison is reported. Data 
on comorbidities were not assessed in these 
trials. Three trials contributed evidence to the 
comparison of vertical banded gastroplasty 
versus adjustable gastric banding and the 
results continue to be conflicting regarding 
which procedure leads to greater weight loss. 
There was no new information to include on 
comorbidities for this comparison. There was 
no new information to include on QoL for 
either the gastric bypass versus vertical banded DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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gastroplasty or the vertical banded gastroplasty 
versus adjustable gastric banding comparisons. 
•	 It has not been possible for us to determine 
how similar the results of this review are to 
the results of reviews of bariatric surgery 
undertaken by other authors because these 
have generally focused on one particular 
surgical intervention, and/or have included 
study types other than RCTs and/or have 
included interventions that are no longer 
in current use. Therefore the results are not 
directly comparable.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Implications for 
service provision 
A NICE commissioning guide for the bariatric 
surgical service was produced alongside the NICE 
obesity guideline. The commissioning guide has 
estimated that the benchmark rate at five years for 
a bariatric surgical service is 0.01% per year (or 10 
per 100,000 population).68 This means that for a 
standard PCT population of 250,000, the average 
number of people receiving bariatric surgery (in 
line with NICE guidance) would be 25 per year 
in five years time. The commissioning guide 
indicates that this equates to more than a threefold 
increase compared with the current estimated rate 
of bariatric surgery commissioned by the NHS in 
2006.
Suggested research priorities
•	 There continues to be a need for good-
quality, long-term RCTs comparing different 
operative techniques for obesity that include 
an assessment of patient QoL. To enable 
future meta-analysis, RCT data should be 
comprehensively reported, ideally including 
more than one widely used outcome measure 
such as weight, per cent excess weight loss or 
BMI, and details of the standard deviation 
about the mean for each outcome reported.
•	 A comparison of procedures which combine 
restrictive and malabsorption components such 
as gastric bypass with the purely restrictive 
procedures in current use, particularly 
adjustable gastric banding, would be desirable 
as only two small RCTs contribute evidence on 
these comparisons. However, this may not be 
possible because expert opinion suggests that 
in practice severity of obesity and the presence 
of comorbid conditions determines which 
procedure is suitable for an individual patient.
•	 The evidence base for the clinical effectiveness 
of bariatric surgery for adults with Class I or 
Class II obesity is very limited. Similarly, no 
evidence to inform on the clinical effectiveness 
of surgical intervention for obesity in young 
people was found that met our inclusion 
criteria. Further good-quality RCTs are 
required to provide clinical effectiveness 
and QoL evidence for these two groups. In 
addition, it is essential that any new research 
reports on the resolution and/or development 
of comorbidities such as Type 2 diabetes and 
hypertension so that the potential benefits of 
early intervention can be assessed.
•	 Assessing the risks of different bariatric 
procedures is hampered by a lack of 
consistency in the reporting of adverse 
outcomes. A core set of important adverse 
outcomes should be identified so that a 
standardised approach to describing adverse 
outcomes can be developed.
•	 It was beyond the remit of this review to 
assess the impact of preintervention and 
postintervention education, counselling 
and support on patients’ understanding 
of the procedures and the consequences 
of undergoing surgery. The provision of 
postsurgical care, e.g. frequency and amount 
of band adjustment, was also beyond the 
remit of this review. As all of these aspects 
have the potential to affect the outcome of 
the intervention they should be reviewed. The 
impact that these aspects have on outcomes 
should be reviewed. 
•	 In addition to good-quality, long-term RCTs, 
there is a need for good-quality, long-term 
cohort studies to:
  – identify reoperation for late complications 
following all bariatric procedures and 
conversion to gastric bypass for patients 
initially managed with gastric banding
  – identify the duration of remission, 
following surgical or non-surgical 
management, of comorbidities associated 
with obesity to determine whether this 
is primarily associated with durability of 
weight loss or with other prognostic factors
  – identify providers at different stages of the 
learning curve and to document the impact 
of experience on the safety, effectiveness 
and efficiency of surgery
  – identify resource use for patients during 
preoperative assessment, surgical 
admissions and postoperative management 
to develop robust costings for bariatric 
procedures.
Chapter 8 
Conclusions Conclusions
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•	 Current utility models indicate that reduction 
in BMI is associated with gains in utility. 
However, there is uncertainty over the 
magnitude of this gain. Further research is 
required to establish the utility gain associated 
with reduction in BMI, to establish the most 
appropriate functional forms (current models 
tend to assume linear additivity which may 
lead to infeasible values) and to investigate 
interactions between utility gain from reduction 
in BMI and baseline BMI, proximity to the 
non-obese range or to a target ‘ideal’ value. 
The research should also consider whether 
utility gains from reduction in BMI that are 
observed over the short-term, are maintained 
over the longer term.
•	 Current utility models relate gains in utility to 
change in BMI. Further research is required 
to investigate whether there are additional 
utility gains associated with the resolution of 
comorbidity following surgical or non-surgical 
management of obesity. Similarly, economic 
models of surgical or non-surgical management 
of obesity would be improved by including 
estimates of the QoL impact of the side 
effects of treatment. This would require more 
systematic recording and reporting of adverse 
effects, as well as additional research on their 
impact on patients’ QoL and the extent to 
which these may offset quality of life gains 
associated with reduction in BMI.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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Report methods for synthesis of 
evidence of clinical effectiveness 
A review of the evidence for clinical effectiveness 
and cost-effectiveness will be undertaken 
systematically following the general principles 
outlined in CRD Report Number 4 (2nd edition) 
‘Undertaking Systematic Reviews of Research on 
Effectiveness’.74
Search strategy 
The search strategies will be devised and tested 
by an experienced information scientist. The 
strategies will be designed to identify: (1) clinical 
effectiveness studies reporting on comparisons 
between different bariatric surgical techniques, and 
comparisons between bariatric surgery and non-
surgical interventions for obesity; and (2) studies 
reporting on the cost-effectiveness of different 
bariatric surgical techniques, and comparisons 
between bariatric surgery and non-surgical 
interventions for obesity.
The search strategy will involve searching the 
following electronic databases: MEDLINE; 
EMBASE; PreMedline In-Process & Other Non-
Indexed Citations; The Cochrane Library including 
the Cochrane Systematic Reviews Database, 
Cochrane Controlled Trials Register, DARE, NHS 
EED and HTA databases; Web of Knowledge 
Science Citation Index (SCI); Web of Knowledge 
ISI Proceedings; PsycInfo; CRD; and Biosis.
This work will update a previous assessment,15 but 
the updated work will include obese people as 
well as morbidly obese people. The searches for 
the previous assessment were carried out in 2001. 
Clinical effectiveness searches were then carried out 
again in 2004 to inform the Cochrane review which 
was updated in 2005. The results of these searches 
will help to inform our review. In particular we 
will check the 2001–2004 search results for studies 
that were excluded because the patients were 
not morbidly obese, but which would meet the 
criteria for this updated review that will include 
obese people. New searches will be conducted 
for clinical effectiveness evidence published since 
2004. For the cost-effectiveness section searches 
will be carried out from 2001. Searches for other 
evidence to inform cost-effectiveness modelling 
will be conducted as required and may include 
a wider range of study types (including non-
randomised studies and cost-effectiveness analyses 
of pharmaceuticals for weight reduction).
All searches will be updated when the draft report 
is under review, before submission of the final 
report.
Bibliographies of related papers will be assessed for 
relevant studies.
Members of the Expert Advisory Group will be 
asked to review the adequacy of the searches and to 
indicate whether they are aware of any additional 
published or unpublished evidence.
Inclusion and exclusion criteria 
Patients
Inclusion criteria
•	 Adult patients fulfilling the standard definition 
of obese, i.e. people with a BMI of 30 kg/m2 or 
over.
•	 Young people who fulfil the definition of 
obesity for their age, sex and height.
•	 Where data are available clinical effectiveness 
and cost-effectiveness will be reported 
separately for patients who meet current NICE 
guidelines for bariatric surgery, those with a 
lower BMI who would not currently meet the 
NICE criteria for bariatric surgery, and young 
people.
Exclusion criteria
•	 Adults with a BMI under 30 kg/m2.
Interventions
Inclusion criteria
•	 Open and laparoscopic bariatric surgical 
procedures in current use. The procedures 
likely to be included are vertical banded 
gastroplasty, gastric banding (including 
adjustable gastric banding), biliopancreatic 
diversion (including biliopancreatic diversion 
with duodenal switch), gastric bypass and 
sleeve gastrectomy.
Appendix 1   
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Comparators
Inclusion criteria
•	 Surgical procedures in current use will be 
compared with one another.
•	 Open surgery will be compared with 
laparoscopic surgery for the same procedure.
•	 Surgical procedures in current use will be 
compared to non-surgical interventions. 
These non-surgical interventions may include 
drugs such as orlistat, sibutramine and 
rimonabant, dietary interventions, exercise 
and combinations of non-surgical interventions 
such as diet and exercise.
Exclusion criteria
•	 Comparisons of variations in technique for a 
single type of surgical procedure.
Outcomes
Inclusion criteria
•	 Studies must have reported on at least one of 
the following outcomes following a minimum 
of 12 months of follow-up: weight change; 
quality of life; or change in obesity-related 
comorbidities.
•	 Data will also be extracted on perioperative 
and postoperative mortality and morbidity, 
revision rates for surgical procedures, change 
in obesity-related comorbidities and cost-
effectiveness.
Exclusion criteria
•	 Studies will not be included if they have only 
reported short-term outcomes (less than 
12 months).
Types of studies
Inclusion criteria
•	 RCTs will be included. For the comparisons 
of surgical procedures with non-surgical 
procedures it is likely that few or no RCTs 
will be found, controlled clinical trials and 
prospective cohort studies (with a control 
cohort) will therefore also be eligible for 
inclusion.
•	 For the systematic review of cost-effectiveness 
study types will include full cost-effectiveness 
analyses, cost–utility analyses, cost–benefit 
analyses and cost–consequence analyses.
•	 Studies published as abstracts or conference 
presentations will only be included if sufficient 
details are presented to allow an appraisal of 
the methodology and the assessment of results 
to be undertaken. 
Exclusion criteria
•	 Case series and case studies.
•	 Narrative reviews, editorials and opinions.
Inclusion and data extraction process
Reference screening strategy
•	 Titles and abstracts identified by searching will 
be examined for inclusion, according to the 
inclusion/exclusion criteria detailed above, by 
two reviewers independently. Disagreements 
will be resolved by consensus or by recourse to 
a third reviewer where necessary.
•	 For studies which appear potentially relevant 
on title or abstract, full papers will be requested 
for further assessment. All full papers will be 
screened independently by two reviewers and 
a final decision regarding inclusion will be 
agreed. Any disagreements will be resolved 
by discussion, with involvement of the third 
reviewer where necessary.
Data extraction strategy
•	 Data will be extracted by one reviewer using a 
standardised data extraction form. Extracted 
data will be independently checked by a 
second reviewer. Discrepancies will be resolved 
by discussion, with involvement of another 
reviewer when necessary.
Quality assessment
•	 Cohort studies will be assessed using criteria 
recommended by the NHS CRD (University of 
York).74 
•	 RCTs will be assessed using the Cochrane 
criteria for judging risk of bias.75 These criteria 
include consideration of the following factors:
  – sequence generation
  – allocation concealment
  – blinding of participants, personnel and 
outcome assessors
  – incomplete outcome data
  – selective outcome reporting
  – topic-specific, design-specific or other 
potential threats to validity.
•	 Economic evaluations will be assessed using 
the critical appraisal checklist for economic 
evaluations proposed by Drummond and 
Jefferson.76
•	 The checklist for assessing good practice in 
decision analytic modelling will be used for 
critically appraising any decision models 
identified.77
Methods of analysis/synthesis 
•	 Clinical effectiveness and cost-effectiveness 
data will be tabulated and discussed in a 
narrative review.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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If clinical effectiveness data are of sufficient 
quantity, quality and homogeneity, a meta-analysis 
will be performed to estimate a summary measure 
of effect on relevant outcomes based on ITT 
analyses. If a meta-analysis is appropriate it will be 
performed using review manager (revman) software.
Methods for synthesising 
evidence of cost-effectiveness 
The inclusion and exclusion criteria for evidence 
required to inform the economic model will be 
identical to the criteria for the systematic review of 
clinical effectiveness, with the following exceptions:
•	 The cost-effectiveness model will focus on the 
surgical procedures identified in the clinical 
effectiveness review as being those that are 
clinically effective and in current use. These 
will be further restricted to those that are in 
widespread current use within the UK NHS if 
necessary.
•	 Searches for other evidence to inform cost-
effectiveness modelling [for example long-term 
cohort studies to obtain parameter estimates 
for the comparator arm of the model (non-
surgical treatment), studies assessing HRQoL 
in obese people, studies estimating the 
relationship between improvements in obesity-
related risk factors and the associated potential 
changes in morbidity and mortality], will be 
conducted as required and may be drawn 
from the wide range of sources (such as non-
randomised studies and the cost-effectiveness 
analyses of pharmaceuticals for weight 
reduction).
A new economic evaluation will be carried out, 
from the perspective of the UK NHS and Personal 
Social Services (PSS), using a decision analytic 
modelling approach. Model structure will be 
determined on the basis of research evidence and 
clinical expert opinion of:
•	 the biological disease process (i.e. knowledge of 
the natural history of the disease)
•	 the main diagnostic and care pathways for 
patients in the UK NHS context [both with and 
without the intervention(s) of interest]
•	 the disease states or events that are most 
important in determining patients’ clinical 
outcomes, quality of life and consumption of 
NHS or PSS resources.
Where possible, the incremental cost-effectiveness 
of each intervention will be estimated in 
comparison with other surgical procedures, as 
well as the non-surgical comparator(s) for adults 
meeting the current NICE criteria for bariatric 
surgery. Cost-effectiveness will be estimated in 
terms of incremental cost per QALY gained. Cost-
effectiveness modelling of bariatric surgery for 
adults with a lower BMI than suggested by current 
NICE criteria, and bariatric surgery for obese 
young people will only be considered if sufficient 
data to inform the cost-effectiveness model are 
available.
Parameter values will be obtained from relevant 
research literature, including the systematic review 
of clinical and cost-effectiveness. Where parameter 
estimates are not available from good-quality 
published studies data may be obtained from 
lower quality evidence sources or expert clinical 
opinion. Sources for parameters will be stated 
clearly. A specific systematic literature search will be 
conducted for publications reporting health-related 
quality of life and/or health state utility associated 
with obesity. 
Resource use will be specified from the perspective 
of the NHS and PSS and will be valued using 
appropriate NHS185 and PSS177 reference costs. 
Where national reference costs are not appropriate, 
unit cost estimates will be extracted from published 
work. If insufficient data are retrieved from 
published sources, costs may be obtained from 
individual NHS Trusts or groups of Trusts.
The simulated population will be defined on the 
basis of evidence about the characteristics of the 
UK adult population undergoing bariatric surgery. 
Simulated populations of (1) adult patients with 
a lower BMI who do not meet NICE criteria for 
bariatric surgery, and (2) young people will only 
be defined separately if good-quality effectiveness, 
resource use, and cost data are available for these 
groups.
If data allow, the time horizon of our analysis will 
be a patient’s lifetime in order to reflect the chronic 
nature of the disease. Alternatively, the base-case 
analysis will be based on best available data, with 
lifetime horizon explored in a scenario analysis. 
Both cost and QALY will be discounted at 3.5%.
Analysis of uncertainty will focus on cost–utility. 
Uncertainty will be explored through both one-Appendix 1
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way sensitivity analysis and probabilistic sensitivity 
analysis (PSA) if the modelling approach permits 
this. If PSA is undertaken the outputs will be 
presented both as plots on the cost-effectiveness 
plane and cost-effectiveness acceptability curves.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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Appendix 2 
Literature search strategies
The databases searched for the 2008 update of this review are listed below, together with the full search 
strategies employed. Further information regarding the searches undertaken for the identification of 
studies in the original review and earlier updates is provided in Appendix 3
Database searched
Clinical effectiveness 
searches
Cost-effectiveness 
and QoL searches
Medline: 1996–2008 Restricted to 2004–2008 2001–2008
EMBASE 2004–2008 2001–2008
PreMEDLINE: In-Process & Other Non-Indexed Citations 2004–2008 2001–2008
Cochrane: includes Central, Dare, CDSR, and HTA databases 2004–2008 2001–2008
Web of Knowledge: Science Citation Index (SCI) 2004–2008 2001–2008
Web of Knowledge: ISI Proceedings 2004–2008 2004–2008
PsycInfo 2004–2008 2001–2008
CRD 2004–2008 2001–2008
BIOSIS 2008 2008
CINAHL 2004–2008 2001–2008
AMED 2004–2008 2001–2008
BNI 2004–2008 2001–2008
Searched for Ongoing Trials
UKCRN
National Research Register
Clinicaltrials.gov
Controlled clinical trials
Australian New Zealand Clinical Trials RegistryAppendix 2
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Clinical effectiveness
The MEDLINE search strategy for the clinical 
effectiveness section of the review is reproduced 
below. This was adjusted as necessary for cost-
effectiveness searches and for searching the other 
electronic databases listed in the table above for 
both clinical effectiveness and cost-effectiveness 
Search strategy
1  exp obesity/(44949)
2  Overweight/(1562)
3  over?weight.ti,ab. (11311)
4  over weight.ti,ab. (106)
5  overeating.ti,ab. (440)
6  over?eating.ti,ab. (626)
7  exp Weight Loss/(11322)
8  weight loss.ti,ab. (18540)
9  weight reduc$.ti,ab. (2722)
10  or/1–9 (66439)
11  bariatric surg$.ti,ab. (1788)
12  exp bariatric surgery/(5414)
13  (surg$adj5 bariatric).ti,ab. (1825)
14  anti?obesity surg$.ti,ab. (6)
15  antiobesity surg$.ti,ab. (6)
16  (obesity adj5 surgery).ti,ab. (842)
17  (obesity adj5 surgical).ti,ab. (503)
18  (gastroplasty or gastro?gastostomy or “gastric bypass” or “gastric surgery” or “restrictive surgery”).ti,ab. (2723)
19  exp gastric bypass/(2110)
20  exp jejunoileal bypass/(159)
21  jejuno?ileal bypass.ti,ab. (75)
22  jejunoileal bypass.ti,ab. (75)
23  gastrointestinal surg$.ti,ab. (524)
24  gastrointestinal diversion$.ti,ab. (1)
25  exp biliopancreatic diversion/(405)
26  biliopancreatic diversion.ti,ab. (304)
27  bilio?pancreatic diversion.ti,ab. (304)
28  biliopancreatic bypass.ti,ab. (14)
29  bilio?pancreatic bypass.ti,ab. (14)
30  gastric band$.ti,ab. (1033)
31  silicon band$.ti,ab. (5)
32  exp gastroenterostomy/(2415)
33  gastrectomy.ti,ab. (4171)
34  gastrectomy.ti,ab. (4171)
35  gastroplasty/(1745)
literature (including quality of life information). 
Search strategies are available from the report 
authors on request. The MEDLINE database search 
was restricted to 2004–08. Citations identified 
by the search were added to a reference manager 
database on 6 February 2008.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
177
Search strategy
36  LAGB.ti,ab. (236)
37  stomach stapl$.ti,ab. (7)
38  lap band$.ti,ab. (165)
39  lap-band$.ti,ab. (165)
40  malabsorptive surg$.ti,ab. (7)
41  mason$procedure.ti,ab. (9)
42  Roux-en-Y”.ti,ab. (1930)
43  anastomosis, Roux-en-Y/(1338)
44  malabsorptive procedure$.ti,ab. (34)
45  duodenal switch$.ti,ab. (177)
46  stomach stapl$.ti,ab. (7)
47  obesity/su (746)
48  exp Obesity, Morbid/su [Surgery] (2991)
49  or/11–46 (12551)
50  10 and 49 (4612)
51  47 or 48 or 50 (4902)
52  limit 51 to yr=“2001 – 2008” (4023)
53  limit 52 to humans (3963)
54  limit 53 to yr=“2004 – 2008” (2914)
55  limit 54 to (clinical trial, phase iii or clinical trial, phase iv or clinical trial or comparative study or controlled clinical trial or 
evaluation studies or guideline or meta analysis or multicenter study or practice guideline or randomized controlled trial 
or “scientific integrity review” or technical report or twin study or validation studies) (555)
56  Cohort Studies/(66145)
57  Randomized Controlled Trial/(150030)
58  Prospective Studies/(156648)
59  Evaluation Studies/(96370)
60  Follow-Up Studies/(185572)
61  (control$or prospectiv$or volunteer$or placebo$or random$).ti,ab. (1202900)
62  ((single$or doubl$or trebl$or tripl$) adj (mask$or blind$)).ti,ab. (47022)
63  or/56–62 (1477917)
64  54 and 63 (1130)
65  55 or 64 (1284)
Update search run on 29 July 2008: number retrieved = 108
Reference lists
The reference lists of relevant trials and reviews 
identified were examined.
Other searches
Authors of included studies and relevant experts 
were contacted where possible in order to obtain 
additional references, missing data, unpublished 
trials and any ongoing trials.The authors of 
a systematic review of treatments for obesity51 
provided the results of hand searches of the 
following journals:
•	 International Journal of Obesity (1977 to 2000, 
volume 24, part 12);
•	 Obesity Research (1993 to 2001, volume 9, part 
2);Appendix 2
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•	 Obesity Surgery (1991 to 2001, volume 11, part 
2);
•	 American Journal of Clinical Nutrition (1966 to 
2000, volume 72, part 6);
•	 Proceedings of the Nutrition Society (1960 to 2000, 
volume 59, part 4);
•	 Journal of Human Nutrition and Dietetics (1988 to 
2001, volume 14, part 1);
•	 Journal of the American Dietetic Association (1980 
to 1990, volume 90, part 12)DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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There are three previously published versions of 
this systematic review of bariatric surgery;15,70,71 
each differs slightly in the studies included as 
the review has evolved. This section explains 
how the review has evolved and notes the main 
differences between the reviews. A flow chart of the 
identification of studies at each stage can be seen in 
Figure 9.
Original review 200215 
For the first edition of this review 2707 citations 
were identified by the searches, of which 2631 
were excluded and 76 were retrieved for detailed 
examination. Thirty-seven studies were then 
excluded.15 Eighteen studies and one systematic 
review were included (reported in 39 publications). 
This version included jejunoileal bypass (an 
intervention that is no longer practised and is not 
included in subsequent versions of this review), 
and excluded abstracts and non-English language 
publications.
Cochrane 200370
The 2003 Cochrane review was conducted using 
the same 2707 citations obtained from the 
2002 report.15 The citations were rescreened to 
identify non-English language publications and 
studies published only as abstracts for inclusion 
in the Cochrane review. Three additional studies 
published as abstracts only were included and 
three studies (seven publications) of jejunoileal 
bypass were excluded from the Cochrane review 
(Appendix 16). Eighteen trials reported in 33 
publications therefore met the inclusion criteria.
The three additional studies included in the 2003 
Cochrane review were:
•	 RCTs: Agren and Naslund (1989),73 van Rij 
(1984)192 and van Woert et al. (1992)106 (all 
abstracts).
Cochrane 2005 update71
The updated searches in 2005 identified 516 
citations, of which 488 were excluded and 28 
were retrieved for detailed examination. Thirteen 
studies were then excluded, and authors of one 
study were contacted as the eligibility was unclear, 
but no response was received so this was also 
excluded (Appendix 16). Fourteen new studies 
therefore met the inclusion criteria; eight of these 
were primary studies and six were additional 
publications of the SOS study included in the first 
edition of the review.91–96
The eight additional primary studies included in 
the 2005 Cochrane update were:
•	 RCTs: Davila-Cervantes et al. (2002),111 Lee et 
al. (2004),124 Lujan et al. (2004),130 Mingrone et 
al. (2002),119 Morino et al. (2003),110 Sundbom 
and Gustavsson (2004)112 
•	 Cohort studies: Stoeckli et al. (2004),102 von 
Mach et al. (2004).103
Current update 2008
The updated searches in 2008 identified 2163 
citations, of which 2126 were excluded and 37 
were retrieved for detailed examination. Eighteen 
studies were then excluded (Appendix 16). 
Nineteen publications therefore met the inclusion 
criteria; nine of these were new primary studies 
(three studies each had two publications), two 
were updates of studies included in previous 
versions of the review102,113 and five were additional 
publications of the SOS study included in all 
versions of this review.97–101
The nine additional primary studies included in 
this update are: 
•	 RCTs: Angrisani et al. (2007),107 Bessler et al. 
(2007),118 Dixon et al. (2008),117 Himpens et al. 
(2006),129 Karamanakos et al. (2008),125 O’Brien 
et al. (2006),115,116 Olbers et al. (2005),108,109 van 
Dielen et al. (2005),127,128
•	 Cohort study: Buddeberg-Fischer et al. 
(2006).105
Appendix 3  
Identification of studies in the 
original review and updatesAppendix 3 
180
Studies in original review that 
were excluded from 2008 update
As a result of the changes in the eligibility criteria 
for the 2008 update (Chapter 2, Decision problem), 
a further eight studies (in 14 publications) that 
were included in previous versions of this review 
have now been excluded as the surgical procedures 
assessed (horizontal gastroplasty and vertical 
gastroplasty without banding) are not in current 
use (Appendix 16). 
A total of 11 studies (in 21 publications) of 
jejunoileal bypass, horizontal gastroplasty and 
vertical gastroplasty without banding have 
therefore been excluded from this update. These 
are listed in Appendix 16. 
In addition, two studies that were included in the 
2005 update (Stoeckli et al.102 and von Mach et 
al.103) were later identified to be two publications of 
the same study (this was confirmed by the authors), 
and have therefore been combined in this update.
Summary of included studies
In summary, a total of 5386 references were 
identified through the original and updated 
searches. Twenty-six studies reported in 52 
publications met the current inclusion criteria 
(Figure 9).DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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Original 2002 2707 citations identified 2631 excluded
76 retrieved 37 excluded
39 publications
(1 review, 18 studies)  
18 studies included in
Original 2002
Cochrane 2003 2707 citations
re-screened
23 more retrieved
3 additional abstracts
included
20 excluded
18 studies included in
Cochrane 2003
3 jejeunoileal studies
excluded
Cochrane 2005 516 citations identified 488 excluded
28 retrieved 14 excluded
14 included:
8 new studies
(6 SOS updates) 
19 included:
9 new studies
(12 publications)
5 SOS updates
2 other updates 
26 studies included in
Cochrane 2005
8 studies of outdated
procedures excluded
1 study removed–
additional publication
Current 2008 2163 citations identified 2126 excluded
37 retrieved 18 excluded
26 studies included
in update 2008
FIGURE 9  Flow chart of inclusion through the review updates. SOS, Swedish Obese Subjects.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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Appendix 4 
Quality assessment
Risk of bias table for included RCTs 
Item Judgement a Description
Adequate sequence generation? 
(Describe the method used to generate the allocation sequence 
in sufficient detail to allow an assessment of whether it should 
produce comparable groups.)
Allocation concealment? 
(Describe the method used to conceal the allocation sequence 
in sufficient detail to determine whether intervention allocations 
could have been foreseen in advance of, or during, recruitment.)
Blinding of outcome assessors? a 
(Describe all measures used, if any, to blind study participants 
and personnel from knowledge of which intervention a 
participant received. Provide any information relating to 
whether the intended blinding was effective.)
Blinding of participants on self-reported outcomes? 
Incomplete outcome data addressed?a Weight loss 
[Describe the completeness of outcome data for each main 
outcome, including attrition and exclusions from the analysis. 
State whether attrition and exclusions were reported, the 
numbers (compared with total randomised participants), 
reasons for attrition/exclusions where reported, and any 
reinclusions in analyses performed by the review authors.]
Incomplete outcome data addressed?a QoL
Incomplete outcome data addressed?a Comorbidity
Free of selective outcome reporting? 
(State how the possibility of selective outcome reporting was 
examined by the review authors, and what was found.)
Free of other sources of bias? 
(State any important concerns about bias not addressed in 
the other items in the tool. If particular questions/items were 
prespecified in the review’s protocol, responses should be 
provided for each question/item.)
QoL, quality of life.
a  ’Yes’ indicates low risk of bias, ‘No’ indicates high risk of bias and ‘Unclear’ indicates uncertain risk of biasAppendix 4
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Quality assessment criteria for cohort studies
Quality item Yes/No/Uncertain
1.  Is there sufficient description of the groups and the distribution of prognostic factors?
2.  Are the groups assembled at a similar point in their disease progression?
3.  Is the intervention/treatment reliably ascertained?
4.  Were the groups comparable on all important confounding factors?
5.  Was there adequate adjustment for the effects of these confounding variables?
6.  Was outcome assessment blind to exposure status?
7.  Was follow-up long enough for the outcomes to occur?DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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Table 74 reports the total costs and QALYs for each 
morbidly obese (BMI > 40) patient undergoing 
surgical and non-surgical management, as reported 
in the previous assessment report. Table 75 reports 
the incremental costs for surgical management, 
with adjustable gastric banding or gastric bypass, 
compared with non-surgical management. Both 
surgical procedures are associated with increased 
total costs and increased QALYs, with ICERs of 
£8527 for adjustable gastric banding and £6289 for 
gastric bypass.
The following two tables (Tables 76 and Table 77) 
report the same analysis, but applying the same 
discount rate of 3.5% to both costs and QALYs, as is 
conventional practice in current health technology 
assessments. This change in discounting practice 
leads to higher total costs, and reduces the total 
QALYs as would be expected. However, this change 
in discounting practice has very little impact on the 
ICERs, see the final column of Table 77.
Appendix 18 
Updating discounting practice for 
previous assessment report
TABLE 74  Total net costs and QALYs – discount rates of 6% for costs and 1.5% for QALYs
Total Cost (£) QALYs
Usual care 6964 11.23
SAGB 10,795 11.68
Gastric bypass 9764 11.67
QALYs, quality-adjusted life-years; SAGB, Swedish adjustable gastric band.
TABLE 75  Net cost per QALY gained, surgery compared with non-surgical management – discount rates of 6% for costs and 1.5% for 
QALYs
Intervention Comparator Additional cost (£) Additional QALYs
Net cost per QALY 
gained (£)
SAGB Non-surgical 3831 0.45 8527
Gastric bypass Non-surgical 2800 0.45 6289
QALYs, quality-adjusted life-years; SAGB, Swedish adjustable gastric band.Appendix 18
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TABLE 76  Total net costs and QALYs – discount rates of 3.5% for costs and QALYs
Total cost (£) QALYs
Usual care 9044 9.22
SAGB 12,588 9.63
Gastric bypass 11,512 9.64
QALY(s), quality-adjusted life-year(s); SAGB
TABLE 77  Net cost per QALY, surgery compared with non-surgical management – discount rates of 3.5% for costs and QALYs
Intervention Comparator Additional cost (£) Additional QALYs
Net cost per QALY 
gained (£)
SAGB Non-surgical 3544 0.41 8553
Gastric bypass Non-surgical 2468 0.42 5822
QALY(s), quality-adjusted life-year(s); SAGBDOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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Table 78 reports the parameters for the 
Framingham Heart Study CHD risk equation, as 
reported by Andersen and colleagues.168 Andersen 
and colleagues168 also outline the method used 
to derive an individual’s risk of a CHD event 
given their characteristics, in terms of age, sex, 
systolic blood pressure, smoking status, ratio of 
total cholesterol to high-density lipoproteins and 
whether they have developed diabetes.
Table 79 reproduces the steps outlined in the 
original article by Andersen and colleagues168 
to derive the 10-year predicted probability of 
a 55-year-old woman, who is a current smoker, 
with systolic blood pressure of 135 mmHg, and 
a TC : HDL ratio of 4.79 and who has developed 
diabetes. The second column in Table 78 shows 
the parameter estimates from the Framingham 
Heart Study CHD equation, while the third column 
lists the input values as described in the previous 
sentence. The final column in Table 78 lists these 
input values as they are entered into the risk 
equation, with log transformations where required 
(for age, systolic blood pressure and TC : HDL 
ratio). The first stage in deriving an individual’s 
risk is to multiply the transformed input values 
by the relevant parameter estimate – the result of 
this is reported in the row labelled µ in Table 79. 
Following the remaining steps outlined in Table 79, 
gives an estimated 10-year probability of a CHD 
event of 22%.
Appendix 19 
Caro reparameterisation of Framingham 
Heart Study accelerated failure time models
TABLE 78  Parameters for Framingham Heart Study CHD equation from Andersen and colleagues168
Parameter estimate
Untransformed input 
value Transformed input value
θ0 0.9145  
θ1 – 0.2784
Constant 15.5305 1 1.0000
Female 28.4441 1 1.0000
ln(Age) – 1.4792 55 4.0073
ln(Age)*Female – 14.4588   4.0073
[ln(Age)]2*Female 1.8515   16.0587
ln(SBP) – 0.9119 135 4.9053
Smoker – 0.2767 1 1.0000
ln(TC : HDL) – 0.7181 4.79 1.5669
Diabetes – 0.1759 1 1.0000
Diabetes*Female – 0.1999   1.0000
SBP , systolic blood pressure; TC:HDL, total cholesterol to high-density lipoprotein ratio.Appendix 19
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Alternatively, reparameterising the equation as 
suggested by Caro and colleagues169 so that:
λ
µ =
1
e
γ
θ θ µ =
+
1
0 1 e
allows the use of a more standard Weibull 
formulation to calculate the hazard in any cycle t:
TABLE 79  Steps in calculating an individual’s risk of a CHD event
Calculate example in original paper
µ 3.58765
log(s) = θ0 + θ1 µ – 0.08430
s = exp(θ0 + θ1µ) 0.91915
u = [ln(10) – µ]/s – 1.39809
10-year predicted probability
{1 – exp[– exp(u)]}
0.21891
h t
t =
− λ γ
γ γ 1
In the above example, this yields an annual risk 
(assuming annual cycles) from 0.0217 in year 1 to 
0.0265 in year 10. Adopting the DEALE method162 
to derive an annual risk from the 10-year risk 
[– 1/10 * ln(1 – 0.21891)], would yield a constant risk 
of 0.0247 which would tend to slightly overestimate 
the risk compared with the method based on the 
reparameterised FHS equations.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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Appendix 20 
Variables included in probabilistic 
sensitivity analyses, distributions and 
parameters of distributions used
Table 80 and Table 81 provide details of the included variables.
TABLE 80  Variables included in probabilistic sensitivity analysis for moderate-to-severely obese (BMI ≥ 30 and < 40) patients with Type 
2 diabetes, showing distributions and parameters
Variable Distribution Parameters
Weight loss – surgical Normal Mean = 21.1; SD = 1.917
Systolic blood pressure – surgical Normal Mean = 6.00; SD = 3.268
TC : HDL – surgical Normal Mean = 0.82; SD = 0.347
Weight loss – non-surgical Normal Mean = 1.5; SD = 0.986
Systolic blood pressure – non-surgical Normal Mean = 1.70; SD = 2.593
TC : HDL – non-surgical Normal Mean = 0.14; SD = 0.190
Utility change per unit change in BMI Uniform Minimum = 0.0075; SD = 0.0166
Diabetes remission – surgical Beta Alpha = 22; Beta = 8
Diabetes remission – non-surgical Beta Alpha = 4; Beta = 26
Diabetes heath state Gamma Alpha = 4394.9051; Beta = 0.5
Acute AMI Gamma Alpha = 3226.4959; Beta = 0.5
Chronic AMI Gamma Alpha = 1130.3026; Beta = 0.5
Acute stroke Gamma Alpha = 19079.7077; Beta = 0.5
Chronic stroke Gamma Alpha = 5129.1832; Beta = 0.5
AMI, acute myocardial infarction; BMI, body mass index; SD, standard deviation; TC:HDL, total cholesterol to high-density 
lipoprotein ratio.Appendix 20
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•	 TABLE 81  Variables included in probabilistic sensitivity analysis for moderately obese (BMI ≥ 30 and < 35) patients, showing 
distributions and parameters.
Variable Distribution Parameters
Baseline BMI – surgical Normal Mean = 37.7; SD = 0.3827
BMI at 6 months – surgical Normal Mean = 28.9; SD = 0.4082
BMI at 12 months – surgical Normal Mean = 27; SD = 0.4082
BMI at 18 months – surgical Normal Mean = 26.7; SD = 0.4082
BMI at 24 months – surgical Normal Mean = 26.4; SD = 0.4082
Systolic blood pressure (% change) – surgical  Beta Alpha = 4.104; Beta = 33.896
TC : HDL (% change) – surgical  Beta Alpha = 8.094; Beta = 29.906
Baseline BMI – non-surgical Normal Mean = 37.5; SD = 0.4082
BMI at 6 months – non-surgical Normal Mean = 28.7; SD = 0.4337
BMI at 12 months – non-surgical Normal Mean = 29.9; SD = 0. 4337
BMI at 18 months – non-surgical Normal Mean = 30.9; SD = 0. 4337
BMI at 24 months – non-surgical Normal Mean = 31.5; SD = 0. 4337
Systolic blood pressure (% change) – non-surgical  Beta Alpha = 2.160; Beta = 27.840
TC : HDL (% change) – non-surgical  Beta Alpha = 2.400; Beta = 27.600
Utility change per unit change in BMI Uniform Minimum = 0.0075; Maximum = 0.0166
Diabetes remission – surgical Beta Alpha = 14; Beta = 1
Diabetes remission – non-surgical Beta Alpha = 7; Beta = 8
Diabetes heath state Gamma Alpha = 4394.9051; Beta = 0.5
Acute AMI Gamma Alpha = 3226.4959; Beta = 0.5
Chronic AMI Gamma Alpha = 1130.3026; Beta = 0.5
Acute stroke Gamma Alpha = 19079.7077; Beta = 0.5
Chronic stroke Gamma Alpha = 5129.1832; Beta = 0.5
AMI, acute myocardial infarction; BMI, body mass index; SD, standard deviation; TC:HDL, total cholesterol to high-density 
lipoprotein ratio.DOI: 10.3310/hta13410  Health Technology Assessment 2009; Vol. 13: No. 41
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